UNIQUE ASSOCIATED KAPOSI'S SARCOMA VIRUS SEQUENCES AND USES THEREOF

Abstract: This invention provides an isolated DNA molecule which is at least 30 nucleotides in length and which uniquely defines a herpesvirus associated with Kaposi's sarcoma. This invention provides an isolated herpesvirus associated with Kaposi's sarcoma. This invention provides an antibody specific to the peptide. Antisense and triplex oligonucleotide molecules are also provided. This invention provides a method of vaccinating a subject for KS, prophylaxis diagnosing or treating a subject with KS and detecting expression of a DNA virus associated with Kaposi's sarcoma in a cell.

Description: UNIQUE ASSOCIATED KAPOSI'S SARCOMA VIRUS SEQUENCES AND USES THEREOF The invention disclosed herein was made with Government support under a co-operative agreement CCU210852 from the Centers for Disease Control and Prevention, of the Department of Health and Human Services. Accordingly, the U.S. Government has certain rights in this invention. This application is a continuation-in-part application of U.S. Serial No. 08/420,235, filed on April 11, 1995 which is a continuation-in-part application of U.S. Serial No. 08/343,101, filed on November 21, 1994, a continuation-in-part application of U.S. Serial No. 08/292,365, filed on August 18, 1994, which is hereby incorporated by reference. Throughout this application, various publications may be referenced by Arabic numerals in brackets. Full citations for these publications may be found at the end of each Experimental Details Section. The disclosures of the publications cited herein are in their entirety hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains. BACKGROUND OF THE INVENTION Kaposi's sarcoma (KS) is the most common neoplasm occurring in persons with acquired immunodeficiency syndrome (AIDS) . Approximately 15-20% of AIDS patients develop this neoplasm which rarely occurs in immunocompetent individuals [13, 14] . Epidemiologic evidence suggests that AIDS-associated KS (AIDS-KS) has an infectious etiology. Gay and bisexual AIDS patients are approximately twenty times more likely than hemophiliac AIDS patients to develop KS, and KS may be associated with specific sexual practices among gay men with AIDS [6, 15, 55, 83] . KS is uncommon among adult AIDS patients infected through heterosexual or parenteral HIV transmission, or among pediatric AIDS patients infected through vertical HIV transmission [77] . Agents previously suspected of causing KS include cytomegalovirus, hepatitis B virus, human papillomavirus, Epstein-Barr virus, human herpesvirus 6, human immunodeficiency virus (HIV) , and Mycoplasma penetrans [18, 23, 85, 91, 92] . Non- infectious environmental agents, such as nitrite inhalants, also have been proposed to play a role in KS tumorigenesis [33] . Extensive investigations, however, have not demonstrated an etiologic association between any of these agents and AIDS-KS [37, 44, 46, 90] . SUMMARY OF THE INVENTION This invention provides an isolated DNA molecule which is at least 30 nucleotides in length and which uniquely defines a herpesvirus associated with Kaposi's sarcoma. This invention provides an isolated herpesvirus associated with Kaposi's sarcoma. This invention provides a method of vaccinating a subject for KS, prophylaxis diagnosing or treating a subject with KS and detecting expression of a DNA virus associated with Kaposi's sarcoma in a cell. BRIEF DESCRIPTION OF THE FIGURES Figure 1; Agarose gel electrophoresis of RDA products from AIDS-KS tissue and uninvolved tissue. RDA was performed on DNA extracted from KS skin tissue and uninvolved normal skin tissue obtained at autopsy from a homosexual man with AIDS-KS. Lane 1 shows the initial PCR amplified genomic representation of the AIDS-KS DNA after Bam HI digestion. Lanes 2-4 show that subsequent cycles of ligation, amplification, hybridization and digestion of the RDA products resulted in amplification of discrete bands at 380, 450, 540 and 680 bp. RDA of the extracted AIDS-KS DNA performed against itself resulted in a single band at 540 bp (lane 5) . Bands at 380 bp and 680 bp correspond to KS330Bam and KS627Bam respectively after removal of 28 bp priming sequences. Bands at 450 and 540 bp hybridized nonspecifically to both KS and non-KS human DNA. Lane M is a molecular weight marker. Figures 2A-2B: Hybridization of 3 P-labelled KS330Bam (Figure 2A) and KS627Bam (Figure 2B) sequences to a representative panel of 19 DNA samples extracted from KS lesions and digested with Bam HI. KS330Bam hybridized to 11 of the 19 and KS627Bam hybridized to 12 of the 19 DNA samples from AIDS- KS lesions. Two additional cases (lanes 12 and 13) were shown to have faint bands with both KS330Bam and KS627Bam probes after longer exposure. One negative specimen (lane 3) did not have microscopically detectable KS in the tissue specimen. Seven of 8 additional KS DNA samples also hybridized to both sequences. Figures 3A-3F; Nucleotide sequences of the DNA herpesvirus associated with KS (KSHV) . Figures 4A-4B: PCR amplification of a representative set of KS- derived DNA samples using KS330 234 primers. Figure 4A shows the agarose gel of the amplification products from 19 KS DNA samples (lanes 1-19) and Figure 4B shows specific hybridization of the PCR products to a 32 P end- labelled 25 bp internal oligonucleotide (Figure 3B) after transfer of the gel to a nitrocellulose filter. Negative samples in lanes 3 and 15 respectively lacked microscopically detectable KS in the sample or did not amplify the constitutive p53 exon 6, suggesting that these samples were negative for technical reasons. An additional 8 AIDS-KS samples were amplified and all were positive for KS330 234 . Lane 20 is a negative control and Lane M is a molecular weight marker. Figure 5; Southern blot hybridization of KS330Bam and KS627Bam to AIDS-KS genomic DNA extracted from three subjects (lanes 1, 2, and 3) and digested with PvuII. Based on sequence information (Figure 3A) , restricted sites for Pvu II occur between bp 12361-12362 of the KSHV sequence (Figure 3A, SEQ ID NO: 1) , at bp 134 in KS330Bam (Figure 3B, SEQ ID NO: 2) and bp 414 in KS627Bam (Figure 3C, SEQ ID NO: 3) . KS330Bam and KS627Bam failed to hybridize to the same fragments in the digests indicating that the two sequences are separated from each other by one or more intervening Bam HI restriction fragments. Digestion with Pvu II and hybridization to KS330Bam resulted in two distinct banding patterns (lanes 1 and 2 vs. lane 3) suggesting variation between KS samples. Figure 6: Comparison of amino acid homologies between EBV ORF BDLFl, HSVSA ORF 26 and a 918 bp reading frame of the Kaposi's sarcoma agent which includes KS330Bam. Amino acid identity is denoted by reverse lettering. In HSVSA, ORF 26 encodes a minor capsid VP23 which is a late gene product. Figure 7; Subculture of Raji cells co-cultivated with BCBL- 1 cells treated with TPA for 2 days. PCR shows that Raji cells are positive for KSHV sequences and indicate that the agent is a transmissible virus. Figure 8; A schematic diagram of the orientation of KSHV open reading frames identified on the KS5 20,710 bp DNA fragment . Homologs to each open reading frame from a corresponding region of the herpesvirus saimiri (HSVSA) genome are present in an identical orientation, except for the region corresponding to the ORF 28 of HSVSA (middle schematic section) . The shading for each open reading frame corresponds to the approximate % amino acid identity for the KSHV ORF compared to this homolog in HSVSA. Noteworthy homologs that are present in this section of DNA include homologs to thymidine kinase (ORF21) , gH glycoprotein (ORF22) , major capsid protein (ORF25) and the VP23 protein (ORF26) which contains the original KS330Bam sequence derived by representational difference analysis. Figure 9 ; The -200 kD antigen band appearing on a Western blot of KS patient sera against BCBL1 lysate (Bl) and Raji lysate (RA) . M is molecular weight marker. The antigen is a doublet between ca. 210 kD and 240 kD. Figure 10; 5 control patient sera without KS (A1N, A2N, A3N, A4N and A5N) . B1=BCBL1 lysate, RA=Raji lysate. The 220 kD band is absent from the Western blots using patient sera without KS. Figure 11; In this figure, 0.5 ml aliquots of the gradient have been fractionated (fractions 1-62) with the 30% gradient fraction being at fraction No. 1 and the 10% gradient fraction being at fraction No. 62. Each fraction has been dot hybridized to a nitrocellulose membrane and then a 32 P-labeled KSHV DNA fragment, KS631Bam has been hybridized to the membrane using standard techniques . The figure shows that the major solubilized fraction of the KSHV genome bands (i.e. is isolated) in fractions 42 through 48 of the gradient with a high concentration of the genome being present in fraction 44. A second band of solubilized KSHV DNA occurs in fractions 26 through 32. Figure 12; Location, feature, and relative homologies of KS5 open reading frames compared to translation products of herpesvirus saimiri (HSV) , equine herpesvirus 2 (EHV2) and Epstein-Barr virus (EBV) . Figure 13 ; Indirect immunofluorescence end-point and geometric mean titers (GMT) in AIDS-KS and AIDS control sera against BHL-6 and P3H3 prior to and after adsorption with P3H3. Figure 14 ; Genetic map of KS5, a 20.7 kb lambda phage clone insert derived from a human genomic library prepared from an AIDS-KS lesion. Seventeen partial and complete open reading frames (ORFs) are identified with arrows denoting reading frame orientations. Comparable regions of the Epstein- Barr virus (EBV) and herpesvirus saimiri (HVS) genomes are shown for comparison. Levels of amino acid similarity between KSHV ORFs are indicated by shading of EBV and HVS ORFs (black, over 70% similarity; dark gray, 55-70% similarity; light gray, 40-54% similarity; white, no detectable homology) . Domains of conserved herpesvirus sequence blocks and locations of restriction endonuclease sites used in subcloning are shown beneath the KSHV map (B, Bam HI site; N, Not I site) . The small Bam HI fragment (black) in the VP23 gene homolog corresponds to the KS330Bam fragment generated by representational difference analysis which was used to identify the KS5 lambda phage clone. Figures 15A-15B; Phylogenetic trees of KSHV based on comparison of aligned amino acid sequences between herpesviruses for the MCP gene and for a concatenated nine-gene set. The comparison of MCP sequences (Figure 15A) was obtained by the neighbor-joining method and is shown in unrooted form with branch lengths proportional to divergence (mean number of substitution events per site) between the nodes bounding each branch. Comparable results were obtained by maximum parsimony analysis. The number of times out of 100 bootstrap samplings the division indicated by each internal branch was obtained are shown next to each branch; bootstrap values below 75 are not shown. Figure 15B is a phylogenetic tree of gammaherpesvirus sequences based on a nine-gene set CS1 (see text) and demonstrates that KSHV is most closely related to the gamma-2 herpesvirus sublineage, genus Rhadinovirus . The CS1 amino acid sequence was used to infer a tree by the Protml maximum likelihood method; comparable results, not shown were obtained with the neighbor-joining and maximum parsimony methods. The bootstrap value for the central branch is marked. On the basis of the MCP analysis, the root must lie between EBV and the other three species. Abbreviations for virus species used in the sequence comparisons are 1) Alphaherpesvirinae: HSV1 and HSV2, herpes simplex virus types 1 and 2; EHV1, equine herpesvirus 1; PRV, pseudorabies virus; and VZV, varicella-zoster virus, 2) Betaherpesvirinae : HCMV, human cytomegalovirus; HHV6 and HHV7 , human herpesviruses 6 and 7, and 3) Gammaherpesvirinae : HVS, herpesvirus saimiri; EHV2 , equine herpesvirus 2; EBV, Epstein-Barr virus; and Kaposi's sarcoma-associated herpesvirus. Figures 16A-16B ; CHEF gel electrophoresis of BCBL-1 DNA hybridized to KS631Bam (Figure 16A) and EBV terminal repeat (Figure 16B) . KS631Bam hybridizes to a band at 270 kb as well as to a diffuse band at the origin. The EBV termini sequence hybridizes to a 150-160 kb band consistent with the linear form of the genome. Both KS631Bam (dark arrow) and an EBV terminal sequence hybridize to high molecular weight bands immediately below the origin indicating possible concatemeric or circular DNA. The high molecular weight KS631Bam hybridizing band reproduces poorly but is visible on the original autoradiographs . Figure 17; Induction of KSHV and EBV replication in BCBL-1 with increasing concentrations of TPA. Each determination was made in triplicate after 48 h of TPA incubation and hybridization was standardized to the amount of cellular DNA by hybridization to beta-actin. The figure shows the mean and range of relative increase in hybridizing genome for EBV and KSHV induced by TPA compared to uninduced BCBL-1. TPA at 20 ng/ml induced an eight-fold increase in EBV genome (upper line) at 48 h compared to only a 1.4 fold increase in KSHV genome (lower line) . Despite the lower level of KSHV induction, increased replication of KSHV genome after induction with TPA concentrations over 10 ng/ml was reproducibly detected. Figures 18A-18C; In si tu hybridization with an ORF26 oligomer to BCBL-1, Raji and RCC-1 cells. Hybridization occurred to nuclei of KSHV infected BCBL-1 (Figure 18A) , but not to uninfected Raji cells (Figure 18B) . RCC-1, a Raji cell line derived by cultivation of Raji with BCBL-1 in communicating chambers separated by a 0.45 μ filter, shows rare cells with positive hybridization to the KSHV ORF26 probe (Figure 18C) . Figures 19A-19D; Representative example of IFA staining of BHL-6 with AIDS-KS patient sera and control sera from HIV-infected patients without KS. Both AIDS-KS (Figure 19A) and control (Figure 19B) sera show homogeneous staining of BHL-6 at 1:50 dilution. After adsorption with paraformaldehyde-fixed P3H3 to remove cross-reacting antibodies directed against lymphocyte and EBV antigens, antibodies from AIDS-KS sera localize to BHL-6 nuclei (Figure 19C) . P3H3 adsorption of control sera eliminates immunofluorescent staining of BHL-6 (Figure 19D) . Figures 20A-20B; Longitudinal PCR examination for KSHV DNA of paired PBMC samples from AIDS-KS patients (A) and homosexual/bisexual AIDS patients without KS (B) . Time 0 is the date of KS onset for cases or other AIDS-defining illness for controls. All samples were randomized and examined blindly. Overall, 7 of the KS patients were KSHV positive at both examination dates (solid bars) and 5 converted from a negative to positive PBMC sample (forward striped bars) immediately prior to or after KS onset. Two previously positive KS patients were negative after KS diagnosis (reverse striped bars) and the remaining KS patients were negative at both timepoints (open bars) . Two homosexual/bisexual control PBMC samples without KS converted from negative to positive and one control patient reverted from PCR positive to negative for KSHV DNA. Figure 21; Sample collection characteristics for AIDS-KS patients, gay/bisexual AIDS patients and hemophilic AIDS patients. Figure 22; PCR analysis of KS330 233 in DNA samples from patients with Kaposi's sarcoma and tumor controls . Figure 23; Characteristics of the study population of patients with KS and without KS. Figure 24 ; Prevalence of antibody to KSHV p40 in HIV-1 positive patients with and without KS . Figure 25; Comparison of KS patients with and without antibody to KSHV p40. Figure 26; Prevalence of antibody detectable by indirect immunofluorescence to KSHV antigens in chemically induced BCBL-1 cells in HIV-1 positive patients with and without KS. Figures 27A-27B; Specific recognition of KSHV polypeptides in chemically treated BCBL-1 cells. Figure 27A shows reactivity of untreated BCBL-1 and B95-8 cells with RM, a reference human antibody to EBV. RM recognizes the EBV polypeptides EBNA1 and p21 in the BCBL-1 cells. Figure 27B shows reactivity of untreated and chemically treated cells with serum 01-03 from a patient with KS. Cells were treated with TPA and n-butyrate for 48 hrs. For description of the cell lines see Materials and Methods. The immunoblots were prepared from 10% SDS polyacrylamide gels. Figures 28A-28D; Detection of KSHV p40 by sera from patients with KS. Extracts were prepared from BCBL-1 cells (containing KSHV and EBV) and Clone HH514-16 cells (containing only EBV) that were uninduced or treated for 48 hrs with chemical inducing agents, n-butyrate, TPA, or a combination of the two chemicals. Immunoblots prepared from 12% SDS polyacrylamide gels were reacted with a 1:200 dilution of serum from HIV-1 positive patients. Figure 28A shows serum 01-06 from a patient with KS. Figure 28B shows serum 01-07 from a patient without KS. Figure 28C shows serum 04-01 from a patient with KS. Figure 28D shows serum 01-03 from a patient with KS. Figures 29A-29F; Detection of KSHV lytic cycle antigens by indirect immunofluorescence . BCBL-1 cells were untreated (Figures 29A, 29C, and 29E) or treated with n-butyrate (Figures 29B, 29D, and 29F) for 48 hrs. Indirect immunofluorescence with a 1:10 dilution of serum from two patients with KS, 04- 18 (Figures 29A, and 29B) and 04-38 (Figures 29E, and 29F) and a serum, 04-37 (Figures 29C, and 29D) , from a patient without KS. DETAILED DESCRIPTION OF THE INVENTION Definitions The following standard abbreviations are used throughout the specification to indicate specific nucleotides: C=cytosine A=adenosine T=thyτnidine G=guanosine The term "nucleic acids", as used herein, refers to either DNA or RNA. "Nucleic acid sequence" or "polynucleotide sequence" refers to a single- or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases read from the 5' to the 3' end. It includes both self-replicating plasmids, infectious polymers of DNA or RNA and nonfunctional DNA or RNA. By a nucleic acid sequence "homologous to" or "complementary to", it is meant a nucleic acid that selectively hybridizes, duplexes or binds to viral DNA sequences encoding proteins or portions thereof when the DNA sequences encoding the viral protein are present in a human genomic or cDNA library. A DNA sequence which is homologous to a target sequence can include sequences which are shorter or longer than the target sequence so long as they meet the functional test set forth. Hybridization conditions are specified along with the source of the CDNA library. Typically, the hybridization is done in a Southern blot protocol using a 0.2XSSC, 0.1% SDS, 65°C wash. The term "SSC" refers to a citrate-saline solution of 0.15 M sodium chloride and 20 Mm sodium citrate. Solutions are often expressed as multiples or fractions of this concentration. For example, 6XSSC refers to a solution having a sodium chloride and sodium citrate concentration of 6 times this amount or 0.9 M sodium chloride and 120 mM sodium citrate. 0.2XSSC refers to a solution 0.2 times the SSC concentration or 0.03 M sodium chloride and 4 mM sodium citrate. The phrase "nucleic acid molecule encoding" refers to a nucleic acid molecule which directs the expression of a specific protein or peptide. The nucleic acid sequences include both the DNA strand sequence that is transcribed into RNA and the RNA sequence that is translated into protein. The nucleic acid molecule include both the full length nucleic acid sequences as well as non-full length sequences derived from the full length protein. It being further understood that the sequence includes the degenerate codons of the native sequence or sequences which may be introduced to provide codon preference in a specific host cell. The phrase "expression cassette", refers to nucleotide sequences which are capable of affecting expression of a structural gene in hosts compatible with such sequences. Such cassettes include at least promoters and optionally, transcription termination signals. Additional factors necessary or helpful in effecting expression may also be used as described herein. The term "operably linked" as used herein refers to linkage of a promoter upstream from a DNA sequence such that the promoter mediates transcription of the DNA sequence. The term "vector", refers to viral expression systems, autonomous self-replicating circular DNA (plasmids) , and includes both expression and nonexpression plasmids. Where a recombinant microorganism or cell culture is described as hosting an "expression vector, " this includes both extrachromosomal circular DNA and DNA that has been incorporated into the host chromosome (s) . Where a vector is being maintained by a host cell, the vector may either be stably replicated by the cells during mitosis as an autonomous structure, or is incorporated within the host's genome. The term "plasmid" refers to an autonomous circular DNA molecule capable of replication in a cell, and includes both the expression and nonexpression types . Where a recombinant microorganism or cell culture is described as hosting an "expression plasmid", this includes latent viral DNA integrated into the host chromosome (s) . Where a plasmid is being maintained by a host cell, the plasmid is either being stably replicated by the cells during mitosis as an autonomous structure or is incorporated within the host's genome. The phrase "recombinant protein" or "recombinantly produced protein" refers to a peptide or protein produced using non-native cells that do not have an endogenous copy of DNA able to express the protein. The cells produce the protein because they have been genetically altered by the introduction of the appropriate nucleic acid sequence. The recombinant protein will not be found in association with proteins and other subcellular components normally associated with the cells producing the protein. The following terms are used to describe the sequence relationships between two or more nucleic acid molecules or polynucleotides : "reference sequence", "comparison window", "sequence identity", "percentage of sequence identity", and "substantial identity". A "reference sequence" is a defined sequence used as a basis for a sequence comparison; a reference sequence may be a subset of a larger sequence, for example, as a segment of a full-length cDNA or gene sequence given in a sequence listing or may comprise a complete cDNA or gene sequence. Optimal alignment of sequences for aligning a comparison window may be conducted by the local homology algorithm of Smith and Waterman (1981) Adv. Appl . Ma th . 2:482, by the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol . Biol . 48:443, by the search for similarity method of Pearson and Lipman (1988) Proc . Na tl . Acad . Sci . (USA) 85:2444, or by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, 575 Science Dr., Madison, WI) . As applied to polypeptides, the terms "substantial identity" or "substantial sequence identity" mean that two peptide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap which share at least 90 percent sequence identity, preferably at least 95 percent sequence identity, more preferably at least 99 percent sequence identity or more . "Percentage amino acid identity" or "percentage amino acid sequence identity" refers to a comparison of the amino acids of two polypeptides which, when optimally aligned, have approximately the designated percentage of the same amino acids. For example, "95% amino acid identity" refers to a comparison of the amino acids of two polypeptides which when optimally aligned have 95% amino acid identity. Preferably, residue positions which are not identical differ by conservative amino acid substitutions. For example, the substitution of amino acids having similar chemical properties such as charge or polarity are not likely to effect the properties of a protein. Examples include glutamine for asparagine or glutamic acid for aspartic acid. The phrase "substantially purified" or "isolated" when referring to a herpesvirus peptide or protein, means a chemical composition which is essentially free of other cellular components. It is preferably in a homogeneous state although it can be in either a dry or aqueous solution. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high performance liquid chromatography. A protein which is the predominant species present in a preparation is substantially purified. Generally, a substantially purified or isolated protein will comprise more than 80% of all macromolecular species present in the preparation. Preferably, the protein is purified to represent greater than 90% of all macromolecular species present. More preferably the protein is purified to greater than 95%, and most preferably the protein is purified to essential homogeneity, wherein other macromolecular species are not detected by conventional techniques. The phrase "specifically binds to an antibody" or "specifically immunoreactive with", when referring to a protein or peptide, refers to a binding reaction which is determinative of the presence of the herpesvirus of the invention in the presence of a heterogeneous population of proteins and other biologies including viruses other than the herpesvirus. Thus, under designated immunoassay conditions, the specified antibodies bind to the herpesvirus antigens and do not bind in a significant amount to other antigens present in the sample. Specific binding to an antibody under such conditions may require an antibody that is selected for its specificity for a particular protein. For example, antibodies raised to the human herpesvirus immunogen described herein can be selected to obtain antibodies specifically immunoreactive with the herpesvirus proteins and not with other proteins. These antibodies recognize proteins homologous to the human herpesvirus protein. A variety of immunoassay formats may be used to select antibodies specifically immunoreactive with a particular protein. For example, solid-phase ELISA immunoassays are routinely used to select monoclonal antibodies specifically immunoreactive with a protein. See Harlow and Lane [32] for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity. "Biological sample" as used herein refers to any sample obtained from a living organism or from an organism that has died. Examples of biological samples include body fluids and tissue specimens. I . Kaposis's Sarcoma (KS) - Associated Herpesvirus. This invention provides an isolated DNA molecule which is at least 30 nucleotides in length and which uniquely defines a herpesvirus associated with Kaposi's sarcoma. In one embodiment the isolated DNA molecule comprises at least a portion of the nucleic acid sequence as shown in Figure 3A (SEQ ID NO: 1) . In another embodiment the isolated DNA molecule is a 330 base pair (bp) sequence. In another embodiment the isolated DNA molecule is a 12-50 bp sequence. In another embodiment the isolated DNA molecule is a 30- 37 bp sequence. In another embodiment the isolated DNA molecule is genomic DNA. In another embodiment the isolated DNA molecule is cDNA. In another embodiment a RNA is derived form the isolated nucleic acid molecule or is capable of hybridizing with the isolated DNA molecule. As used herein "genomic" means both coding and non- coding regions of the isolated nucleic acid molecule. Further, the DNA molecule above may be associated with lymphoproliferative diseases including, but not limited to: Hodgkin's disease, non-Hodgkin' s lymphoma, lymphatic leukemia, lymphosarcoma, splenomegaly, reticular cell sarcoma, Sezary's syndrome, mycosis fungoides, central nervous system lymphoma, AIDS related central nervous system lymphoma, post- transplant lymphoproliferative disorders, and Burkitt's lymphoma. A lymphoproliferative disorder is characterized as being the uncontrolled clonal or polyclonal expansion of lymphocytes involving lymph nodes, lymphoid tissue and other organs. This invention provides an isolated nucleic acid molecule encoding an ORF20 (SEQ ID NOs: 22 and 23), ORF21 (SEQ ID NOs:14 and 15) , ORF22 (SEQ ID NOs: 16 and 17) , ORF23 (SEQ ID NOs:18 and 19) , ORF24 (SEQ ID NOs : 20 and 21) , ORF25 (SEQ ID NOs : 2 and 3), ORF26 (SEQ ID NOs:24 and 25) , ORF27 (SEQ ID NOs:26 and 27) , ORF28 (SEQ ID NOs:28 and 29) , ORF29A (SEQ ID NOs :30 and 31) , ORF29B (SEQ ID NOs :4 and 5) , ORF30 (SEQ ID NOs:6 and 7) , ORF31 (SEQ ID NOs:8 and 9) , ORF32 (SEQ ID NOs:32 and 33) , ORF33 (SEQ ID NOs: 10 and 11) , ORF34 (SEQ ID NOs: 34 and 35) , or ORF35 (SEQ ID NOs:12 AND 13) . This invention provides an isolated polypeptide encoded by ORF20 (SEQ ID NOs: 22 and 23) , ORF21 (SEQ ID NOs:14 and 15) , ORF22 (SEQ ID NOs : 16 and 17) , ORF23 (SEQ ID NOs:18 and 19) , ORF24 (SEQ ID NOs: 20 and 21) , ORF25 (SEQ ID NOs : 2 and 3) , ORF26 (SEQ ID NOs:24 and 25) , ORF27 (SEQ ID NOs:26 and 27) , ORF28 (SEQ ID NOs:28 and 29) , ORF29A (SEQ ID NOs :30 and 31) , ORF29B (SEQ ID NOs:4 and 5) , ORF30 (SEQ ID NOs : 6 and 7) , ORF31 (SEQ ID NOs : 8 and 9) , ORF32 (SEQ ID NOs:32 and 33) , ORF33 (SEQ ID NOs : 10 and 11) , ORF34 (SEQ ID NOs: 34 and 35) , or ORF35 (SEQ ID NOs:12 AND 13) . For Example, TK is encoded by ORF 21; glycoprotein H (gH) by ORF 22; major capsid protein (MCP) by ORF 25; virion polypeptide (VP23) by ORF 26; and minor capsid protein by ORF 27. This invention provides for a replicable vector comprising the isolated DNA molecule of the DNA virus. The vector includes, but is not limited to: a plasmid, cosmid, λ phage or yeast artificial chromosome (YAC) which contains at least a portion of the isolated nucleic acid molecule. As an example to obtain these vectors, insert and vector DNA can both be exposed to a restriction enzyme to create complementary ends on both molecules which base pair with each other and are then ligated together with DNA ligase. Alternatively, linkers can be ligated to the insert DNA which correspond to a restriction site in the vector DNA, which is then digested with the restriction enzyme which cuts at that site. Other means are also available and known to an ordinary skilled practitioner. Regulatory elements required for expression include promoter or enhancer sequences to bind RNA polyτnerase and transcription initiation sequences for ribosome binding. For example, a bacterial expression vector includes a promoter such as the lac promoter and for transcription initiation the Shine-Dalgarno sequence and the start codon AUG. Similarly, a eukaryotic expression vector includes a heterologous or homologous promoter for RNA polymerase II, a downstream polyadenylation signal, the start codon AUG, and a termination codon for detachment of the ribosome. Such vectors may be obtained commercially or assembled from the sequences described by methods well-known in the art, for example the methods described above for constructing vectors in general. This invention provides a host cell containing the above vector. The host cell may contain the isolated DNA molecule artificially introduced into the host cell. The host cell may be a eukaryotic or bacterial cell (such as E.coli) , yeast cells, fungal cells, insect cells and animal cells. Suitable animal cells include, but are not limited to Vero cells, HeLa cells, Cos cells, CVl cells and various primary mammalian cells. This invention provides an isolated herpesvirus associated with Kaposi's sarcoma. In one embodiment the herpesvirus comprises at least a portion of a nucleotide sequence as shown in Figures 3A (SEQ ID NO: l) . In one embodiment the herpesvirus may be a DNA virus. In another embodiment the herpesvirus may be a Herpesviridae. In another embodiment the herpesvirus may be a gammaherpesvirinae. The classification of the herpesvirus may vary based on the phenotypic or molecular characteristics which are known to those skilled in the art. This invention provides an isolated DNA virus wherein the viral DNA is about 270 kb in size, wherein the viral DNA encodes a thymidine kinase, and wherein the viral DNA is capable of selectively hybridizing to a nucleic acid probe selected from the group consisting of SEQ ID NOs: 38-40. The KS-associated human herpesvirus of the invention is associated with KS and is involved in the etiology of the disease. The taxonomic classification of the virus has not yet been made and will be based on phenotypic or molecular characteristics known to those of skill in the art. However, the novel KS-associated virus is a DNA virus that appears to be related to the Herpesviridae family and the gammaherpesvirinae subfamily, on the basis of nucleic acid homology. A. Sequence identity of the viral DNA and its proteins. The human herpesvirus of the invention is not limited to the virus having the specific DNA sequences described herein. The KS-associated human herpesvirus DNA shows substantial sequence identity, as defined above, to the viral DNA sequences described herein. DNA from the human herpesvirus typically selectively hybridizes to one or more of the following three nucleic acid probes: Probe 1 (SEQ ID NO:38) AGCCGAAAGG ATTCCACCAT TGTGCTCGAA TCCAACGGAT TTGACCCCGT GTTCCCCATG GTCGTGCCGC AGCAACTGGG GCACGCTATT CTGCAGCAGC TGTTGGTGTA CCACATCTAC TCCAAAATAT CGGCCGGGGC CCCGGATGAT GTAAATATGG CGGAACTTGA TCTATATACC ACCAATGTGT CATTTATGGG GCGCACATAT CGTCTGGACG TAGACAACAC GGA Probe 2 (SEQ ID NO : 39 ) : GAAATTACCC ACGAGATCGC TTCCCTGCAC ACCGCACTTG GCTACTCATC AGTCATCGCC CCGGCCCACG TGGCCGCCAT AACTACAGAC ATGGGAGTAC ATTGTCAGGA CCTCTTTATG ATTTTCCCAG GGGACGCGTA TCAGGACCGC CAGCTGCATG ACTATATCAA AATGAAAGCG GGCGTGCAAA CCGGCTCACC GGGAAACAGA ATGGATCACG TGGGATACAC TGCTGGGGTT CCTCGCTGCG AGAACCTGCC CGGTTTGAGT CATGGTCAGC TGGCAACCTG CGAGATAATT CCCACGCCGG TCACATCTGA CGTTGCCT Probe 3 (SEQ ID NO: 40) : AACACGTCAT GTGCAGGAGT GACATTGTGC CGCGGAGAAA CTCAGACCGC ATCCCGTAAC CACACTGAGT GGGAAAATCT GCTGGCTATG TTTTCTGTGA TTATCTATGC CTTAGATCAC AACTGTCACC CG Hybridization of a viral DNA to the nucleic acid probes listed above is determined by using standard nucleic acid hybridization techniques as described herein. In particular, PCR amplification of a viral genome can be carried out using the following three sets of PCR primers: 1) AGCCGAAAGGATTCCACCAT; TCCGTGTTGTCTACGTCCAG (SEQ ID NO: 41) 2) GAAATTACCCACGAGATCGC; AGGCAACGTCAGATGTGA (SEQ ID NO: 42) 3) AACACGTCATGTGCAGGAGTGAC; CGGGTGACAGTTGTGATCTAAGG (SEQ ID NO:43) In PCR techniques, oligonucleotide primers, as listed above, complementary to the two 3' borders of the DNA region to be amplified are synthesized. The polymerase chain reaction is then carried out using the two primers. See PCR Protocols : A Guide to Methods and Applications [74] . Following PCR amplification, the PCR-amplified regions of a viral DNA can be tested for their ability to hybridize to the three specific nucleic acid probes listed above. Alternatively, hybridization of a viral DNA to the above nucleic acid probes can be performed by a Southern blot procedure without viral DNA amplification and under stringent hybridization conditions as described herein. Oligonucleotides for use as probes or PCR primers are chemically synthesized according to the solid phase phosphoramidite triester method first described by Beaucage and Carruthers [19] using an automated synthesizer, as described in Needham-VanDevanter [69] . Purification of oligonucleotides is by either native acrylamide gel electrophoresis or by anion-exchange HPLC as described in Pearson, J.D. and Regnier, F.E. [75A] . The sequence of the synthetic oligonucleotide can be verified using the chemical degradation method of Maxam, A.M. and Gilbert, W. [63] . B. Isolation and propagation of KS-inducing strains of the Human Herpesvirus Using conventional methods, the human herpesvirus can be propagated in vi tro . For example, standard techniques for growing herpes viruses are described in Ablashi, D.V. [1] . Briefly, PHA stimulated cord blood mononuclear cells, macrophage, neuronal, or glial cell lines are cocultivated with cerebrospinal fluid, plasma, peripheral blood leukocytes, or tissue extracts containing viral infected cells or purified virus. The recipient cells are treated with 5 μg/ml polybrene for 2 hours at 37° C prior to infection. Infected cells are observed by demonstrating morphological changes, as well as being positive for antigens from the human herpesvirus by using monoclonal antibodies immunoreactive with the human herpes virus in an immunofluorescence assay. For virus isolation, the virus is either harvested directly from the culture fluid by direct centrifugation, or the infected cells are harvested, homogenized or lysed and the virus is separated from cellular debris and purified by standard methods of isopycnic sucrose density gradient centrifugation. One skilled in the art may isolate and propagate the DNA herpesvirus associated with Kaposi's sarcoma (KSHV) employing the following protocol. Long-term establishment of a B lymphoid cell line infected with the KSHV from body-cavity based lymphomas (RCC-1 or BHL-6) is prepared extracting DNA from the Lymphoma tissue using standard techniques [27, 49, 66] . The KS associated herpesvirus may be isolated from the cell DNA in the following manner. An infected cell line (BHL-6 RCC-1) , which can be lysed using standard methods such as hyposomatic shocking and Dounce homogenization, is first pelleted at 2000xg for 10 minutes, the supernatant is removed and centrifuged again at 10,000xg for 15 minutes to remove nuclei and organelles. The supernatant is filtered through a 0.45μ filter and centrifuged again at 100,000xg for 1 hour to pellet the virus. The virus can then be washed and centrifuged again at 100,000xg for 1 hour. The DNA is tested for the presence of the KSHV by Southern blotting and PCR using the specific probes as described hereinafter. Fresh lymphoma tissue containing viable infected cells is simultaneously filtered to form a single cell suspension by standard techniques [49, 66] . The cells are separated by standard Ficoll-Plaque centrifugation and lymphocyte layer is removed. The lymphocytes are then placed at >lxl0 6 cells/ml into standard lymphocyte tissue culture medium, such as RMP 1640 supplemented with 10% fetal calf serum. Immortalized lymphocytes containing the KSHV virus are indefinitely grown in the culture media while nonimmortilized cells die during course of prolonged cultivation. Further, the virus may be propagated in a new cell line by removing media supernatant containing the virus from a continuously infected cell line at a concentration of >lxl0 6 cells/ml. The media is centrifuged at 2000xg for 10 minutes and filtered through a 0.45μ filter to remove cells. The media is applied in a 1:1 volume with cells growing at >lxl0 6 cells/ml for 48 hours. The cells are washed and pelleted and placed in fresh culture medium, and tested after 14 days of growth. RCC-1 and RCC-1 2F5 were deposited on October 19, 1994 under ATCC Accession No. CRL 11734 and CRL 11735, respectively, pursuant to the Budapest Treaty on the International Deposit of Microorganisms for the Purposes of Patent Procedure with the Patent Culture Depository of the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852 U.S.A. BHL-6 was deposited on November 18, 1994 under ATCC Accession No. CRL 11762 pursuant to the Budapest Treaty on the International Deposit of Microorganisms for the Purposes of Patent Procedure with the Patent Culture Depository of the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852 U.S.A. C. Immunoloqical Identity of the Virus The KS-associated human herpesvirus can also be described immunologically. KS-associated human herpesviruses are selectively immunoreactive to antisera generated against a defined immunogen such as the viral major capsid protein depicted in Seq. ID No. 12, herein. Immunoreactivity is determined in an immunoassay using a polyclonal antiserum which was raised to the protein which is encoded by the amino acid sequence or nucleic acid sequence of SEQ ID NOs: 18-20. This antiserum is selected to have low crossreactivity against other herpes viruses and any such crossreactivity is removed by immunoabsorbtion prior to use in the immunoassay. In order to produce antisera for use in an immunoassay, the protein which is encoded by the amino acid sequence or nucleic acid of SEQ ID NOs: 18-20 is isolated as described herein. For example, recombinant protein can be produced in a mammalian cell line. An inbred strain of mice such as balb/c is immunized with the protein which is encoded by the amino acid sequence or nucleic acid of SEQ ID NOs: 2- 37 using a standard adjuvant, such as Freund's adjuvant, and a standard mouse immunization protocol (see [32] , supra) . Alternatively, a synthetic peptide derived from the sequences disclosed herein and conjugated to a carrier protein can be used an immunogen. Polyclonal sera are collected and titered against the immunogen protein in an immunoassay, for example, a solid phase immunoassay with the immunogen immobilized on a solid support. Polyclonal antisera with a titer of 10 4 or greater are selected and tested for their cross reactivity against other viruses of the gammaherpesvirinae subfamily, particularly human herpes virus types 1-7, by using a standard immunoassay as described in [32] , supra . These other gammaherpesvirinae virus can be isolated by standard techniques for isolation herpes viruses as described herein. The ability of the above viruses to compete with the binding of the antisera to the immunogen protein is determined. The percent crossreactivity for other viruses is calculated, using standard calculations. Those antisera with less than 10% crossreactivity with each of the other viruses listed above is selected and pooled. The cross-reacting antibodies are then removed from the pooled antisera by immunoabsorption with the above-listed viruses. The immunoabsorbed and pooled antisera are then used in a competitive binding immunoassay procedure as described above to compare an unknown virus preparation to the specific KS herpesvirus preparation described herein and containing the nucleic acid sequence described in SEQ ID NOs: 2-37. In order to make this comparison, the immunogen protein which is encoded by the amino acid sequence or nucleic acid of SEQ ID NOs: 2-37 is the labeled antigen and the virus preparations are each assayed at a wide range of concentrations. The amount of each virus preparation required to inhibit 50% of the binding of the antisera to the labeled immunogen protein is determined. Those viruses that specifically bind to an antibody generated to an immunogen consisting of the protein of SEQ ID NOs: 2-37 are those virus where the amount of virus needed to inhibit 50% of the binding to the protein does not exceed an established amount. This amount is no more than 10 times the amount of the virus that is needed for 50% inhibition for the KS- associated herpesvirus containing the DNA sequence of SEQ ID NO: 1. Thus, the KS-associated herpesviruses of the invention can be defined by immunological comparison to the specific strain of the KS-associated herpesvirus for which nucleic acid sequences are provided herein. This invention provides, a nucleic acid molecule of at least 14 nucleotides capable of specifically hybridizing with the isolated DNA molecule. In one embodiment, the molecule is DNA. In another embodiment, the molecule is RNA. In another embodiment the nucleic acid molecule may be 14-20 nucleotides in length. In another embodiment the nucleic acid molecule may be 16 nucleotides in length. This invention provides, a nucleic acid molecule of at least 14 nucleotides capable of specifically hybridizing with a nucleic acid molecule which is complementary to the isolated DNA molecule. In one embodiment, the molecule is DNA. In another embodiment, the molecule is RNA. The nucleic acid molecule of at least 14 nucleotides may hybridize with moderate stringency to at least a portion of a nucleic acid molecule with a sequence shown in Figures 3A-3F (SEQ ID NOs: 1, 10-17, and 38- 40) . High stringent hybridization conditions are selected at about 5° C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Typically, stringent conditions will be those in which the salt concentration is at least about 0.02 molar at pH 7 and the temperature is at least about 60°C. As other factors may significantly affect the stringency of hybridization, including, among others, base composition and size of the complementary strands, the presence of organic solvents, ie . salt or formamide concentration, and the extent of base mismatching, the combination of parameters is more important than the absolute measure of any one. For Example high stringency may be attained for example by overnight hybridization at about 68°C in a 6x SSC solution, washing at room temperature with 6x SSC solution, followed by washing at about 68°C in a 6x SSC in a 0.6x SSX solution. Hybridization with moderate stringency may be attained for example by: 1) filter pre-hybridizing and hybridizing with a solution of 3x sodium chloride, sodium citrate (SSC), 50% formamide, 0.1M Tris buffer at Ph 7.5, 5x Denhardt's solution; 2.) pre- hybridization at 37°C for 4 hours; 3) hybridization at 37°C with amount of labelled probe equal to 3,000,000 cpm total for 16 hours; 4) wash in 2x SSC and 0.1% SDS solution; 5) wash 4x for 1 minute each at room temperature at 4x at 60°C for 30 minutes each; and 6) dry and expose to film. The phrase "selectively hybridizing to" refers to a nucleic acid probe that hybridizes, duplexes or binds only to a particular target DNA or RNA sequence when the target sequences are present in a preparation of total cellular DNA or RNA. By selectively hybridizing it is meant that a probe binds to a given target in a manner that is detectable in a different manner from non-target sequence under high stringency conditions of hybridization, in a different "Complementary" or "target" nucleic acid sequences refer to those nucleic acid sequences which selectively hybridize to a nucleic acid probe. Proper annealing conditions depend, for example, upon a probe's length, base composition, and the number of mismatches and their position on the probe, and must often be determined empirically. For discussions of nucleic acid probe design and annealing conditions, see, for example, Sambrook et al . , [81] or Ausubel, F., et al . , [8] . It will be readily understood by those skilled in the art and it is intended here, that when reference is made to particular sequence listings, such reference includes sequences which substantially correspond to its complementary sequence and those described including allowances for minor sequencing errors, single base changes, deletions, substitutions and the like, such that any such sequence variation corresponds to the nucleic acid sequence of the pathogenic organism or disease marker to which the relevant sequence listing relates. Nucleic acid probe technology is well known to those skilled in the art who readily appreciate that such probes may vary greatly in length and may be labeled with a detectable label, such as a radioisotope or fluorescent dye, to facilitate detection of the probe. DNA probe molecules may be produced by insertion of a DNA molecule having the full-length or a fragment of the isolated nucleic acid molecule of the DNA virus into suitable vectors, such as plasmids or bacteriophages, followed by transforming into suitable bacterial host cells, replication in the transformed bacterial host cells and harvesting of the DNA probes, using methods well known in the art. Alternatively, probes may be generated chemically from DNA synthesizers. DNA virus nucleic acid rearrangements/mutations may be detected by Southern blotting, single stranded conformational polymorphism gel electrophoresis (SSCP) , PCR or other DNA based techniques, or for RNA species by Northern blotting, PCR or other RNA-based techniques. RNA probes may be generated by inserting the full length or a fragment of the isolated nucleic acid molecule of the DNA virus downstream of a bacteriophage promoter such as T3 , T7 or SP6. Large amounts of RNA probe may be produced by incubating the labeled nucleotides with a linearized isolated nucleic acid molecule of the DNA virus or its fragment where it contains an upstream promoter in the presence of the appropriate RNA polymerase. As defined herein nucleic acid probes may be DNA or RNA fragments. DNA fragments can be prepared, for example, by digesting plasmid DNA, or by use of PCR, or synthesized by either the phosphoramidite method described by Beaucage and Carruthers, [19] , or by the triester method according to Matteucci, et al . , [62] , both incorporated herein by reference. A double stranded fragment may then be obtained, if desired, by annealing the chemically synthesized single strands together under appropriate conditions or by synthesizing the complementary strand using DNA polymerase with an appropriate primer sequence . Where a specific sequence for a nucleic acid probe is given, it is understood that the complementary strand is also identified and included. The complementary strand will work equally well in situations where the target is a double-stranded nucleic acid. It is also understood that when a specific sequence is identified for use a nucleic probe, a subsequence of the listed sequence which is 25 basepairs or more in length is also encompassed for use as a probe. The DNA molecules of the subject invention also include DNA molecules coding for polypeptide analogs, fragments or derivatives of antigenic polypeptides which differ from naturally-occurring forms in terms of the identity or location of one or more amino acid residues (deletion analogs containing less than all of the residues specified for the protein, substitution analogs wherein one or more residues specified are replaced by other residues and addition analogs where in one or more amino acid residues is added to a terminal or medial portion of the polypeptides) and which share some or all properties of naturally- occurring forms. These molecules include: the incorporation of codons "preferred" for expression by selected non-mammalian hosts; the provision of sites for cleavage by restriction endonuclease enzymes; and the provision of additional initial, terminal or intermediate DNA sequences that facilitate construction of readily expressed vectors. This invention provides for an isolated DNA molecule which encodes at least a portion of a Kaposi's sarcoma associated herpesvirus: virion polypeptide 23, major capsid protein, capsid proteins, thymidine kinase, or tegument protein. This invention also provides a method of producing a polypeptide encoded by isolated DNA molecule, which comprises growing the above host vector system under suitable conditions permitting production of the polypeptide and recovering the polypeptide so produced. This invention provides an isolated peptide encoded by the isolated DNA molecule associated with Kaposi's sarcoma. In one embodiment the peptide may be a polypeptide. Further, this invention provides a host cell which expresses the polypeptide of isolated DNA molecule. In one embodiment the isolated peptide or polypeptide is encoded by at least a portion of an isolated DNA molecule. In another embodiment the isolated peptide or polypeptide is encoded by at least a portion of a nucleic acid molecule with a sequence as set forth in (SEQ ID NOs: 2-37) . Further, the isolated peptide or polypeptide encoded by the isolated DNA molecule may be linked to a second nucleic acid molecule to form a fusion protein by expression in a suitable host cell. In one embodiment the second nucleic acid molecule encodes beta- galactosidase. Other nucleic acid molecules which are used to form a fusion protein are known to those skilled in the art. This invention provides an antibody which specifically binds to the peptide or polypeptide encoded by the isolated DNA molecule. In one embodiment the antibody is a monoclonal antibody. In another embodiment the antibody is a polyclonal antibody. The antibody or DNA molecule may be labelled with a detectable marker including, but not limited to: a radioactive label, or a colorimetric, a luminescent, or a fluorescent marker, or gold. Radioactive labels include, but are not limited to: 3 H, 14 C, 32 P, 33 P; 35 S, 36 C1, 51 Cr, 57 Co, 59 Co, 59 Fe, 90 Y, 125 I, 131 I, and 186 Re . Fluorescent markers include but are not limited to: fluorescein, rhodamine and auramine. Colorimetric markers include, but are not limited to: biotin, and digoxigenin. Methods of producing the polyclonal or monoclonal antibody are known to those of ordinary skill in the art. Further, the antibody or nucleic acid molecule complex may be detected by a second antibody which may be linked to an enzyme, such as alkaline phosphatase or horseradish peroxidase. Other enzymes which may be employed are well known to one of ordinary skill in the art . This invention provides a method to select specific regions on the polypeptide encoded by the isolated DNA molecule of the DNA virus to generate antibodies. The protein sequence may be determined from the cDNA sequence. Amino acid sequences may be analyzed by methods well known to those skilled in the art to determine whether they produce hydrophobic or hydrophilic regions in the proteins which they build. In the case of cell membrane proteins, hydrophobic regions are well known to form the part of the protein that is inserted into the lipid bilayer of the cell membrane, while hydrophilic regions are located on the cell surface, in an aqueous environment. Usually, the hydrophilic regions will be more immunogenic than the hydrophobic regions. Therefore the hydrophilic amino acid sequences may be selected and used to generate antibodies specific to polypeptide encoded by the isolated nucleic acid molecule encoding the DNA virus. The selected peptides may be prepared using commercially available machines. As an alternative, DNA, such as a cDNA or a fragment thereof, may be cloned and expressed and the resulting polypeptide recovered and used as an immunogen. Polyclonal antibodies against these peptides may be produced by immunizing animals using the selected peptides. Monoclonal antibodies are prepared using hybridoma technology by fusing antibody producing B cells from immunized animals with myeloma cells and selecting the resulting hybridoma cell line producing the desired antibody. Alternatively, monoclonal antibodies may be produced by in vitro techniques known to a person of ordinary skill in the art. These antibodies are useful to detect the expression of polypeptide encoded by the isolated DNA molecule of the DNA virus in living animals, in humans, or in biological tissues or fluids isolated from animals or humans. II. Immunoassays The antibodies raised against the viral strain or peptides may be detectably labelled, utilizing conventional labelling techniques well-known to the art. Thus, the antibodies may be radiolabelled using, for example, radioactive isotopes such as 3 H, 1 5 I, 131 I, and 35 S. The antibodies may also be labelled using fluorescent labels, enzyme labels, free radical labels, or bacteriophage labels, using techniques known in the art. Typical fluorescent labels include fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, alophycocyanin, and Texas Red. Since specific enzymes may be coupled to other molecules by covalent links, the possibility also exists that they might be used as labels for the production of tracer materials. Suitable enzymes include alkaline phosphatase, beta-galactosidase, glucose- 6 -phosphate dehydrogenase , maleate dehydrogenase, and peroxidase. Two principal types of enzyme immunoassay are the enzyme-linked immunosorbent assay (ELISA) , and the homogeneous enzyme immunoassay, also known as enzyme-multiplied immunoassay (EMIT, Syva Corporation, Palo Alto, CA) . In the ELISA system, separation may be achieved, for example, by the use of antibodies coupled to a solid phase. The EMIT system depends on deactivation of the enzyme in the tracer-antibody complex; the activity can thus be measured without the need for a separation step. Additionally, chemiluminescent compounds may be used as labels. Typical chemiluminescent compounds include luminol, isoluminol, aromatic acridinium esters, imidazoles, acridinium salts, and oxalate esters. Similarly, bioluminescent compounds may be utilized for labelling, the bioluminescent compounds including luciferin, luciferase, and aequorin. Once labeled, the antibody may be employed to identify and quantify immunologic counterparts (antibody or antigenic polypeptide) utilizing techniques well-known to the art. A description of a radioimmunoassay (RIA) may be found in Laboratory Techniques in Biochemistry and Molecular Biology [52] , with particular reference to the chapter entitled "An Introduction to Radioimmune Assay and Related Techniques" by Chard, T., incorporated by reference herein. A description of general immunometric assays of various types can be found in the following U.S. Pat. Nos. 4,376,110 (David et al . ) or 4,098,876 (Piasio) . A. Assays for viral antigens In addition to the detection of the causal agent using nucleic acid hybridization technology, one can use immunoassays to detect for the virus, specific peptides, or for antibodies to the virus or peptides. A general overview of the applicable technology is in Harlow and Lane [32] , incorporated by reference herein. In one embodiment, antibodies to the human herpesvirus can be used to detect the agent in the sample. In brief, to produce antibodies to the agent or peptides, the sequence being targeted is expressed in transfected cells, preferably bacterial cells, and purified. The product is injected into a mammal capable of producing antibodies. Either monoclonal or polyclonal antibodies (as well as any recombinant antibodies) specific for the gene product can be used in various immunoassays. Such assays include competitive immunoassays, radioimmunoassays, Western blots, ELISA, indirect immunofluorescent assays and the like. For competitive immunoassays, see Harlow and Lane [32] at pages 567-573 and 584-589. Monoclonal antibodies or recombinant antibodies may be obtained by various techniques familiar to those skilled in the art. Briefly, spleen cells or other lymphocytes from an animal immunized with a desired antigen are immortalized, commonly by fusion with a myeloma cell (see, Kohler and Milstein [50] , incorporated herein by reference) . Alternative methods of immortalization include transformation with Epstein Barr Virus, oncogenes, or retroviruses, or other methods well known in the art. Colonies arising from single immortalized cells are screened for production of antibodies of the desired specificity and affinity for the antigen, and yield of the monoclonal antibodies produced by such cells may be enhanced by various techniques, including injection into the peritoneal cavity of a vertebrate host. New techniques using recombinant phage antibody expression systems can also be used to generate monoclonal antibodies. See for example: McCafferty, J et al . [64] ; Hoogenboom, H.R. e al. [39] ; and Marks, J.D. et al . [60] . Such peptides may be produced by expressing the specific sequence in a recombinantly engineered cell such as bacteria, yeast, filamentous fungal, insect (especially employing baculoviral vectors) , and mammalian cells. Those of skill in the art are knowledgeable in the numerous expression systems available for expression of herpes virus protein. Briefly, the expression of natural or synthetic nucleic acids encoding viral protein will typically be achieved by operably linking the desired sequence or portion thereof to a promoter (which is either constitutive or inducible) , and incorporated into an expression vector. The vectors are suitable for replication or integration in either prokaryotes or eukaryotes. Typical cloning vectors contain antibiotic resistance markers, genes for selection of transformants, inducible or regulatable promoter regions, and translation terminators that are useful for the expression of viral genes. Methods for the expression of cloned genes in bacteria are also well known. In general, to obtain high level expression of a cloned gene in a prokaryotic system, it is advisable to construct expression vectors containing a strong promoter to direct mRNA transcription. The inclusion of selection markers in DNA vectors transformed in E. coli is also useful. Examples of such markers include genes specifying resistance to antibiotics. See [81] supra , for details concerning selection markers and promoters for use in E. coli . Suitable eukaryote hosts may include plant cells, insect cells, mammalian cells, yeast, and filamentous fungi. Methods for characterizing naturally processed peptides bound to MHC (major histocompatibility complex) I molecules have been developed. See, Falk et al . [24] , and PCT publication No. WO 92/21033 published November 26, 1992, both of which are incorporated by reference herein. Typically, these methods involve isolation of MHC class I molecules by immunoprecipitation or affinity chromatography from an appropriate cell or cell line. Other methods involve direct amino acid sequencing of the more abundant peptides in various HPLC fractions by known automatic sequencing of peptides eluted from Class I molecules of the B cell type (Jardetzkey, et al . [45] , incorporated by reference herein, and of the human MHC class I molecule, HLA-A2.1 type by mass spectrometry (Hunt, et al . [40] , incorporated by reference herein) . See also, Rδtzschke and Falk [79] , incorporated by reference herein for a general review of the characterization of naturally processed peptides in MHC class I. Further, Marloes, et al . [61] , incorporated by reference herein, describe how class I binding motifs can be applied to the identification of potential viral immunogenic peptides in vitro. The peptides described herein produced by recombinant technology may be purified by standard techniques well known to those of skill in the art. Recombinantly produced viral sequences can be directly expressed or expressed as a fusion protein. The protein is then purified by a combination of cell lysis (e.g., sonication) and affinity chromatography. For fusion products, subsequent digestion of the fusion protein with an appropriate proteolytic enzyme releases the desired peptide. The proteins may be purified to substantial purity by standard techniques well known in the art, including selective precipitation with such substances as ammonium sulfate, column chromatography, immunopurification methods, and others. See, for instance, Scopes, R. [84], incorporated herein by reference. B. Seroloqical tests for the presence of antibodies to the human herpesvirus. This invention further embraces diagnostic kits for detecting the presence of a KS agent in biological samples, such as serum or solid tissue samples, comprising a container containing antibodies to the human herpesvirus, and instructional material for performing the test. Alternatively, inactivated viral particles or peptides or viral proteins derived from the human herpesvirus may be used in a diagnostic kit to detect for antibodies specific to the KS associated human herpesvirus. Diagnostic kits for detecting the presence of a KS agent in tissue samples, such as skin samples or samples of other affected tissue, comprising a container containing a nucleic acid sequence specific for the human herpesvirus and instructional material for detecting the KS-associated herpesvirus are also included. A container containing nucleic acid primers to any one of such sequences is optionally included as are antibodies to the human herpesvirus as described herein. Antibodies reactive with antigens of the human herpesvirus can also be measured by a variety of immunoassay methods that are similar to the procedures described above for measurement of antigens. For a review of immunological and immunoassay procedures applicable to the measurement of antibodies by immunoassay techniques, see Basic and Clinical Immunology 7th Edition [12] , and [32] , supra . In brief, immunoassays to measure antibodies reactive with antigens of the KS-associated human herpesvirus can be either competitive or noncompetitive binding assays. In competitive binding assays, the sample analyte competes with a labeled analyte for specific binding sites on a capture agent bound to a solid surface. Preferably the capture agent is a purified recombinant human herpesvirus protein produced as described above. Other sources of human herpesvirus proteins, including isolated or partially purified naturally occurring protein, may also be used. Noncompetitive assays are typically sandwich assays, in which the sample analyte is bound between two analyte-specific binding reagents. One of the binding agents is used as a capture agent and is bound to a solid surface. The second binding agent is labelled and is used to measure or detect the resultant complex by visual or instrument means. A number of combinations of capture agent and labelled binding agent can be used. A variety of different immunoassay formats, separation techniques and labels can be also be used similar to those described above for the measurement of the human herpesvirus antigens. Hemagglutination Inhibition (HI) and Complement Fixation (CF) which are two laboratory tests that can be used to detect infection with human herpesvirus by testing for the presence of antibodies against the virus or antigens of the virus. Serological methods can be also be useful when one wishes to detect antibody to a specific variant. For example, one may wish to see how well a vaccine recipient has responded to the new variant. Alternatively, one may take serum from a patient to see which variant the patient responds to the best . This invention provides an antagonist capable of blocking the expression of the peptide or polypeptide encoded by the isolated DNA molecule. In one embodiment the antagonist is capable of hybridizing with a double stranded DNA molecule. In another embodiment the antagonist is a triplex oligonucleotide capable of hybridizing to the DNA molecule. In another embodiment the triplex oligonucleotide is capable of binding to at least a portion of the isolated DNA molecule with a nucleotide sequence as shown in Figure 3A-3F (SEQ ID NOs: 1-37) . This invention provides an antisense molecule capable of hybridizing to the isolated DNA molecule. In one embodiment the antisense molecule is DNA. In another embodiment the antisense molecule is RNA. The antisense molecule may be DNA or RNA or variants thereof (i.e. DNA or RNA with a protein backbone) . The present invention extends to the preparation of antisense nucleotides and ribozymes that may be used to interfere with the expression of the receptor recognition proteins at the translation of a specific mRNA, either by masking that MRNA with an antisense nucleic acid or cleaving it with a ribozyme. Antisense nucleic acids are DNA or RNA molecules that are complementary to at least a portion of a specific MRNA molecule. In the cell, they hybridize to that MRNA, forming a double stranded molecule. The cell does not translate an MRNA in this double-stranded form. Therefore, antisense nucleic acids interfere with the expression of MRNA into protein. Oligomers of about fifteen nucleotides and molecules that hybridize to the AUG initiation codon are particularly efficient, since they are easy to synthesize and are likely to pose fewer problems than larger molecules upon introduction to cells. This invention provides a transgenic nonhuman mammal which comprises at least a portion of the isolated DNA molecule introduced into the mammal at an embryonic stage. Methods of producing a transgenic nonhuman mammal are known to those skilled in the art. This invention provides a cell line containing the isolated KS associated herpesvirus of the subject invention. In one embodiment the isolated DNA molecule is artificially introduced into the cell. Cell lines include, but are not limited to: fibroblasts, such as HFF, NIH/3T3 ; Epithelial cells, such as 5637; lymphocytes, such as FCB; T-cells, such as CCRF-CEM (ATCC CCL 119) ; B-cellε, such as BJAB and Raji (ATCC CCL 86) ; and myeloid cells such as K562 (ATCC CCL 243); Vero cells and carcinoma cells. Methods of producing such cell lines are known to those skilled in the art. In one embodiment the isolated KS associated herpesvirus is introduced into a RCC-1 cell line. Ill . In vitro diagnostic assays for the detection of KS This invention provides a method of diagnosing Kaposi's sarcoma in a subject which comprises: (a) obtaining a nucleic acid molecule from a tumor lesion of the subject; (b) contacting the nucleic acid molecule with a labelled nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with the isolated DNA, under hybridizing conditions; and (c) determining the presence of the nucleic acid molecule hybridized, the presence of which is indicative of Kaposi's sarcoma in the subject, thereby diagnosing Kaposi's sarcoma in the subject . In one embodiment the DNA molecule from the tumor lesion is amplified before step (b) . In another embodiment PCR is employed to amplify the nucleic acid molecule. Methods of amplifying nucleic acid molecules are known to those skilled in the art. A person of ordinary skill in the art will be able to obtain appropriate DNA sample for diagnosing Kaposi's sarcoma in the subject. The DNA sample obtained by the above described method may be cleaved by restriction enzyme. The uses of restriction enzymes to cleave DNA and the conditions to perform such cleavage are well-known in the art. In the above described methods, a size fractionation may be employed which is effected by a polyacrylamide gel. In one embodiment, the size fractionation is effected by an agarose gel. Further, transferring the DNA fragments into a solid matrix may be employed before a hybridization step. One example of such solid matrix is nitrocellulose paper. This invention provides a method of diagnosing Kaposi's sarcoma in a subject which comprises: (a) obtaining a nucleic acid molecule from a suitable bodily fluid of the subject; (b) contacting the nucleic acid molecule with a labelled nucleic acid molecules of at least 15 nucleotides capable of specifically hybridizing with the isolated DNA, under hybridizing conditions; and (c) determining the presence of the nucleic acid molecule hybridized, the presence of which is indicative of Kaposi's sarcoma in the subject, thereby diagnosing Kaposi's sarcoma in the subject. This invention provides a method of diagnosing a DNA virus in a subject, which comprises (a) obtaining a suitable bodily fluid sample from the subject, (b) contacting the suitable bodily fluid of the subject to a support having already bound thereto a Kaposi's sarcoma antibody, so as to bind the Kaposi's sarcoma antibody to a specific Kaposi's sarcoma antigen, (c) removing unbound bodily fluid from the support, and (d) determining the level of Kaposi's sarcoma antibody bound by the Kaposi's sarcoma antigen, thereby diagnosing the subject for Kaposi's sarcoma. This invention provides a method of diagnosing Kaposi's sarcoma in a subject, which comprises (a) obtaining a suitable bodily fluid sample from the subject, (b) contacting the suitable bodily fluid of the subject to a support having already bound thereto a Kaposi's sarcoma antigen, so as to bind Kaposi's sarcoma antigen to a specific Kaposi's sarcoma antibody, (c) removing unbound bodily fluid from the support, and (d) determining the level of the Kaposi's sarcoma antigen bound by the Kaposi's sarcoma antibody, thereby diagnosing Kaposi's sarcoma. This invention provides a method of detecting expression of a DNA virus associated with Kaposi's sarcoma in a cell which comprises obtaining total cDNA obtained from the cell, contacting the cDNA so obtained with a labelled DNA molecule under hybridizing conditions, determining the presence of cDNA hybridized to the molecule, and thereby detecting the expression of the DNA virus. In one embodiment mRNA is obtained from the cell to detect expression of the DNA virus. The suitable bodily fluid sample is any bodily fluid sample which would contain Kaposi's sarcoma antibody, antigen or fragments thereof. A suitable bodily fluid includes, but is not limited to: serum, plasma, cerebrospinal fluid, lymphocytes, urine, transudates, or exudates. In the preferred embodiment, the suitable bodily fluid sample is serum or plasma. In addition, the bodily fluid sample may be cells from bone marrow, or a supernatant from a cell culture. Methods of obtaining a suitable bodily fluid sample from a subject are known to those skilled in the art. Methods of determining the level of antibody or antigen include, but are not limited to: ELISA, IFA, and Western blotting. Other methods are known to those skilled in the art. Further, a subject infected with a DNA virus associated with Kaposi's sarcoma may be diagnosed with the above described methods. The detection of the human herpesvirus and the detection of virus-associated KS are essentially identical processes. The basic principle is to detect the virus using specific ligands that bind to the virus but not to other proteins or nucleic acids in a normal human cell or its environs. The ligands can either be nucleic acid or antibodies. The ligands can be naturally occurring or genetically or physically modified such as nucleic acids with non-natural or antibody derivatives, i.e., Fab or chimeric antibodies. Serological tests for detection of antibodies to the virus may also be performed by using protein antigens obtained from the human herpesvirus, and described herein. Samples can be taken from patients with KS or from patients at risk for KS, such as AIDS patients. Typically the samples are taken from blood (cells, serum and/or plasma) or from solid tissue samples such as skin lesions. The most accurate diagnosis for KS will occur if elevated titers of the virus are detected in the blood or in involved lesions. KS may also be indicated if antibodies to the virus are detected and if other diagnostic factors for KS is present. A. Nucleic acid assays. The diagnostic assays of the invention can be nucleic acid assays such as nucleic acid hybridization assays and assays which detect amplification of specific nucleic acid to detect for a nucleic acid sequence of the human herpesvirus described herein. Accepted means for conducting hybridization assays are known and general overviews of the technology can be had from a review of: Nucleic Acid Hybridization : A Practical Approach [72] ; Hybridization of Nucleic Acids Immobilized on Solid Supports [41] ; Analytical Biochemistry [4] and Innis et al. , PCR Protocols [74] , supra, all of which are incorporated by reference herein. If PCR is used in conjunction with nucleic acid hybridization, primers are designed to target a specific portion of the nucleic acid of the herpesvirus. For example, the primers set forth in SEQ ID NOs: 38-40 may be used to target detection of regions of the herpesvirus genome encoding ORF 25 homologue - ORF 32 homologue. From the information provided herein, those of skill in the art will be able to select appropriate specific primers. Target specific probes may be used in the nucleic acid hybridization diagnostic assays for KS. The probes are specific for or complementary to the target of interest. For precise allelic differentiations, the probes should be about 14 nucleotides long and preferably about 20-30 nucleotides. For more general detection of the human herpesvirus of the invention, nucleic acid probes are about 50 to about 1000 nucleotides, most preferably about 200 to about 400 nucleotides. A sequence is "specific" for a target organism of interest if it includes a nucleic acid sequence which when detected is determinative of the presence of the organism in the presence of a heterogeneous population of proteins and other biologies. A specific nucleic acid probe is targeted to that portion of the sequence which is determinative of the organism and will not hybridize to other sequences especially those of the host where a pathogen is being detected. The specific nucleic acid probe can be RNA or DNA polynucleotide or oligonucleotide, or their analogs. The probes may be single or double stranded nucleotides. The probes of the invention may be synthesized enzymatically, using methods well known in the art (e.g., nick translation, primer extension, reverse transcription, the polymerase chain reaction, and others) or chemically (e.g., by methods such as the phosphoramidite method described by Beaucage and Carruthers [19] , or by the triester method according to Matteucci, et al . [62] , both incorporated herein by reference) . The probe must be of sufficient length to be able to form a stable duplex with its target nucleic acid in the sample, i.e., at least about 14 nucleotides, and may be longer ( e . g. , at least about 50 or 100 bases in length) . Often the probe will be more than about 100 bases in length. For example, when probe is prepared by nick-translation of DNA in the presence of labeled nucleotides the average probe length may be about 100- 600 bases. As noted above, the probe will be capable of specific hybridization to a specific KS-associated herpes virus nucleic acid. Such "specific hybridization" occurs when a probe hybridizes to a target nucleic acid, as evidenced by a detectable signal, under conditions in which the probe does not hybridize to other nucleic acids (e.g., animal cell or other bacterial nucleic acids) present in the sample. A variety of factors including the length and base composition of the probe, the extent of base mismatching between the probe and the target nucleic acid, the presence of salt and organic solvents, probe concentration, and the temperature affect hybridization, and optimal hybridization conditions must often be determined empirically. For discussions of nucleic acid probe design and annealing conditions, see, for example, [81], supra, Ausubel, F., et al . [8] [hereinafter referred to as Sambrook] , Methods in Enzymology [67] or Hybridization wi th Nucleic Acid Probes [42] all of which are incorporated herein by reference. Usually, at least a part of the probe will have considerable sequence identity with the target nucleic acid. Although the extent of the sequence identity required for specific hybridization will depend on the length of the probe and the hybridization conditions, the probe will usually have at least 70% identity to the target nucleic acid, more usually at least 80% identity, still more usually at least 90% identity and most usually at least 95% or 100% identity. A probe can be identified as capable of hybridizing specifically to its target nucleic acid by hybridizing the probe to a sample treated according the protocol of this invention where the sample contains both target virus and animal cells (e.g., nerve cells) . A probe is specific if the probe's characteristic signal is associated with the herpesvirus DNA in the sample and not generally with the DNA of the host cells and non-biological materials [ e . g. , substrate) in a sample. The following stringent hybridization and washing conditions will be adequate to distinguish a specific probe (e.g., a fluorescently labeled DNA probe) from a probe that is not specific: incubation of the probe with the sample for 12 hours at 37°C in a solution containing denatured probe, 50% formamide, 2X SSC, and 0.1% (w/v) dextran sulfate, followed by washing in IX SSC at 70°C for 5 minutes; 2X SSC at 37°C for 5 minutes; 0.2X SSC at room temperature for 5 minutes, and H 2 0 at room temperature for 5 minutes. Those of skill will be aware that it will often be advantageous in nucleic acid hybridizations (i.e., in si tu . Southern, or other) to include detergents (e.g., sodium dodecyl sulfate), chelating agents (e.g., EDTA) or other reagents (e.g., buffers, Denhardt's solution, dextran sulfate) in the hybridization or wash solutions. To test the specificity of the virus specific probes, the probes can be tested on host cells containing the KS-associated herpesvirus and compared with the results from cells containing non- KS-associated virus. It will be apparent to those of ordinary skill in the art that a convenient method for determining whether a probe is specific for a KS-associated viral nucleic acid utilizes a Southern blot (or Dot blot) using DNA prepared from one or more KS-associated human herpesviruses of the invention. Briefly, to identify a target specific probe DNA is isolated from the virus. Test DNA either viral or cellular is transferred to a solid (e.g., charged nylon) matrix. The probes are labelled following conventional methods. Following denaturation and/or prehybridization steps known in the art, the probe is hybridized to the immobilized DNAs under stringent conditions. Stringent hybridization conditions will depend on the probe used and can be estimated from the calculated T m (melting temperature) of the hybridized probe (see, e.g., Sambrook for a description of calculation of the T m ) . For radioactively-labeled DNA or RNA probes an example of stringent hybridization conditions is hybridization in a solution containing denatured probe and 5x SSC at 65°C for 8-24 hours followed by washes in 0.lx SSC, 0.1% SDS (sodium dodecyl sulfate) at 50-65°C. In general, the temperature and salt concentration are chosen so that the post hybridization wash occurs at a temperature that is about 5°C below the T M of the hybrid. Thus for a particular salt concentration the temperature may be selected that is 5°C below the T M or conversely, for a particular temperature, the salt concentration is chosen to provide a T M for the hybrid that is 5°C warmer than the wash temperature. Following stringent hybridization and washing, a probe that hybridizes to the KS-associated viral DNA but not to the non-KS associated viral DNA, as evidenced by the presence of a signal associated with the appropriate target and the absence of a signal from the non-target nucleic acids, is identified as specific for the KS associated virus. It is further appreciated that in determining probe specificity and in utilizing the method of this invention to detect KS-associated herpesvirus, a certain amount of background signal is typical and can easily be distinguished by one of skill from a specific signal. Two fold signal over background is acceptable. A preferred method for detecting the KS-associated herpesvirus is the use of PCR and/or dot blot hybridization. The presence or absence of an KS agent for detection or prognosis, or risk assessment for KS includes Southern transfers, solution hybridization or non-radioactive detection systems, all of which are well known to those of skill in the art. Hybridization is carried out using probes. Visualization of the hybridized portions allows the qualitative determination of the presence or absence of the causal agent. Similarly, a Northern transfer may be used for the detection of message in samples of RNA or reverse transcriptase PCR and cDNA can be detected by methods described above. This procedure is also well known in the art. See [81] incorporated by reference herein. An alternative means for determining the presence of the human herpesvirus is in si tu hybridization, or more recently, in situ polymerase chain reaction. In situ PCR is described in Neuvo et al . [71] , Intracellular localization of polymerase chain reaction (PCR) -amplified Hepatitis C cDNA; Bagasra et al . [10] , Detection of Human Immunodeficiency virus type 1 provirus in mononuclear cells by in situ polymerase chain reaction; and Heniford et al . [35] , Variation in cellular EGF receptor mRNA expression demonstrated by n situ reverse transcriptase polymerase chain reaction. In si tu hybridization assays are well known and are generally described in Methods Enzymol . [67] incorporated by reference herein. In an in si tu hybridization, cells are fixed to a solid support, typically a glass slide. The cells are then contacted with a hybridization solution at a moderate temperature to permit annealing of target-specific probes that are labelled. The probes are preferably labelled with radioisotopes or fluorescent reporters. The above described probes are also useful for in-situ hybridization or in order to locate tissues which express this gene, or for other hybridization assays for the presence of this gene or its MRNA in various biological tissues. In-situ hybridization is a sensitive localization method which is not dependent on expression of antigens or native vs. denatured conditions. Oligonucleotide (oligo) probes, synthetic oligonucleotide probes or riboprobes made from KSHV phagemids/plasmids, are relatively homogeneous reagents and successful hybridization conditions in tissue sections is readily transferable from one probe to another. Commercially synthesized oligonucleotide probes are prepared against the identified genes. These probes are chosen for length (45-65 mers) , high G-C content (50-70%) and are screened for uniqueness against other viral sequences in GenBank. Oligonucleotides are 3'end-labeled with [α- S]dATP to specific activities in the range of 1 x 10 10 dpm/ug using terminal deoxynucleotidyl transferase. Unincorporated labeled nucleotides are removed from the oligo probe by centrifugation through a Sephadex G-25 column or by elution from a Waters Sep Pak C-18 column. KS tissue embedded in OCT compound and snap frozen in freezing isopentane cooled with dry ice is cut at 6 μm intervals and thawed onto 3-aminopropyltriethoxysilane treated slides and allowed to air dry. The slides are then be fixed in 4% freshly prepared paraformaldehyde, rinsed in water. Formalin-fixed, paraffin embedded KS tissues cut at 6 μm and baked onto glass slides can also be used. The sections are then deparaffinized in xylenes and rehydrated through graded alcohols. Prehybridization in 20mM Tris Ph 7.5, 0.02% Denhardt' s solution, 10% dextran sulfate for 30 min at 37°C is followed by hybridization overnight in a solution of 50% formamide (v/v) , 10% dextran sulfate (w/v) , 20mM sodium phosphate (Ph 7.4) , 3X SSC, IX Denhardt's solution, 100 ug/ml salmon sperm DNA, 125 ug/ml yeast tRNA and the oligo probe (10 6 cpm/ml) at 42°C overnight. The slides are washed twice with 2X SSC and twice with IX SSC for 15 minutes each at room temperature and visualized by autoradiography. Briefly, sections are dehydrated through graded alcohols containing 0.3M ammonium acetate and air dried. The slides are dipped in Kodak NTB2 emulsion, exposed for days to weeks, developed, and counterstained with hematoxylin and eoxin. Alternative immunohistochemical protocols may be employed which are known to those skilled in the art. IV. Treatment of human herpesvirus-induced KS This invention provides a method of treating a subject with Kaposi's sarcoma, comprising administering to the subject an effective amount of the antisense molecule capable of hybridizing to the isolated DNA molecule under conditions such that the antisense molecule selectively enters a tumor cell of the subject, so as to treat the subject. This invention provides a method for treating a subject with Kaposi's sarcoma (KS) comprising administering to the subject having a human herpesvirus-associated KS a pharmaceutically effective amount of an antiviral agent in a pharmaceutically acceptable carrier, wherein the agent is effective to treat the subject with KS-associated human herpes virus. Further, this invention provides a method of prophylaxis or treatment for Kaposi's sarcoma (KS) by administering to a patient at risk for KS, an antibody that binds to the human herpesvirus in a pharmaceutically acceptable carrier. In one embodiment the antiviral drug is used to treat a subject with the DNA herpesvirus of the subject invention. The use of combinations of antiviral drugs and sequential treatments are useful for treatment of herpesvirus infections and will also be useful for the treatment of herpesvirus-induced KS. For example, Snoeck et al . [88] , found additive or synergistic effects against CMV when combining antiherpes drugs (e.g., combinations of zidovudine [3 ' -azido-3' - deoxythymidine, AZT] with HPMPC, ganciclovir, foscarnet or acyclovir or of HPMPC with other antivirals) . Similarly, in treatment of cytomegalovirus retinitis, induction with ganciclovir followed by maintenance with foscarnet has been suggested as a way to maximize efficacy while minimizing the adverse side effects of either treatment alone. An anti-herpetic composition that contains acyclovir and, e.g., 2-acetylpyridine-5- ( (2- pyridyla ino) thiocarbonyl) -thiocarbonohydrazone is described in U.S. Pat. 5,175,165 (assigned to Burroughs Wellcome Co.) . Combinations of TS- inhibitors and viral TK-inhibitors in antiherpetic medicines are disclosed in U.S. Pat. 5,137,724, assigned to Stichting Rega VZW. A synergistic inhibitory effect on EBV replication using certain ratios of combinations of HPMPC with AZT was reported by Lin et al . [56] . U.S. Patent Nos . 5,164,395 and 5,021,437 (Blumenkopf; Burroughs Wellcome) describe the use of a ribonucleotide reductase inhibitor (an acetylpyridine derivative) for treatment of herpes infections, including the use of the acetylpyridine derivative in combination with acyclovir. U.S. Patent No. 5,137,724 (Balzari et al . [11]) describes the use of thymilydate synthase inhibitors (e.g., 5-fluoro-uracil and 5- fluro-2' -deoxyuridine) in combination with compounds having viral thymidine kinase inhibiting activity. With the discovery of a disease causal agent for KS now identified, effective therapeutic or prophalactic protocols to alleviate or prevent the symptoms of herpes virus-associated KS can be formulated. Due to the viral nature of the disease, antiviral agents have application here for treatment, such as interferons, nucleoside analogues, ribavirin, amantadine, and pyrophosphate analogues of phosphonoacetic acid (foscarnet) (reviewed in Gorbach, S.L., et al . [28]) and the like. Immunological therapy will also be effective in many cases to manage and alleviate symptoms caused by the disease agents described here. Antiviral agents include agents or compositions that directly bind to viral products and interfere with disease progress; and, excludes agents that do not impact directly on viral multiplication or viral titer. Antiviral agents do not include immunoregulatory agents that do not directly affect viral titer or bind to viral products. Antiviral agents are effective if they inactivate the virus, otherwise inhibit its infectivity or multiplication, or alleviate the symptoms of KS. A. Antiviral Agents. The antiherpesvirus agents that will be useful for treating virus-induced KS can be grouped into broad classes based on their presumed modes of action. These classes include agents that act (i) by inhibition of viral DNA polymerase, (ii) by targeting other viral enzymes and proteins, (iii) by miscellaneous or incompletely understood mechanisms, or (iv) by binding a target nucleic acid (i.e., inhibitory nucleic acid therapeutics) . Antiviral agents may also be used in combination (i.e., together or sequentially) to achieve synergistic or additive effects or other benefits. Although it is convenient to group antiviral agents by their supposed mechanism of action, the applicants do not intend to be bound by any particular mechanism of antiviral action. Moreover, it will be understood by those of skill that an agent may act on more than one target in a virus or virus-infected cell or through more than one mechanism. i) Inhibitors of viral DNA polymerase Many antiherpesvirus agents in clinical use or in development today are nucleoside analogs believed to act through inhibition of viral DNA replication, especially through inhibition of viral DNA polymerase. These nucleoside analogs act as alternative substrates for the viral DNA polymerase or as competitive inhibitors of DNA polymerase substrates. Usually these agents are preferentially phosphorylated by viral thymidine kinase (TK) , if one is present, and/or have higher affinity for viral DNA polymerase than for the cellular DNA polymerases, resulting in selective antiviral activity. Where a nucleoside analogue is incorporated into the viral DNA, viral activity or reproduction may be affected in a variety of ways. For example, the analogue may act as a chain terminator, cause increased lability ( e . g. , susceptibility to breakage) of analogue-containing DNA, and/or impair the ability of the substituted DNA to act as template for transcription or replication ( see, e . g. , Balzarini et al . [11]) . It will be known to one of skill that, like many drugs, many of the agents useful for treatment of herpes virus infections are modified (i.e., "activated") by the host, host cell, or virus-infected host cell metabolic enzymes. For example, acyclovir is triphosphorylated to its active form, with the first phosphorylation being carried out by the herpes virus thymidine kinase, when present. Other examples are the reported conversion of the compound HOE 602 to ganciclovir in a three-step metabolic pathway (Winkler et al . [95]) and the phosphorylation of ganciclovir to its active form by, e.g., a CMV nucleotide kinase. It will be apparent to one of skill that the specific metabolic capabilities of a virus can affect the sensitivity of that virus to specific drugs, and is one factor in the choice of an antiviral drug. The mechanism of action of certain anti-herpesvirus agents is discussed in De Clercq [22] and in other references cited supra and infra, all of which are incorporated by reference herein. Anti-herpesvirus medications suitable for treating viral induced KS include, but are not limited to, nucleoside analogs including acyclic nucleoside p h o s p h o n a t e a n a l o g s ( e . g . , phosphonylmethoxyalkylpurines and -pyrimidines) , and cyclic nucleoside analogs. These include drugs such as: vidarabine (9-/3-D-arabinofuranosyladenine; adenine arabinoside, ara-A, Vira-A, Parke-Davis) ; 1-β-Ω- arabinofuranosyluracil (ara-U) ; 1- 3-D- arabinofuranosyl-cytosine (ara-C) ; HPMPC [(S)-l-[3- hydroxy-2- (phosphonylmethoxy) propyl] cytosine (e.g. , GS 504 Gilead Science)] and its cyclic form (cHPMPC) ; H P M P A [ ( S ) - 9 - ( 3 - h y d r o x y - 2 - phosphonylmethoxypropyl) adenine] and its cyclic form (cHPMPA) ; (S)-HPMPDAP [ ( S ) - 9 - ( 3 -hydroxy - 2 - phosphonylmethoxypropyl) -2, 6-diaminopurine] ; PMEDAP [9- (2-phosphonyl-methoxyethyl) -2,6-diaminopurine] ; HOE 602 [2-amino-9- (1, 3 -bis (isopropoxy) - 2 - propoxymethyl ) purine] ; PMEA [ 9 - ( 2 - phosphonylmethoxyethyl) adenine] ; bromovinyl- deoxyuridine (Burns and Sandford. [21]) ; 1-/3-D- arabinofuranosyl-E-5- (2-bromovinyl) -uridine or -2'- deoxyuridine; BVaraU (l-3-D-arabinofuranosyl-E-5- (2- bromovinyl) -uracil, brovavir, Bristol-Myers Squibb, Yamsa Shoyu) ; BVDU [ (E) -5- (2-bromovinyl) -2' - deoxyuridine, brivudin, e.g., Helpin] and its carbocyclic analogue (in which the sugar moiety is replaced by a cyclopentane ring) ; IVDU [(E) -5- (2- iodovinyl) -2' -deoxyuridine] and its carbocyclic analogue, C-IVDU (Balzarini et al. [11])] ; and 5- mercutithio analogs of 2' -deoxyuridine (Holliday, J., and Williams, M.V. [38]); acyclovir [9- ( [2- hydroxyethoxy]methyl)guanine; e.g., Zovirax (Burroughs Wellcome) ] ; penciclovir ( 9 - [4 - hydroxy- 2 - (hydroxymethyl) butyl] -guanine) ; ganciclovir [ (9- [1,3- dihydroxy-2 propoxymethyl] -guanine) e.g., Cymevene, Cytovene (Syntex) , DHPG (Stals et al . [89]] ; isopropylether derivatives of ganciclovir (see, e.g., Winkelmann et al. [94]) ; cygalovir; famciclovir [2- amino-9- (4-acetoxy-3- (acetoxymethyl) but -1-yl) purine (Smithkline Beecham) ] ; valacyclovir (Burroughs Wellcome) ; desciclovir [ (2-amino-9- (2- e t hoxyme t hyl ) pur ine ) ] and 2 - amino - 9 - ( 2 - hydroxyethoxymethyl) -9H-purine, prodrugs of acyclovir] ; CDG (carbocyclic 2' -deoxyguanosine) ; and purine nucleosides with the pentafuranosyl ring replaced by a cyclo butane ring (e.g., cyclobut-A [(+- ) -9- [ ljS , 2α , 3 jβ) -2 , 3 -bis (hydroxymethyl) - 1 - cyclobutyl] adenine] , cyclobut-G [ (+- ) -9- [lβ, 2α, 3β) - 2, 3-bis (hydroxymethyl) -1-cyclobutyl] guanine] , BHCG [ ( R ) - ( 1 α , 2 0 , 1 α ) - 9 - ( 2 , 3 - bis (hydroxymethyl) cyclobutyl] guanine] , and an active isomer of racemic BHCG, SQ 34,514 [1R-Iα, 2β, 3α) -2- amino-9- [2, 3-bis (hydroxymethyl) cyclobutyl] -6H-purin-6- one (see, Braitman et al. (1991) [20]] . Certain of these antiherpesviral agents are discussed in Gorach et al . [28] ; Saunders et al . [82] ; Yamanaka et al . , [96] ,- Greenspan et al . [29] , all of which are incorporated by reference herein. Triciribine and triciribine monophosphate are potent inhibitors against herpes viruses. (Ickes et al . [43] , incorporated by reference herein) , HIV-1 and HIV-2 (Kucera et al . [51] , incorporated by reference herein) and are additional nucleoside analogs that may be used to treat KS. An exemplary protocol for these agents is an intravenous injection of about 0.35 mg/ eter 2 (0.7 mg/kg) once weekly or every other week for at least two doses, preferably up to about four to eight weeks. Acyclovir and ganciclovir are of interest because of their accepted use in clinical settings. Acyclovir, an acyclic analogue of guanine, is phosphorylated by a herpesvirus thymidine kinase and undergoes further phosphorylation to be incorporated as a chain terminator by the viral DNA polymerase during viral replication. It has therapeutic activity against a broad range of herpesviruses, Herpes simplex Types 1 and 2, Varicella- Zoster, Cytomegalovirus, and Epstein-Barr Virus, and is used to treat disease such as herpes encephalitis, neonatal herpesvirus infections, chickenpox in immunocompromised hosts, herpes zoster recurrences, CMV retinitis, EBV infections, chronic fatigue syndrome, and hairy leukoplakia in AIDS patients. Exemplary intravenous dosages or oral dosages are 250 mg/kg/m 2 body surface area, every 8 hours for 7 days, or maintenance doses of 200-400 mg IV or orally twice a day to suppress recurrence. Ganciclovir has been shown to be more active than acyclovir against some herpesviruses. See, e . g. , Oren and Soble [73] . Treatment protocols for ganciclovir are 5 mg/kg twice a day IV or 2.5 mg/kg three times a day for 10-14 days. Maintenance doses are 5-6 mg/kg for 5-7 days. Also of interest is HPMPC. HPMPC is reported to be more active than either acyclovir or ganciclovir in the chemotherapy and prophylaxis of various HSV-1, HSV-2, TK- HSV, VZV or CMV infections in animal models ( [22] , supra) . Nucleoside analogs such as BVaraU are potent inhibitors of HSV-1, EBV, and VZV that have greater activity than acyclovir in animal models of encephalitis. FIAC (fluroidoarbinosyl cytosine) and its related fluroethyl and iodo compounds ( e . g. , FEAU, FIAU) have potent selective activity against herpesviruses, and HPMPA ( (S) -1- ( [3-hydroxy-2- phosphorylmethoxy] propyl) adenine) has been demonstrated to be more potent against HSV and CMV than acyclovir or ganciclovir and are of choice in advanced cases of KS . Cladribine (2- chlorodeoxyadenosine) is another nucleoside analogue known as a highly specific antilymphocyte agent (i.e., a immunosuppressive drug) . Other useful antiviral agents include: 5-thien-2-yl- 2' -deoxyuridine derivatives, e.g., BTDU [5-5(5- bromothien-2-yl) -2' -deoxyuridine] and CTDU [b- (5- chlorothien-2-yl) -2' -deoxyuridine] ; and OXT-A [9- (2- deoxy-2-hydroxymethyl-S-D-erythro-oxetanosyl) adenine] and OXT-G [9- (2-deoxy-2-hydroxymethyl-β-D-erythro- oxetanosyl) guanine] . Although OXT-G is believed to act by inhibiting viral DNA synthesis its mechanism of action has not yet been elucidated. These and other compounds are described in Andrei et al . [5] which is incorporated by reference herein. Additional antiviral purine derivatives useful in treating herpesvirus infections are disclosed in US Pat. 5,108,994 (assigned to Beecham Group P.L.C.) . 6- Methoxypurine arabinoside (ara-M; Burroughs Wellcome) is a potent inhibitor of varicella-zoster virus, and will be useful for treatment of KS. Certain thymidine analogs [e.g., idoxuridine (5-ido- 2' -deoxyuridine) ] and triflurothymidine) have antiherpes viral activity, but due to their systemic toxicity, are largely used for topical herpesviral infections, including HSV stromal keratitis and uveitis, and are not preferred here unless other options are ruled out. Other useful antiviral agents that have demonstrated antiherpes viral activity include foscarnet sodium (trisodium phosphonoformate, PFA, Foscavir (Astra) ) and phosphonoacetic acid (PAA) . Foscarnet is an inorganic pyrophosphate analogue that acts by competitively blocking the pyrophosphate-binding site of DNA polymerase. These agents which block DNA polymerase directly without processing by viral thymidine kinase. Foscarnet is reported to be less toxic than PAA. ii) Agents that target viral proteins other than DNA polymerase or other viral functions . Although applicants do not intend to be bound by a particular mechanism of antiviral action, the antiherpes-virus agents described above are believed to act through inhibition of viral DNA polymerase. However, viral replication requires not only the replication of the viral nucleic acid but also the production of viral proteins and other essential components. Accordingly, the present invention contemplates treatment of KS by the inhibition of viral proliferation by targeting viral proteins other than DNA polymerase (e.g., by inhibition of their synthesis or activity, or destruction of viral proteins after their synthesis) . For example, administration of agents that inhibit a viral serine protease, e.g., such as one important in development of the viral capsid will be useful in treatment of viral induced KS. Other viral enzyme targets include: OMP decarboxylase inhibitors (a target of, e.g., parazofurin) , CTP synthetase inhibitors (targets of, e.g., cyclopentenylcytosine) , IMP dehydrogenase, ribonucleotide reductase (a target of, e.g., carboxyl- containing N-alkyldipeptides as described in U.S. Patent No. 5,110,799 (Tolman et al. , Merck) ) , thymidine kinase (a target of, e.g., l- [2- (hydroxymethyl) cycloalkylmethyl] - 5-substituted -uracils and -guanines as described in, e.g., U.S. Patent Nos. 4,863,927 and 4,782,062 (Tolman et al . ; Merck)) as well as other enzymes. It will be apparent to one of ordinary skill in the art that there are additional viral proteins, both characterized and as yet to be discovered, that can serve as target for antiviral agents. iv) Other agents and modes of antiviral action. Kutapressin is a liver derivative available from Schwarz Parma of Milwaukee, Wisconsin in an injectable form of 25 mg/ml . The recommended dosage for herpesviruses is from 200 to 25 mg/ml per day for an average adult of 150 pounds. Poly(I) Poly(C 12 U) , an accepted antiviral drug known as Ampligen from HEM Pharmaceuticals of Rockville, MD has been shown to inhibit herpesviruses and is another antiviral agent suitable for treating KS. Intravenous injection is the preferred route of administration. Dosages from about 100 to 600 mg/m 2 are administered two to three times weekly to adults averaging 150 pounds. It is best to administer at least 200 mg/m 2 per week. Other antiviral agents reported to show activity against herpes viruses ( e . g. , varicella zoster and herpes simplex) and will be useful for the treatment of herpesvirus-induced KS include mappicine ketone (SmithKline Beecham) ; Compounds A, 79296 and A, 73209 (Abbott) for varicella zoster, and Compound 882C87 (Burroughs Wellcome) [see, The Pink Sheet 55(20) May 17, 1993] . Interferon is known inhibit replication of herpes viruses. See [73] , supra . Interferon has known toxicity problems and it is expected that second generation derivatives will soon be available that will retain interferon' s antiviral properties but have reduced side affects. It is also contemplated that herpes virus-induced KS may be treated by administering a herpesvirus reactivating agent to induce reactivation of the latent virus. Preferably the reactivation is combined with simultaneous or sequential administration of an anti-herpesvirus agent. Controlled reactivation over a short period of time or reactivation in the presence of an antiviral agent is believed to minimize the adverse effects of certain herpesvirus infections (e.g., as discussed in PCT Application WO 93/04683) . Reactivating agents include agents such as estrogen, phorbol esters, forskolin and / S-adrenergic blocking agents. Agents useful for treatment of herpesvirus infections and for treatment of herpesvirus-induced KS are described in numerous U.S. Patents. For example, ganciclovir is an example of a antiviral guanine acyclic nucleotide of the type described in US Patent Nos. 4,355,032 and 4,603,219. Acyclovir is an example of a class of antiviral purine d e r i v a t i v e s , i n c l u d i n g 9 - ( 2 - hydroxyethylmethyl) adenine, of the type described in U.S. Pat. Nos. 4,287,188, 4,294,831 and 4,199,574. Brivudin is an example of an antiviral deoxyuridine derivative of the type described in US Patent No. 4,424,211. Vidarabine is an example of an antiviral purine nucleoside of the type described in British Pat. 1,159,290. Brovavir is an example of an antiviral deoxyuridine derivative of the type described in US Patent Nos. 4,542,210 and 4,386,076. BHCG is an example of an antiviral carbocyclic nucleoside analogue of the type described in US Patent Nos. 5,153,352, 5,034,394 and 5,126,345. HPMPC is an example of an antiviral phosphonyl methoxyalkyl derivative with of the type described in US Patent No. 5,142,051. CDG (Carbocyclic 2' -deoxyguanosine) is an example of an antiviral carbocyclic nucleoside analogue of the type described in US Patent Nos. 4,543,255, 4,855,466, and 4, 894,458. Foscarnet is described in US Patent No. 4,339,445. Trifluridine and its corresponding ribonucleoside is described in US Patent No. 3,201,387. U.S. Patent No. 5,321,030 (Kaddurah-Daouk et al . ; Amira) describes the use of creatine analogs as antiherpes viral agents. U.S. Patent No. 5,306,722 (Kim et al . ; Bristol-Meyers Squibb) describes thymidine kinase inhibitors useful for treating HSV infections and for inhibiting herpes thymidine kinase. Other antiherpesvirus compositions are described in U.S. Patent Nos. 5,286,649 and 5,098,708 (Konishi et al . , Bristol-Meyers Squibb) and 5,175,165 (Blumenkopf et al . ; Burroughs Wellcome) . U.S. Patent No. 4,880,820 (Ashton et al . ; Merck) describes the antiherpes virus agent (S) -9- (2, 3-dihydroxy-1- propoxymethyl) guanine. U.S. Patent No. 4,708,935 (Suhadolnik et al . ; Research Corporation) describes a 3 ' -deoxyadenosine compound effective in inhibiting HSV and EBV. U.S. Patent No. 4,386,076 (Machida et al . ; Yamasa Shoyu Kabushiki K a i s h a ) d e s c r i b e s u s e o f (E) -5- (2-halogenovinyl) -arabinofuranosyluracil as an antiherpesvirus agent. U.S. Patent No. 4,340,599 (Lieb et al . ; Bayer Aktiengesellschaft) describes phosphonohydroxyacetic acid derivatives useful as antiherpes agents. U.S. Patent Nos. 4,093,715 and 4,093,716 (Lin et al . Research Corporation) describe 5 ' -amino- 5 ' -deoxythymidine and 5-iodo-5' - amino-2' , 5' -dideoxycytidine as potent inhibitors of herpes simplex virus. U.S. Patent No. 4,069,382 (Baker et al . ; Parke, Davis & Company) describes 9- (5-O-Acyl-beta-D-arabinofuranosyl) adenine compounds useful as antiviral agents. U.S. Patent No. 3,927,216 (Witkowski et al.) describes the use of l , 2 , 4 - t r i a z o l e - 3 - c a rboxam i de and 1, 2 ,4-triazole-3-thiocarboxamide for inhibiting herpes virus infections. Patent No. 5,179,093 (Afonso et al . , Schering) describes quinoline-2, 4-dione derivatives active against herpes simplex virus 1 and 2 , cytomegalovirus and Epstein Barr virus . v) Inhibitory nucleic acid therapeutics Also contemplated here are inhibitory nucleic acid therapeutics which can inhibit the activity of herpesviruses in patients with KS. Inhibitory nucleic acids may be single-stranded nucleic acids, which can specifically bind to a complementary nucleic acid sequence. By binding to the appropriate target sequence, an RNA-RNA, a DNA-DNA, or RNA-DNA duplex or triplex is formed. These nucleic acids are often termed "antisense" because they are usually complementary to the sense or coding strand of the gene, although recently approaches for use of "sense" nucleic acids have also been developed. The term "inhibitory nucleic acids" as used herein, refers to both "sense" and "antisense" nucleic acids. By binding to the target nucleic acid, the inhibitory nucleic acid can inhibit the function of the target nucleic acid. This could, for example, be a result of blocking DNA transcription, processing or poly(A) addition to mRNA, DNA replication, translation, or promoting inhibitory mechanisms of the cells, such as promoting RNA degradation. Inhibitory nucleic acid methods therefore encompass a number of different approaches to altering expression of herpesvirus genes. These different types of inhibitory nucleic acid technology are described in Helene, C. and Toulme, J. [34] , which is hereby incorporated by reference and is referred to hereinafter as "Helene and Toulme. ' • In brief, inhibitory nucleic acid therapy approaches can be classified into those that target DNA sequences, those that target RNA sequences (including pre-mRNA and mRNA) , those that target proteins (sense strand approaches) , and those that cause cleavage or chemical modification of the target nucleic acids. Approaches targeting DNA fall into several categories. Nucleic acids can be designed to bind to the major groove of the duplex DNA to form a triple helical or "triplex" structure. Alternatively, inhibitory nucleic acids are designed to bind to regions of single stranded DNA resulting from the opening of the duplex DNA during replication or transcription. See Helene and Toulme. More commonly, inhibitory nucleic acids are designed to bind to mRNA or mRNA precursors. Inhibitory nucleic acids are used to prevent maturation of pre- mRNA. Inhibitory nucleic acids may be designed to interfere with RNA processing, splicing or translation. The inhibitory nucleic acids can be targeted to mRNA. In this approach, the inhibitory nucleic acids are designed to specifically block translation of the encoded protein. Using this approach, the inhibitory nucleic acid can be used to selectively suppress certain cellular functions by inhibition of translation of mRNA encoding critical proteins. For example, an inhibitory nucleic acid complementary to regions of c-myc mRNA inhibits c-myc protein expression in a human promyelocytic leukemia cell line, HL60, which overexpresses the c-myc proto- oncogene. See Wickstrom E.L., et al . [93] and Harel-Bellan, A., et al . [31A] . As described in Helene and Toulme, inhibitory nucleic acids targeting mRNA have been shown to work by several different mechanisms to inhibit translation of the encoded protein (s) . The inhibitory nucleic acids introduced into the cell can also encompass the "sense" strand of the gene or mRNA to trap or compete for the enzymes or binding proteins involved in mRNA translation. See Helene and Toulme. Lastly, the inhibitory nucleic acids can be used to induce chemical inactivation or cleavage of the target genes or mRNA. Chemical inactivation can occur by the induction of crosslinks between the inhibitory nucleic acid and the target nucleic acid within the cell. Other chemical modifications of the target nucleic acids induced by appropriately derivatized inhibitory nucleic acids may also be used. Cleavage, and therefore inactivation, of the target nucleic acids may be effected by attaching a substituent to the inhibitory nucleic acid which can be activated to induce cleavage reactions. The substituent can be one that affects either chemical, or enzymatic cleavage. Alternatively, cleavage can be induced by the use of ribozymes or catalytic RNA. In this approach, the inhibitory nucleic acids would comprise either naturally occurring RNA (ribozymes) or synthetic nucleic acids with catalytic activity. The targeting of inhibitory nucleic acids to specific cells of the immune system by conjugation with targeting moieties binding receptors on the surface of these cells can be used for all of the above forms of inhibitory nucleic acid therapy. This invention encompasses all of the forms of inhibitory nucleic acid therapy as described above and as described in Helene and Toulme. This invention relates to the targeting of inhibitory nucleic acids to sequences the human herpesvirus of the invention for use in treating KS. An example of an antiherpes virus inhibitory nucleic acid is ISIS 2922 (ISIS Pharmaceuticals) which has activity against CMV [ see, Biotechnology News 14(14) p. 5] . A problem associated with inhibitory nucleic acid therapy is the effective delivery of the inhibitory nucleic acid to the target cell in vivo and the subsequent internalization of the inhibitory nucleic acid by that cell. This can be accomplished by linking the inhibitory nucleic acid to a targeting moiety to form a conjugate that binds to a specific receptor on the surface of the target infected cell, and which is internalized after binding. iii) Administration The subjects to be treated or whose tissue may be used herein may be a mammal, or more specifically a human, horse, pig, rabbit, dog, monkey, or rodent. In the preferred embodiment the subject is a human. The compositions are administered in a manner compatible with the dosage formulation, and in a therapeutically effective amount. Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner and are peculiar to each subject. Suitable regimes for initial administration and booster shots are also variable, but are typified by an initial administration followed by repeated doses at one or more hour intervals by a subsequent injection or other administration. As used herein administration means a method of administering to a subject. Such methods are well known to those skilled in the art and include, but are not limited to, administration topically, parenterally, orally, intravenously, intramuscularly, subcutaneously or by aerosol. Administration of the agent may be effected continuously or intermittently such that the therapeutic agent in the patient is effective to treat a subject with Kaposi's sarcoma or a subject infected with a DNA virus associated with Kaposi's sarcoma. The antiviral compositions for treating herpesvirus- induced KS are preferably administered to human patients via oral, intravenous or parenteral administrations and other systemic forms. Those of skill in the art will understand appropriate administration protocol for the individual compositions to be employed by the physician. The pharmaceutical formulations or compositions of this invention may be in the dosage form of solid, semi-solid, or liquid such as, e . g. , suspensions, aerosols or the like. Preferably the compositions are administered in unit dosage forms suitable for single administration of precise dosage amounts . The compositions may also include, depending on the formulation desired, pharmaceutically-acceptable, non- toxic carriers or diluents, which are defined as vehicles commonly used to formulate pharmaceutical compositions for animal or human administration. The diluent is selected so as not to affect the biological activity of the combination. Examples of such diluents are distilled water, physiological saline, Ringer's solution, dextrose solution, and Hank's solution. In addition, the pharmaceutical composition or formulation may also include other carriers, adjuvants; or nontoxic, nontherapeutic, nonimmunogenic stabilizers and the like. Effective amounts of such diluent or carrier are those amounts which are effective to obtain a pharmaceutically acceptable formulation in terms of solubility of components, or biological activity, etc. V. Immunological Approaches to Therapy. Having identified a primary causal agent of KS in humans as a novel human herpesvirus, there are immunosuppressive therapies that can modulate the immunologic dysfunction that arises from the presence of viral infected tissue. In particular, agents that block the immunological attack of the viral infected cells will ameliorate the symptoms of KS and/or reduce the disease progress. Such therapies include antibodies that specifically block the targeting of viral infected cells. Such agents include antibodies which bind to cytokines that upregulate the immune system to target viral infected cells. The antibody may be administered to a patient either singly or in a cocktail containing two or more antibodies, other therapeutic agents, compositions, or the like, including, but not limited to, immuno¬ suppressive agents, potentiators and side-effect re¬ lieving agents. Of particular interest are immuno- suppressive agents useful in suppressing allergic re¬ actions of a host. Immunosuppressive agents of inter¬ est include prednisone, prednisolone, DECADRON (Merck, Sharp & Dohme, West Point, PA) , cyclophosphamide, cyclosporine, 6-mercaptopurine, methotrexate, azathioprine and i.v. gamma globulin or their combination. Potentiators of interest include monensin, ammonium chloride and chloroquine. All of these agents are administered in generally accepted efficacious dose ranges such as those disclosed in the Physician Desk Reference, 41st Ed. (1987) , Publisher Edward R. Barnhart, New Jersey. Immune globulin from persons previously infected with human herpesviruses or related viruses can be obtained using standard techniques. Appropriate titers of antibodies are known for this therapy and are readily applied to the treatment of KS. Immune globulin can be administered via parenteral injection or by intrathecal shunt. In brief, immune globulin preparations may be obtained from individual donors who are screened for antibodies to the KS-associated human herpesvirus, and plasmas from high-titered donors are pooled. Alternatively, plasmas from donors are pooled and then tested for antibodies to the human herpesvirus of the invention; high-titered pools are then selected for use in KS patients. Antibodies may be formulated into an injectable preparation. Parenteral formulations are known and are suitable for use in the invention, preferably for i.m. or i.v. administration. The formulations containing therapeutically effective amounts of antibodies or immunotoxins are either sterile liquid solutions, liquid suspensions or lyophilized versions and optionally contain stabilizers or excipients. Lyophilized compositions are reconstituted with suitable diluents, e . g. , water for injection, saline, 0.3% glycine and the like, at a level of about from .01 mg/kg of host body weight to 10 mg/kg where appropriate. Typically, the pharmaceutical compositions containing the antibodies or immunotoxins will be administered in a therapeutically effective dose in a range of from about .01 mg/kg to about 5 mg/kg of the treated mammal. A preferred therapeutically effective dose of the pharmaceutical composition containing antibody or immunotoxin will be in a range of from about 0.01 mg/kg to about 0.5 mg/kg body weight of the treated mammal administered over several days to two weeks by daily intravenous infusion, each given over a one hour period, in a sequential patient dose-escalation regimen. Antibody may be administered systemically by injection i. ., subcutaneously or intraperitoneally or directly into KS lesions. The dose will be dependent upon the properties of the antibody or immunotoxin employed, e.g., its activity and biological half-life, the concentration of antibody in the formulation, the site and rate of dosage, the clinical tolerance of the patient involved, the disease afflicting the patient and the like as is well within the skill of the physician. The antibody of the present invention may be administered in solution. The pH of the solution should be in the range of pH 5 to 9.5, preferably pH 6.5 to 7.5. The antibody or derivatives thereof should be in a solution having a suitable pharmaceutically acceptable buffer such as phosphate, tris (hydroxymethyl) aminomethane-HCl or citrate and the like. Buffer concentrations should be in the range of 1 to 100 mM. The solution of antibody may also contain a salt, such as sodium chloride or potassium chloride in a concentration of 50 to 150 mM. An effective amount of a stabilizing agent such as an albumin, a globulin, a gelatin, a protamine or a salt of protamine may also be included and may be added to a solution containing antibody or immunotoxin or to the composition from which the solution is prepared. Systemic administration of antibody is made daily, generally by intramuscular injection, although intravascular infusion is acceptable. Administration may also be intranasal or by other nonparenteral routes. Antibody or immunotoxin may also be administered via microspheres, liposomes or other microparticulate delivery systems placed in certain tissues including blood. In therapeutic applications, the dosages of compounds used in accordance with the invention vary depending on the class of compound and the condition being treated. The age, weight, and clinical condition of the recipient patient; and the experience and judgment of the clinician or practitioner administering the therapy are among the factors affecting the selected dosage. For example, the dosage of an immunoglobulin can range from about 0.1 milligram per kilogram of body weight per day to about 10 mg/kg per day for polyclonal antibodies and about 5% to about 20% of that amount for monoclonal antibodies. In such a case, the immunoglobulin can be administered once daily as an intravenous infusion. Preferably, the dosage is repeated daily until either a therapeutic result is achieved or until side effects warrant discontinuation of therapy. Generally, the dose should be sufficient to treat or ameliorate symptoms or signs of KS without producing unacceptable toxicity to the patient. An effective amount of the compound is that which provides either subjective relief of a symptom(s) or an objectively identifiable improvement as noted by the clinician or other qualified observer. The dosing range varies with the compound used, the route of administration and the potency of the particular compound. VI . Vaccines and Prophylaxis for KS This invention provides a method of vaccinating a subject against Kaposi's sarcoma, comprising administering to the subject an effective amount of the peptide or polypeptide encoded by the isolated DNA molecule, and a suitable acceptable carrier, thereby vaccinating the subject. In one embodiment naked DNA is administering to the subject in an effective amount to vaccinate a subject against Kaposi's sarcoma. This invention provides a method of immunizing a subject against a disease caused by the DNA herpesvirus associated with Kaposi's sarcoma which comprises administering to the subject an effective immunizing dose of the isolated herpesvirus vaccine. A. Vaccines The invention also provides substances suitable for use as vaccines for the prevention of KS and methods for administering them. The vaccines are directed against the human herpesvirus of the invention, and most preferably comprise antigen obtained from the KS- associated human herpesvirus. Vaccines can be made recombinantly. Typically, a vaccine will include from about 1 to about 50 micrograms of antigen or antigenic protein or peptide. More preferably, the amount of protein is from about 15 to about 45 micrograms. Typically, the vaccine is formulated so that a dose includes about 0.5 milliliters. The vaccine may be administered by any route known in the art. Preferably, the route is parenteral. More preferably, it is subcutaneous or intramuscular. There are a number of strategies for amplifying an antigen's effectiveness, particularly as related to the art of vaccines. For example, cyclization or circularization of a peptide can increase the peptide' s antigenic and immunogenic potency. See U.S. Pat. No. 5,001,049 which is incorporated by reference herein. More conventionally, an antigen can be conjugated to a suitable carrier, usually a protein molecule. This procedure has several facets. It can allow multiple copies of an antigen, such as a peptide, to be conjugated to a single larger carrier molecule. Additionally, the carrier may possess properties which facilitate transport, binding, absorption or transfer of the antigen. For parenteral administration, such as subcutaneous injection, examples of suitable carriers are the tetanus toxoid, the diphtheria toxoid, serum albumin and lamprey, or keyhole limpet, hemocyanin because they provide the resultant conjugate with minimum genetic restriction. Conjugates including these universal carriers can function as T cell clone activators in individuals having very different gene sets. The conjugation between a peptide and a carrier can be accomplished using one of the methods known in the art. Specifically, the conjugation can use bifunctional cross-linkers as binding agents as detailed, for example, by Means and Feeney, "A recent review of protein modification techniques," Biocon jugate Chem. 1:2-12 (1990) . Vaccines against a number of the Herpesviruses have been successfully developed. Vaccines against Varicella-Zoster Virus using a live attenuated Oka strain is effective in preventing herpes zoster in the elderly, and in preventing chickenpox in both immunocompromised and normal children (Hardy, I., et al . [30]; Hardy, I. et al . [31]; Levin, M.J. et al . [54] ; Gershon, A.A. [26] . Vaccines against Herpes simplex Types 1 and 2 are also commercially available with some success in protection against primary disease, but have been less successful in preventing the establishment of latent infection in sensory ganglia (Roizman, B. [78]; Skinner, G.R. et al . [87]). Vaccines against the human herpesvirus can be made by isolating extracellular viral particles from infected cell cultures, inactivating the virus with formaldehyde followed by ultracentrifugation to concentrate the viral particles and remove the formaldehyde, and immunizing individuals with 2 or 3 doses containing 1 x 10 9 virus particles (Skinner, G.R. et al . [86]). Alternatively, envelope glycoproteins can be expressed in E. coli or transfected into stable mammalian cell lines, the proteins can be purified and used for vaccination (Lasky, L.A. [53] ) . MHC - binding peptides from cells infected with the human herpesvirus can be identified for vaccine candidates per the methodology of [61], supra . The antigen may be combined or mixed with various solutions and other compounds as is known in the art. For example, it may be administered in water, saline or buffered vehicles with or without various adjuvants or immunodiluting agents. Examples of such adjuvants or agents include aluminum hydroxide, aluminum phosphate, aluminum potassium sulfate (alum) , beryllium sulfate, silica, kaolin, carbon, water-in- oil emulsions, oil-in-water emulsions, muramyl dipeptide, bacterial endotoxin, lipid X, Corynebacterium parvum (Propionibacterium acnes) , Bordetella pertussis, polyribonucleotides, sodium alginate, lanolin, lysolecithin, vitamin A, saponin, liposomes, levamisole, DEAE-dextran, blocked copolymers or other synthetic adjuvants. Such adjuvants are available commercially from various sources, for example, Merck Adjuvant 65 (Merck and Company, Inc., Rahway, N.J.) or Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, Michigan) . Other suitable adjuvants are Amphigen (oil-in-water) , Alhydrogel (aluminum hydroxide), or a mixture of Amphigen and Alhydrogel. Only aluminum is approved for human use. The proportion of antigen and adjuvant can be varied over a broad range so long as both are present in effective amounts. For example, aluminum hydroxide can be present in an amount of about 0.5% of the vaccine mixture (A1 2 0 3 basis) . On a per-dose basis, the amount of the antigen can range from about 0.1 μg to about 100 μg protein per patient. A preferable range is from about 1 μg to about 50 μg per dose. A more preferred range is about 15 μg to about 45 μg. A suitable dose size is about 0.5 ml. Accordingly, a dose for intramuscular injection, for example, would comprise 0.5 ml containing 45 μg of antigen in admixture with 0.5% aluminum hydroxide. After formulation, the vaccine may be incorporated into a sterile container which is then sealed and stored at a low temperature, for example 4°C, or it may be freeze-dried. Lyophilization permits long-term storage in a stabilized form. The vaccines may be administered by any conventional method for the administration of vaccines including oral and parenteral (e.g., subcutaneous or intramuscular) injection. Intramuscular administration is preferred. The treatment may consist of a single dose of vaccine or a plurality of doses over a period of time. It is preferred that the dose be given to a human patient within the first 8 months of life. The antigen of the invention can be combined with appropriate doses of compounds including influenza antigens, such as influenza type A antigens. Also, the antigen could be a component of a recombinant vaccine which could be adaptable for oral administration. Vaccines of the invention may be combined with other vaccines for other diseases to produce multivalent vaccines. A pharmaceutically effective amount of the antigen can be employed with a pharmaceutically acceptable carrier such as a protein or diluent useful for the vaccination of mammals, particularly humans. Other vaccines may be prepared according to methods well-known to those skilled in the art. Those of skill will readily recognize that it is only necessary to expose a mammal to appropriate epitopes in order to elicit effective immunoprotection. The epitopes are typically segments of amino acids which are a small portion of the whole protein. Using recombinant genetics, it is routine to alter a natural protein's primary structure to create derivatives embracing epitopes that are identical to or substantially the same as (immunologically equivalent to) the naturally occurring epitopes. Such derivatives may include peptide fragments, amino acid substitutions, amino acid deletions and amino acid additions of the amino acid sequence for the viral proteins from the human herpesvirus. For example, it is known in the protein art that certain amino acid residues can be substituted with amino acids of similar size and polarity without an undue effect upon the biological activity of the protein. The human herpesvirus proteins have significant tertiary structure and the epitopes are usually conformational. Thus, modifications should generally preserve conformation to produce a protective immune response. B. Antibody Prophylaxis Therapeutic, intravenous, polyclonal or monoclonal antibodies can been used as a mode of passive im unotherapy of herpesviral diseases including perinatal varicella and CMV. Immune globulin from persons previously infected with the human herpesvirus and bearing a suitably high titer of antibodies against the virus can be given in combination with antiviral agents (e.g. ganciclovir) , or in combination with other modes of immunotherapy that are currently being evaluated for the treatment of KS, which are targeted to modulating the immune response (i.e. treatment with copolymer-1, antiidiotypic monoclonal antibodies, T cell "vaccination"). Antibodies to human herpesvirus can be administered to the patient as described herein. Antibodies specific for an epitope expressed on cells infected with the human herpesvirus are preferred and can be obtained as described above. A polypeptide, analog or active fragment can be formulated into the therapeutic composition as neutralized pharmaceutically acceptable salt forms. Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the polypeptide or antibody molecule) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed from the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like. C. Monitoring therapeutic efficacy This invention provides a method for monitoring the therapeutic efficacy of treatment for Kaposi's sarcoma, which comprises determining in a first sample from a subject with Kaposi's sarcoma the presence of the isolated DNA molecule, administering to the subject a therapeutic amount of an agent such that the agent is contacted to the cell in a sample, determining after a suitable period of time the amount of the isolated DNA molecule in the second sample from the treated subject, and comparing the amount of isolated DNA molecule determined in the first sample with the amount determined in the second sample, a difference indicating the effectiveness of the agent, thereby monitoring the therapeutic efficacy of treatment for Kaposi's sarcoma. As defined herein "amount" is viral load or copy number. Methods of determining viral load or copy number are known to those skilled in the art. VII . Screening Assays For Pharmaceutical Agents of Interest in Alleviating the Symptoms of KS. Since an agent involved in the causation or progression of KS has been identified and described here, assays directed to identifying potential pharmaceutical agents that inhibit the biological activity of the agent are possible. KS drug screening assays which determine whether or not a drug has activity against the virus described herein are contemplated in this invention. Such assays comprise incubating a compound to be evaluated for use in KS treatment with cells which express the KS associated human herpesvirus proteins or peptides and determining therefrom the effect of the compound on the activity of such agent. I_n vitro assays in which the virus is maintained in suitable cell culture are preferred, though in vivo animal models would also be effective. Compounds with activity against the agent of interest or peptides from such agent can be screened in in vitro as well as in vivo assay systems. in vitro assays include infecting peripheral blood leukocytes or susceptible T cell lines such as MT-4 with the agent of interest in the presence of varying concentrations of compounds targeted against viral replication, including nucleoside analogs, chain terminators, antisense oligonucleotides and random polypeptides (Asada, H. et al . [7]; Kikuta et al . [48] both incorporated by reference herein) . Infected cultures and their supernatants can be assayed for the total amount of virus including the presence of the viral genome by quantitative PCR, by dot blot assays, or by using immunologic methods. For example, a culture of susceptible cells could be infected with the human herpesvirus in the presence of various concentrations of drug, fixed on slides after a period of days, and examined for viral antigen by indirect immunofluorescence with monoclonal antibodies to viral peptides ([48], supra . Alternatively, chemically adhered MT-4 cell monolayers can be used for an infectious agent assay using indirect immunofluorescent antibody staining to search for focus reduction (Higashi, K. et al . [36], incorporated by reference herein) . As an alternative to whole cell in vitro assays, purified enzymes isolated from the human herpesvirus can be used as targets for rational drug design to determine the effect of the potential drug on enzyme activity, such as thymidine phosphotransferase or DNA polymerase. The genes for these two enzymes are provided herein. A measure of enzyme activity indicates effect on the agent itself. Drug screens using herpes viral products are known and have been previously described in EP 0514830 (herpes proteases) and WO 94/04920 (U L 13 gene product) . This invention provides an assay for screening anti-KS chemotherapeutics. Infected cells can be incubated in the presence of a chemical agent that is a potential chemotherapeutic against KS (e.g. acyclo-guanosine) . The level of virus in the cells is then determined after several days by IFA for antigens or Southern blotting for viral genome or Northern blotting for MRNA and compared to control cells. This assay can quickly screen large numbers of chemical compounds that may be useful against KS. Further, this invention provides an assay system that is employed to identify drugs or other molecules capable of binding to the DNA molecule or proteins, either in the cytoplasm or in the nucleus, thereby inhibiting or potentiating transcriptional activity. Such assay would be useful in the development of drugs that would be specific against particular cellular activity, or that would potentiate such activity, in time or in level of activity. This invention is further illustrated in the Experimental Details section which follows. This section is set forth to aid in an understanding of the invention but is not intended to, and should not be construed to, limit in any way the invention as set forth in the claims which follow thereafter. EXPERIMENTAL DETAILS SECTION I: Experiment 1; Representational difference analysis (RDA) to identify and characterize unique DNA sequences in KS tissue To search for foreign DNA sequences belonging to an infectious agent in AIDS-KS, representational difference analysis (RDA) was employed to identify and characterize unique DNA sequences in KS tissue that are either absent or present in low copy number in non-diseased tissue obtained from the same patient [58] . This method can detect adenovirus genome added in single copy to human DNA but has not been used to identify previously uncultured infectious agents. RDA is performed by making simplified "representations" of genomes from diseased and normal tissues from the same individual through PCR amplification of short restriction fragments. The DNA representation from the diseased tissue is then ligated to a priming sequence and hybridized to an excess of unligated, normal tissue DNA representation. Only unique sequences found in the diseased tissue have priming sequences ou both DNA strands and are preferentially amplified during subsequent rounds of PCR amplification. This process can be repeated using different ligated priming sequences to enrich the sample for unique DNA sequences that are only found in the tissue of interest. DNA (10 μg) extracted from both the KS lesion and unaffected tissue were separately digested to completion with Bam HI (20 units/μg) at 37° C for 2 hours and 2 μg of digestion fragments were ligated to NBaml2 and NBam24 priming sequences [primer sequences described in 58] . Thirty cycles of PCR amplification were performed to amplify "representations" of both genomes . After construction of the genomic representations, KS tester amplicons between 150 and 1500 bp were isolated from an agarose gel and NBam priming sequences were removed by digestion with Bam HI . To search for unique DNA sequences not found in non-KS driver DNA, a second set of priming sequences (JBaml2 and JBam24) was ligated onto only the KS tester DNA amplicons (Figure 1, lane 1) . 0.2 μg of ligated KS lesion amplicons were hybridized to 20 μg of unligated, normal tissue representational amplicons. An aliquot of the hybridization product was then subjected to 10 cycles of PCR amplification using JBam24, followed by mung bean nuclease digestion. An aliquot of the mung bean-treated difference product was then subjected to 15 more cycles of PCR with the JBam24 primer (Figure 1, lane 2) . Amplification products were redigested with Bam HI and 200 ng of the digested product was ligated to RBaml2 and RBam24 primer sets for a second round of hybridization and PCR amplification (Figure 1, lane 3) . This enrichment procedure was repeated a third time using the JBam primer set (Figure 1, lane 4) . Both the original driver and the tester DNA samples (Table 2, Patient A) were subsequently found to contain the AIDS-KS specific sequences KS330Bam and KS631Bam (previously identified as KS627Bam) indicating that RDA can be successfully employed when the target sequences are present in unequal copy number in both tissues. The initial round of DNA amplification-hybridization from KS and normal tissue resulted in a diffuse banding pattern (Figure 1, lane 2) , but four bands at approximately 380, 450, 540 and 680 bp were identifiable after the second amplification- hybridization (Figure 1, lane 3) . These bands became discrete after a third round of amplification- hybridization (Figure 1, lane 4) . Control RDA, performed by hybridizing DNA extracted from AIDS-KS tissue against itself, produced a single band at approximately 540 bp (Figure 1, lane 5) . The four KS- associated bands (designated KS330Bam, KS390Bam, KS480Bam, KS627Bam after digestion of the two flanking 28 bp ligated priming sequences with Bam HI) were gel purified and cloned by insertion into the pCRII vector. PCR products were cloned in the pCRII vector using the TA cloning system (Invitrogen Corporation, San Diego, CA) . Experiment 2 ; Determination of the specificity of AIDS-KS unique sequences. To determine the specificity of these sequences for AIDS-KS, random-primed 32 P-labeled inserts were hybridized to Southern blots of DNA extracted from cryopreserved tissues obtained from patients with and without AIDS. All AIDS-KS specimens were examined microscopically for morphologic confirmation of KS and immunohistochemically for Factor VIII, Ulex europaeus and CD34 antigen expression. One of the AIDS-KS specimens was apparently mislabeled since KS tissue was not detected on microscopic examination but was included in the KS specimen group for purposes of statistical analysis. Control tissues used for comparison to the KS lesions included 56 lymphomas from patients with and without AIDS, 19 hyperplastic lymph nodes from patients with and without AIDS, 5 vascular tumors from nonAIDS patients and 13 tissues infected with opportunistic infections that commonly occur in AIDS patients. Control DNA was also extracted from a consecutive series of 49 surgical biopsy specimens from patients without AIDS. Additional clinical and demographic information on the specimens was not collected to preserve patient confidentiality. The tissues, listed in Table 1, were collected from diagnostic biopsies and autopsies between 1983 and 1993 and stored at -70°C. Each tissue sample was from a different patient, except as noted in Table 1. Most of the 27 KS specimens were from lymph nodes dissected under surgical conditions which diminishes possible contamination with normal skin flora. All specimens were digested with Bam HI prior to hybridization. KS390Bam and KS480Bam hybridized nonspecifically to both KS and non-KS tissues and were not further characterized. 20 of 27 (74%) AIDS-KS DNAs hybridized with variable intensity to both KS330Bam and KS627Bam, and one additional KS specimen hybridized only to KS627Bam by Southern blotting (Figure 2 and Table 1) . In contrast to AIDS-KS lesions, only 6 of 39 (15%) non-KS tissues from patients with AIDS hybridized to the KS330Bam and KS627Bam inserts (Table 1) . Specific hybridization did not occur with lymphoma or lymph node DNA from 36 persons without AIDS or with control DNA from 49 tissue biopsy specimens obtained from a consecutive series of patients. DNA extracted from several vascular tumors, including a hemangiopericytoma, two angiosarcomas and a lymphangioma, were also negative by Southern blot hybridization. DNA extracted from tissues with opportunistic infections common to AIDS patients, including 7 acid-fast bacillus (undetermined species) , 1 cytomegalovirus, 1 cat-scratch bacillus, 2 cryptococcus and 1 toxoplasmosis infected tissues, were negative by Southern blot hybridization to KS330Bam and KS627Bam (Table 1) . Table 1. Southern blot hybridization for KS330Bam and KS627Bam and PCR amplification for KS330 234 in human tissues from individual patients. Legend to Table 1; *Includes one AIDS-KS specimen unamplifiable for p53 exon 6 and one tissue which on microscopic examination did not have any detectable KS tissue present . Both of these samples were negative by Southern blot hybridization to KS330Bam and KS627Bam and by PCR amplification for the KS330 234 amplicon. tIncludes 7 small non-cleaved cell lymphomas, 20 diffuse large cell and immunoblastic lymphomas. Three of the lymphomas with immunoblastic morphology were positive for KS330Bam and KS627Bam. t Includes 13 anaplastic large cell lymphomas, 4 diffuse large cell lymphomas, 4 small lymphocytic lymphomas/chronic lymphocytic leukemias, 3 hairy cell leukemias, 2 monocytoid B-cell lymphomas, 1 follicular small cleaved cell lymphoma, 1 Burkitt's lymphoma, 1 plasmacytoma. § Includes 2 angiosarcomas, 1 hemangiopericytoma and 1 lymphangioma. IT Includes 2 cryptococcus, 1 toxoplasmosis, 1 cat- scratch bacillus, 1 cyto egalovirus, 1 Epstein-Barr virus, and 7 acid-fast bacillus infected tissues. In addition, pure cultures of Mycobacterium avium-complex were negative by Southern hybridization and PCR, and pure cultures of Mycoplasma penetrans were negative by PCR. Tissues included skin, appendix, kidney, prostate, hernia sac, lung, fibrous tissue, gallbladder, colon, foreskin, thyroid, small bowel, adenoid, vein, axillary tissue, lipoma, heart, mouth, hemorrhoid, pseudoaneurysm and fistula track. Tissues were collected from a consecutive series of biopsies on patients without AIDS but with unknown HIV serostatus . **Apparent nonspecific hybridization at approximately 20 Kb occurred in 4 consecutive surgical biopsy DNA samples: one colon and one hernia sac DNA sample hybridized to KS330Bam alone, another hernia sac DNA sample hybridized to KS627Bam alone and one appendix DNA sample hybridized to both KS330Bam and KS627Bam. These samples did not hybridize in the 330-630 bp range expected for these sequences and were PCR negative for KS330 234 . In addition, DNA from Epstein-Barr virus-infected peripheral blood lymphocytes and pure cultures of Mycobacterium avium-complex were also negative by Southern hybridization. Overall, 20 of 27 (74%) AIDS- KS specimens hybridized to KS330Bam and 21 of 27 (78%) AIDS-KS specimens hybridized to KS627Bam, compared to only 6 of 142 (4%) non-KS human DNA control specimens (χ 2 =85.02, p< 10 "7 and χ 2 =92.4, p< 10 "7 respectively) . The sequence copy number in the AIDS-KS tissues was estimated by simultaneous hybridization with KS330Bam and a 440 bp probe for the constant region of the T cell receptor β gene [76] . Samples in lanes 5 and 6 of Figures 2A-2B showed similar intensities for the two probes indicating an average copy number of approximately two KS330Bam sequences per cell, while remaining tissues had weaker hybridization signals for the KS330Bam probe. Experiment 3 ; Characterization of KS330Bam and KS627Bam To further characterize KS330Bam and KS627Bam, six clones for each insert were sequenced. The Sequenase version 2.0 (United States Biochemical, Cleveland, OH) system was used and sequencing was performed according to manufacturer' s instructions. Nucleotides sequences were confirmed with an Applied Biosystems 373A Sequencer in the DNA Sequencing Facilities at Columbia University. KS330Bam is a 330 bp sequence with 51% G:C content (Figure 3B) and KS627Bam is a 627 bp sequence with a 63% G:C content (Figure 3C) . KS330Bam has 54% nucleotide identity to the BDLFl open reading frame (ORF) of Epstein-Barr virus (EBV) . Further analysis revealed that both KS330Bam and KS627Bam code for amino acid sequences with homology to polypeptides of viral origin. SwissProt and PIR protein databases were searched for homologous ORF using BLASTX [3] . KS330Bam is 51% identical by amino acid homology to a portion of the ORF26 open reading frame encoding the capsid protein VP23 (NCBI g.i. 60348, bp 46024 - 46935) of herpesvirus saimiri [2] , a gammaherpesvirus which causes fulminant lymphoma in New world monkeys . This fragment also has a 39% identical amino acid sequence to the theoretical protein encoded by the homologous open reading frame BDLFl in EBV (NCBI g.i. 59140, bp 132403 -133307) [9] . The amino acid sequence encoded by KS627Bam is homologous with weaker identity (31%) to the tegument protein, gpl40 (ORF 29, NCBI g.i. 60396, bpl08782-112681) of herpesvirus saimiri. Sequence data from KS330Bam was used to construct PCR primers to amplify a 234bp fragment designated KS330 234 (Figure 3B) . The conditions for PCR analyses were as follows: 94°C for 2 min (1 cycle) ; 94°C for 1 min, 58°C for 1 min, 72°C for 1 min (35 cycles) ; 72°C extension for 5 min (1 cycle) . Each PCR reaction used 0.1 μg of genomic DNA, 50 pmoles of each primer, 1 unit of Taq polymerase, 100 μM of each deoxynucleotide triphosphate, 50 mM KCl, lOmM Tris-HCl (pH 9.0) , and 0.1% Triton-X-100 in a final volume of 25 μl. Amplifications were carried out in a Perkin- Elmer 480 Thermocycler with 1-s ramp times between steps. Although Southern blot hybridization detected the KS330Bam sequence in only 20 of 27 KS tissues, 25 of the 27 tissues were positive by PCR amplification for KS330 234 (Figures 4A-4B) demonstrating that KS330Bam is present in some KS lesions at levels below the threshold for detection by Southern blot hybridization. All KS330 234 PCR products hybridized to a 32 P end-labelled 25 bp internal oligomer, confirming the specificity of the PCR (Figure 4B) . Of the two AIDS-KS specimens negative for KS330 234 , both specimens appeared to be negative for technical reasons: one had no microscopically detectable KS tissue in the frozen sample (Figures 4A-4B, lane 3) , and the other (Figures 4A-4B, lane 15) was negative in the control PCR amplification for the p53 gene indicating either DNA degradation or the presence of PCR inhibitors in the sample. PCR amplification of the p53 tumor suppressor gene was used as a control for DNA quality. Sequences of p53 primers from P6-5, 5'- ACAGGGCTGGTTGCCCAGGGT-3' (SEQ ID No: 44) ; and P6-3. 5'- AGTTGCAAACCAGACCTCAG-3' (SEQ ID NO: 45) [25] . Except for the 6 control samples from AIDS patients that were also positive by Southern blot hybridization, none of the other 136 control specimens were positive by PCR for KS330 234 . All of these specimens were amplifiable for the p53 gene, indicating that inadequate PCR amplification was not the reason for lack of detection of KS330 234 in the control tissues. Samples containing DNA from two candidate KS agents, EBV and Mycoplasma penetrans (ATCC Accession No. 55252), a pathogen commonly found in the genital tract of patients with AIDS-KS [59] were also negative for amplification of KS330 234 . In addition, several KS specimens were tested using commercial PCR primers (Stratagene, La Jolla, CA) specific for mycoplasmata and primers specific for the EBNA-2, EBNA-3C and EBER regions of EBV and were negative [57] . Overall, DNA from 25 (93%) of 27 AIDS-KS tissues were positive by PCR compared with DNA from 6 (4%) of 142 control tissues, including 6 (15%) of 39 non-KS lymph nodes and lymphomas from AIDS patients (χ 2 =38.2, p < 10 "6 ) , 0 of 36 lymph nodes and lymphomas from nonAIDS patients (χ 2 =55.2, p < 10 ~7 ) and 0 of 49 consecutive biopsy specimens (χ 2 =67.7, p < 10 "7 ) . Thus, KS330 234 was found in all 25 amplifiable tissues with microscopically detectable AIDS-KS, but rarely occurred in non-KS tissues, including tissues from AIDS patients. Of the six control tissues from AIDS patients that were positive by both PCR and Southern hybridization, two patients had KS elsewhere, two did not develop KS and complete clinical histories for the remaining two patients were unobtainable. Three of the six positive non-KS tissues were lymph nodes with follicular hyperplasia taken from patients with AIDS. Given the high prevalence of KS among patients with AIDS, it is possible that undetected microscopic foci of KS were present in these lymph nodes. The other three positive tissue specimens were B cell immunoblastic lymphomas from AIDS patients. It is possible that the putative KS agent is also a cofactor for a subset of AIDS-associated lymphomas [16, 17, 80] . To determine whether KS330Bam and KS627Bam are portions of a larger genome and to determine the proximity of the two sequences to each other, samples of KS DNA were digested with Pvu II restriction enzymes. Digested genomic DNA from three AIDS-KS samples were hybridized to KS330Bam and KS627Bam by Southern blotting (Figure 5) . These sequences hybridized to various sized fragments of the digested KS DNA indicating that both sequences are fragments of larger genomes. Differences in the KS330Bam hybridization pattern to Pvu II digests of the three AIDS-KS specimens indicate that polymorphisms may occur in the larger genome. Individual fragments from the digests failed to simultaneously hybridize with both KS330Bam and KS627Bam, demonstrating that these two Bam HI restriction fragments are not adjacent to one another. If KS330Bam and KS627Bam are heritable polymorphic DNA markers for KS, these sequences should be uniformly detected at non-KS tissue sites in patients with AIDS- KS. Alternatively, if KS330Bam and KS627Bam are sequences specific for an exogenous infectious agent, it is likely that some tissues are uninfected and lack detectable KS330Bam and KS627Bam sequences. DNA extracted from multiple uninvolved tissues from three patients with AIDS-KS were hybridized to 32 P-labelled KS330Bam and KS627Bam probes as well as analyzed by PCR using the KS330 234 primers (Table 2) . While KS lesion DNA samples were positive for both bands, unaffected tissues were frequently negative for these sequences. KS lesions from patients A, B and C, and uninvolved skin and muscle from patient A were positive for KS330Bam and KS627Bam, but muscle and brain tissue from patient B and muscle, brain, colon, heart and hilar lymph node tissues from patient C were negative for these sequences. Uninvolved stomach lining adjacent to the KS lesion in patient C was positive by PCR, but negative by Southern blotting which suggests the presence of the sequences in this tissue at levels below the detection threshold for Southern blotting. Table 2 ; Differential detection of KS330Bam, KS627Bam and KS330- 34 sequences in KS-involved and non-involved tissues from three patients with AIDS-KS. Experiment ; Subcloning and sequencing of KSHV KS330Bam and KS627Bam are genomic fragments of a novel infectious agent associated with AIDS-KS. A genomic library from a KS lesion was made and a phage clone with a 20 kb insert containing the KS330Bam sequence was identified. The 20 kb clone digested with PvuII (which cuts in the middle of the KS330Bam sequence) produced 1.1 kb and 3 kb fragments that hybridized to KS330Bam. The 1.1 kb subcloned insert and -900 bp from the 3 kb subcloned insert resulting in 9404 bp of contiguous sequence was entirely sequenced. This sequence contains partial and complete open reading frames homologous to regions in gamma herpesviruses. The KS330Bam sequence is an internal portion of an 918 bp ORF with 55-56% nucleotide identity to the ORF26 and BDLFl genes of HSVSA and EBV respectively. The EBV and HSVSA translated amino acid sequences for these ORFs demonstrate extensive homology with the amino acid sequence encoded by the KS-associated 918 bp ORF (Figure 6) . In HSVSA, the VP23 protein is a late structural protein involved in capsid construction. Reverse transcriptase (RT) -PCR of mRNA from a KS lesion is positive for transcribed KS330Bam mRNA and that indicates that this ORF is transcribed in KS lesions. Additional evidence for homology between the KS agent and herpesviruses comes from a comparison of the genomic organization of other potential ORFs on the 9404 bp sequence (Figure 3A) The 5' terminus of the sequence is composed nucleotides having 66-67% nucleotide identity and 68- 71% amino acid identity to corresponding regions of the major capsid protein (MCP) ORFs for both EBV and HSVSA. This putative MCP ORF of the KS agent lies immediately 5' to the BDLF1/ORF26 homolog which is a conserved orientation among herpesvirus subfamilies for these two genes. At the 3' end of this sequence, the reading frame has strong amino acid and nucleotide homology to HSVSA ORF 27. Thus, KS-associated DNA sequences at four loci in two separate regions with homologies to gamma herpesviral genomes have been identified. In addition to fragments obtained from Pvu II digest of the 21 Kb phage insert described above, fragments obtained from a BamHI/NotI digest were also subcloned into pBluescript (Stratagene, La Jolla, CA) . The termini of these subcloned fragments were sequenced and were also found to be homologous to nucleic acid sequence EBV and HSVSA genes. These homologs have been used to develop a preliminary map of subcloned fragments (Figure 9) . Thus, sequencing has revealed that the KS agent maintains co-linear homology to gamma herpesviruses over the length of the 21 Kb phage insert . Experiment 5; Determination of the phylogeny of KSHV Regions flanking KS330Bam were sequenced and characterized by directional walking. This was performed by the following strategy: 1) KS genomic libraries were made and screened using the KS330Bam fragment as a hybridization probe, 2) DNA inserts from phage clones positive for the KS330Bam probe were isolated and digested with suitable restriction enzyme (s), 3) the digested fragments were subcloned into pBluescript (Stratagene, La Jolla, CA) , and 4) the subclones were sequenced. Using this strategy, the major capsid protein (MCP) ORF homolog was the first important gene locus identified. Using sequenced unique 3' and 5' end-fragments from positive phage clones as probes, and following the strategy above a KS genomic library are screened by standard methods for additional contiguous sequences. For sequencing purposes, restriction fragments are subcloned into phagemid pBluescript KS+, pBluescript KS-, pBS+, or pBS- (Stratagene) or into plasmid pUC18 or pUC19. Recombinant DNA was purified through CsCl density gradients or by anion-exchange chromatography (Qiagen) . Nucleotide sequenced by standard screening methods of cloned fragments of KSHV were done by direct sequencing of double- stranded DNA using oligonucleotide primers synthesized commercially to "walk" along the fragments by the dideoxy-nucleotide chain termination method. Junctions between clones are confirmed by sequencing overlapping clones. Targeted homologous genes in regions flanking KS330Bam include, but are not limited to: 11-10 homolog, thymidine kinase (TK) , g85, g35, gH, capsid proteins and MCP. TK is an early protein of the herpesviruses functionally linked to DNA replication and a target enzyme for anti-herpesviral nucleosides. TK phosphorylates acyclic nucleosides such as acyclovir which in turn inhibit viral DNA polymerase chain extension. Determining the sequence of this gene will aid in the prediction of chemotherapeutic agents useful against KSHV. TK is encoded by the EBV BXLF1 ORF located -9700 bp rightward of BDLFl and by the HSVSA ORF 21 -9200 bp rightward of the ORF 26. A subcloned fragment of KS5 was identified with strong homology to the EBV and HSVSA TK open reading frames . g85 is a late glycoprotein involved in membrane fusion homologous to gH in HSV1. In EBV, this protein is encoded by BLXF2 ORF located -7600 bp rightward of BDLFl, and in HSVSA it is encoded by ORF 22 located -7100 bp rightward of ORF26. g35 is a late EBV glycoprotein found in virion and plasma membrane. It is encoded by BDLF3 ORF which is 1300 bp leftward of BDLFl in EBV. There is no BDLF3 homolog in HSVSA. A subcloned fragment has already been identified with strong homology to the EBV gp35 open reading frame. Major capsid protein (MCP) is a conserved 150 KDa protein which is the major component of herpesvirus capsid. Antibodies are generated against the MCP during natural infection with most herpesviruses. The terminal 1026 bp of this major capsid gene homolog in KSHV have been sequenced. Targeted homologous genes/loci in regions flanking KS627Bam include, but are not limited to: terminal reiterated repeats, LMPI, EBERs and Ori P. Terminal reiterated sequences are present in all herpesviruses. In EBV, tandomly reiterated 0.5 Kb long terminal repeats flank the ends of the linear genome and become joined in the circular form. The terminal repeat region is immediately adjacent to BNRFl in EBV and ORF 75 in HSVSA. Since the number of terminal repeats varies between viral strains, identification of terminal repeat regions may allow typing and clonality studies of KSHV in KS legions. Sequencing through the terminal repeat region may determine whether this virus is integrated into human genome in KS. LMPI is an latent protein important in the transforming effects of EBV in Burkitt's lymphoma. This gene is encoded by the EBV BNRFl ORF located -2000 bp rightward of tegument protein ORF BNRFl in the circularized genome. There is no LMPI homolog in HSVSA. EBERs are the most abundant RNA in latently EBV infected cells and Ori-P is the origin of replication for latent EBV genome. This region is located between -4000-9000 bp leftward of the BNRFl ORF in EBV; there are no corresponding regions in HSVSA. The data indicates that the KS agent is a new human herpesvirus related to gamma herpesviruses EBV and HSVSA. The results are not due to contamination or to incidental co-infection with a known herpesvirus since the sequences are distinct from all sequenced herpesviral genomes (including EBV, CMV, HHV6 and HSVSA) and are associated specifically with KS in three separate comparative studies. Furthermore, PCR testing of KS DNA with primers specific for EBV-1 and EBV-2 failed to demonstrate these viral genomes in these tissues. Although KSHV is homologous to EBV regions, the sequence does not match any other known sequence and thus provides evidence for a new viral genome, related to but distinct from known members of the herpesvirus family. Experiment 6; Serological studies Indirect immunofluorescence assay (IFA) Virus-containing cells are coated to a microscope slide. The slides are treated with organic fixatives, dried and then incubated with patient sera. Antibodies in the sera bind to the cells, and then excess nonspecific antibodies are washed off. An antihuman immunoglobulin linked to a fluorochrome, such as fluorescein, is then incubated with the slides, and then excess fluorescent immunoglobulin is washed off. The slides are then examined under a microscope and if the cells fluoresce, then this indicates that the sera contains antibodies directed against the antigens present in the cells, such as the virus . An indirect immunofluorescence assay (IFA) was performed on the Body Cavity-Based Lymphoma cell line (BCBL-1) , which is a naturally transformed EBV infected (nonproducing) B cell line, using 4 KS patient sera and 4 control sera (from AIDS patients without KS) . Initially, both sets of sera showed similar levels of antibody binding. To remove nonspecific antibodies directed against EBV and lymphocyte antigens, sera at 1:25 dilution were pre- adsorbed using 3xl0 6 1% paraformaldehyde-fixed Raji cells per ml of sera. BCBL1 cells were fixed with ethanol/acetone, incubated with dilutions of patient sera, washed and incubated with fluorescein-conjugated goat anti-human IgG. Indirect immunofluorescent staining was determined. Table 3 shows that unabsorbed case and control sera have similar end-point dilution indirect immunofluorescence assay (IFA) titers against the BCBL1 cell line. After Raji adsorption, case sera have four-fold higher IFA titers against BCBL1 cells than control sera. Results indicated that pre- adsorption against paraformaldehyde-fixed Raji cells reduces fluorescent antibody binding in control sera but do not eliminate antibody binding to KS case sera. These results indicate that subjects with KS have specific antibodies directed against the KS agent that can be detected in serological assays such as IFA, Western blot and Enzyme immunoassays (Table 3) . Table 3 ; Indirect immunofluorescence end-point titers for KS case and non-KS control sera against the BCBL-1 cell line Legend Table 3 : * KS=autopsy-confirmed male, AIDS patient Control=*autopsy-confirmed female, AIDS patient, no KS ** Adsorbed against RAJI cells treated with 1% paraformaldehyde Immunoblotting ("Western blot") Virus-containing cells or purified virus (or a portion of the virus, such as a fusion protein) is electrophoresed on a polyacrylamide gel to separate the protein antigens by molecular weight. The proteins are blotted onto a nitrocellulose or nylon membrane, then the membrane is incubated in patient sera. Antibodies directed against specific antigens are developed by incubating with a anti-human immunoglobulin attached to a reporter enzyme, such as a peroxidase. After developing the membrane, each antigen reacting against antibodies in patient sera shows up as a band on the membrane at the corresponding molecular weight region. Enzyme immunoassay ("EIA or ELISA") Virus-containing cells or purified virus (or a portion of the virus, such as a fusion protein) is coated to the bottom of a 96-well plate by various means (generally incubating in alkaline carbonate buffer) . The plates are washed, then the wells are incubated with patient sera. Antibodies in the sera directed against specific antigens stick on the plate. The wells are washed again to remove nonspecific antibody, then they are incubated with a antihuman immunoglobulin attached to a reporter enzyme, such as a peroxidase. The plate is washed again to remove nonspecific antibody and then developed. Wells containing antigen that is specifically recognized by antibodies in the patients sera change color and can be detected by an ELISA plate reader (a spectrophotomer) . All three of these methods can be made more specific by pre-incubating patient sera with uninfected cells to adsorb out cross-reacting antibodies against the cells or against other viruses that may be present in the cell line, such as EBV. Cross-reacting antibodies can potentially give a falsely positive test result (i.e. the patient is actually not infected with the virus but has a positive test result because of cross- reacting antibodies directed against cell antigens in the preparation) . The importance of the infection experiments with Raji is that if Raji cells, or another well-defined cell line, can be infected, then the patient's sera can be pre-adsorbed against the uninfected parental cell line and then tested in one of the assays. The only antibodies left in the sera after pre-adsorption that bind to antigens in the preparation should be directed against the virus. Experiment 7 ; BCBL 1, from lymphomatous tissues belonging to a rare infiltrating, anaplastic body cavity lymphoma occurring in AIDS patients has been placed in continuous cell culture and shown to be continuously infected with the KS agent. This cell line is also naturally infected with Epstein-Barr Virus (EBV) . The BCBL cell line was used as an antigen substrate to detect specific KS antibodies in persons infected with the putative virus by Western-blotting. Three lymphoid B cell lines were used as controls. These included the EBV genome positive cell line P3H3, the EBV genome defective cell line Raji and the EBV genome negative cell line Bjab. Cells from late-log phase culture were washed 3 time with PBS by centrifugation at 500 g for lOmin. and suspended in sample buffer containing 50 mM Tris-HCl pH 6.8, 2% SDS (w/v) , 15% glycerol (v/v) , 5% β- mercaptoethanol (v/v) and 0.001% bromophenol (w/v) with protease inhibitor, 100 μM phenylmethylsulfonyl fluoride (PMSF) . The sample was boiled at 100°C for 5 min and centrifuged at 14,000 g for 10 min. The proteins in the supernatant was then fractionated by sodium, dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions with a separation gel of 15% and a stacking gel of 5% (3) . Prestained protein standards were included: yosin, 200 kDa; S-galactosidase, 118 kDA; BSA, 78 kDa; ovalbumin, 47.1 kDa; carbonic anhydrase, 31.4 kDa; soybean trypsin inhibitor, 25.5 kDa, lysozyme, 18.8 kDa and aprotinin, 8.3 kDa (Bio-Rad) . Immunoblotting experiments were performed according to the method of Towbin et al. (4) . Briefly, the proteins were electrophorectically transferred to Hybon-C extra membranes (Pharmacia) at 24 V for 70 min. The membranes were then dried at 37°C for 30 min, saturated with 5% skim milk in Tris-buffered saline, pH 7.4 (TBS) containing 50 mM Tris-HCl and 200 mM NaCl, at room temperature for 1 h. The membranes were subsequently incubated with human sera at dilution 1:200 in 1% skim milk overnight at room temperature, washed 3 times with a solution containing TBS, 0.2% Triton X-100 and 0.05% skim milk and then 2 times with TBS. The membranes were then incubated for 2 h at room temperature with alkaline phosphatase conjugated goat anti-mouse IgG + IgM + IgA (Sigma) diluted at 1:5000 in 1% skim milk. After repeating the washing,the membranes were stained with nitroblue tetranolium chloride and 5-bromo-4-chloro-3- indolylphosphate p-toluidine salt (Gibco BRL) . Two bands of approximately 226 kDa and 234 kDa were identified to be specifically present on the Wester- blot of BCBL cell lysate in 5 sera from AIDS gay man patients infected with KS. These 2 bands were absent from the lysates of P3H3, Raji and Bjab cell lysates. 5 sera from AIDS gay man patients without KS and 2 sera from AIDS woman patients without KS as well as 1 sera from nasopharyncel carcinoma patient were not able to detect these 2 bands in BCBL 1, P3H3, Raji and Bjab cell lysates. In a blinded experiment, using the 226 kDa and 234 kDa markers, 15 out of 16 sera from KS patients were correctly identified. In total, the 226 kDa and 234 kDa markers were detected in 20 out of 21 sera from KS patients. The antigen is enriched in the nuclei fraction of BCBL1. Enriched antigen with low background can be obtained by preparing nucleic from BCBC as the starting antigen preparation using standard, widely available protocols. For example, 500-750ml of BCBL at 5X10 5 cells/ml can be pelleted at low speed. The pellet is placed in 10 mM NaCl, 10 mM Tris pH 7.8, 1.5 mM MgCl 2 (equi volume) -+■ 1.0% NP-40 on ice for 20 min to lyse cells. The lysate is then spun at 1500 rpm for 10 min. to pellet nucleic. The pellet is used as the starting fraction for the antigen preparation for the Western blot. This will reduce cross- reactive cytoplasmic antigens. Experiment 8; Transmission studies Co-infection experiments BCBL1 cells were co-cultivated with Raji cell lines separated by a 0.45 μ tissue filter insert. Approximately, 1-2 x 10 6 BCBL1 and 2xl0 6 Raji cells were co-cultivated for 2-20 days in supplemented RPMI alone, in 10 μg/ml 5' -bromodeoxyuridine (BUdR) and 0.6 μg/ml 5' -flourodeoxyuridine or 20 ng/ml 12-0- tetradecanoylphorbol-13-acetate (TPA) . After 2,8,12 or 20 days co-cultivation, Raji cells were removed, washed and placed in supplemented RPMI 1640 media. A Raji culture co-cultivated with BCBL1 in 20 ng/ml TPA for 2 days survived and has been kept in continuous suspension culture for >10 weeks. This cell line, designated RCC1 (Raji Co-Culture, No. 1) remains PCR positive for the KS330 234 sequence after multiple passages. This cell line is identical to its parental Raji cell line by flow cyto etry using EMA, Bl, B4 and BerH2 lymphocyte-flow cytometry (approximately 2% ) . RCCl periodically undergo rapid cytolysis suggestive of lytic reproduction of the agent. Thus, RCCl is a Raji cell line newly infected with KSHV. The results indicate the presence of a new human virus, specifically a herpesvirus in KS lesions. The high degree of association between this agent and AIDS-KS (>90%) , and the low prevalence of the agent in non-KS tissues from immunocompromised AIDS patients, indicates that this agent has a causal role in AIDS-KS [47, 68] . Experiment 10; Isolation of KSHV Crude virus preparations are made from either the supernatant or low speed pelleted cell fraction of BCBL1 cultures. Approximately 650ml or more of log phase cells should be used (>5X10 6 cells/ml) . For bonding whole virion from supernatant, the cell free supernatant is spun at 10,000 rpm in a GSA rotor for 10 min to remove debris. PEG-8000 is added to 7%, dissolved and placed on ice for >2.5 hours. The PEG- supernatant is then spun at 10,000 xg for 30 min. supernatant is poured off and the pellet is dried and scraped together from the centrifuge bottles. The pellet is then resuspended in a small volume (1-2 ml) of virus buffer (VB, 0.1 M NaCl, 0.01 M Tris, pH 7.5) . This procedure will precipitate both naked genome and whole virion. The virion are then isolated by centrifugation at 25,000 rpm in a 10-50% sucrose gradient made with VB. One ml fractions of the gradient are then obtained by standard techniques (e.g. using a fractionator) and each fraction is then tested by dot blotting using specific hybridizing primer sequences to determine the gradient fraction containing the purified virus (preparation of the fraction maybe needed in order to detect the presence of the virus, such as standard DNA extraction) . To obtain the episomal DNA from the virus, the pellet of cells is washed and pelleted in PBS, then lysed using hypotonic shock and/or repeated cycles of freezing and thawing in a small volume (<3 ml) . Nuclei and other cytoplasmic debris are removed by centrifugation at 10,000g for 10 min, filtration through a 0.45 m filter and then repeat centrifugation at 10,000g for 10 min. This crude preparation contains viral genome and soluble cell components. The genome preparation can then be gently chloroform- phenol extracted to remove associated proteins or can be placed in neutral DNA buffer (1 M NaCl, 50 mM Tris, 10 mM EDTA, pH 7.2-7.6) with 2% sodium dodecylsulfate (SDS) and 1% sarcosyl . The genome is then banded by centrifugation through 10-30% sucrose gradient in neutral DNA buffer containing 0.15% sarcosyl at 20,000 rpm in a SW 27.1 rotor for 12 hours (for 40,000 rpm for 2-3 hours in an SW41 rotor) . The band is detected as described above. An example of the method for isolating KSHV genome from KSHV infected cell cultures (97 and 98) . Approximately 800 ml of BCBL1 cells are pelleted, washed with saline, and pelleted by low speed centrifugation. The cell pellet is lysed with an equal volume of RSB (10 mM NaCl, 10 mM Tris-HCl, 1.5 mM MgC12, pH 7.8) with 1% NP-40 on ice for 10 minutes. The lysate is centrifuged at 900xg for 10 minutes to pellet nuclei. This step is repeated. To the supernatant is added 0.4% sodium dodecylsulfate and EDTA to a final concentration of 10 mM. The supernatant is loaded on a 10-30% sucrose gradient in 1.0 M NaCl, lmM EDTA, 50mM Tris-HCl, pH 7.5. The gradients are centrifuged at 20,000 rpm on a SW 27.1 rotor for 12 hours. In figure 11, 0.5 ml aliquots of the gradient have been fractionated (fractions 1-62) with the 30% gradient fraction being at fraction No. 1 and the 10% gradient fraction being at fraction No. 62. Each fraction has been dot hybridized to a nitrocellulose membrane and then a "P-labeled KSHV DNA fragment, KS631Bam has been hybridized to the membrane using standard techniques. Figure 11 shows that the major solubilized fraction of the KSHV genome bands (i.e. is isolated) in fractions 42 through 48 of the gradient with a high concentration of the genome being present in fraction 44. A second band of solubilized KSHV DNA occurs in fractions 26 through 32. Experiment 11; Purification of KSHV DNA is extracted using standard techniques from the RCC-1 or RCC-1 2F5 cell line [27, 49, 66] . The DNA is tested for the presence of the KSHV by Southern blotting and PCR using the specific probes as described hereinafter. Fresh lymphoma tissue containing viable infected cells is simultaneously filtered to form a single cell suspension by standard techniques [49, 66] . The cells are separated by standard Ficoll-Plaque centrifugation and lymphocyte layer is removed. The lymphocytes are then placed at >lxl0 6 cells/ml into standard lymphocyte tissue culture medium, such as RMP 1640 supplemented with 10% fetal calf serum. Immortalized lymphocytes containing the KSHV virus are indefinitely grown in the culture media while nonimmortilized cells die during course of prolonged cultivation. Further, the virus may be propagated in a new cell line by removing media supernatant containing the virus from a continuously infected cell line at a concentration of >lxl0 6 cells/ml. The media is centrifuged at 2000xg for 10 minutes and filtered through a 0.45μ filter to remove cells. The media is applied in a 1:1 volume with cells growing at >lxl0 6 cells/ml for 48 hours. The cells are washed and pelleted and placed in fresh culture medium, and tested after 14 days of growth. The herpesvirus may be isolated from the cell DNA in the following manner. An infected cell line, which can be lysed using standard methods such as hyposmotic shocking and Dounce homogenization, is first pelleted at 2000xg for 10 minutes, the supernatant is removed and centrifuged again at 10,000xg for 15 minutes to remove nuclei and organelles. The supernatant is filtered through a 0.45μ filter and centrifuged again at 100,000xg for 1 hour to pellet the virus. The virus can then be washed and centrifuged again at 100,000xg for 1 hour. REFERENCES; 1. Ablashi, D.V. , et al. Virology 184:545-552. 2. Albrecht, J.C., et al . (1992) J. Virol. 66:5047. 3. Altshul, S.F., et al . (1990) J. Molec. Biol . 215:403. 4. Analytical Biochemistry (1984) 238:267-284. 5. Andrei, et al . (1992) Eur. J. Clin. Microbiol . Infect. Pis. 11 (2) : 143-51. 6. Archibald, C.P., e al. (1992) Epidemiol. 3:203. 7. Asada, H., et al (1989) J. Clin. Microbiol. 27(10) -.2204. 8. Ausubel, F., et al . (1987) Current Protocols in Molecular Biology. New York. 9. Baer, R.J., et al . (1984) Nature 310:207. 10. Bagasra, et al . (1992) J. New England Journal of Medicine 326 (21) :1385-1391. 11. Balzarini, et al. (1990) Mol . Pharm. 37,402-7. 12. Basic and Clinical Immunology 7th Edition D. Stites and A. Terr ed. 13. Beral, V., et al. (1990) Lancet 335:123. 14. Beral, V., et al . (1991) Brit. Med. J. 302:624. 15. Beral, V., et al . (1992) Lancet 339:632. 16. Bendsόe, N. , et al . (1990) Eur. J. Cancer 26:699. 17. Biggar, R.J., et al . (1994) Am. J. Epidemiol. 139:362. 18. Bovenzi, P., et al. (1993) Lancet 341:1288. 19. Beaucage and Carruthers (1981) Tetrahedron Lett . 22:1859-1862. 20. Braitman, et al. (1991) Antimicrob. Agents and Chemotherapy 35 (7) :1464-8. 21. Burns and Sanford, (1990) J. Infect. Pis. 162 (3) :634-7. 22. De Clercq, (1993) Antimicrobial Chemotherapy 32, Suppl. A, 121-132. 23. Drew, W.L., et al . (1982) Lancet ii:125. 24. Falk, et al . (1991) Nature 351:290. 25. Gaidano, G., et al . (1991) Proc. Natl. Acad. Sci . USA 88:5413. 26. Gershon, A.A. , (1992) J. Inf. Des. 166 (Suppl) :563. 27. Glick, J.L., (1980) Fundamentals of Human Lvmphoid Culture. Marcel Dokker, New York. 28. Gorbach, S.L., et al. (1992) Infectious Disease Ch.35:289, W.B. Saunders, Philadelphia, Pennsylvania. 29. Greenspan, et al . (1990) J. Acquir. Immune Defic. Svndr. 3 (6) :571. 30. Hardy, I., et al . (1990) Inf. Pis. Clin. N. Amer. 4 (1) :159. 31. Hardy, I., et al . (1991) New Engl . J. Med. 325 (22) :1545. 31A. Harel-Bellan, A., et al . (1988) EX . Med. 168:2309-2318 32. Harlow and Lane, (1988) Antibodies, A Laboratory Manual, Cold Spring Harbor Publication, New York. 33. Haverkos, H.W., et al. (1985) Sexually Transm. Pis. 12 :203. 34. Helene, C. and Toulme, J. (1990) Biochim. Biophys. Acta. 1049:99-125. 35. Heniford, et al. (1993) Nucleic Acids Research 21(14) :3159-3166. 36. Higashi, K. , et al . (1989) J. Clin. Micro. 27 (10) :2204. 37. Holmberg, S.D., et al . (1990) Cancer Detection and Prevention 14:331. 38. Holliday, J. , and Williams, M.V. , (1992) Antimicrob. Agents Chemother. 36(9) :1935. 39. Hoogenboo , H.R., et al. (1991) Nuc . Acids Res. 19:4133. 40. Hunt, et al. (1991) Eur. J. Immunol. 21:2963- 2970. 41. Hybridization of Nucleic Acids Immobilized on Solid Supports Meinkoth, J. and Wahl, G. 42. Hybridization with Nucleic Acid Probes pp. 495- 524, (1993) Elsevier, Amsterdam. 43. Ickes, et al. (1994) Antiviral Research 23, Seventh International Conf . on Antiviral Research, Abstract No. 122, Supp. 1. 44. Jahan, N. , et al . (1989) AIDS Research and Human Retroviruses 5:225. 45. Jardetzkey, et al . (1991) Nature 353:326. 46. Johnston, G.S., et al . (1990) Cancer Detection and Prevention 14:337. 47. Jung, J.U., et al . (1991) Proc. Natl. Acad. Sci . USA 88:7051. 48. Kikuta, et al. (1989) Lancet Oct. 7:861. 49. Knowles, D.M. , et al. (1989) Blood 73:792-798. 50. Kohler and Milstein, (1976) Eur. J. Immunol. 6:511-519. 51. Kucera, et al. (1993) AIDS Res . Human Retroviruses 9:307-314. 52. Laboratory Techniques in Biochemistry and Molecular Biology (1978) North Holland Publishing Company, New York. 53. Lasky, L.A. , (1990) J. Med. Virol. 31(1) :59. 54. Levin, M.J., et al. (1992) J. Inf. Pis. 166 (2) :253. 55. Lifson, A.R. , et al . (1990) Am. J. Epidemiol. 131:221. 56. Lin, et al. (1991) Antimicrob Agents Chemother 35 (11) :2440-3. 57. Lin, J.C., et al. (1993) Blood 81:3372. 58. Lisitsyn, N. , et al . (1993) Science 259:946. 59. Lo, S -C, et al. (1992) Internat . J. Systematic Bacteriol . 42:357. 60. Marks, J.P., et al. (1991) J. Mol Biol . 222:581- 597. 61. Marloes, et al . (1991) Eur. J. Immunol. 21:2963- 2970. 62. Matteucci, et al . (1981) Am. Chem. Soc. 103:3185. 63. Maxam, A.M. and Gilbert, W. Methods in Enzymology (1980) Grossman, L. and Moldave, P., eds. , Academic Press, New York, 65:499-560. 64. McCafferty, J., et al. (1990) Nature 348:552. 65. Means and Feeney, (1990) Bioconiugate Chem. A recent reveiw of protein modification techniques, 1:2-12. 66. Metcalf, P. (1984) Clonal Culture of Hematopoeitic Cells :Techniques and Applications, Elvier, New York. 67. Methods in Enzymology Vol . 152, (1987) Berger, S. and Kimmel, A. ed. , Academic Press, New York 68. Miller, G., Virology (1990) B. N. Fields, P.M. Knipe eds., Raven Press, New York, 2:1921. 69. Needham-VanPevanter, P.R., et al . , (1984) Nucelic Acids Res. 12:6159-6168. 70. Needleman and Wunsch, (1970) J. Mol. Biol. 48:443. 71. Neuvo, et al. (1993) American Journal of Surgical Pathology 17(7) , 683-690. 72. Nucleic Acid Hybridization: A Practical Approach (1985) Ed. Hames, B.D. and Higgins, S.J., IRL Press. 73. Oren and Soble, (1991) Clinical Infectious Diseases 14:741-6. 74. PCR Protocols: A Guide to Methods and Applications. (1990) Innis, M. , Gelfand D., Sninsky, J. and White, T., eds., Academic Press, San Diego. 75. Pearson and Lipman, (1988) Proc. Natl. Acad. Sci . (USA) 85:2444. 75A. Pearson, J.D., and Regnier, F.E., (1983) J Chro . 255:137-14976. 76. Pellici, P.G., et al. (1985) J. Ex . Med. 162:1015. 77. Peterman, T.A., et al. (1991) Cancer Surveys Imperial Cancer Research Fund, London, 10:23-37. 78. Roizman, B. (1991) Rev. Inf. Pisease 13 Suppl. 11:S892. 79. Rόtzschke and Falk, (1991) Immunol. Today 12:447. 80. Safai, B., et al . (1980) Cancer 45:1472. 81. Sambrook, et al . (1989) Molecular Cloning: A Laboratory Manual (2nd ed.) , Cold Spring Harbor Laboratory, Vols. 1-3. 82. Saunders, et al . (1990) J. Acquir. Immune Pefic. Svndr. 3 (6) :571. 83. Schecter, M.T., et al . (1991) Am. J. Epidemiol. 134:485. 84. Scopes, R., (1982) Protein Purification: Principles and Practice Springer-Verlag, New York. 85. Siddiqui, A., et al . (1983) Proc. Natl . Acad. Sci. USA 80:4861. 86. Skinner, G.R., et al . (1991) Comp. Immuno. Microbiol. Inf. Pis. 14(2) :13. 87. Skinner, G.R., et al. (1992) Med. Microbiol. Immunol . 180(6) :305. Smith and Waterman (1981) Adv. Appl. Math. 2:482. 88. Snoeck, et al . (1992) Eur. J. Clin. Micro. Infect. Pis. 11 (12) :1144-55. 89. Stals, et al. (1993) Antimicrobial Agents Chemother. 37 (2) :218-23. 90. van den Berg, F. et al . (1989) J. Clin. Pathol . 42:128. 91. Vogel, J. , et al . (1988) Nature 335:606. 92. Wang, R.H. -Y. , et al. (1993) Clin. Infect. Pis. 17:724. 93. Wickstrom, E.L., et al . (1988) PNAS (USA) 85:1028-1032. 94. Winkelmann, et al. (1988) Prug Res. 38, 1545-48. 95. Winkler, et al . (1990) Antiviral Research 14:61- 74. 96. Yamandaka, et al. (1991) Mol . Pharmacol . 40(3) :446. 97. Pellicer, A. et al . (1978) Cell 14:133-141. 98. Gibson, W. and Roizmann B. (1972) J. Virol. 10:1044-52. EXPERIMENTAL DETAILS SECTION II; Sequencing Studies: A lambda phage (KS5) from a KS lesion genomic library identified by positive hybridization with KS330Bam was digested with BavπHI and Not I (Boehringer-Mannheim, Indianapolis IN) ; five fragments were gel isolated and subcloned into Bluescript II KS (Stratagene, La Jolla CA) . The entire sequence was determined by bidirectional sequencing at a seven fold average redundancy by primer walking and nested deletions. DNA sequence data were compiled and aligned using ALIGN (IBI-Kodak, Rochester NY) and analyzed using the Wisconsin Sequence Analysis Package Version 8-UNIX (Genetics Computer Group, Madison WI) and the GRAIL Sequence Analysis, Gene Assembly and Sequence Comparison System v. 1.2 (Informatics Group, Oak Ridge TN) . Protein site motifs were identified using Motif (Genetics Computer Group, Madison WI) . Sources of Herpesvirus Gene Sequence Comparisons : Complete genomic sequences of three gammaherpesviruses were available: Epstein-Barr virus (EBV) , a herpesvirus of humans [4] ; herpesvirus saimiri (HVS) , a herpesvirus of the New World monkey Saimiri sciureus [1] ; and equine herpesvirus 2 (EHV2 [49] ) . Additional thymidine kinase gene sequences were obtained for alcelaphine herpesvirus 1 (AHV1 [22] ) and bovine herpesvirus 4 (BHV4 [31] ) . Sequences for the major capsid protein genes of human herpesvirus 6B and human herpesvirus 7 (HHV7) were from Mukai et al . [34] . The sources of all other sequences used are listed previously in McGeoch and Cook [31] and McGeoch et al . [32] . Phylo q enetic Inference: Predicted amino acid sequences used for tree construction were based on previous experience with herpesviral phylogenetic analyses [31] . Alignments of homologous sets of amino acid sequences were made with the AMPS [5] and Pileup [16] programs. Regions of alignments that showed extreme divergence with marked length heterogeneity, typically terminal sections, were excised. Generally, positions in alignments that contained inserted gaps in one or more sequences were removed before use for tree construction. Phylogenetic inference programs were from the Phylip set, version 3.5c [14] and from the GCG set [16] . Trees were built with the maximum parsimony (MP) , neighbor joining (NJ) methods. For the NJ method, which utilizes estimates of pairwise distances between sequences, distances were estimated as mean numbers of substitution events per site with Protdist using the PAM 250 substitution probability matrix of Schwartz & Dayhoff [46] . Bootstrap analysis [15] was carried out for MP and NJ trees, with 100 sub-replicates of each alignment, and consensus trees obtained with the program Consense. In addition the program Protml was used to infer trees by the maximum likelihood (ML) method. Protml was obtained form J. Adachi, Department of Statistical Science, The Graduate University for Advanced Study, Tokyo 106, Japan. Because of computational constraints, Protml was used only with the 4-species CS1 alignment. Clamped Homogeneous Electric Field (CHEF) Gel Electrophoresis : Agarose plugs were prepared by resuspending BCBL-1 cells in 1% LMP agarose (Biorad, Hercules CA) and 0.9% NaCl at 42°C to a final concentration of 2.5 x 10 7 cells/ml. Solidified agarose plugs were transferred into lysis buffer (0.5M EDTA pH 8.0, 1% sarcosyl, proteinase K at 1 mg/ml final concentration) and incubated for 24 hours. Approximately 10 7 BCBL-1 cells were loaded in each lane . Gels were run at a gradient of 6.0 V/cm with a run time of 28 h 28 min. on a CHEF Mapper XA pulsed field gel electrophoresis apparatus (Biorad, Hercules CA) , Southern blotted and hybridized to KS627Bam, KS330Bam and an EBV terminal repeat sequence [40] . TPA Induction of Genome Replication: Late log phase BCBL-1 cells (5xl0 5 cells per ml) were incubated with varying amounts of 12-0-tetradecanoylphorbol-13- acetate (TPA, Sigma Chemical Co., St. Louis MO) for 48 h, cells were then harvested and washed with phosphate-buffered saline (PBS) and DNA was isolated by chloroform-phenol extraction. DNA concentrations were determined by UV absorbance; 5 μg of whole cell DNA was quantitatively dot blot hybridized in triplicate (Manifold I, Schleicher and Schuell, Keene NH) . KS631Bam, EBV terminal repeat and beta- actin sequences were random-primer labeled with 32 P [13] . Specific hybridization was quantitated on a Molecular Dynamics Phosphorlmager 425E. Cell Cultures and Transmission Studies: Cells were maintained at 5xl0 5 cells per ml in RPMI 1640 with 20% fetal calf serum (FCS, Gibco-BRL, Gaithersburg MD) and periodically examined for continued KSHV infection by PCR and dot hybridization. The T cell line Molt-3 (a gift from Dr. Jodi Black, Centers for Disease Control and Prevention) , Raji cells (American Type Culture Collection, Rockville MD) and RCC-1 cells were cultured in RPMI 1640 with 10% FCS. Owl monkey kidney cells (American Type Culture Collection, Rockville MD) were cultured in MEM with 10% FCS and 1% nonessential amino acids (Gibco-BRL, Gaithersburg MD) . To produce the RCC-1 cell line, 2xl0 6 Raji cells were cultivated with 1.4xl0 6 BCBL-1 cells in the presence of 20 ng/ml TPA for 2 days in chambers separated by Falcon 0.45 μg filter tissue culture inserts to prevent contamination of Raji with BCBL-1. Demonstration that RCC-1 was not contaminated with BCBL-1 was obtained by PCR typing of HLA-DR alleles [27] (Raji and RCC-1: DR3l*0310, DR?3*02; BCBL-1: DR3104,*07, Dr34*01) and confirmed by flow cytometry to determine the presence (Raji, RCCl) or absence (BCBL-1) of EMA membrane antigen. Clonal sublines of RCC-1 were obtained by dilution in 96 well plates to 0.1 cells/well in RPMI 1640, 20% FCS and 30% T- STIM culture supplement (Collaborative Biomedical Products, Bedford MA) . Subcultures were examined to ensure that each was derived from a single cluster of growing cells. In si tu hybridization was performed with a previously described 25 bp oligomer located in ORF26 which was 5' labeled with fluorescein (Operon, Alameda CA) and hybridized to cytospin preparations of BCBL-1 , RCC-1 and Raji cells using the methods of Lungu et al. [29] . Slides were both directly visualized by UV microscopy and by incubating slides with anti-fluorescein-alkaline phosphatase (AP) - conjugated antibody (Boehringer-Mannheim, Indianapolis IN) , allowing immunohistochemical detection of bound probe. Positive control hybridization was performed using a 26 bp TET- labeled EBV DNA polymerase gene oligomer (Applied Biosystems, Alameda CA) which was visualized by UV microscopy only and negative control hybridization was performed using a 25 bp 5' fluorescein-labeled HSV1 α47 gene oligomer (Operon, Alameda CA) which was visualized in a similar manner as the KSHV ORF26 probe. All nuclei of BCBL-1, RCC-1 and Raji appropriately stained with the EBV hybridization probe whereas no specific staining of the cells occurred after hybridization with the HSV1 probe. The remaining suspension cell lines used in transmission experiments were pelleted, and resuspended in 5 ml of 0.22 or 0.45 μ filtered BCBL- 1 tissue culture supernatant for 16 h. BCBL-1 supernatants were either from unstimulated cultures or from cultures stimulated with 20 ng/ml TPA. No difference in transmission to recipient cell lines was noted using various filtration or stimulation conditions. Fetal cord blood lymphocytes (FCBL) were obtained from heparinized fresh post-partum umbilical cord blood after separation on Ficoll- Paque (Pharmacia LKB, Uppsala Sweden) gradients and cultured in RPMI 1640 with 10% fetal calf serum. Adherent recipient cells were washed with sterile Hank's Buffered Salt Solution (HBSS, Gibco-BRL, Gaithersburg MD) and overlaid with 5 ml of BCBL-1 media supernatant. After incubation with BCBL-1 media supernatant, cells were washed three times with sterile HBSS, and suspended in fresh media. Cells were subsequently rewashed three times every other day for six days and grown for at least two weeks prior to DNA extraction and testing. PCR to detect KSHV infection was performed using nested and unnested primers from ORF 26 and ORF 25 as previously described [10, 35] . Indirect Immunofluorescence Assay: AIDS-KS sera were obtained from ongoing cohort studies (provided by Drs. Scott Holmberg, Thomas Spira and Harold Jaffe, Centers for Disease Control, and Prevention, and Isaac Weisfuse, New York City Department of Health) . Sera from AIDS-KS patients were drawn between 1 and 31 months after initial KS diagnosis, sera from intravenous drug user and homosexual/bisexual controls were drawn after non-KS AIDS diagnosis, and sera from HIV-infected hemophiliac controls were drawn at various times after HIV infection. Immunofluorescence assays were performed using an equal volume mixture of goat anti-human IgG-FITC conjugate (Molecular Probes, Eugene OR) and goat anti-human IgM-FITC conjugate (Sigma Chemical Co., St. Louis MO) diluted 1:100 and serial dilutions of patient sera. End-point titers were read blindly and specific immunoglobulin binding was assessed by the presence or absence of a specular fluorescence pattern in the nuclei of the plated cells. To adsorb cross-reacting antibodies, 20 μl serum diluted 1:10 in phosphate-buffer saline (PBS), pH 7.4, were adsorbed with l-3xl0 7 paraformaldehyde- fixed P3H3 cells for 4-10 h at 25° C and removed by low speed centrifugation. P3H3 were induced prior to fixation with 20 ng/ml TPA for 48 h , fixed with 1% paraformaldehyde in PBS for 2 h at 4° C, and washed three times in PBS prior to adsorption. RESULTS Sequence Analysis of a 20.7 kb KSHV DNA Sequence: To demonstrate that KS330Bam and KS631Bam are genomic fragments from a new and previously uncharacterized herpesvirus, a lambda phage clone (KS5) derived from an AIDS-KS genomic DNA library was identified by hybridization to the KS330Bam sequence. The KS5 insert was subcloned after NotI / Ba ΑI digestion into five subfragments and both strands of each fragment were sequenced by primer walking or nested deletion with a 7-fold average redundancy. The KS5 sequence is 20,705 bp in length and has a G+C content of 54.0%. The observed/expected CpG dinucleotide ratio is 0.92 indicating no overall CpG suppression in this region. Open reading frame (ORF) analysis identified 15 complete ORFs with coding regions ranging from 231 bp to 4128 bp in length, and two incomplete ORFs at the termini of the KS5 clone which were 135 and 552 bp in length (Figure 12) . The coding probability of each ORF was analyzed using GRAIL 2 and CodonPreference which identified 17 regions having excellent to good protein coding probabilities. Each region is within an ORF encoding a homolog to a known herpesvirus gene with the exception of one ORF located at the genome position corresponding to ORF28 in herpesvirus saimiri (HVS) . Codon preference values for all of the ORFs were higher across predicted ORFs than in non-coding regions when using a codon table composed of KS5 homologs to the conserved herpesvirus major capsid (MCP) , glycoprotein H (gH) , thymidine kinase (TK) , and the putative DNA packaging protein (ORF29a/ORF29b) genes. The translated sequence of each ORF was used to search GenBank/EMBL databases with BLASTX and FastA algorithms [2, 38] . All of the putative KS5 ORFs, except one, have sequence and collinear positional homology to ORFs from gamma-2 herpesviruses, especially HVS and equine herpesvirus 2 (EHV2) . Because of the high degree of collinearity and amino acid sequence similarity between KSHV and HVS, KSHV ORFs have been named according to their HVS positional homologs (i.e. KSHV ORF25 is named after HVS ORF 25) . The KS5 sequence spans a region which includes three of the seven conserved herpesvirus gene blocks (Figure 14) [10] . ORFs present in these blocks include genes which encode herpesvirus virion structural proteins and enzymes involved in DNA metabolism and replication. Amino acid identities between KS5 ORFs and HVS ORFs range from 30% to 60%, with the conserved MCP ORF25 and ORF29b genes having the highest percentage amino acid identity to homologs in other gammaherpesviruseε. KSHV ORF28, which has no detectable sequence homology to HVS or EBV genes, has positional homology to HVS ORF28 and EBV BDLF3. ORF28 lies at the junction of two gene blocks (Figure 14) ; these junctions tend to exhibit greater sequence divergence than intrablock regions among herpesviral genomes [17] . Two ORFs were identified with sequence homology to the putative spliced protein packaging genes of HVS (ORF29a/ORF29b) and herpes simplex virus type 1 (UL15) . The KS330Bam sequence is located within KSHV ORF26, whose HSV-1 counterpart, VP23, is a minor virion structural component. For every KSHV homolog, the HVS amino acid similarity spans the entire gene product, with the exception of ORF21, the TK gene. The KSHV TK homolog contains a proline-rich domain at its amino terminus (nt 20343-19636; aa 1-236) that is not conserved in other herpesvirus TK sequences, while the carboxyl terminus (nt 19637-18601; aa 237-565) is highly similar to the corresponding regions of HVS, EHV2, and bovine herpesvirus 4 (BHV4) TK. A purine binding motif with a glycine-rich region found in herpesviral TK genes, as well as other TK genes, is present in the KSHV TK homolog (GVMGVGKS; aa 260-267) . The KS5 translated amino acid sequences were searched against the PROSITE Dictionary of Protein Sites and Patterns (Dr. Amos Bairoch, University of Geneva, Switzerland) using the computer program Motifs. Four sequence motif matches were identified among KSHV hypothetical protein sequences. These matches included: (i) a cytochrome c family heme-binding motif in ORF33 (CVHCHG; aa 209-214) and ORF34 (CLLCHI; aa 257-261) , (ii) an immunoglobulin and major histocompatibility complex protein signature in ORF25 (FICQAKH; aa 1024-1030), (iii) a mitochondrial energy transfer protein motif in ORF26 (PDDITRMRV; aa 260- 268) , and (iv) the purine nucleotide binding site identified in 0RF21. The purine binding motif is the only motif with obvious functional significance. A cytosine-specific methylase motif present in HVS ORF27 is not present in KSHV ORF27. This motif may play a role in the methylation of episomal DNA in cells persistently infected with HVS [1] . Phylogenetic Analysis of KSHV: Amino acid sequences translated from the KS5 sequence were aligned with corresponding sequences from other herpesviruses . On the basis of the level of conserved aligned residues and the low incidence of introduced gaps, the amino acid alignments for ORFs 21, 22, 23, 24, 25, 26, 29a, 29b, 31 and 34 were suitable for phylogenetic analyses. To demonstrate the phylogenetic relationship of KSHV to other herpesviruses, a single-gene comparison was made for ORF25 (MCP) homologs from KS5 and twelve members of Herpesviridae (Figures 15A-15B) . The thirteen available MCP amino acid sequences are large (1376 a.a. residues for the KSHV homolog) and alignment required only a low level of gapping; however, the overall similarity between viruses is relatively low [33] . The MCP set gave stable trees with high bootstrap scores and assigned the KSHV homolog to the gamma-2 sublineage (genus Rhadinovirus ) , containing HVS, EHV2 and BVH4 [20, 33, 43] . KSHV was most closely associated with HVS. Similar results were obtained for single-gene alignments of TK and UL15/ORF29 sets but with lower bootstrap scores so that among gamma-2 herpesvirus members branching orders for EHV2, HVS and KSHV were not resolved. To determine the relative divergence between KSHV and other gammaherpesviruses, alignments for the nine genes listed above were concatenated to produce a combined gammaherpesvirus gene set (CS1) containing EBV, EHV2, HVS and KSHV amino acid sequences. The total length of CS1 was 4247 residues after removal of positions containing gaps introduced by the alignment process in one or more of the sequences. The CS1 alignment was analyzed by the ML method, giving the tree shown in Figure 15B and by the MP and NJ methods used with the aligned herpesvirus MCP sequences. All three methods identified KSHV and HVS as sister groups, confirming that KSHV belongs in the gamma-2 sublineage with HVS as its closest known relative. It was previously estimated that divergence of the HVS and EHV2 lineages may have been contemporary with divergence of the primate and ungulate host lineages [33] . The results for the CS1 set suggest that HVS and KSHV represent a lineage of primate herpesviruses and, based on the distance between KSHV and HVS relative to the position of EHV2, divergence between HVS and KSHV lines is ancient . Genomic Studies of KSHV: CHEF electrophoresis performed on BCBL-1 cells embedded in agarose plugs demonstrated the presence of a nonintegrated KSHV genome as well as a high molecular weight species (Figures 16A-16B) . KS631Bam (Figure 16A) and KS330Bam specifically hybridized to a single CHEF gel band comigrating with 270 kilobase (kb) linear DNA standards. The majority of hybridizing DNA was present in a diffuse band at the well origin; a low intensity high molecular weight (HMW) band was also present immediately below the origin (Figure 16A. arrow) . The same filter was stripped and probed with an EBV terminal repeat sequence [40] yielding a 150-160 kb band (Figure 16B) corresponding to linear EBV DNA [24] . The HMW EBV band may correspond to either circular or concatemeric EBV DNA [24] . The phorbol ester TPA induces replication-competent EBV to enter a lytic replication cycle [49] . To determine if TPA induces replication of KSHV and EBV in BCBL-1 celLs, these cells were incubated with varying concentrations of TPA for 48 h (Figure 17) . Maximum stimulation of EBV occurred at 20 ng/ml TPA which resulted in an eight-fold increase in hybridizing EBV genome. Only a 1.3-1.4 fold increase in KSHV genome abundance occurred after 20-80 ng/ml TPA incubation for 48 h. Transmission Studies : Prior to determining that the agent was likely to be a member of Herpesviridae by sequence analysis, BCBL-1 cells were cultured with Raji cells, a nonlytic EBV transformed B cell line, in chambers separated by a 0.45 μ tissue culture filter. Recipient Raji cells generally demonstrated rapid cytolysis suggesting transmission of a cytotoxic component from the BCBL-1 cell line. One Raji line cultured in 10 ng/ml TPA for 2 days, underwent an initial period of cytolysis before recovery and resumption of logarithmic growth. This cell line (RCC- 1) is a monoculture derived from Raji uncontaminated by BCBL-1 as determined by PCR amplification of HLA-DR sequences. RCC-1 has remained positive for the KS330 233 PCR product for >6 months in continuous culture (approximately 70 passages) , but KSHV was not detectable by dot or Southern hybridization at any time. In si tu hybridization, however, with a 25 bp KSHV ORF26-derived oligomer was used to demonstrate persistent localization of KSHV DNA to RCC-1 nuclei. As indicated in Figures 18A-18C, nuclei of BCBL-1 and RCC-1 (from passage -65) cells had detectable hybridization with the ORF26 oligomer, whereas no specific hybridization occurred with parental Raji cells (Figure 18B) . KSHV sequences were detectable in 65% of BCBL-1 and 2.6% of RCC-1 cells under these conditions. In addition, forty-five monoclonal cultures were subcultured by serial dilution from RCC-1 at passage 50, of which eight (18%) clones were PCR positive by KS330 233 . While PCR detection using unnested KS330 233 primer pairs was lost by passage 15 in each of the clonal cultures, persistent KSHV genome was detected in 5 clones using two more sensitive nonoverlapping nested PCR primer sets [33] suggesting that KSHV genome is lost over time in RCC-1 and its clones. Low but persistent levels of KS330 233 PCR positivity were found for one of four Raji, one of four Bjab, two of three Molt-3, one of one owl monkey kidney cell lines and three of eight human fetal cord blood lymphocyte (FCBL) cultures after inoculation with 0.2-0.45 μ filtered BCBL-1 supernatants. Among the PCR positive cultures, PCR detectable genome was lost after 2-6 weeks and multiple washings. Five FCBL cultures developed cell clusters characteristic of EBV immortalized lymphocytes and were positive for EBV by PCR using EBER primers [23) ; three of these cultures were also initially KS330 233 positive. None of the recipient cell lines had detectable KSHV genome by dot blot hybridization. Serologic Studies: Indirect immunofluorescence antibody assays (IFA) were used to assess the presence of specific antibodies against the KSHV- and EBV-infected cell line BHL-6 in the sera from AIDS-KS patients and control patients with HIV infection or AIDS. BHL-6 was substituted for BCBL-1 for reasons of convenience; preliminary studies showed no significant differences in IFA results between BHL-6 and BCBL-1. BHL-6 have diffuse immunofluorescent cell staining with most KS patient and control unabsorbed sera suggesting nonspecific antibody binding (Figures 19A-19D) . After adsorption with paraformaldehyde-fixed, TPA-induced P3H3 (an EBV producer subline of P3J-HR1, a gift of Dr. George Miller) to remove cross-reacting antibodies against EBV and lymphocyte antigens, patient sera generally showed specular nuclear staining at high titers while this staining pattern was absent from control patient sera (Figures 19B and 19P) . Staining was localized primarily to the nucleus but weak cytoplasmic staining was also present at low sera dilutions. With unadsorbed sera, the initial endpoint geometric mean titers (GMT) against BHL-6 cell antigens for the sera from AIDS-KS patients (GMT=1:1153, range: 1:150 to 1:12,150) were higher than for sera from control, non-KS patients (GMT=1:342; range 1:50 to 1:12,150; p=0.04) (Figure 13) . While AIDS-KS patients and HIV-infected gay/bisexual and intravenous drug user control patients had similar endpoint titers to BHL-6 antigens (GMT=1:1265 and GMT=1:1578, respectively), hemophilic AIPS patient titers were lower (GMT=1:104) . Both case and control patient groups had elevated IFA titers against the EBV infected cell line P3H3. The difference in endpoint GMT between case and control titers against BHL-6 antigens increased after adsorption with P3H3. After adsorption, case GMT declined to 1:780 and control GMT declined to 1:81 (p=0.00009) . Similar results were obtained by using BCBL-1 instead of BHL-6 cells, by pre-adsorbing with EBV-infected nonproducer Raji cells instead of P3H3 and by using sera from a homosexual male KS patient without HIV infection, in complete remission for KS for 9 months (BHL-6 titer 1:450, P3H3 titer 1:150) . Paired sera taken 8-14 months prior to KS onset and after KS onset were available for three KS patients: KS patients 8 and 13 had eight-fold rises and patient 8 had a three-fold fall in P3H3- adsorbed BCBL-1 titers from pre-onset sera to post-KS sera. DISCUSSION These studies demonstrate that specific DNA sequences found in KS lesions by representational difference analysis belong to a newly identified human herpesvirus. The current studies define this agent as a human gamma-2 herpesvirus that can be continuously cultured in naturally-transformed, EBV-coinfected lymphocytes from AIDS-related body-cavity based lymphomas. Sequence analysis of the KS5 lambda phage insert provides clear evidence that the KS330Bam sequence is part of a larger herpesvirus genome. KS5 has a 54.0% G+C content which is considerably higher than the corresponding HVS region (34.3% G+C) . While there is no CpG dinucleotide suppression in the KS5 sequence, the corresponding HVS region has a 0.33 expected:observed CpG dinucleotide ratio [1] . The CpG dinucleotide frequency in herpesviruses varies from global CpG suppression among gammaherpesviruses to local CpG suppression in the betaherpesviruses, which may result from deamination of 5' -methylcytosine residues at CpG sites resulting in TpG substitutions [21] . CpG suppression among herpesviruses [21, 30, 44] has been hypothesized to reflect co-replication of latent genome in actively dividing host cells, but it is unknown whether or not KSHV is primarily maintained by a lytic replication cycle in vivo . The 20,705 bp KS5 fragment has 17 protein-coding regions, 15 of which are complete ORFs with appropriately located TATA and polyadenylation signals, and two incomplete ORFs located at the phage insert termini . Sixteen of these ORFs correspond by sequence and collinear positional homology to 15 previously identified herpesviral genes including the highly conserved spliced gene. The conserved positional and sequence homology for KSHV genes in this region are consistent with the possibility that the biological behavior of the virus is similar to that of other gammaherpesviruses. For example, identification of a thymidine kinase-like gene on KS5 implies that the agent is potentially susceptible to TK-activated PNA polymerase inhibitors and like other herpesviruses possesses viral genes involved in nucleotide metabolism and DNA replication [41] . The presence of major capsid protein and glycoprotein H gene homologs suggest that replication competent virus would produce a capsid structure similar to other herpesviruses. Phylogenetic analyses of molecular sequences show that KSHV belongs to the gamma-2 sublineage of the Gammaherpesvirinae subfamily, and is thus the first human gamma-2 herpesvirus identified. Its closest known relative based on available sequence comparisons is HVS, a squirrel monkey gamma-2 herpesvirus that causes fulminant polyclonal T cell lymphoproliferative disorders in some New World monkey species . Data for the gamma-2 sublineage are sparse: only three viruses (KSHV, HVS and EHV2) can at present be placed on the phylogenetic tree with precision (the sublineage also contains murine herpesvirus 68 and BHV4 [33] ) . Given the limitation in resolution imposed by this thin background, KSHV and HVS appear to represent a lineage of primate gamma-2 viruses. Previously, McGeoch et al . [33] proposed that lines of gamma-2 herpesviruses may have originated by cospeciation with the ancestors of their host species. Extrapolation of this view to KSHV and HVS suggests that these viruses diverged at an ancient time, possibly contemporaneously with the divergence of the Old World and New World primate host lineages. Gammaherpesviruses are distinguished as a subfamily by their lymphotrophism [41] and this grouping is supported by phylogenetic analysis based on sequence data [33] . The biologic behavior of KSHV is consistent with its phylogenetic designation in that KSHV can be found in in vitro lymphocyte cultures and in in vivo samples of lymphocytes [3] . This band appears to be a linear form of the genome because other "high molecular weight" bands are present for both EBV and KSHV in BCBL-1 which may represent circular forms of their genomes. The linear form of the EBV genome, associated with replicating and packaged DNA [41] migrates substantially faster than the closed circular form associated with latent viral replication [24] . While the 270 kb band appears to be a linear form, it is also consistent with a replicating dimer plasmid since the genome size of HVS is approximately 135 kb. The true size of the genome may only be resolved by ongoing mapping and sequencing studies. Replication deficient EBV mutants are common among EBV strains passaged through prolonged tissue culture [23] . The EBV strain infecting Raji, for example, is an BALF-2 deficient mutant [19] ; virus replication is not inducibile with TPA and its genome is maintained only as a latent circular form [23, 33] . The EBV strain coinfecting BCBL-1 does not appear to be replication deficient because TPA induces eight-fold increases in DNA content and has an apparent linear form on CHEF electrophoresis. KSHV replication, however, is only marginally induced by comparable TPA treatment indicating either insensitivity to TPA induction or that the genome has undergone loss of genetic elements required for TPA induction. Additional experiments, however, indicate that KSHV DNA can be pelleted by high speed centrifugation of filtered organelle-free, DNase I-protected BCBL-1 cell extracts, which is consistent with KSHV encapsidation. Transmission of KSHV DNA from BCBL-1 to a variety of recipient cell lines is possible and KSHV DNA can be maintained at low levels in recipient cells for up to 70 passages. However, detection of virus genome in recipient cell lines by PCR may be due to physical association of KSHV DNA fragments rather than true infection. This appears to be unlikely given evidence for specific nuclear localization of the ORF26 sequence in RCC-1. If transmission of infectious virus from BCBL-1 occurs, it is apparent that the viral genome declines in abundance with subsequent passages of recipient cells. This is consistent with studies of spindle cell lines derived from KS lesions. Spindle cell cultures generally have PCR detectable KSHV genome when first explanted, but rapidly lose viral genome after initial passages and established spindle cell cultures generally do not have detectable KSHV sequences [3] . Infections with the human herpesviruses are generally ubiquitous in that nearly all humans are infected by early adulthood with six of the seven previously identified human herpesviruses [42] . Universal infection with EBV, for example, is the primary reason for the difficulty in clearly establishing a causal role for this virus in EBV-associated human tumors. The serologic studies identified nuclear antigen in BCBL-1 and BHL-6 which is recognized by sera from AIDS-KS patients but generally not by sera from control AIDS patients without KS after removal of EBV-reactive antibodies. These data are consistent with PCR studies of KS and control patient lymphocytes suggesting that KSHV is not ubiquitous among adult humans, but is specifically associated with persons who develop Kaposi's sarcoma. In this respect, it appears to be epidemiologically similar to HSV2 rather than the other known human herpesviruses. An alternative possibility is that elevated IFA titers against BCBL-1 reflect disease status rather than infection with the virus. REFERENCES 1. Albrecht, J.-C, J. Nicholas, D. Biller, K. R. Cameron, B. Biesinger, C. Newamn, S. Wittmann, M. A. Craxton, H. Coleman, B. Fleckenstein, and R. W. Honess. 1992. Primary structure of the Herpesvirus saimiri genome. J Virol. 66:5047-5058. 2. Altschul, S. F., W. Gish, W. Miller, E. W. Myers, and D. J. Lipman. 1990. Basic local alignment search tool. J Mol Biol. 215:403- 410. 3. Ambroziak, J. A., D. J. Blackbourn, B. G. Herndier, R. G. Glogau, J. H. Gullett, A. R. McDonald, E. T. Lennette, and J. A. Levy. 1995. Herpes-like sequences in HIV-infected and uninfected Kaposi's sarcoma patients. Science. 268:582-583. 4. Baer, R. , A. T. Bankier, P. L. Biggin, P. L. Deininger, P. J. Farrell, T. J. Gibson, G. Hatfull, G. S. Hudson, S. C. Satchwell, C. Seguin, P. S. Tuffnell, and B. G. Barrell. 1984. DNA sequence and expression of the B95- 8 Epstein-Barr virus genome. Nature. 310:207- 211. 5. Barton, G. J. , and M. J. E. Sternberg. 1987. A strategy for the rapid multiple alignment of protein sequences. Confidence levels from tertiary structure comparisons. J Mol Biol. 198:327-37. 6. Beral, V., T. A. Peter an, R. L. Berkelman, and H. W. Jaffe. 1990. Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? Lancet. 335:123-128. 7. Boshoff, C, D. Whitby, T. Hatziionnou, C. Fisher, J. van der Walt, A. Hatzakis, R. Weiss, and T. Schulz. 1995. Kaposi's sarcoma- associated herpesvirus in HIV-negative Kaposi's sarcoma. Lancet. 345:1043-44. 8. Cesarman, E., Y. Chang, P. S. Moore, J. W. Said, and D. M. Knowles . 1995. Kaposi's sarcoma-associated herpesvirus-like DNA sequences are present in AIDS-related body cavity based lymphomas. New England J Med. 332:1186-1191. 9. Chang, Y. , E. Cesarman, M. S. Pessin, F. Lee, J. Culpepper, D. M. Knowles, and P. S. Moore. 1994. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 265:1865-69. 10. Chee, M. S., S. B. Bankier, C. M. Bohni, R. C. Brown, T. Horsnell, C. A. Hutchison, T. Kouzarides, J. A. Martignetti, E. Preddie, S. C. Satchwell, P. Tomlinson, K. M. Weston, and B. G. Barrell. 1990. Analysis of the protein coding content of the sequence of cytomeg lovirus strain AD169. Curr Top Microbiol Immunol. 154:125-69. 11. Collandre, H. , S. Ferris, O. Grau, L. Montagnier, and A. Blanchard. 1995. Kaposi's sarcoma and new herpesvirus. Lancet . 345:1043. 12. Dupin, N. , M. Grandadam, V. Calvez, I. Gorin, J. T. Aubin, S. Harvard, F. Lamy, M. Leibowitch, J. M. Huraux, J. P. Escande, and H. Agut. 1995. Herpesvirus-like DNA in patients with Mediterranean Kaposi's sarcoma. Lancet. 345:761-2. 13. Feinberg, A. P., and B. Vogelstein. 1983. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem. 132:6. 14. Felsenstein, J. 1989. PHYLIP-phylogeny inference package (ver 3.2) . Cladistics. 5:164-6. 15. Felsenstein, J. 1988. Phylogenies from molecular sequences: inferences and reliability. Annual Rev Microbiol . 22:521-65. 16. Genetics Computer Group. 1994. Program manual for the GCG package, version 8, Madison, Wisconsin. 17. Gompels, U. A., J. Nicholas, G. Lawrence, M. Jones, B. J. Thomson, M. E. D. Martin, S. Efstathiou, M. Craxton, and H. A. Macaulay. 1995. The DNA sequence of human herpesvirus- 6: Structure, coding content and genome evolution. Virology. 209:29-51. 18. Hatfull, G., A. T. Bankier, B. G. Barrell, and P. J. Farrell. 1988. Sequence analysis of Raji Epstein-Barr virus DNA. Virol. 164:334- 40. 19. Holmberg, S. D. 1990. Possible cofactors for the development of AIDS-related neoplasms. Cancer Detection and Prevention. 14:331-336. 20. Honess, R. W. 1984. Herpes simplex and 'the herpes complex' : diverse observations and a unifying hypothesis. J Gen Virol. 65:2077- 2107. 21. Honess, R. W. , U. A. Gompels, B. G. Barrell, M. Craxton, K. R. Cameron, R. Staden, Y.-N. Chang, and G. S. Hayward. 1989. Deviations from expected frequencies of CpG dinucleotides in herpesvirus DNAs may be diagnostic of differences in the states of their latent genomes. J Gen Virol. 70:837-55. 22. Hsu, D., L. M. Shih, and Y. C. Zee. 1990. Nucleotide sequence of a 3.5 nucleotide fragment of malignant catarrhal fever virus strain WC11. Arch Virol. 113:53-60. 23. Kieff, E., and D. Liebowitz. 1990. Epstein- Barr virus and its replication, p. 1889-1920. In B. N. Fields and D. M. Knipe (ed.), Virology, vol. 2. Raven Press, New York. 24. Kolman, J. L., C. J. Kolman, and G. Miller. 1992. Marked variation in the size of genomic plasmids among members of the family of related Epstein-Barr viruses. Proc Natl Acad Sci, USA. 89:7772-7776. 25. Lebbe, C. , P. de Cremoux, M. Rybojad, C. Costa da Cunha, P. Morel, and F. Calvo. 1995. Kaposi's sarcoma and new herpesvirus. Lancet. 345:1180. 26. Lin, J. C, S. C. Lin, B. K. De, W. P. Chan, and B. L. Evatt. 1993. Precision of genotyping of Epstein-Barr virus by polymerase chain reaction using three gene loci (EBNA-2, EBNA-3C and EBER) : predominance of type A virus associated with Hodgkin's disease. Blood. 81:3372-81. 27. Liu, Z., S. Yu-Kai, Y.-P. Xi, P. Harris, and N. Suciu-Foca. 1992. T cell recognition of self-human histocompatibility leukocyte antigens (HLA) -DR peptides in the context of syngeneic HLA-DR molecules. J Exp Med. 175:1663-8. 28. Lomonte, P. , M. Bublot, P-P. Pastoret, and E. Thiry. 1992. Location and characterization of the bovine herpesvirus type 4 thymidine kinase gene; comparison with thymidine kinase of other herpesviruses. Arch. Virol. 127:327- 337. 29. Martin, M. E. D. , J. Nicholas, B. J. Thomson, C. Newman, and R. W. Honess. 1991. Identification of a transactivating function mapping to the putative immediate-early locus of human herpesvirus 6. J Virol. 65:5381- 5390. 30. McGeoch, D. J., and S. Cook. 1994. Molecular phylogeny of the Alphaherpesvirinae subfamily and a proposed evolutionary timescale. J Mol Biol. 238:9-22. 31. McGeoch, D. J. , S. Cook, A. Dolan, F. E. Jamieson, and E. A. R. Telford. 1995. Molecular phylogeny and evolutionary timescale for the family of mammalian herpesviruses. J Molec Biol. 247:443-58. 32. Miller, G. 1990. Epstein-Barr virus: Biology, pathogenesis and medical aspects, p. 1921-1957. In B. N. Fields and D. M. Knipe (ed.) , Virology, 2nd ed, vol. 2. Raven Press, New York. 33. Moore, P. S- , and Y. Chang. 1995. Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma lesions from persons with and without HIV infection. New England J Med. 332:1181- 1185. 34. Mukai, T., Y. Isegawa, and K. Yamanishi . 1995. Identification of the major capsid protein gene of human herpesvirus 7. Virus Res. 37:55-62. 35. Oettle, A. G. 1962. Geographic and racial differences in the frequency of Kaposi's sarcoma as evidence of environmental or genetic causes, vol. 18. Symposium on Kaposi's sarcoma: Unio Internationalis Contra Cancrum, Karger, Basel. 36. Pearson, W. R. , and D. J. Lipman. 1988. Improved tools for biological sequence analysis. Proc Natl Acad Sci, USA. 85:2444-8. 37. Peterman, T. A., H. W. Jaffe, A. E. Friedman- Kien, and R. A. Weiss. 1991. The aetiology of Kaposi's sarcoma, p. 23-37, Cancer, HIV, and AIDS, vol. 10. Imperial Cancer Research Fund. London. 38. Raab-Traub, N. , and K. Flynn. 1986. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell. 47:883-889. 39. Roizman, B. 1993. The family Herpesviridae, p. 1-9. In B. Roizman and R. J. Whitley and C. Lopez (ed.), The Human Herpeviruses. Raven Press, Ltd., New York. 40. Roizman, B. 1995. New viral footprints in Kaposi's sarcoma. N Engl J Med. 332:1227- 1228. 41. Roizman, B., R. C. Desrosiers, B. Fleckenstein, C. Lopez, A. C. Minson, and M. J. Studdert. 1992. The family Herpesviridae: an update. Arch Virol. 123:425-449. 42. Sandford, G. R. , K. Ho, and W. H. Burns. 1993. Characterization of the major locus of immediate-early genes of rat cyto egalovirus . J Virol. 67:4093-4103. 43. Schalling, M., M. Ekman, E. E. Kaaya, A. Linde, and P. Bieberfeld. 1995. A role for a new herpesvirus (KSHV) in different forms of Kaposi's sarcoma. Nature Med. 1:707-8. 44. Schwartz, R. M. , and M. 0. Dayhoff. 1978. Matrices for detecting distant relationships, p. 353-8. In M. 0. Dayhoff (ed.), Atlas of protein sequence and structure, vol. 5, supple 3. National Biomedical Research Foundation, Washington. 45. Su, I.-J., Y.-S. Hsu, Y.-C. Chang, and I.-W. Wang. 1995. Herpesvirus-like DNA sequence in Kaposi's sarcoma from AIDS and non-AIDS patients in Taiwan. Lancet. 345:722-23. 46. Telford, E. A. R. , M. S. Watson, H. C. Aird, J. Perry, and A. J. Davison. 1995. The DNA sequence of equine herpesvirus 2. J Molec Biol. 249:520-8. 47. zur Hausen, H., F. J. O'Neill, and U. K. Freese. 1978. Persisting oncogenic herpesvirus induced by the tumor promoter TPA. Nature. 272:373-375. EXPERIMENTAL DETAILS SECTION III; KS Patient Enrollment: Cases and controls were selected from ongoing cohort studies based on the availability of clinical information and appropriate PBMC samples. 21 homosexual or bisexual men with AIDS who developed KS during their participation in prospective cohort studies were identified [14-16] . Fourteen of these patients had paired PBMC samples collected after KS diagnosis (median +4 months) and at least four months prior to KS diagnosis (median -13 months) , while the remaining 7 had paired PBMC taken at the study visit immediately prior to KS diagnosis (median -3 months) and at entry into their cohort study (median -51 months prior to KS diagnosis) . Hemophilic and Homosexual/Bisexual Male AIDS Patient Control Enrollment: Two control groups of AIDS patients were examined: 23 homosexual/bisexual men with AIDS followed until death who did not develop KS ("high risk" control group) from the Multicenter AIDS Cohort Study [16]), and 19 hemophilic men ("low risk" control group) enrolled from joint projects of the National Hemophilia Foundation and the Centers for Disease Control and Prevention. Of the 16 hemophilic controls with available follow-up information, none are known to have developed KS and <2% of hemophilic AIDS patients historically develop KS [2] . For homosexual/bisexual AIDS control patients who did not develop KS, paired PBMC specimens were available at entry into their cohort study (median -35 months prior to AIDS onset) and at the study visit immediately prior to nonKS AIDS diagnosis (median BHL-6 months prior to AIDS onset) . DNA Extraction and Analyses: DNA from 10 6 -10 7 PBMC in each specimen was extracted and quantitated by spectrophotometry. Samples were prepared in physically isolated laboratories from the laboratory where polymerase chain reaction (PCR) analyses were performed. All samples were tested for amplifiability using primers specific for either the HLA-DQ locus (GH26/GH27) or b- globin [18] . PCR detection of KSHV DNA was performed as previously described [7] with the following nested primer sets: No. 1 outer 5' -AGCACTCGCAGGGCAGTACG-3' , 5' -GACTCTTCGCTGATGAACTGG-3' ; No. 1 inner 5'- TCCGTGTTGTCTACGTCCAG-3' , 5' -AGCCGAAAGGATTCCACCAT-3 ' ; No. 2 outer 5 ' -AGGCAACGTCAGATGTGAC- 3 ' , 5' - GAAATTACCCACGAGATCGC-3' ; No. 2 inner 5'- CATGGGAGTACATTGTCAGGACCTC-3' , 5' -GGAATTATCTCGCAGGTTGCC- 3'; No. 3 outer 5' -GGCGACATTCATCAACCTCAGGG-3' , 5'- ATATCATCCTGTGCGTTCACGAC-3' ,- No. 3 inner 5'- CATGGGAGTACATTGTCAGGACCTC-3' , 5' -GGAATTATCTCGCAGGTTGCC- 3' . The outer primer set was amplified for 35 cycles at 94° C for 30 seconds, 60° C for 1 minute and 72° C for 1 minute with a 5 minute final extension cycle at 72° C. One to three ml of the PCR product was added to the inner PCR reaction mixture and amplified for 25 additional cycles with a 5 minute final extension cycle. Primary determination of sample positivity was made with primer set No. 1 and confirmed with either primer sets 2 or 3 which amplify nonoverlapping regions of the KSHV hypothetical major capsid gene. Sampling two portions of the KSHV genome decreased the likelihood of intraexperimental PCR contamination. These nested primer sets are 2-3 logs more sensitive for detecting KSHV sequences than the previously published KS330 233 primers [6] and are estimated to be able to detect <10 copies of KSHV genome under optimal conditions. Sample preparations were prealiquoted and amplified with alternating negative control samples without DNA to monitor and control possible contamination. All samples were tested in a blinded fashion and a determination of the positivity/negativity made before code breaking. Significance testing was performed with Mantel-Haenszel chi-squared estimates and exact confidence intervals using Epi-Info ver. 6 (USD Inc., Stone Mt. GA) . RESULTS KSHV Positivity of Case and Control PBMC Samples: Paired PBMC samples were available from each KS patient and homosexual/bisexual control patient; a single sample was available from each hemophilic control patient. To determine the KSHV positivity rate for each group of AIDS patients, a single specimen from each participant taken closest to KS or other AIDS-defining illness ("second sample") was analyzed. Overall, 12 of 21 (57%) of PBMC specimens from KS patients taken from 6 months prior to KS diagnosis to 20 months after KS diagnosis were KSHV positive. There was no apparent difference in positivity rate between immediate pre-diagnosis and post-diagnosis visit specimens (4 of 7 (57%) vs. 8 of 14 (57%) respectively) . The number of KSHV positive control PBMC specimens from both homosexual/bisexual (second visit) and hemophilic patient controls was significantly lower. Only 2 of 19 (11%) hemophilic PBMC samples were positive (odds ratio 11.3, 95 % confidence interval 1.8 to 118) and only 2 of 23 (9%) PBMC samples from homosexual/bisexual men who did not develop KS were positive (odds ratio 14.0, 95% confidence interval 2.3 to 144) . If all KS patient PBMC samples taken immediately prior to or after diagnosis were truly infected, the PCR assay was at least 57% sensitive in detecting KSHV infection among PBMC samples. No significant differences in CD4+ counts were found for KS patients and homosexual/bisexual patients without KS at the second sample evaluation (Kruskall- Wallis p=0.15) (Figure 21) . CD4+ counts from the single sample from hemophilic AIDS patients were higher than CD4 + counts from KS patients (Kruskall-Wallis p=0.004) , although both groups showed evidence of HIV-related immunosuppression. Longitudinal Studies : Paired specimens were available from all 21 KS patients and 23 homosexual/bisexual male AIDS control patients who did not develop KS. For the KS group, initial PBMC samples were taken four to 87 months (median 13 months) prior to the onset of KS. Initial PBMC samples from the control group were drawn 13 to 106 months (median 55 months) prior to onset of first nonKS AIDS-defining illness (1987 CDC surveillance definition) . 11 of 21 (52%) of KS patients had detectable KSHV DNA in PBMC samples taken prior to KS onset compared to 2 of 19 (11%, p=0.005) hemophilic control samples, and 1 (4%, p=0.0004) and 2 (9%, p=0.002) of 23 homosexual/bisexual control samples taken at the first and second visits respectively (Figures 20A-20B) . The figure shows that 7 of the paired KS patient samples were positive at both visits, 5 KS patients and 2 control patients converted from negative to positive and two KS patients and one control patient reverted from positive to negative between visits. The remaining 7 KS patients and 20 control patients were negative at both visits. For the 5 KS patients that converted from an initial negative PBMC result to a positive result at or near to KS diagnosis, the median length of time between the first sample and the KS diagnosis was 19 months. Three of the 6 KS patients that were negative at both visits had their last PBMC sample drawn 2-3 months prior to onset of illness. It is unknown whether these patients became infected between their last study visit and the KS diagnosis date. DISCUSSION Ambroziak and coworkers have found evidence that KSHV preferentially infects CD19+ B cells by PBMC subset examination of three patients [19] . Other gammaherpesviruses, such as Epstein-Barr virus (EBV) and herpesvirus saimiri are also lymphotrophic herpesviruses and can cause lymphoproliferative disorders in primates [11, 20] . It is possible that KSHV, like most human herpesviruses, is a ubiquitous infection of adults [21] . EBV, for example, is detectable by PCR in CD19+ B lymphocytes from virtually all seropositive persons [22] and approximately 98% MACS study participants had EBV VCA antibodies at entry into the cohort study [23] . The findings, however, are most consistent with control patients having lower KSHV infection rates than cases and that KSHV is specifically associated with the subsequent development of KS. While it is possible that control patients are infected but have an undetectably low KSHV viral PBMC load, the inability to find evidence of infection in control patients under a variety of PCR conditions suggests that the majority of control patients are not infected. Nonetheless, approximately 10% of these patients were KSHV infected and did not develop KS. It is unknown whether or not this is similar to the KSHV infection rate for the general human population. This study demonstrates that KSHV infection is both strongly associated with KS and precedes onset of disease in the majority of patients. 57% of KS patients had detectable KSHV infection at their second follow-up visit (52% prior to the onset of KS] compared to only 9% of homosexual/bisexual (p=0.002) and 11% of hemophilic control patients (p=0.005) . Despite similar CD4+ levels between homosexual/bisexual KS cases and controls, KSHV DNA positivity rates were significantly higher for cases at both the first (p=0.005) and second sample visits indicating that immunosuppression alone was not responsible for these elevated detection rates. It is also unlikely that KSHV simply colonizes existing KS lesions in AIDS patients since neither patient group had KS at the time the initial sample was obtained. Five KS patients and two homosexual/bisexual control patients converted from a negative to a positive, possibly due to new infection acquired during the study period. The findings are in contrast to PCR detection of KSHV DNA in all 10 PBMC samples from KS patients by Ambroziak et al . [19] . It is possible that the assay was not sensitive enough to detect virus in all samples since it was required that each positive sample to be repeatedly positive by two independent primers in blinded PCR assays. This appears unlikely, however, given the sensitivity of the PCR nested primer sets. The 7 KS patients who were persistently negative on both paired samples may represent an aviremic or low viral load subpopulation of KS patients. The PCR conditions test a DNA amount equivalent to approximately 2xl0 3 lymphocytes; an average viral load less than 1 copy per 2xl0 3 cells may be negative in the assay. Two KS patients and a homosexual/bisexual control patient initially positive for KSHV PCR amplification reverted to negative in samples drawn after diagnosis. These results probably reflect inability to detect KSHV DNA in peripheral blood rather than true loss of infection although more detailed studies of the natural history of infection are needed. The study was designed to answer the fundamental question of whether or not infection with KSHV precedes development of the KS phenotype. The findings indicate that there is a strong antecedent association between KSHV infection and KS. This temporal relationship is an absolute requirement for establishing that KSHV is central to the causal pathway for developing KS. This study contributes additional evidence for a possible causal role for this virus in the development of KS. REFERENCES 1. Katz MH, Hessol NA, Buchbinder SP, Hirozawa A, O'Malley P, Holmberg SD. Temporal trends of opportunistic infections and malignancies in homosexual men with AIDS. J Infect Dis . 1994;170:198-202. 2. Beral V, Peterman TA, Berkelman RL, Jaffe HW. Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? Lancet . 1990;335:123-128. 3. Archibald CP, Schechter MT, Le TN, Craib KJP, Montaner JSG, O' Shaughnessy MV. Evidence for a sexually transmitted cofactor for AIDS-related Kaposi's sarcoma in a cohort of homosexual men. Epidemiol . 1992;3:203-209. 4. Beral V, Bull D, Jaffe H, Evans B, Gill N, Tillett H et al . Is risk of Kaposi's sarcoma in AIDS patients in Britain increased if sexual partners came from United States or Africa? BMJ. 1991;302:624-5. 5. Beral V. Epidemiology of Kaposi's sarcoma. Cancer, HIV and AIDS. London: Imperial Cancer Research Fund; 1991:5-22. 6. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, et al . Identification of herpesvirus- like DNA sequences in AIDS-associated Kaposi's sarcoma. Science . 1994;265:1865-69. 7. Moore PS, Chang Y. Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma lesions from persons with and without HIV infection. New England J Med. 1995;332:1181-1185. 8. Boshoff C, Whitby D, Hatziionnou T, Fisher C, van der Walt J, Hatzakis A et al. Kaposi's sarcoma- associated herpesvirus in HIV-negative Kaposi's sarcoma. Lancet . 1995;345:1043-44. 9. Su I-J, Hsu Y-S, Chang Y-C, Wang I-W. Herpesvirus- like DNA sequence in Kaposi's sarcoma from AIDS and non-AIDS patients in Taiwan. Lancet . 1995,-345 : 722- 23. 10. Dupin N, Grandadam M, Calvez V, Gorin I, Aubin JT, Harvard S, et al . Herpesvirus-like DNA in patients with Mediterranean Kaposi's sarcoma. Lancet. 1995;345:761-2. 11. Miller G. Oncogenicity of Epstein-Barr virus. J Infect Dis. 1974;130:187-205. 12. Hill AB. Environment and disease: association or causation? Proc Roy Soc Med. 1965;58:295-300. 13. Susser M. Judgment and causal inference: criteria in epidemiologic studies. Am J Epid. 1977;105:1-15. 14. Fishbein DB, Kaplan JE, Spira TJ, Miller B, Schonberger LB, Pinsky PF, et al . Unexplained lymphadenopathy in homosexual men: a longitudinal study. JAMA. 1985;254:930-5. 15. Holmberg SD. Possible cofactors for the development of AIDS-related neoplasms. Cancer Detection and Prevention. 1990;14:331-336. 16. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR. The Multicenter AIDS Cohort Study: rationale, organization and selected characteristics of the participants. Am J Epidemiol. 1987;126:310-318. 17. Wolinsky S, Rinaldo C, Kwok S, Sinsky J, Gupta P, Imagawa D, et al . Human immunodeficiency virus type 1 (HIV-1) infection a median of 18 months before a diagnostic Western blot. Ann Internal Med. 1989;111:961. 18. Bauer HM, Ting Y, Greer CE, Chambers JC, Tashiro CJ, Chimera J, et al . Genital papillomavirus infection in female university students as determined by a PCR-based method. JAMA. 1991;265:2809-10. 19. Ambroziak JA, Blackbourn DJ, Herndier BG, Glogau RG, Gullett JH, McDonald AR, et al. Herpes-like sequences in HIV-infected and uninfected Kaposi's sarcoma patients. Science. 1995;268:582-583. 20. Roizman B. The family Herpesviridae. In: Roizman B, Whitley RJ, Lopez C, eds. The Human Herpeviruses . New York: Raven Press, Ltd.; 1993:1-9. 21. Roizman B. New viral footprints in Kaposi's sarcoma. N Engl J Med. 1995;332:1227-1228. 22. Miyashita EM, Yang B, Lam KMC, Crawford DH, Thorley-Lawson DA. A novel form of Epstein-Barr virus latency in normal B cells in vivo. Cell. 1995;80:593-601. 23. Rinaldo CR, Kingsley LA, Lyter DW, Rabin BS, Atchison RW, Bodner AJ, et al . Association of HTLV- III with Epstein-Barr virus infection and abnormalities of T lymphocytes in homosexual men. J Infect Dis. 1986;154:556-61. EXPERIMENTAL DETAILS SECTION IV; To determine if the KHV-KS virus is also present in both endemic and HIV-associated KS lesions from African patients, formalin-fixed, paraffin-embedded tissues from both HIV seropositive and HIV seropositive Ugandan KS patients were compared to cancer tissues from patients without KS in a blinded case-control study. Patient Enrollment: Archival KS biopsy specimens were selected from approximately equal numbers of HIV- associated and endemic HIV-negative KS patients enrolled in an ongoing case-control study of cancer and HIV infection at Makerere University, Kampala Uganda. Control tissues were consecutive archival biopsies from patients with various malignancies enrolled in the same study, chosen without prior knowledge of HIV serostatus. All patients were tested for HIV antibody (measured by Cambridge Bioscience Recombigen Elisa assay) . Tissue preparation: Each sample examined was from an individual patient. Approximately ten tissue sections were cut (10 micron) from each paraffin block using a cleaned knife blade for each specimen. Tissue sections were deparaffinized by extracting the sections twice with 1 ml xylene for 15 min. followed by two extractions with 100% ethanol for 15 min. The remaining pellet was then resuspended and incubated overnight at 50° C in 0.5 ml of lysis buffer (25 mM KC1, 10 mM Tris-HCl, pH 8.3, 1.4 mM MgC12, 0.01% gelatin, 1 mg/ml proteinase K) . DNA was extracted with phenol/chloroform, ethanol precipitated and resuspended in 10 mM Tris-HCl, 0.1 mM EDTA, pH 8.3. PCR Amplification: 0.2-0.4 ug of DNA was used in PCR reactions with KS330 233 primers as previously described [7] . The samples which were negative were retested by nested PCR amplification, which is approximately 10 2 -10 3 fold more sensitive in detecting KS330 233 sequence than the previously published KS330 233 primer set [7] . These samples were tested twice and samples showing discordant results were retested a third time. 51 of 74 samples initially examined were available for independent extraction and testing at Chester Beatty Laboratories, London using identical nested PCR primers and conditions to ensure fidelity of the PCR results. Results from eight samples were discordant between laboratories and were removed from the analysis as uninterpretable (four positive samples from each laboratory) . Statistical comparisons were made using EPI-INFO ver. 5 (USD, Stone Mt . GA, USA) with exact confidence intervals. RESULTS; Of 66 tissues examined, 24 were from AIDS-KS cases, 20 were from endemic HIV seronegative KS cases, and 22 were from cancer control patients without KS. Seven of the cancer control patients were HIV seropositive and 15 were HIV seronegative (Figure 22) . Tumors examined in the control group included carcinomas of the breast, ovaries, rectum, stomach, and colon, fibrosarcoma, lymphocytic lymphomas, Hodgkin's lymphomas, choriocarcinoma and anaplastic carcinoma of unknown primary site. The median age of AIDS-KS patients was 29 years (range 3-50) compared to 36 years (range 3-79) for endemic KS patients and 38 years (range 21-73) for cancer controls. Among KS lesions, 39 of 44 (89%) were positive for KS330 233 PCR product, including KS tissues from 22 of 24 (92%) HIV seropositive and 17 of 20 (85%) HIV seronegative patients. In comparison, 3 of 22 (14%) nonKS cancer control tissues were positive, including 1 of 7 (14%) HIV seropositive and 2 of 15 (13%) HIV seronegative control patients (Figure 19) . These control patients included a 73 year old HIV seronegative male and a 29 year old HIV seronegative female with breast carcinomas, and a 36 year old HIV seropositive female with ovarian carcinoma. The odds ratios for detecting the sequences in tissues from HIV seropositive and HIV seronegative cases and controls was 66 (95% confidence interval (95% C.I.) 3.8-3161) and 36.8 (95% C.I. 4.3-428) respectively. The overall weighted Mantel-Haenzel odds ratio stratified by HIV serostatus was 49.2 (95% C.I. 9.1-335) . KS tissues from four HIV seropositive children (ages 3, 5, 6, and 7 years) and four HIV seronegative children (ages 3, 4, 4, and 12 years) were all positive for KS330 233 . All discordant results (i.e. KSHV negative KS or KSHV positive nonKS cancers) were reviewed microscopically. All KS330 233 PCR negative KS samples were confirmed to be KS. Likewise, all KS330 233 PCR positive nonKS cancers were found not to have occult KS histopathologically. DISCUSSION These results indicate that KSHV DNA sequences are found not only in AIDS-KS [5] , classical KS [6] and transplant KS [7] but also in African KS from both HIV seropositive and seronegative patients. Despite differences in clinical and epidemiological features, KSHV DNA sequences are present in all major clinical subtypes of KS from widely dispersed geographic settings. This study was performed on banked, formalin-fixed tissues which prevented the use of specific detection assays such as Southern hybridization. DNA extracted after such treatment is often fragmented which reduces the detection sensitivity of PCR and may account for the 5 PCR negative KS samples found in the study. The results, however, are unlikely to be due to PCR contamination or nonspecific amplification. Specimens were tested blindly and a subset of samples were independently extracted and tested at a physically separate laboratory. Specimen blinding is essential to ensure the integrity of results based solely on PCR analyses. A subset of amplicons was sequenced and found to be more than 98% identical to the published KS330 233 sequence confirming their specific nature and, because of minor sequence variation, making the possibility of contamination unlikely. In contrast to previous studies in North American and European populations, it was found 3 of 22 control tissues to have evidence of KSHV infection. Since these cancers represent a variety of tissue types, it is unlikely that KSHV has an etiologic role in these tumors. One possible explanation for the findings is that these results reflect the rate of KSHV infection in the nonKS population in Uganda. Four independent controlled studies from North America [5 and9 ] Europe [7] and Asia [8] have failed to detect evidence of KSHV infection in over 200 cancer control tissues, with the exception of an unusual AIDS-associated, body-cavity- based lymphoma [9] . Taken together, these studies indicate that DNA-based detection of KSHV infection is rare in most nonKS cancer tissues from developed countries. KSHV infection has been reported in post- transplant skin tumors, although well-controlled studies are needed to confirm that these findings are not due to PCR contamination [10] . Since the rate of HIV-negative KS is much more frequent in Uganda than the United States, detection of KSHV in control tissues from cancer patients in the study may reflect a relatively high prevalence infection in the general Ugandan population. While KS is extremely rare among children in developed countries [2] , the rate of KS in Ugandan children has risen dramatically over the past 3 decades: age- standardized rates (per 100,000) for boys age 0-14 years were 0.25 in 1964-68 and 10.1 in 1992-93. Detection of KSHV genome in KS lesions from prepubertal children suggests that the virus has a nonsexual mode of transmission among Ugandan children. That five of these children were 5 years old or less raises the possibility that the agent can be transmitted perinatally. Whether or not immune tolerance due to perinatal transmission accounts for the more fulminant form of KS occurring in African children remains to be investigated. REFERENCES 1. Oettle A.G. Geographic and racial differences in the frequency of Kaposi's sarcoma as evidence of environmental or genetic causes. Acta Un Int Cancer 1962;18:330-363. 2. Beral V. Epidemiology of Kaposi's sarcoma. In: Cancer, HIV and AIDS. London: Imperial Cancer Research Fund, 1991: 5-22. 3. Wabinga H.R., Parkin D.M. , Wabwire-Mangen F., Mugerwa J. Cancer in Kampala, Uganda, in 1989-91: changes in incidence in the era of AIDS. Int J Cancer 1993;54:26-36. 4. Kestens L. et al . Endemic Kaposi's sarcoma is not associated with immunodeficiency. Int. J. Cancer 1985;36:49-54. 5. Chang Y. et al . Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266:1865-9. 6. Moore P.S. and Chang Y. Detection of herpesvirus- like DNA sequences in Kaposi's sarcoma lesions from persons with and without HIV infection. New England J Med 1995; 332:1181-85. 7. Boshoff C. et al . Kaposi's sarcoma-associated herpesvirus in HIV negative Kaposi's sarcoma (letter) . Lancet 1995; 345:1043-44. Su, I.-J., Hsu, Y.-S., Chang, Y.-C, Wang, I.-W. Herpevirus-like DNA sequence in Kaposi's sarcoma from AIDS and non-AIDS patients in Taiwan. Lancet 1995;345: 722-3. 9. Cesarman E., Chang Y. , Moore P.S., Said J.W., Knowles D.M. Kaposi's sarcoma-associated herpesvirus-like DNA sequences are present in AIDS- related body cavity based lymphomas. New England J Med 1995; 332:1186-1191. 10. Rady P.L., et al . Herpesvirus-like DNA sequences in nonKaposi's sarcoma skin lesions of transplant patients. Lancet 1995;345:1339-40. EXPERIMENTAL DETAILS SECTION V; Serologic marker for KSHV infection. METHODS Patients Serum was collected from a convenience sample of 89 HIV-infected patients seen at several clinical sites in Connecticut, New York, and California. Demographic and clinical information was recorded on standardized forms which were linked to samples by a numerical code. Patients were classified as having KS if the diagnosis was histologically confirmed or, in the opinion of the primary clinician, the diagnosis of KS was unequivocal on clinical grounds. Eighty six (97%) were male; 90 of the 86 men (93%) were homosexual or bisexual. Forty seven patients, all male, had KS. The characteristics of the study population are found in Figure 23] . Cell lines The BCBL-1 line was established from an AIDS-associated body cavity B cell non-Hodgkin' s lymphoma [30] . Neither BCBL-1 cells, nor the tumor from which they were derived, express surface immunoglobulin or B cell specific surface markers; however BCBL-1 cells contain immunoglobulin gene rearrangements that are characteristic of B cells [31] . KSHV DNA sequences can be detected in BCBL-1 cells by DNA representational difference analysis [23,32] . BCBL-1 cells also contain an EBV genome detectable with several different EBV DNA probes. B95-8 is an EBV producer marmoset cell line that can be efficiently induced into EBV lytic cycle gene expression by phorbol esters (TPA) [33,34] . HH 514- 16 is an EBV containing cell line, originally from a Burkitt lymphoma, that is optimally inducible into EBV lytic cycle gene expression by n-butyrate [35,36] . B141 is an EBV-negative Burkitt lymphoma cell line [37] . B95-8, HH514-16 and BL41 do not hybridize with the KSHV probes. All cell lines were cultured in RPMI 1640 medium containing 8% fetal calf serum. Immunoblotting Assays Extracts of uninduced BCBL-1 cells or BCBL-1 cells that had been treated with 20ng/ml TPA and 3 mM n-butyrate for 48 hrs were prepared by sonication. HH514-16 cells, treated similarly, served to control for antibody reactivity to EBV polypeptides. Each lane of a 10% or 12% polyacrylamide gel was loaded with extract of 5 X 10 s cells in SDS sample buffer; electrophoresis, transfer to nitrocellulose and blocking with skim milk followed standard protocols [38] . Sera were screened at 1"100 dilution. The reaction was developed by 1.0 μCi of 12S I Staphylococcal protein A. Radioautographs were exposed to film for 24-48 hrs. Immunoblotting assays were performed and interpreted on coded sera. Immunofluorescent assay The antigens were BCBL-1 cells that were untreated or treated with 3mM n-butyrate for 48 hrs. Cells were dropped onto slides that were fixed in acetone and methanol . Sera were tested at 1:10 dilution, followed by 1:30 dilution of fluoresceinated goat anti-human Ig. The reactivity of a serum was compared on untreated and n-butyrate treated BCBL-1 cells. Reactivity with 30-50% of the chemically treated BCBL-1 cells was considered a positive reaction. All immunofluorescence tests were performed on coded sera. The two readers were blinded to disease status or results of immunoblotting assays. RESULTS Chemical Induction of lvtic cycle KSHV proteins in BCBL cells : Initial experiments using the immunoblotting technique were designed to determine whether BCBL-1 cells expressed unique antigenic polypeptides that might be specific for KSHV infection. Since sera from HIV-l infected patients with or without KS would be expected to contain antibodies to EBV polypeptides and since BCBL-1 cells are dually infected with KSHV and EBV it was essential to distinguish EBV polypeptides from those encoded or induced by KSHV. Figures 27A-27B, an immunoblot prepared from BCBL-1 cells reacted with a reference EBV antiserum, shows that BCBL-1 cells expressed two polypeptides, representing the latent nuclear antigen EBNAl and p21, a late antigen complex [39] , that were present in other EBV producer cell lines, such as B95-8 (Figure 27A) and HH514-16 (Figure 27B and Figures 28A-28D) . When sera from patients with KS were used as a source of antibody they failed to identify in extracts from untreated BCBL-1 cells additional antigenic polypeptides that were not also seen in the EBV producer cell lines. However, if extracts were prepared from BCBL-1 cells that had first been treated witha combination of phorbol ester, TPA, and n-butyrate, KS patient sera now recognized a number of novel polypeptides that were present int eh BCBL-1 cell line but not in standard EBV producer cell lines (Figure 27B) . The molecular weights of the most prominent of these many polypeptides were estimated at about 27 KDa, 40 KDa and 60 KDa on 10% polyacrylamide gels. These polypeptides were detected within 24 hrs after addition of the chemical inducing agents, but were not evident in BCBL-1 held in culture for as long as 5 days without chemical treatment. Further experiments showed that n-butyrate was the chemical agent primarily responsible for induction of p40, whereas p60 could be induced by TPA or n-butyrate (Figures 28A-28D) . Since p27, p40 and p60 were not detected in untreated cells and appeared after treatment with chemicals they likely represented lytic cycle rather than latent cycle polypeptides of KSHV. p4Q and p60 are KSHV specific: Figures 27A-27B shows that antigenic polypeptides corresponding in molecular weight to p40 were not observed in two EBV producer lines, B95-8 and HH514-16, that were induced into the EBV lytic cycle by the same chemicals or in comparably treated EBV-negative BL41 cells. Furthermore n-butyrate strongly induced expression of p40 in BCBL-1 cells but had little or no effect on the level of expression of the EBV p21 complex in the same cells. In related experiments it was found that n-butyrate also induced an increase in the abundance of KSHV DNA and KSHV lytic cycle mRNA. TPA, by contrast, induced the EBV lytic cycle efficiently' treatment with TPA caused an increase in the abundance of the EBV p21 protein and minimal induction of KSHV p40. These findings suggested that latency to lytic cycle switch of the two gamma herpes viruses carried by BCBL-1 cells was under separate control and that the p40 complex was specific to the KSHV genome. p40 as a serologic marker for KSHV: While a few highly reactive sera, such as KS 01-03, (Figure 27B) recognized multiple antigenic proteins unique to the chemically induced BCBL-1 cells, including p27, p60 and p40, sera from other patients with KS did not react with p27 or p60 but still recognized p40 (Figure 28A and 28B) . Therefore recognition of p40 was investigated as a serologic marker for infection with KSHV. Sera from 89 HIV-l infected patients from Connecticut, New York and California were examined for presence of antibodies to p40; only 3 of 42 patients (7%) without KS had antibodies to p40 (p<0.0001 by Chi square) . These three patients were homosexual or bisexual men from New York city. The positive and negative predictive values of the serologic marker for the presence of KS were 84% and 78% respectively. Three HIV-l infected men from New York with non-Hodgkin' s lymphoma but without KS were non-reactive to the KSHV p40 antigen. Figure 25 compares the patients with KS whose serum did or did not contain antibodies to KSHV p40. Neither CD4 cell number nor the extent of KS disease predicted the presence or absence of a serologic response to p40. Immunofluorescence assays: Immunoblots showed that n- butyrate induced expression of KSHV lytic cycle polypeptides in BCBL-1 cells without significantly affecting expression of EBV polypeptides (Figure 28A) . Therefore it was reasoned that n-butyrate might also induce many more BCBL-1 cells into the KSHV lytic cycle than into the EBV lytic cycle. Using indirect immunofluorescence with a reference human antiserum, RM in Figure 27B, that contains antibodies to EBV but not KSHV there were about 2% antigen positive untreated BCBL-1 cells and a similar number of antigen positive BCBL cell that had been treated with n-butyrate. Serum 01-03 that is EBV-positive and KS-positive (Figure 27B) detected 2% antigen positive cells in the untreated BCBL population, presumably the EBV expressing cells, while it detected 50% antigen positive BCBL-1 cells that had been treated with n-butyrate. This increase in the number of antigen positive BCBL-1 cells among the n- butyrate treated population served as the basis of an immunofluorescence screening assay for antibodies to KSHV lytic cycle antigens (Figures 29A-29F) . The results of the immunofluorescence assay were nearly identical to the immunoblotting assay (Figure 26) . Among 89 sera there were only 4 (3%) that were discordant in the two assays. Three sera scored positive by IFA and negative by immunoblotting: one was considered positive by immunoblotting and negative by IFA. 68% of patients with KS and 12% of HIV-l infected patients without KS were reactive by indirect immunofluorescence assay (IFA) . Thus using two different assays, antibodies to KSHV lytic cycle antigens were found 6 to 9 times more frequently among patients with KS than among HIV-l infected patients without KS. Stated another way, among individuals who were seropositive to KSHV p40 32/35 (91%) had KS. Among those seropositive by the immunofluorescence assay 32/37 (86%) had KS. Thus infection with KSHV, as defined by these serologic markers, carries a high risk of development of KS. DISCUSSION The recent discovery of genetic sequences representative of a new human herpes virus in KS tumor tissue, taken together with past epidemiologic observations, strongly implicate this novel agent in the pathogenesis of KS. However, these observations, by themselves, do not permit the construction of a unified theory of pathogenesis that accounts for the many mysterious features of KS. For example, the relative contribution of HIV-l, other forms of immunosuppression, geographic factors, sex differences, the role of cytokines and growth factors, and the occurrence of distinct clinical variants must all be eventually understood. By identifying the infection rate in different populations a serologic marker for infection with KSHV would be great aid in unravelling the significance of the new virus in this complicated puzzle. One possibility is that KSHV, the putative etiologic agent is, like all the other human herpes viruses, a ubiquitous, or at least widespread virus which infects large segments of the human population. Individuals who are immunosuppressed would have a greater likelihood of developing disease, whereas immunocompetent individuals would remain healthy. This pathogenetic model is similar to that postulated for the role that EBV plays in non-Hodgkin's lymphoma or cytomegalovirus in retinitis in patients with AIDS. If this model is correct a very high proportion of the adult human population might be found to be seropositive for KSHV. The model of a ubiquitous virus selectively causing disease in immunodeficient individuals does not account for classical KS affecting patients who are not immunocompromised nor does it account for the observations that endemic KS in Africa preceded the HIV- 1 epidemic. Since many African patients with KS are HIV-l negative other co-factors must be implicated. The other possibility is that KSHV infection occurs selectively in the human population. Transmission may be promoted by sexual behavior that also carries a high risk of acquiring HIV-l. In this scenario seroprevalence of KSHV would be expected to be higher in HIV-l seropositive and HIV-l seronegative homosexual men than in other populations. If the virus alone were capable of inducing disease, acquisition of KSHV infection, as monitored by the presence of antibody, would be associated with a high rate of clinically evident KS. However, if KSHV infection needed to accompanied by other co-factors to cause disease, the prevalence of antibody of KSHV might be similar among patients with and without KS. The other co-factors would not be identified in a serologic test for antibodies to KSHV antigens. The findings, using tests for antibodies to KSHV lytic cycle antigens, are consistent with the general model in which infection with KSHV is infrequent but associated with a high rate of apparent disease. Only a few HIV-l infected patients without KS had antibodies to the KSHV lytic cycle antigens; by contrast a very high proportion of HIV-l infected men who had clinically evident KS were seropositive. This finding suggests that a high proportion of individuals who are dually infected with HIV-l and KSHV develop KS. However, another interpretation of the data is possible, though this interpretation is novel and no other examples are known among the human herpes virus family. Infection with KSHV might be ubiquitous, antibodies to the virus would not normally be detected in healthy infected individuals. Antibodies would only appear after the virus has been reactivated from the latent into the lytic cycle as might occur during the course of immunosuppression. Thus the two serologic tests that are described would indicate reactivated infection but would not be an index of past exposure to the virus. If this interpretation is correct, it should be possible to demonstrate KSHV DNA sequences or tot isolate the virus from healthy individuals who are KSHV seronegative. Regardless of which of these two interpretations is correct, the serologic studies provide a strong correlation between the presence of antibodies to KSHV lytic cycle gene products and clinical KS. Nonetheless there are two groups of patients whose serologic results require further explanation. One group consists of the few patients with positive serology for KSHV p40 without clinical KS. They may have subclinical or visceral disease, or they may develop KS in the future. The other group is the approximately 30% of patients with KS whose sera lacked antibody to p40. The patients with KS who were p40 seronegative were not misclassified since the diagnosis was confirmed in all of them by biopsy (Figure 25) . It is possible that the antibodies being measured are variable and wax and wane with time following infection. The appearance of antibody to p40 may reflect the extent of lytic viral replication which may vary during different phases of the disease. To determine whether this is true prospective studies including serial bleedings are required. p40 is likely to be only one among a number of KSHV antigens recognized by the infected patients. Antibody recognition of other KSHV antigens may not be possible on immunoblots because they comigrate with EBV polypeptides, because the BCBL-1 cells cannot be induced to express these antigens, or because the antigens are of low abundance or denatured on the immunoblots . In some individuals serum antibodies to p40 may be consumed in immune complexes with p40 antigen in the circulation. Thus detection of p40 on immunoblots may not be of optimal sensitivity. In this connection three sera recognized antigens in immunofluorescence tests but did not react with p40 on western blots. The serologic test employing whole BCBL-1 cells as antigen are clearly first generation assays to be improved by better characterization of the KSHV gene products and preparation of recombinant antigens. Lack of a serologic response to p40 could also reflect severely impaired humoral immunity. Although humoral immunity is usually relatively intact in HIV infection, examples of impaired antibody response have been described. For instance, some individuals are known to have impaired antibody responses to parvovirus B19(40 and others have been observed to lose antibodies to hepatitis B surface antigen (41] . An association between the degree of immunosuppression, as monitored by the number of CD4 cells, and the presence or absence of antibody p40 among patients with KS was not found (Figure 25) . Furthermore all the patients with or without antibodies to KSHV p40 had antibodies to EBV p21 suggesting an intact humoral immune response. In these serologic studies, as in the genetic probe studies previously reported, KSHV infection was found in the majority, but not all, patients with KS. Assuming that methodologic explanations do not account exclusively for the seronegative patients, other pathways, in addition to infection with KSHV, may lead to development of KS. In fact, most data suggest that the pathogenesis of KS is a multifactorial process. It has been observed that the product of the HIV-tat gene stimulates growth of KS tissue culture cells [42] and can induce KS-like lesions in mice [43] . These findings suggest a direct role for HIV-l in the pathogenesis of KS, at least in HIV-infected hosts. In other settings, other growth factors may play a similar or complementary function. Interleukin-6 and basic fibroblast growth factor are both known stimulate growth of KS cells invitro [44] . Interleukin-6 is also produced in AIDS-KS derived cell culture [44] . Thus, KS pathogenesis may involve autocrine and paracrine growth factors together with infection with KSHV in some patients or with certain strains of HIV-l in other patients. If infection with KSHV is the sine qua non of this process on would expect to see evidence of KSHV infection in all patients with KS. In summary, an immunoblotting and a immunofluorescence screening assay for detection of antibodies to lytic cycle antigens of KSHV is disclosed. These assays should permit detailed seroepidemiologic investigations of KSHV. The findings support the notion of a strong association between infection with KSHV and the development of KS in HIV-infected patients. Infection with KSHV, as defined by these serologic assays, appears to carry an extremely high risk of development of clinical KS. REFERENCES; 1. Kaposi M. Idiopathic multiple pigmented sarcoma of the skin. Cancer 1892; 31:3 2. Safai B, Good RA. Kaposi's sarcoma: A review and recent developments. Clin Bull 1980; 10:62-8. 3. Loethe R. Kaposi's sarcoma in Ugandan Africans. Acta Pathol Microbiol Scand 1963 (suppl) ; 161:1-70. 4. Gordon JA. Clinical features of Kaposi's sarcoma amongst Rhodesian Africans. Central African Journal of Medicine 1972; 19:1-6. 5. Penn I. Kaposi's sarcoma in organ transplant recipients. Transplantation 1979; 27:8-1. 6. Friedman-Kien AE . Kaposi's sarcoma and Pneumocystis carinii pneumonia among homosexual men - New York City and California. MMWR. 1981; 30:305-8. 7. Friedman-Kien AE, Laubensin LJ, Rubenstein P, et al . Disseminated Kaposi's sarcoma in homosexual men. Ann Intern Med 1982; 96:693-700. 8. Berel V, Peterman TA, Berkel RL, Jaffe HW. Kaposi's sarcoma among persons with AIDS: a sexually transmitted disease? Lancet 1990; 335:123-128. 9. Drew WL, Mills J, Hauer LB, et al . Declining prevalence of Kaposi's sarcoma in homosexual AIDS patients paralleled by a fall in cytomegalovirus transmission. Lancet 1988; 66. 10. Beral V, Peterman TA, Berkelman RL, et al . Kaposi's sarcoma among persons with AIDS: A sexually transmitted infection? Lancet 1990; 2:123. 11. Barley AC, Downng RG, Cheingson-Popov R et al . HTLV-III serology distinguishes atypical and endemic Kaposi's sarcoma in Africa. Lancet 1985; 1:359. 12. Ziegler, J. L., J.A. Beckstead, P.A. Volberding, et al . 1984. Non-Hodgkin' s lymphoma in 90 homosexual men: Relation to generalized lymphoadenopathy and the acquired immunodeficiency syndrome. N. Engl . J. Med. 311:565-570. 13. Levine AM. Non-Hodgkins lymphomas and other malifnancies in the acquired immunodeficiency syndrome. Semin Oncol 1987; 14:34-9. 14. Knowles DM, Chamulak M, Subar M, et al . Lymphoid neoplasia associated with the acquired immunodeficiency syndrome. Ann Intern Med 1988; 108:744-53. 15. MacMahon EME, Glass JD, Hayward SD, Mann RB, Becher PS, Charache P, McArthur JC, Ambender RF. Epstein- Barr virus in AIDS-related primary central nervous system lymphoma. Lancet 1991; 338:969-73. 16. Sillman FH, Sedlis A. Anogenital papillomavirus infection adn neoplasia in immunodeficiency women. Obstet Gynecol Clin North Am 1987; 260:348-53. 17. Drew WL, Mills J. Hauer LB, Miner RC, et al . Cytomegalovirus and Kaposi's sarcoma in young homosexual men. Lancet. 1982; 2:125-127. 18. Callant JE, Moore RD, Richman DD, Keruly J, Chaisson RE. Risk factors for Kaposi's sarcoma in patients with advanced human immunodeficiency virus disease treated wiht zidovudine. Arch Inter Med 1994; 154:566-72. 19. Giraldo, G., E. Beth, and E. Huang. 1980. Kaposi's sarcoma and its relationship to cytomegalovirus III CMV DNA and CMV early antigens in Kaposi's sarcoma. Int. J. Cancer 26:23-29. 20. Ambinder, R.F., Newman, C, Hawyard, G.S. et al . 1987 Lack of association of cytomegalovirus with endemic African Kaposi's sarcoma J. Inf. Dis . 156:193-7. 21. Jahan N, Razzaque A, Greenspan J et al . Analysis of human KS biopsies and cloned cell lines for cytomegalovirus, HIV-l and other selected DNA virus sequences. ADIS Res Human Retrovirus 1989; 5:225. 22. Wang RY-H, Shih, JW-k, Weiss SH, et al . Mycoplasma penetrans infections in male homosexuals with AIDS: high seroprevalence and association with Kaposi's sarcoma. Clin Infect Dis 1993; 17:724-29. 23. Chang YE, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994: 266; 1865-9. 24. Moore PS, Cahng Y. Dectection of Herpes virus-like DNA sequences in Kaposi's sarcoma inpateints with and those without HIV infection. N Engl J Med 1995; 332"1181-5. 25. Su IJ, Hsu YS, Chang YC, Wang IW. Herpesvirus-like DNA sequences in Kaposi's sarcoma from AIDS and non-AIDS pateints in Taiwan. Lancet 1995; 345:722- 3. 26. Huang YQ, Li JJ, Kaplan MH, Polesz B, Katabira WC, Zhang D, et al . Human herpesvirus-like nucleic acid in various forms of Kaposi's sarcoma. Lancet 1995; 345:759-61. 27. Dupin N, Grandadam M, Calvez V, Gorin I, Aubin JT, Harvard S, et al . Herpesviurs-like DNA sequence sin pateints with Mediterranean Kaposi's sarcoma. Lancet 1995; 345:761-2. 28. Collandre H, Ferris S, Grau 0, MontagnierL, Blanchard A, Kaposi's sarcoma and new herpes virus. Lancet 1995;345 : 1043. 29. Boshoff C, Whitby D, Hatziioannu T, Fisher C, van der Walt J, Hatzakis A, Weiss R Schultz T. Kaposi's sarcoma - associated herpes virus in HIV-negative Kaposi's Sarcoma. Lancet 1995; 345:1043-4. 30. Cesarman E, Chang Y, Moore PS, Said JW< Knowles DM. Kaposi's sarcoma associated herpes virus-like DNA sequences in alDS-related body-cavity-based lymphomas. N Engl J Med 1995; 332:1186-91. 31. Knowles, D. M. , G. Inghirami, A. Ubriaco, and R. Dalla-Favera. 1989. Molecular genetic analysis of three AIDS-associated neoplamss of uncertain lineage demonstrate their B-cell derivation and the possible pathogenetic role of the Epstein-Barr virus. Blod 74:792-799. 32. Lisitsyn, N. , N. Lisitsyn, and M. Wigler. 1993. Cloning the differences between two complex genomes. Science 259:946-951. 33. Miller G, Lipman M, Release of infectious Epstein- Barr virus by transformed marmoset leukocytes. Proc Nat Acad Sci USA 1973; 70:190-4. 34. zur Hausen, H. , F. J. O'Neill, U. K. Freese, and E. Hecker. 1978. Persisting oncogenic herpesvirus induced bytumor pomoter TPA. Naturer 272:373-375. 35. Rabson, M. , L. Heston, and G, Miller. 1983. Identification of a rare Epstein-Barr virus variant which enhances early antigen expression in Raji cells. Proc. Natl . aCad. Sci. USA 80:2762-2766. 36. Luka, J., B. Kallin, and G. Klien. 1979. Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology 94:228-231. 37. Calendar A, Billaud M, Aubry J-P, Bauchereau J, Vuillaume M, Lenoir GM. Epstein-Barr virus (EBV) induces expression of B-cell activation markers on in vitro infection of EBV-neative B-lymphoma cells. Proc nat Acad Sci USA 1987; 84 ,-8060-4. 38. Twobin, H., Staehelin, T., Gordon, J. Electrophoeretic transfer of proteins from polyacrylamide gels to nitrocullulose sheets: procedure and some applications Proc Natl Acad Sci USA 1979; 76: 4350-4354. 39. van Grunsven, W.M.J., E. C. van Heerde, H.J.W. de Haard, W.J.M. Spaan, and J Middledorp. 1993. Gene mapping and expression of two immunodominant Epstein-Barr virus capsid proteins. J. Virol. 67:3908-3916. 40. Frickhofen N, Abkowitz JL, Safford M, Berry M, Antunez-de-Mayolo J, et al . Persistent B19 Parvovirus infection in pateints infected with human immunodeficiency virus type 1 (HIV-l) : a treatable cause of anemia in ADIS. Ann Intern Med 1990; 113:926-33. 41. Biggar RJ, Goedert JJ, Hoofnagle J: Accelerated loss of antibody to hepatitis B surface antigen among immunodeficient homosexual men infected with HIV. N Engl J Med 1987; 316:630-31. 42. Ensoli B, Barillari G, Salahuddin SZ et al . Tat protein of HIV-l stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature 1990; 345:84. 43. Vogel J, Hinrichs SH, Reynolds RK, Luciw PA, Jay G. The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice. Nature 1994; 335:601-11. 44. Miles SA, Rezai AR, Salazar-Gonzalez JF, Stevens RH, Logan DM, Mistuyasu RT, Taga T, et al . AIDS Kaposi's sarcoma-derived cells produce and resond to interleukin-6. Proc Nath Acad Sci USA 1990; 87: 4068-72. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: The Trustees of Columbia University in the City of New York City (ii) TITLE OF INVENTION: UNIQUE ASSOCIATED KAPOSI'S SARCOMA VIRUS SEQUENCES AND USES THEREOF (iii) NUMBER OF SEQUENCES: 45 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Cooper & Dunham LLP (B) STREET: 1185 Avenue of the Americas (C) CITY: New York (D) STATE: New York (E) COUNTRY: U.S.A. (F) ZIP: 10036 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentln Release #1.25 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: White, John P. (B) REGISTRATION NUMBER: 28,678 (C) REFERENCE/DOCKET NUMBER: 45185-C-PCT/JPW/MSC (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (212) 278-0400 (B) TELEFAX: (212) 391-0525 (2) INFORMATION FOR SEQ ID NO:1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20710 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: N (iv) ANTI-SENSE: N (xi) SEQUENCE DESCRIPTION: SEQ ID Nθ:l: TCGAGTCGGA GAGTTGGCAC AGGCCTTGAG CTCGCTGTGA CGTTCTCACG GTGTTGGTTG 60 GGATCAGCTG GTGACTCAGA CAAGTCTTGA GCTCTACAAC GTAACATACG GGCTGATGCC 120 CACCCGATAC CAGAATTACG CAGTCGGCAA TTCTGTGCCC TAGAGTCACC TCAAAGAATA 180 ATCTGTGGTG TCCAAGGGGA GGGTTCTGGG GCCGGCTACT TAGAAACCGC CATAGATCGG 240 GCAGGGTGGA GTACTTGAGG AGCCGGCGGT AGGTGGCCAG GTGGGCCCGG TTACCTGCTC 300 TTTTGCGTGC TGCTGGAAGC CTGCTCAGGG ATTTCTTAAC CTCGGCCTCG GTTGGACGTA 360 CCATGGCAGA AGGCGGTTTT GGAGCGGACT CGGTGGGGCG CGGCGGAGAA AAGGCCTCTG 420 TGACTAGGGG AGGCAGGTGG GACTTGGGGA GCTCGGACGA CGAATCAAGC ACCTCCACAA 480 CCAGCACGGA TATGGACGAC CTCCCTGAGG AGAGGAAACC ACTAACGGGA AAGTCTGTAA 540 AAACCTCGTA CATATACGAC GTGCCCACCG TCCCGACCAG CAAGCCGTGG CATTTAATGC 600 ACGACAACTC CCTCTACGCA ACGCCTAGGT TTCCGCCCAG ACCTCTCATA CGGCACCCTT 660 CCGAAAAAGG CAGCATTTTT GCCAGTCGGT TGTCAGCGAC TGACGACGAC TCGGGAGACT 720 ACGCGCCAAT GGATCGCTTC GCCTTCCAGA GCCCCAGGGT GTGTGGTCGC CCTCCCCTTC 780 CGCCTCCAAA TCACCCACCT CCGGCAACTA GGCCGGCAGA CGCGTCAATG GGGGACGTGG 840 GCTGGGCGGA TCTGCAGGGA CTCAAGAGGA CCCCAAAGGG ATTTTTAAAA ACATCTACCA 900 AGGGGGGCAG TCTCAAAGCC CGTGGACGCG ATGTAGGTGA CCGTCTCAGG GACGGCGGCT 960 TTGCCTTTAG TCCTAGGGGC GTGAAATCTG CCATAGGGCA AAACATTAAA TCATGGTTGG 1020 GGATCGGAGA ATCATCGGCG ACTGCTGTCC CCGTCACCAC GCAGCTTATG GTACCGGTGC 1080 ACCTCATTAG AACGCCTGTG ACCGTGGACT ACAGGAATGT TTATTTGCTT TACTTAGAGG 1140 GGGTAATGGG TGTGGGCAAA TCAACGCTGG TCAACGCCGT GTGCGGGATC TTGCCCCAGG 1200 AGAGAGTGAC AAGTTTTCCC GAGCCCATGG TGTACTGGAC GAGGGCATTT ACAGATTGTT 1260 ACAAGGAAAT TTCCCACCTG ATGAAGTCTG GTAAGGCGGG AGACCCGCTG ACGTCTGCCA 1320 AAATATACTC ATGCCAAAAC AAGTTTTCGC TCCCCTTCCG GACGAACGCC ACCGCTATCC 1380 TGCGAATGAT GCAGCCCTGG AACGTTGGGG GTGGGTCTGG GAGGGGCACT CACTGGTGCG 1440 TCTTTGATAG GCATCTCCTC TCCCCAGCAG TGGTGTTCCC TCTCATGCAC CTGAAGCACG 1500 GCCGCCTATC TTTTGATCAC TTCTTTCAAT TACTTTCCAT CTTTAGAGCC ACAGAAGGCG 1560 ACGTGGTCGC CATTCTCACC CTCTCCAGCG CCGAGTCGTT GCGGCGGGTC AGGGCGAGGG 1620 GAAGAAAGAA CGACGGGACG GTGGAGCAAA ACTACATCAG AGAATTGGCG TGGGCTTATC 1680 ACGCCGTGTA CTGTTCATGG ATCATGTTGC AGTACATCAC TGTGGAGCAG ATGGTACAAC 1740 TATGCGTACA AACCACAAAT ATTCCGGAAA TCTGCTTCCG CAGCGTGCGC CTGGCACACA 1800 AGGAGGAAAC TTTGAAAAAC CTTCACGAGC AGAGCATGCT ACCTATGATC ACCGGTGTAC 1860 TGGATCCCGT GAGACATCAT CCCGTCGTGA TCGAGCTTTG CTTTTGTTTC TTCACAGAGC 1920 TGAGAAAATT ACAATTTATC GTAGCCGACG CGGATAAGTT CCACGACGAC GTATGCGGCC 1980 TGTGGACCGA AATCTACAGG CAGATCCTGT CCAATCCGGC TATTAAACCC AGGGCCATCA 2040 ACTGGCCAGC ATTAGAGAGC CAGTCTAAAG CAGTTAATCA CCTAGAGGAG ACATGCAGGG 2100 TCTAGCCTTC TTGGCGGCCC TTGCATGCTG GCGATGCATA TCGTTGACAT GTGGAGCCAC 2160 TGGCGCGTTG CCGACAACGG CGACGACAAT AACCCGCTCC GCCACGCAGC TCATCAATGG 2220 GAGAACCAAC CTCTCCATAG AACTGGAATT CAACGGCACT AGTTTTTTTC TAAATTGGCA 2280 AAATCTGTTG AATGTGATCA CGGAGCCGGC CCTGACAGAG TTGTGGACCT CCGCCGAAGT 340 CGCCGAGGAC CTCAGGGTAA CTCTGAAAAA GAGGCAAAGT CTTTTTTTCC CCAACAAGAC 2400 AGTTGTGATC TCTGGAGACG GCCATCGCTA TACGTGCGAG GTGCCGACGT CGTCGCAAAC 2460 TTATAACATC ACCAAGGGCT TTAACTATAG CGCTCTGCCC GGGCACCTTG GCGGATTTGG 2520 GATCAACGCG CGTCTGGTAC TGGGTGATAT CTTCGCATCA AAATGGTCGC TATTCGCGAG 2580 GGACACCCCA GAGTATCGGG TGTTTTACCC AATGAATGTC ATGGCCGTCA AGTTTTCCAT 2640 ATCCATTGGC AACAACGAGT CCGGCGTAGC GCTCTATGGA GTGGTGTCGG AAGATTTCGT 2700 GGTCGTCACG CTCCACAACA GGTCCAAAGA GGCTAACGAG ACGGCGTCCC ATCTTCTGTT 2760 CGGTCTCCCG GATTCACTGC CATCTCTGAA GGGCCATGCC ACCTATGATG AACTCACGTT 2820 CGCCCGAAAC GCAAAATATG CGCTAGTGGC GATCCTGCCT AAAGATTCTT ACCAGACACT 2880 CCTTACAGAG AATTACACTC GCATATTTCT GAACATGACG GAGTCGACGC CCCTCGAGTT 2940 CACGCGGACG ATCCAGACCA GGATCGTATC AATCGAGGCC AGGCGCGCCT GCGCAGCTCA 3000 AGAGGCGGCG CCGGACATAT TCTTGGTGTT GTTTCAGATG TTGGTGGCAC ACTTTCTTGT 3060 TGCGCGGGGC ATTGCCGAGC ACCGATTTGT GGAGGTGGAC TGCGTGTGTC GGCAGTATGC 3120 GGAACTGTAT TTTCTCCGCC GCATCTCGCG TCTGTGCATG CCCACGTTCA CCACTGTCGG 3180 GTATAACCAC ACCACCCTTG GCGCTGTGGC CGCCACACAA ATAGCTCGCG TGTCCGCCAC 3240 GAAGTTGGCC AGTTTGCCCC GCTCTTCCCA GGAAACAGTG CTGGCCATGG TCCAGCTTGG 3300 CGCCCGTGAT GGCGCCGTCC CTTCCTCCAT TCTGGAGGGC ATTGCTATGG TCGTCGAACA 3360 TATGTATACC GCCTACACTT ATGTGTACAC ACTCGGCGAT ACTGAAAGAA AATTAATGTT 3420 GGACATACAC ACGGTCCTCA CCGACAGCTG CCCGCCCAAA GACTCCGGAG TATCAGAAAA 3480 GCTACTGAGA ACATATTTGA TGTTCACATC AATGTGTACC AACATAGAGC TGGGCGAAAT 3540 GATCGCCCGC TTTTCCAAAC CGGACAGCCT TAACATCTAT AGGGCATTCT CCCCCTGCTT 3600 TCTAGGACTA AGGTACGATT TGCATCCAGC CAAGTTGCGC GCCGAGGCGC CGCAGTCGTC 3660 CGCTCTGACG CGGACTGCCG TTGCCAGAGG AACATCGGGA TTCGCAGAAT TGCTCCACGC 3720 GCTGCACCTC GATAGCTTAA ATTTAATTCC GGCGATTAAC TGTTCAAAGA TTACAGCCGA 3780 CAAGATAATA GCTACGGTAC CCTTGCCTCA CGTCACGTAT ATCATCAGTT CCGAAGCACT 3840 CTCGAACGCT GTTGTCTACG AGGTGTCGGA GATCTTCCTC AAGAGTGCCA TGTTTATATC 3900 TGCTATCAAA CCCGATTGCT CCGGCTTTAA CTTTTCTCAG ATTGATAGGC ACATTCCCAT 3960 AGTCTACAAC ATCAGCACAC CAAGAAGAGG TTGCCCCCTT TGTGACTCTG TAATCATGAG 4020 CTACGATGAG AGCGATGGCC TGCAGTCTCT CATGTATGTC ACTAATGAAA GGGTGCAGAC 4080 CAACCTCTTT TTAGATAAGT CACCTTTCTT TGATAATAAC AACCTACACA TTCATTATTT 4140 GTGGCTGAGG GACAACGGGA CCGTAGTGGA GATAAGGGGC ATGTATAGAA GACGCGCAGC 4200 CAGTGCTTTG TTTCTAATTC TCTCTTTTAT TGGGTTCTCG GGGGTTATCT ACTTTCTTTA 4 60 CAGACTGTTT TCCATCCTTT ATTAGACGGT CAATAAAGCG TAGATTTTTA AAAGGTTTCC 4320 TGTGCATTCT TTTTGTATGG GCATATACTT GGCAAGAAAT CCGAGCACCT CAGAAAGTGG 4380 ATTGCCGTCA CATATCAGTT CGACCACCCC TGCACCTAGC CATGCGGCGC TTTGACGGTC 4440 TTTGGGGCTA CACATCATAA AGTACTTTTC CATGGCTTCT ATAAGCACCT TGGAACAATC 4500 TGGGGGTTGG CGAATGGGTT CCCTAAACGG GAAATCCTCT ATGGTATTCA GGCAGAAGAC 4560 CGCGTCCTCC ACCCGACGTT TGAGTCTTTC TAGCAGAGCG CCGAAGAACT CCCGCTCGTG 4620 TGTTTTCGCA GGGGCAAGTT CTGCGCCGTA CAGCGATGAG AAACACGACA CGATGTTTTC 4680 CAGCCCCATG CTGCGCAGCA ACACGTGCTT CAGGAACAGG TGTTGTAGCC GGTTCAGTTT 4740 TAGCTTGGGT AGAAAAGTTA TCGAGTTGTT AGCACGCTCC ATGATGGTAA CGGTGTTGAA 4800 GTCACAGACC GGGCTTTCTC CGAGTCTCGG CCGCCTGAGT CCAATCATGT AGAACATAGA 4860 CGCGGCCTCG TTGTCTGTGT TAAGTGACAC GATATCCCGT TCGCAAACCT GTGCGATGTT 4920 GTGTTTCAGT ATAGATCTGG TCTGACCGGC ACGGGGTGTT ATGGGGTGAC GCGGTAAAGG 4980 CGACTCTGGG TCAAACACCT TTATGCGGTT GGCGGCCTCG TCGATGACGA CACGCTTGTT 5040 CGCGGCGTGT ATGGGGACGC GACGGCATCC CGCTGGCAGA TCTATAATCT TAAAGTTGGT 5100 ATAAGACTGG TCGCTCGTTA TGGCCAGCCG GCACTCCGGT AGTATCTGCG TGTCCTCGAA 5160 TTCGTGGCCG CGTACGACTG GCTTGGAGTG CAGGTAAACG CCAAGAGATG CGGTCTCTTC 5220 GCCTACGCAC AAGTGGCTTC TTAACGCGTA GGGGTGCGGT GAGAGCATGA TCCGTAGCAA 5280 CGATAGTTCC GGGTGCCTAG CCGCGTAGAG TGGCAGGGTA GACGAGTCCG GAGTCCCAAA 5340 CTTTTCGAAC AACAGTGGCA TCGGGACTTC AGGATTAGAG ACTCCCACCA TGGCCGCCAC 5400 CGCCGGAGAG GTCAAGACGT GAAACACGCG CTCGCCTGTC GACAGGCGCG CCGCGCCCTC 5460 TACTAGACTA GCCTTCACGT CCGGAACTCG TAACATAGCT TAGACCAGCG GACGGACGCA 5520 ACGTACGCGG GGATCGGCTG GCGGTGTCTG CTCGTTGGAC GCGGCCGTTC GGTGGCGCCA 5580 GTGCAGGCCT AGTTTGCGAA TGGCGTGACG GACAATTTGT GGCTTTAGAG CGGCGAACCG 5640 ATGACCCGTG GTGGCGACGA ACGAAATGAA GTTTGCATTG CGGCCCAACT CGTCTAGCCT 5700 GGTCTTCTTG TTTCGGGCAT AGATTTTCGG GATTAGGTTA CACTTTTTAT ATCCCAGTAC 5760 TGCGCACTCG TGTTTGCTTT TAGTGTGACT GATTATCTTC TTTGAGAAGT CAAACAGGCC 5820 CCGGGCGGCG GCTCGCCTAA TGCAAGCCAC GTCAAGCCTG AGAAACGAAC AGCATTCCAC 5880 CAGACACTCC AGGAACCTTT TGTGTAGCGT CTGTATTTGG GAACGGTTTC TGTGCTCAAG 5940 TAGGGAGAAT ATTCTATTTT TGTTTCCGTC GATGCGCGCG TGCTGGTCCG TGAGAATGGG 6000 CGCCAGCTCG TGGCGAATCT GTTCCACAAG AGGCTGCCCG TACACTTTAG AAATCGTGGC 6060 TGTCGCGGCC TTAAACCAGG ACACGTTTAG CCCATCCTTG CTGGAGACCA CAGATGGAAA 6120 GTTTGTGGTC CAAAATACGT TTTTTCGCCC CATTCTCACC ATGTACTGGT TTTCCAGTCC 6180 GTGCAGGTCC AACGTGGAGT TCCAATTTGC TATCGATACA GGAAATATGT GCCTGATTGG 6240 CAGAAAGCAT TTCAGCGTAC CCATTGCGAA GAGAAAGTGC AGCATGTCCC CACTGATGTT 6300 GATGTTTATT GCGGTGCCTT GACACATGTT GTCGGAAAAA AACACGCTTA TGGTAAAAGA 6360 AGGTTCCTTT ACGGAGTACT TTCGTATAAC AAAATTGTTG GTCAATCTGG GGATGTTTAA 6420 AATAGTCTTT TGCAGGGTGT TAGGAACGTG GCAGCTTATC TTAGTGTTAA TCACCATGTT 6480 GGTGTTGAAT ATGGTGATCT TGAAGTTTTC CAAACTGACG TGTTTTGTGG GTTCCAGCAT 6540 GTCTGACACT GTAGAGCTGC CCAGAGTCCG CGCGTCCGTG GCCGCGTATC GTTGGAAGCA 6600 CGCCTGCAAA TTTCCTTTCA TGGCTGCTCG CCGGTCTTTC GGCGCGTACC GGATTCTTGA 6660 AAGCGTCGCC GCCAGGAGAC GCGGTGTCTC GTGGGTGCCT AAAAAGTTTG CGCAGGGGTG 6720 CAGTCCGCTG CACGAGTGGC CGATGCAGTC TGCCACTGCC ATACACATGA CGAGTCTGTA 6780 GATGGCCGGT GTGCCCGGAT ACACTAGATA GTAGGTACAA TCTGGGGTAC TGACGACCAC 6840 CCTGTATGGC TTTGGTCCGG GGTCCTTGCG TTGGATTTTT ACGTGCAGAC GGGACACGAG 6900 CTGGTTTAGA GCCAGCTGAA AGCCCACCAG ATCCCGTCCG TTAACCTTGA CGTCCTGGTG 6960 CTTACTCTGT TTCGACAGGT TCTTCAGCAC GGTGGGCAGT CGCTCTACGT TGTGAGCGAT 7020 GGCACGGCGC AGCGAGACCA GCTCTCCGTG CCACCCCCAC GTGGCCATGA AGCTGCTGAT 7080 GTTAAACTTT AAAAAATGTA GCTGTGCGTC TGGGGATGCG GGTGGCATTA TTGAAAACGA 7140 GAGATGCTTC AGGCTCTCCA GGAGTGCAAA ATAATTTTGA TAGATTGTGG GTTGTAGACT 7200 ATGGGGCAAC ACCGCCAGAA ACGCATGAAA ACACTGTTCG AACTCCCAGA ACTCCAGGTA 7260 CCTGCACACT ATCCTGAACA TGGCTTTGTA ACATATGGTG CACGTTAGTA GCGCGGGAAG 7320 ATACAGCGAG CGTAGCTCCC TGAATTCGCA GGGTTTATCA CAATCATCGG TAAGTTCCCA 7380 TGATCCCACC GCAGGTAGGT AGTTGTCGGT GTCTATCTGT CCGCGCGTAA ACACTCCACC 7440 ACCGTCAATT ATTAAACCTT CGCCGCTGTA CCGTCGACCC ACTTTTCCCA AAAGAGTCCC 7500 TTCTTGATGT ATAAAAGGGT GGAGGCGTTC CCCCAGGAGT AGTCTGCGTA TCGCTCTGCA 7560 GGCGAAAAAG GTGGGCTCGG GCTGCATCAT CTTATCAAGA CCTTCTAAGG TCAGCTCTGC 7620 CTGCAGGTGC GAGTTGGTGG CCAGACAGCA GAATATTTCC AGCTGTGATT CCCAAGTCGC 7680 TTGATAACAC GTGGTCTGCG GACTCGTCGT CAGGGAGGCG CTCGGTGGCA GTAGTAGGGG 7740 GCCCTCGAGC GCTGCCATGG AGGCGACCTT GGAGCAACGA CCTTTCCCGT ACCTCGCCAC 7800 GGAGGCCAAC CTCCTAACGC AGATTAAGGA GTCGGCTGCC GACGGACTCT TCAAGAGCTT 7860 TCAGCTATTG CTCGGCAAGG ACGCCAGAGA AGGCAGTGTC CGTTTCGAAG CGCTACTGGG 7920 CGTATATACC AATGTGGTGG AGTTTGTTAA GTTTCTGGAG ACCGCCCTCG CCGCCGCTTG 7980 CGTCAATACC GAGTTCAAGG ACCTGCGGAG AATGATAGAT GGAAAAATAC AGTTTAAAAT 8040 TTCAATGCCC ACTATTGCCC ACGGAGACGG GAGGAGGCCC AACAAGCAGA GACAGTATAT 8100 CGTCATGAAG GCTTGCAATA AGCACCACAT CGGTGCGGAG ATTGAGCTTG CGGCCGCAGA 8160 CATCGAGCTT CTCTTCGCCG AGAAAGAGAC GCCCTTGGAC TTCACAGAGT ACGCGGGTGC 8220 CATCAAGACG ATTACGTCGG CTTTGCAGTT TGGTATGGAC GCCCTAGAAC GGGGGCTAGT 8280 GGACACGGTT CTCGCAGTTA AACTTCGGCA CGCTCCACCC GTCTTTATTT TAAAGACGCT 8340 GGGCGATCCC GTCTACTCTG AGAGGGGCCT CAAAAAGGCC GTCAAGTCTG ACATGGTATC 8400 CATGTTCAAG GCACACCTCA TAGAACATTC ATTTTTTCTA GATAAGGCCG AGCTCATGAC 8460 AAGGGGGAAG CAGTATGTCC TAACCATGCT CTCCGACATG CTGGCCGCGG TGTGCGAGGA 8520 TACCGTCTTT AAGGGTGTCA GCACGTACAC CACGGCCTCT GGGCAGCAGG TGGCCGGCGT 8580 CCTGGAGACG ACGGACAGCG TCATGAGACG GCTGATGAAC CTGCTGGGGC AAGTGGAAAG 8640 TGCCATGTCC GGGCCCGCGG CCTACGCCAG CTACGTTGTC AGGGGTGCCA ACCTCGTCAC 8700 CGCCGTTAGC TACGGAAGGG CGATGAGAAA CTTTGAACAG TTTATGGCAC GCATAGTGGA 8760 CCATCCCAAC GCTCTGCCGT CTGTGGAAGG TGACAAGGCC GCTCTGGCGG ACGGACACGA 8820 CGAGATTCAG AGAACCCGCA TCGCCGCCTC TCTCGTCAAG ATAGGGGATA AGTTTGTGGC 8880 CATTGAAAGT TTGCAGCGCA TGTACAACGA GACTCAGTTT CCCTGCCCAC TGAACCGGCG 8940 CATCCAGTAC ACCTATTTCT TCCCTGTTGG CCTTCACCTT CCCGTGCCCC GCTACTCGAC 9000 ATCCGTCTCA GTCAGGGGCG TAGAATCCCC GGCCATCCAG TCGACCGAGA CGTGGGTGGT 9060 TAATAAAAAC AACGTGCCTC TTTGCTTCGG TTACCAAAAC GCCCTCAAAA GCATATGCCA 9120 CCCTCGAATG CACAACCCCA CCCAGTCAGC CCAGGCACTA AACCAAGCTT TTCCCGATCC 9180 CGACGGGGGA CATGGGTACG GTCTCAGGTA TGAGCAGACG CCAAACATGA ACCTATTCAG 9240 AACGTTCCAC CAGTATTACA TGGGGAAAAA CGTGGCATTT GTTCCCGATG TGGCCCAAAA 9300 AGCGCTCGTA ACCACGGAGG ATCTACTGCA CCCAACCTCT CACCGTCTCC TCAGATTGGA 9360 GGTCCACCCC TTCTTTGATT TTTTTGTGCA CCCCTGTCCT GGAGCGAGAG GATCGTACCG 9420 CGCCACCCAC AGAACAATGG TTGGAAATAT ACCACAACCG CTCGCTCCAA GGGAGTTTCA 9480 GGAAAGTAGA GGGGCGCAGT TCGACGCTGT GACGAATATG ACACACGTCA TAGACCAGCT 9540 AACTATTGAC GTCATACAGG AGACGGCATT TGACCCCGCG TATCCCCTGT TCTGCTATGT 9600 AATCGAAGCA ATGATTCACG GACAGGAAGA AAAATTCGTG ATGAACATGC CCCTCATTGC 9660 CCTGGTCATT CAAACCTACT GGGTCAACTC GGGAAAACTG GCGTTTGTGA ACAGTTATCA 9720 CATGGTTAGA TTCATCTGTA CGCATATTGG GAATGGAAGC ATCCCTAAGG AGGCGCACGG 9780 CCACTACCGG AAAATCTTAG GCGAGCTCAT CGCCCTTGAG CAGGCGCTTC TCAAGCTCGC 9840 GGGACACGAG ACGGTGGGTC GGACGCCGAT CACACATCTG GTTTCGGCTC TCCTCGACCC 9900 GCATCTGCTG CCTCCCTTTG CCTACCACGA TGTCTTTACG GATCTTATGC AGAAGTCATC 9960 CAGACAACCC ATAATCAAGA TCGGGGATCA AAACTACGAC AACCCTCAAA ATAGGGCGAC 10020 ATTCATCAAC CTCAGGGGTC GCATGGAGGA CCTAGTCAAT AACCTTGTTA ACATTTACCA 10080 GACAAGGGTC AATGAGGACC ATGACGAGAG ACACGTCCTG GACGTGGCGC CCCTGGACGA 10140 GAATGACTAC AACCCGGTCC TCGAGAAGCT ATTCTACTAT GTTTTAATGC CGGTGTGCAG 10200 TAACGGCCAC ATGTGCGGTA TGGGGGTCGA CTATCAAAAC GTGGCCCTGA CGCTGACTTA 10260 CAACGGCCCC GTCTTTGCGG ACGTCGTGAA CGCACAGGAT GATATTCTAC TGCACCTGGA 10320 GAACGGAACC TTGAAGGACA TTCTGCAGGC AGGCGACATA CGCCCGACGG TGGACATGAT 10380 CAGGGTGCTG TGCACCTCGT TTCTGACGTG CCCTTTCGTC ACCCAGGCCG CTCGCGTGAT 10440 CACAAAGCGG GACCCGGCCC AGAGTTTTGC CACGCACGAA TACGGGAAGG ATGTGGCGCA 10500 GACCGTGCTT GTTAATGGCT TTGGTGCGTT CGCGGTGGCG GACCGCTCTC GCGAGGCGGC 10560 GGAGACTATG TTTTATCCGG TACCCTTTAA CAAGCTCTAC GCTGACCCGT TGGTGGCTGC 10620 CACACTGCAT CCGCTCCTGC CAAACTATGT CACCAGGCTC CCCAACCAGA GAAACGCGGT 10680 GGTCTTTAAC GTGCCATCCA ATCTCATGGC AGAATATGAG GAATGGCACA AGTCGCCCGT 10740 CGCGGCGTAT GCCGCGTCTT GTCAGGCCAC CCCGGGCGCC ATTAGCGCCA TGGTGAGCAT 10800 GCACCAAAAA CTATCTGCCC CCAGTTTCAT TTGCCAGGCA AAACACCGCA TGCACCCTGG 10860 TTTTGCCATG ACAGTCGTCA GGACGGACGA GGTTCTAGCA GAGCACATCC TATACTGCTC 10920 CAGGGCGTCG ACATCCATGT TTGTGGGCTT GCCTTCGGTG GTACGGCGCG AGGTACGTTC 10980 GGACGCGGTG ACTTTTGAAA TTACCCACGA GATCGCTTCC CTGCACACCG CACTTGGCTA 11040 CTCATCAGTC ATCGCCCCGG CCCACGTGGC CGCCATAACT ACAGACATGG GAGTACATTG 11100 TCAGGACCTC TTTATGATTT TCCCAGGGGA CGCGTATCAG GACCGCCAGC TGCATGACTA 11160 TATCAAAATG AAAGCGGGCG TGCAAACCGG CTCACCGGGA AACAGAATGG ATCACGTGGG 11220 ATACACTGCT GGGGTTCCTC GCTGCGAGAA CCTGCCCGGT TTGAGTCATG GTCAGCTGGC 11280 AACCTGCGAG ATAATTCCCA CGCCGGTCAC ATCTGACGTT GCCTATTTCC AGACCCCCAG 11340 CAACCCCCGG GGGCGTGCGG CGTCGGTCGT GTCGTGTGAT GCTTACAGTA ACGAAAGCGC 11400 AGAGCGTTTG TTCTACGACC ATTCAATACC AGACCCCGCG TACGAATGCC GGTCCACCAA 11460 CAACCCGTGG GCTTCGCAGC GTGGCTCCCT CGGCGACGTG CTATACAATA TCACCTTTCG 11520 CCAGACTGCG CTGCCGGGCA TGTACAGTCC TTGTCGGCAG TTCTTCCACA AGGAAGACAT 11580 TATGCGGTAC AATAGGGGGT TGTACACTTT GGTTAATGAG TATTCTGCCA GGCTTGCTGG 11640 GGCCCCCGCC ACCAGCACTA CAGACCTCCA GTACGTCGTG GTCAACGGTA CAGACGTGTT 11700 TTTGGACCAG CCTTGCCATA TGCTGCAGGA GGCCTATCCC ACGCTCGCCG CCAGCCACAG 11760 AGTTATGCTT GCCGAGTACA TGTCAAACAA GCAGACACAC GCCCCAGTAC ACATGGGCCA 11820 GTATCTCATT GAAGAGGTGG CGCCGATGAA GAGACTATTA AAGCTCGGAA ACAAGGTGGT 11880 GTATTAGCTA ACCCTTCTAG CGTTGGCTAG TCATGGCACT CGACAAGAGT ATAGTGGTTA 11940 ACTTCACCTC CAGACTCTTC GCTGATGAAC TGGCCGCCCT TCAGTCAAAA ATAGGGAGCG 12000 TACTGCCGCT CGGAGATTGC CACCGTTTAC AAAATATACA GGCATTGGGC CTGGGGTGCG 12060 TATGCTCACG TGAGACATCT CCGGACTACA TCCAAATTAT GCAGTATCTA TCCAAGTGCA 12120 CACTCGCTGT CCTGGAGGAG GTTCGCCCGG ACAGCCTGCG CCTAACGCGG ATGGATCCCT 12180 CTGACAACCT TCAGATAAAA AACGTATATG CCCCCTTTTT TCAGTGGGAC AGCAACACCC 12240 AGCTAGCAGT GCTACCCCCA TTTTTTAGCC GAAAGGATTC CACCATTGTG CTCGAATCCA 12300 ACGGATTTGA CCCCGTGTTC CCCATGGTCG TGCCGCAGCA ACTGGGGCAC GCTATTCTGC 12360 AGCAGCTGTT GGTGTACCAC ATCTACTCCA AAATATCGGC CGGGGCCCCG GATGATGTAA 12420 ATATGGCGGA ACTTGATCTA TATACCACCA ATGTGTCATT TATGGGGCGC ACATATCGTC 12480 TGGACGTAGA CAACACGGAT CCACGTACTG CCCTGCGAGT GCTTGACGAT CTGTCCATGT 12540 ACCTTTGTAT CCTATCAGCC TTGGTTCCCA GGGGGTGTCT CCGTCTGCTC ACGGCGCTCG 12600 TGCGGCACGA CAGGCATCCT CTGACAGAGG TGTTTGAGGG GGTGGTGCCA GATGAGGTGA 12660 CCAGGATAGA TCTCGACCAG TTGAGCGTCC CAGATGACAT CACCAGGATG CGCGTCATGT 12720 TCTCCTATCT TCAGAGTCTC AGTTCTATAT TTAATCTTGG CCCCAGACTG CACGTGTATG 12780 CCTACTCGGC AGAGACTTTG GCGGCCTCCT GTTGGTATTC CCCACGCTAA CGATTTGAAG 12840 CGGGGGGGGT ATGGCGTCAT CTGATATTCT GTCGGTTGCA AGGACGGATG ACGGCTCCGT 12900 CTGTGAAGTC TCCCTGCGTG GAGGTAGGAA AAAAACTACC GTCTACCTGC CGGACACTGA 12960 ACCCTGGGTG GTAGAGACCG ACGCCATCAA AGACGCCTTC CTCAGCGACG GGATCGTGGA 13020 TATGGCTCGA AAGCTTCATC GTGGTGCCCT GCCCTCAAAT TCTCACAACG GCTTGAGGAT 13080 GGTGCTTTTT TGTTATTGTT ACTTGCAAAA TTGTGTGTAC CTAGCCCTGT TTCTGTGCCC 13140 CCTTAATCCT TACTTGGTAA CTCCCTCAAG CATTGAGTTT GCCGAGCCCG TTGTGGCACC 13200 TGAGGTGCTC TTCCCACACC CGGCTGAGAT GTCTCGCGGT TGCGATGACG CGATTTTCTG 13260 TAAACTGCCC TATACCGTGC CTATAATCAA CACCACGTTT GGACGCATTT ACCCGAACTC 13320 TACACGCGAG CCGGACGGCA GGCCTACGGA TTACTCCATG GCCCTTAGAA GGGCTTTTGC 13380 AGTTATGGTT AACACGTCAT GTGCAGGAGT GACATTGTGC CGCGGAGAAA CTCAGACCGC 13440 ATCCCGTAAC CACACTGAGT GGGAAAATCT GCTGGCTATG TTTTCTGTGA TTATCTATGC 13500 CTTAGATCAC AACTGTCACC CGGAAGCACT GTCTATCGCG AGCGGCATCT TTGACGAGCG 13560 TGACTATGGA TTATTCATCT CTCAGCCCCG GAGCGTGCCC TCGCCTACCC CTTGCGACGT 13620 GTCGTGGGAA GATATCTACA ACGGGACTTA CCTAGCTCGG CCTGGAAACT GTGACCCCTG 13680 GCCCAATCTA TCCACCCCTC CCTTGATTCT AAATTTTAAA TAAAGGTGTG TCACTGGTTA 13740 CACCACGATT AAAAACCACT CACTGAGATG TCTTTTTAAC CGCTAAGGGA TTATACCGGG 13800 ATTTAAAACC GCCCACTGAT TTTTTTACGC TAAGAGTTGG GTGCTTGGGG GGTTTTGCAT 13860 TGCTCTGTTG TAAACTATAT ATAAGTTAAA CCAAAATTCG CAGGGAGACA AGGTGACGGT 13920 GGTGAGAACT CAGTTGAGAG TCAGAGAATA CAGTGCTAAT CAGGGTAGAT GAGCATGACT 13980 TTCCCCGTCT CCAGTCACCG GAGGAATGGT GGACGGCTCC GTCCTGGTGC GAATGGCCAC 14040 CAAGCCTCCC GTGATTGGTC TTATAACAGT GCTCTTCCTC CTAGTCATAG GCGCCTGCGT 1 100 CTACTGCTGC ATTCGCGTGT TCCTGGCGGC TCGACTGTGG CGCGCCACCC CACTAGGCAG 14160 GGCCACCGTG GCGTATCAGG TCCTTCGCAC CCTGGGACCG CAGGCCGGGT CACATGCACC 14220 GCCGACGGTG GGCATAGCTA CCCAGGAGCC CTACCGTACA ATATACATGC CAGATTAGAA 14280 CGGGGTGTGT GCTATAATGG ATGGCTATGG GGGGGGGCTG TAGATAATTG AGCGCTGTGC 14340 TTTTATTGTG GGGATATGGG CTTGTACATG TGTCTATCAT CGGTAGCCAT AAAATGGGCC 14400 ATGACAACTG CCACAAGTAA GTCGTCCGAC ATGTGCTTTT GCTTGGCGCT GTATGACTGC 14460 CCTCCATCCC TAAGCGGGAC GCACTTGATC GCGCGGACCT GTTCTACCAG GTAGGTCACC 14520 GGGTCAAATG ATATTTTGAT GGTGTTGGAC ACCACCGTCT GGCTGGCGCT CAGGGTGCCG 14580 GAGTTCAGAG CGTAGATGAA TGTCTCAAAC GCGGAGGATT TCTCGCCTCC CAACATGTAA 14640 ATTGGCCACT GCAGGGCGCT GCTCTTGTCA GTATAGTGTA GAAAATGTAT GGGGAGCGGG 14700 CATATTTCGT TAAGGACGGT TGCAATGGCC ACCCCAGAAT CTTGGCTGCT GTTGCCTTCG 14760 ACCGCCGCGT TCACGCGCTC AATTGTGGTG TGGAGCACAG CGATCGCCTT AATCATCGTG 14820 CATGCGCAGG ACGCTATCTC GTAAGCAGCT GCGCCAGTGA GGTCGCGCAG GAAGAAATGC 14880 TCCATGCCCA ATATGAGGCT TCTGGTGGGA GTCTGAGTAC TCGTGACAAC GGCGCCCACG 14940 CCAGTACCGG ACGCCTCCGT GTTGTTCGTA TACGCGGGGT CGATGTAAAC AAACAGCTGT 15000 TTTCCAAGGC ACTTCTGAAC CTCCTGGGCG GTGGTGTCTA CCCGACACAT GTCAAACTGT 15060 GTCAGCGCTG CGTCACCCAC CACGCGGTAA AGCGTAGCAT TTGACGACGC TGCTCCCTCG 15120 CCCATTAGTT CGGTGTCGAA TGCCCCCTCC ATAAAGAGGT TGGTGGTGGT TTTGATGGAT 15180 TCGTCGATGG TGATGTACGT CGGAATGTGC AGTCTGTAAC AAGGACAGGA CACTAGTGCG 15240 TCTTGCAGGT GGAAATCTTC TCGGTGGTCC GCACACACGT AACTGACCAC ATTCAGCATC 15300 TTTTCCTGGG CGTTCCTGAG GTTAAGCAGG AAACTCGTGG AGCGGTCTGA CGAGTTCACG 15360 GATGATATAA ATATAAGCTT GGCGTCTTTC TGAAGCATGA AACCCAGAAT AGCCGGCAGT 15420 GCATCCTTTT TAATAAAATT CGCCTCGTCT ACGTAGAGCA GGTTAAAGGT CTGTCCCCGA 15480 ATGCTCTGCA GACACGGAAA GACACAAAAG AGGGGCTCAT AAGCGGCTAA CAGTAAAGGA 15540 GAGGAGGCGA ACAGTGCGTG GCTCTTGGTT CTTGGGAATA AAAGGGGGCG TGTGTGCCGA 15600 TCGATCGTAT GGGTGAGCCA GTGGATCCTG GACATGTGGT GAATGAGAAA GATTTTGAGG 15660 AGTGTGAACA ATTTTTCAGT CAACCCCTTA GGGAGCAAGT GGTCGCGGGG GTCAGGGCAC 15720 TCGACGGCCT CGGTCTCGCT GACTCTCTAT GTCACAAAAC AGAAAGACTC TGCCTGCTGA 15780 TGGACCTGGT GGGCACGGAG TGCTTTGCGA GGGTGTGCCG CCTAGACACC GGTGCGAAAT 15840 GAAGAGTGTG GCGAGTCCCT TATGTCAGTT CCACGGCGTG TTTTGCCTGT ACCAGTGTCG 15900 CCAGTGCCTG GCATACCACG TGTGTGATGG GGGCGCCGAA TGCGTTCTCC TGCATACGCC 15960 GGAGAGCGTC ATCTGCGAAC TAACGGGTAA CTGCATGCTC GGCAACATTC AAGAGGGCCA 16020 GTTTTTAGGG CCGGTACCGT ATCGGACTTT GGATAACCAG GTTGACAGGG ACGCATATCA 16080 CGGGATGCTA GCGTGTCTGA AACGGGACAT TGTGCGGTAT TTGCAGACAT GGCCGGACAC 16140 CACCGTAATC GTGCAGGAAA TAGCCCTGGG GGACGGCGTC ACCGACACCA TCTCGGCCAT 16200 TATAGATGAA ACATTCGGTG AGTGTCTTCC CGTACTGGGG GAGGCCCAAG GCGGGTACGC 16260 CCTGGTCTGT AGCATGTATC TGCACGTTAT CGTCTCCATC TATTCGACAA AAACGGTGTA 16320 CAACAGTATG CTATTTAAAT GCACAAAGAA TAAAAAGTAC GACTGCATTG CCAAGCGGGT 16380 GCGGACAAAA TGGATGCGCA TGCTATCAAC GAAAGATACG TAGGTCCTCG CTGCCACCGT 16440 TTGGCCCACG TGGTGCTGCC TAGGACCTTT CTGCTGCATC ACGCCATACC CCTGGAGCCC 16500 GAGATCATCT TTTCCACCTA CACCCGGTTC AGCCGGTCGC CAGGGTCATC CCGCCGGTTG 16560 GTGGTGTGTG GGAAACGTGT CCTGCCAGGG GAGGAAAACC AACTTGCGTC TTCACCTTCT 16620 GGTTTGGCGC TTAGCCTGCC TCTGTTTTCC CACGATGGGA ACTTTCATCC ATTTGACATC 16680 TCGGTACTGC GCATTTCCTG CCCTGGTTCT AATCTTAGTC TTACTGTCAG ATTTCTCTAT 16740 CTATCTCTGG TGGTGGCTAT GGGGGCGGGA CGGAATAATG CGCGGAGTCC GACCGTTGAC 16800 GGGGTATCGC CGCCAGAGGG CGCCGTAGCC CACCCTTTGG AGGAACTGCA GAGGCTGGCG 16860 CGTGCTACGC CGGACCCGGC ACTCACCCGT GGACCGTTGC AGGTCCTGAC CGGCCTTCTC 16920 CGCGCAGGGT CAGACGGAGA CCGCGCCACT CACCACATGG CGCTCGAGGC TCCGGGAACC 16980 GTGCGTGGAG AAAGCCTAGA CCCGCCTGTT TCACAGAAGG GGCCAGCGCG CACACGCCAC 17040 AGGCCACCCC CCGTGCGACT GAGCTTCAAC CCCGTCAATG CCGATGTACC CGCTACCTGG 17100 CGAGACGCCA CTAACGTGTA CTCGGGTGCT CCCTACTATG TGTGTGTTTA CGAACGCGGT 17160 GGCCGTCAGG AAGACGACTG GCTGCCGATA CCACTGAGCT TCCCAGAAGA GCCCGTGCCC 17220 CCGCCACCGG GCTTAGTGTT CATGGACGAC TTGTTCATTA ACACGAAGCA GTGCGACTTT 17280 GTGGACACGC TAGAGGCCGC CTGTCGCACG CAAGGCTACA CGTTGAGACA GCGCGTGCCT 17340 GTCGCCATTC CTCGCGACGC GGAAATCGCA GACGCAGTTA AATCGCACTT TTTAGAGGCG 17400 TGCCTAGTGT TACGGGGGCT GGCTTCGGAG GCTAGTGCCT GGATAAGAGC TGCCACGTCC 17460 CCGCCCCTTG GCCGCCACGC CTGCTGGATG GACGTGTTAG GATTATGGGA AAGCCGCCCC 17520 CACACTCTAG GTTTGGAGTT ACGCGGCGTA AACTGTGGCG GCACGGACGG TGACTGGTTA 17580 GAGATTTTAA AACAGCCCGA TGTGCAAAAG ACAGTCAGCG GGAGTCTTGT GGCATGCGTG 17640 ATCGTCACAC CCGCATTGGA AGCCTGGCTT GTGTTACCTG GGGGTTTTGC TATTAAAGCC 17700 CGCTATAGGG CGTCGAAGGA GGATCTGGTG TTCATTCGAG GCCGCTATGG CTAGCCGGAG 17760 GCGCAAACTT CGGAATTTCC TAAACAAGGA ATGCATATGG ACTGTTAACC CAATGTCAGG 17820 GGACCATATC AAGGTCTTTA ACGCCTGCAC CTCTATCTCG CCGGTGTATG ACCCTGAGCT 17880 GGTAACCAGC TACGCACTGA GCGTGCCTGC TTACAATGTG TCTGTGGCTA TCTTGCTGCA 17940 TAAAGTCATG GGACCGTGTG TGGCTGTGGG AATTAACGGA GAAATGATCA TGTACGTCGT 18000 AAGCCAGTGT GTTTCTGTGC GGCCCGTCCC GGGGCGCGAT GGTATGGCGC TCATCTACTT 18060 TGGACAGTTT CTGGAGGAAG CATCCGGACT GAGATTTCCC TACATTGCTC CGCCGCCGTC 18120 GCGCGAACAC GTACCTGACC TGACCAGACA AGAATTAGTT CATACCTCCC AGGTGGTGCG 18180 CCGCGGCGAC CTGACCAATT GCACTATGGG TCTCGAATTC AGGAATGTGA ACCCTTTTGT 18240 TTGGCTCGGG GGCGGATCGG TGTGGCTGCT GTTCTTGGGC GTGGACTACA TGGCGTTCTG 18300 TCCGGGTGTC GACGGAATGC CGTCGTTGGC AAGAGTGGCC GCCCTGCTTA CCAGGTGCGA 18360 CCACCCAGAC TGTGTCCACT GCCATGGACT CCGTGGACAC GTTAATGTAT TTCGTGGGTA 18420 CTGTTCTGCG CAGTCGCCGG GTCTATCTAA CATCTGTCCC TGTATCAAAT CATGTGGGAC 18480 CGGGAATGGA GTGACTAGGG TCACTGGAAA CAGAAATTTT CTGGGTCTTC TGTTCGATCC 18540 CATTGTCCAG AGCAGGGTAA CAGCTCTGAA GATAACTAGC CACCCAACCC CCACGCACGT 18600 CGAGAATGTG CTAACAGGAG TGCTCGACGA CGGCACCTTG GTGCCGTCCG TCCAAGGCAC 18660 CCTGGGTCCT CTTACGAATG TCTGACTACT TCAGCCGCTT GCTGATATAT GAGTGTAAAA 18720 AACTTAAGGC CCTGGGCTTA CGTTCTTATT GAAGCATGTT GCGCACATCA GCGAGCTGGA 18780 CCGTCCTCCG GGTCGCGTGT AGATTATGGT TCCGTTCTCC TTCTTGATGT TTAAATTTTT 18840 GGGGGGGAAC CACCGACAAA GCGTCTTTAT GATTTCCGCG AACACGGAGT TGGCTACGTG 18900 CTTTTGGTGG GCTACGTACC CAATGTTAAT GTTCTCTACG GATGCCAGTA GCATGCTGAT 18960 GATCGCCACC ACTATCCATG TCTTTCCGTG TCTCCTTGGT ATTAGGAATA CGCTTGCCTT 19020 TTGCTTAAAC GTCTGTAAAA CACTGTTTGG AGTTTCAAAT AAACCGAAGT ACTGCTTAAA 19080 CAATCCAAAC AACTGGTGCG TCTTTTGTGG GGCCTTGATT GAAACCAAAA AGAAAAAAGT 19140 GTGCATTACT AGCTGCTGTT GGAAGGGCTC CAGCCAGTGC ACCCCGGGAA CGTAACAGCC 19200 GTTCAGAAAG GACGAAAGGT TAACCAGAAA AGCCTGAAGT TCGCGGTAGA CAGAGCAGGC 19260 GTGCAGGGAG TCGTGTGTTT TTCTGCCCGC CTGGTACTCG ACCAGTTGAT CGGCCGTGGA 19320 GACGTGCGCG TCCTCGCGCA CACACCGCAT CTGCAAGTAT GTTGATAGGG ACTCCAATAG 19380 GCGCGGCTTT GCGGGGACGT TGTCCTCGGA CGGTCTGGGG GTTCCCACGT CGGGATTTGC 19440 TGACGTGGGC GTGGCGGGAT GGTGCCGTGT GCAGTATGTT TCCAGGACCG AACTGTATGA 19500 GTTTATTCTG TGCACCACGC CAATAAAAGG GTGCGCCATC CGTGCCGTTT TGGGACAGTG 19560 TCGCGTGAAT GTCGGGGCAC TCAGTTCCCA CCTCTCTCCG GCGTCTTTGG CGGTCTCCTC 19620 CAGGTTGGCG GCAAGGCGCT CCCTGTGACG GCTGAGCAGC ATGTTTGCTT TGAGCTCGCT 19680 CGTGTCCGAG GGTGACCCGG AGGTGACCAG TAGGTACGTC AAGGGCGTAC AACTTGCCCT 19740 GGACCTTAGC GAGAACACAC CTGGACAATT TAAGTTGATA GAAACTCCCC TGAACAGCTT 19800 CCTCTTGGTT TCCAACGTGA TGCCCGAGGT CCAGCCAATC TGCAGTGGCC GGCCGGCCTT 19860 GCGGCCAGAC TTTAGTAATC TCCACTTGCC TAGACTGGAG AAGCTCCAGA GAGTCCTCGG 19920 GCAGGGTTTC GGGGCGGCGG GTGAGGAAAT CGCACTGGAC CCGTCTCACG TAGAAACACA 19980 CGAAAAGGGC CAGGTGTTCT ACAACCACTA TGCTACCGAG GAGTGGACGT GGGCTTTGAC 20040 TCTGAATAAG GATGCGCTCC TTCGGGAGGC TGTAGATGGC CTGTGTGACC CCGGAACTTG 20100 GAAGGGTCTT CTTCCTGACG ACCCCCTTCC GTTGCTATGG CTGCTGTTCA ACGGACCCGC 20160 CTCTTTTTGT CGGGCCGACT GTTGCCTGTA CAAGCAGCAC TGCGGTTACC CGGGCCCGGT 20220 GCTACTTCCA GGTCACATGT ACGCTCCCAA ACGGGATCTT TTGTCGTTCG TTAATCATGC 20280 CCTGAAGTAC ACCAAGTTTC TATACGGAGA TTTTTCCGGG ACATGGGCGG CGGCTTGCCG 20340 CCCGCCATTC GCTACTTCTC GGATACAAAG GGTAGTGAGT CAGATGAAAA TCATAGATGC 20400 TTCCGACACT TACATTTCCC ACACCTGCCT CTTGTGTCAC ATATATCAGC AAAATAGCAT 20460 AATTGCGGGT CAGGGGACCC ACGTGGGTGG AATCCTACTG TTGAGTGGAA AAGGGACCCA 20520 GTATATAACA GGCAATGTTC AGACCCAAAG GTGTCCAACT ACGGGCGACT ATCTAATCAT 20580 CCCATCGTAT GACATACCGG CGATCATCAC CATGATCAAG GAGAATGGAC TCAACCAACT 20640 CTAAAAGAGA GTTTATTAAG TCGGCTCTGG AGGCCAACAT CAACAGGAGG GCAGCTGTAT 20700 CGCTATTTGA 20710 (2) INFORMATION FOR SEQ ID NO:2 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4131 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: N (iv) ANTI-SENSE: N (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..4131 (D) OTHER INFORMATION: (xi) SEQUENCE DESCRIPTION: SEQ ID Nθ:2: ATG GAG GCG ACC TTG GAG CAA CGA CCT TTC CCG TAC CTC GCC ACG GAG 48 Met Glu Ala Thr Leu Glu Gin Arg Pro Phe Pro Tyr Leu Ala Thr Glu 1 5 10 15 GCC AAC CTC CTA ACG CAG ATT AAG GAG TCG GCT GCC GAC GGA CTC TTC 96 Ala Asn Leu Leu Thr Gin lie Lys Glu Ser Ala Ala Asp Gly Leu Phe 20 25 30 AAG AGC TTT CAG CTA TTG CTC GGC AAG GAC GCC AGA GAA GGC AGT GTC 144 Lys Ser Phe Gin Leu Leu Leu Gly Lys Asp Ala Arg Glu Gly Ser Val 35 40 45 CGT TTC GAA GCG CTA CTG GGC GTA TAT ACC AAT GTG GTG GAG TTT GTT 192 Arg Phe Glu Ala Leu Leu Gly Val Tyr Thr Asn Val Val Glu Phe Val 50 55 60 AAG TTT CTG GAG ACC GCC CTC GCC GCC GCT TGC GTC AAT ACC GAG TTC 240 Lys Phe Leu Glu Thr Ala Leu Ala Ala Ala Cys Val Asn Thr Glu Phe 65 70 75 80 AAG GAC CTG CGG AGA ATG ATA GAT GGA AAA ATA CAG TTT AAA ATT TCA 288 Lys Asp Leu Arg Arg Met lie Asp Gly Lys lie Gin Phe Lys lie Ser 85 90 95 ATG CCC ACT ATT GCC CAC GGA GAC GGG AGG AGG CCC AAC AAG CAG AGA 336 Met Pro Thr lie Ala His Gly Asp Gly Arg Arg Pro Asn Lys Gin Arg 100 105 110 CAG TAT ATC GTC ATG AAG GCT TGC AAT AAG CAC CAC ATC GGT GCG GAG 384 Gin Tyr lie Val Met Lys Ala Cys Asn Lys His His lie Gly Ala Glu 115 120 125 ATT GAG CTT GCG GCC GCA GAC ATC GAG CTT CTC TTC GCC GAG AAA GAG 432 lie Glu Leu Ala Ala Ala Asp lie Glu Leu Leu Phe Ala Glu Lys Glu 130 135 140 ACG CCC TTG GAC TTC ACA GAG TAC GCG GGT GCC ATC AAG ACG ATT ACG 480 Thr Pro Leu Asp Phe Thr Glu Tyr Ala Gly Ala lie Lys Thr lie Thr 145 150 155 160 TCG GCT TTG CAG TTT GGT ATG GAC GCC CTA GAA CGG GGG CTA GTG GAC 528 Ser Ala Leu Gin Phe Gly Met Asp Ala Leu Glu Arg Gly Leu Val Asp 165 170 175 ACG GTT CTC GCA GTT AAA CTT CGG CAC GCT CCA CCC GTC TTT ATT TTA 576 Thr Val Leu Ala Val Lys Leu Arg His Ala Pro Pro Val Phe lie Leu 180 185 190 AAG ACG CTG GGC GAT CCC GTC TAC TCT GAG AGG GGC CTC AAA AAG GCC 624 Lys Thr Leu Gly Asp Pro Val Tyr Ser Glu Arg Gly Leu Lys Lys Ala 195 200 205 GTC AAG TCT GAC ATG GTA TCC ATG TTC AAG GCA CAC CTC ATA GAA CAT 672 Val Lys Ser Asp Met Val Ser Met Phe Lys Ala His Leu He Glu His 210 215 220 TCA TTT TTT CTA GAT AAG GCC GAG CTC ATG ACA AGG GGG AAG CAG TAT 720 Ser Phe Phe Leu Asp Lys Ala Glu Leu Met Thr Arg Gly Lys Gin Tyr 225 230 235 240 GTC CTA ACC ATG CTC TCC GAC ATG CTG GCC GCG GTG TGC GAG GAT ACC 768 Val Leu Thr Met Leu Ser Asp Met Leu Ala Ala Val Cys Glu Asp Thr 245 250 255 GTC TTT AAG GGT GTC AGC ACG TAC ACC ACG GCC TCT GGG CAG CAG GTG 816 Val Phe Lys Gly Val Ser Thr Tyr Thr Thr Ala Ser Gly Gin Gin Val 260 265 270 GCC GGC GTC CTG GAG ACG ACG GAC AGC GTC ATG AGA CGG CTG ATG AAC 864 Ala Gly Val Leu Glu Thr Thr Asp Ser Val Met Arg Arg Leu Met Asn 275 280 285 CTG CTG GGG CAA GTG GAA AGT GCC ATG TCC GGG CCC GCG GCC TAC GCC 912 Leu Leu Gly Gin Val Glu Ser Ala Met Ser Gly Pro Ala Ala Tyr Ala 290 295 300 AGC TAC GTT GTC AGG GGT GCC AAC CTC GTC ACC GCC GTT AGC TAC GGA 960 Ser Tyr Val Val Arg Gly Ala Asn Leu Val Thr Ala Val Ser Tyr Gly 305 310 315 320 AGG GCG ATG AGA AAC TTT GAA CAG TTT ATG GCA CGC ATA GTG GAC CAT 1008 Arg Ala Met Arg Asn Phe Glu Gin Phe Met Ala Arg He Val Asp His 325 330 335 CCC AAC GCT CTG CCG TCT GTG GAA GGT GAC AAG GCC GCT CTG GCG GAC 1056 Pro Asn Ala Leu Pro Ser Val Glu Gly Asp Lys Ala Ala Leu Ala Asp 340 345 350 GGA CAC GAC GAG ATT CAG AGA ACC CGC ATC GCC GCC TCT CTC GTC AAG 1104 Gly His Asp Glu He Gin Arg Thr Arg He Ala Ala Ser Leu Val Lys 355 360 365 ATA GGG GAT AAG TTT GTG GCC ATT GAA AGT TTG CAG CGC ATG TAC AAC 1152 He Gly Asp Lys Phe Val Ala He Glu Ser Leu Gin Arg Met Tyr Asn 370 375 380 GAG ACT CAG TTT CCC TGC CCA CTG AAC CGG CGC ATC CAG TAC ACC TAT 1200 Glu Thr Gin Phe Pro Cys Pro Leu Asn Arg Arg He Gin Tyr Thr Tyr 385 390 395 400 TTC TTC CCT GTT GGC CTT CAC CTT CCC GTG CCC CGC TAC TCG ACA TCC 1248 Phe Phe Pro Val Gly Leu His Leu Pro Val Pro Arg Tyr Ser Thr Ser 405 410 415 GTC TCA GTC AGG GGC GTA GAA TCC CCG GCC ATC CAG TCG ACC GAG ACG 1296 Val Ser Val Arg Gly Val Glu Ser Pro Ala He Gin Ser Thr Glu Thr 420 425 430 TGG GTG GTT AAT AAA AAC AAC GTG CCT CTT TGC TTC GGT TAC CAA AAC 1344 Trp Val Val Asn Lys Asn Asn Val Pro Leu Cys Phe Gly Tyr Gin Asn 435 440 445 GCC CTC AAA AGC ATA TGC CAC CCT CGA ATG CAC AAC CCC ACC CAG TCA 1392 Ala Leu Lys Ser He Cys His Pro Arg Met His Asn Pro Thr Gin Ser 450 455 460 GCC CAG GCA CTA AAC CAA GCT TTT CCC GAT CCC GAC GGG GGA CAT GGG 1440 Ala Gin Ala Leu Asn Gin Ala Phe Pro Asp Pro Asp Gly Gly His Gly 465 470 475 480 TAC GGT CTC AGG TAT GAG CAG ACG CCA AAC ATG AAC CTA TTC AGA ACG 1488 Tyr Gly Leu Arg Tyr Glu Gin Thr Pro Asn Met Asn Leu Phe Arg Thr 485 490 495 TTC CAC CAG TAT TAC ATG GGG AAA AAC GTG GCA TTT GTT CCC GAT GTG 1536 Phe His Gin Tyr Tyr Met Gly Lys Asn Val Ala Phe Val Pro Asp Val 500 505 510 GCC CAA AAA GCG CTC GTA ACC ACG GAG GAT CTA CTG CAC CCA ACC TCT 1584 Ala Gin Lys Ala Leu Val Thr Thr Glu Asp Leu Leu His Pro Thr Ser 515 520 525 CAC CGT CTC CTC AGA TTG GAG GTC CAC CCC TTC TTT GAT TTT TTT GTG 1632 His Arg Leu Leu Arg Leu Glu Val His Pro Phe Phe Asp Phe Phe Val 530 535 540 CAC CCC TGT CCT GGA GCG AGA GGA TCG TAC CGC GCC ACC CAC AGA ACA 1680 His Pro Cys Pro Gly Ala Arg Gly Ser Tyr Arg Ala Thr His Arg Thr 545 550 555 560 ATG GTT GGA AAT ATA CCA CAA CCG CTC GCT CCA AGG GAG TTT CAG GAA 1728 Met Val Gly Asn He Pro Gin Pro Leu Ala Pro Arg Glu Phe Gin Glu 565 570 575 AGT AGA GGG GCG CAG TTC GAC GCT GTG ACG AAT ATG ACA CAC GTC ATA 1776 Ser Arg Gly Ala Gin Phe Asp Ala Val Thr Asn Met Thr His Val He 580 585 590 GAC CAG CTA ACT ATT GAC GTC ATA CAG GAG ACG GCA TTT GAC CCC GCG 1824 Asp Gin Leu Thr He Asp Val He Gin Glu Thr Ala Phe Asp Pro Ala 595 600 605 TAT CCC CTG TTC TGC TAT GTA ATC GAA GCA ATG ATT CAC GGA CAG GAA 1872 Tyr Pro Leu Phe Cys Tyr Val He Glu Ala Met He His Gly Gin Glu 610 615 620 GAA AAA TTC GTG ATG AAC ATG CCC CTC ATT GCC CTG GTC ATT CAA ACC 1920 Glu Lys Phe Val Met Asn Met Pro Leu He Ala Leu Val He Gin Thr 625 630 635 640 TAC TGG GTC AAC TCG GGA AAA CTG GCG TTT GTG AAC AGT TAT CAC ATG 1968 Tyr Trp Val Asn Ser Gly Lys Leu Ala Phe Val Asn Ser Tyr His Met 645 650 655 GTT AGA TTC ATC TGT ACG CAT ATT GGG AAT GGA AGC ATC CCT AAG GAG 2016 Val Arg Phe He Cys Thr His He Gly Asn Gly Ser He Pro Lys Glu 660 665 670 GCG CAC GGC CAC TAC CGG AAA ATC TTA GGC GAG CTC ATC GCC CTT GAG 2064 Ala His Gly His Tyr Arg Lys He Leu Gly Glu Leu He Ala Leu Glu 675 680 685 CAG GCG CTT CTC AAG CTC GCG GGA CAC GAG ACG GTG GGT CGG ACG CCG 2112 Gin Ala Leu Leu Lys Leu Ala Gly His Glu Thr Val Gly Arg Thr Pro 690 695 700 ATC ACA CAT CTG GTT TCG GCT CTC CTC GAC CCG CAT CTG CTG CCT CCC 2160 He Thr His Leu Val Ser Ala Leu Leu Asp Pro His Leu Leu Pro Pro 705 710 715 720 TTT GCC TAC CAC GAT GTC TTT ACG GAT CTT ATG CAG AAG TCA TCC AGA 2208 Phe Ala Tyr His Asp Val Phe Thr Asp Leu Met Gin Lys Ser Ser Arg 725 730 735 CAA CCC ATA ATC AAG ATC GGG GAT CAA AAC TAC GAC AAC CCT CAA AAT 2256 Gin Pro He He Lys He Gly Asp Gin Asn Tyr Asp Asn Pro Gin Asn 740 745 750 AGG GCG ACA TTC ATC AAC CTC AGG GGT CGC ATG GAG GAC CTA GTC AAT 2304 Arg Ala Thr Phe He Asn Leu Arg Gly Arg Met Glu Asp Leu Val Asn 755 760 765 AAC CTT GTT AAC ATT TAC CAG ACA AGG GTC AAT GAG GAC CAT GAC GAG 2352 Asn Leu Val Asn He Tyr Gin Thr Arg Val Asn Glu Asp His Asp Glu 770 775 780 AGA CAC GTC CTG GAC GTG GCG CCC CTG GAC GAG AAT GAC TAC AAC CCG 2400 Arg His Val Leu Asp Val Ala Pro Leu Asp Glu Asn Asp Tyr Asn Pro 785 790 795 800 GTC CTC GAG AAG CTA TTC TAC TAT GTT TTA ATG CCG GTG TGC AGT AAC 2448 Val Leu Glu Lys Leu Phe Tyr Tyr Val Leu Met Pro Val Cys Ser Asn 805 810 815 GGC CAC ATG TGC GGT ATG GGG GTC GAC TAT CAA AAC GTG GCC CTG ACG 2496 Gly His Met Cys Gly Met Gly Val Asp Tyr Gin Asn Val Ala Leu Thr 820 825 830 CTG ACT TAC AAC GGC CCC GTC TTT GCG GAC GTC GTG AAC GCA CAG GAT 2544 Leu Thr Tyr Asn Gly Pro Val Phe Ala Asp Val Val Asn Ala Gin Asp 835 840 845 GAT ATT CTA CTG CAC CTG GAG AAC GGA ACC TTG AAG GAC ATT CTG CAG 2592 Asp He Leu Leu His Leu Glu Asn Gly Thr Leu Lys Asp He Leu Gin 850 855 860 GCA GGC GAC ATA CGC CCG ACG GTG GAC ATG ATC AGG GTG CTG TGC ACC 2640 Ala Gly Asp He Arg Pro Thr Val Asp Met He Arg Val Leu Cys Thr 865 870 875 880 TCG TTT CTG ACG TGC CCT TTC GTC ACC CAG GCC GCT CGC GTG ATC ACA 2688 Ser Phe Leu Thr Cys Pro Phe Val Thr Gin Ala Ala Arg Val He Thr 885 890 895 AAG CGG GAC CCG GCC CAG AGT TTT GCC ACG CAC GAA TAC GGG AAG GAT 2736 Lys Arg Asp Pro Ala Gin Ser Phe Ala Thr His Glu Tyr Gly Lys Asp 900 905 910 GTG GCG CAG ACC GTG CTT GTT AAT GGC TTT GGT GCG TTC GCG GTG GCG 2784 Val Ala Gin Thr Val Leu Val Asn Gly Phe Gly Ala Phe Ala Val Ala 915 920 925 GAC CGC TCT CGC GAG GCG GCG GAG ACT ATG TTT TAT CCG GTA CCC TTT 2832 Asp Arg Ser Arg Glu Ala Ala Glu Thr Met Phe Tyr Pro Val Pro Phe 930 935 940 AAC AAG CTC TAC GCT GAC CCG TTG GTG GCT GCC ACA CTG CAT CCG CTC 2880 Asn Lys Leu Tyr Ala Asp Pro Leu Val Ala Ala Thr Leu His Pro Leu 945 950 955 960 CTG CCA AAC TAT GTC ACC AGG CTC CCC AAC CAG AGA AAC GCG GTG GTC 2928 Leu Pro Asn Tyr Val Thr Arg Leu Pro Asn Gin Arg Asn Ala Val Val 965 970 975 TTT AAC GTG CCA TCC AAT CTC ATG GCA GAA TAT GAG GAA TGG CAC AAG 2976 Phe Asn Val Pro Ser Asn Leu Met Ala Glu Tyr Glu Glu Trp His Lys 980 985 990 TCG CCC GTC GCG GCG TAT GCC GCG TCT TGT CAG GCC ACC CCG GGC GCC 3024 Ser Pro Val Ala Ala Tyr Ala Ala Ser Cys Gin Ala Thr Pro Gly Ala 995 1000 1005 ATT AGC GCC ATG GTG AGC ATG CAC CAA AAA CTA TCT GCC CCC AGT TTC 3072 He Ser Ala Met Val Ser Met His Gin Lys Leu Ser Ala Pro Ser Phe 1010 1015 1020 ATT TGC CAG GCA AAA CAC CGC ATG CAC CCT GGT TTT GCC ATG ACA GTC 3120 He Cys Gin Ala Lys His Arg Met His Pro Gly Phe Ala Met Thr Val 1025 1030 1035 1040 GTC AGG ACG GAC GAG GTT CTA GCA GAG CAC ATC CTA TAC TGC TCC AGG 3168 Val Arg Thr Asp Glu Val Leu Ala Glu His He Leu Tyr Cys Ser Arg 1045 1050 1055 GCG TCG ACA TCC ATG TTT GTG GGC TTG CCT TCG GTG GTA CGG CGC GAG 3216 Ala Ser Thr Ser Met Phe Val Gly Leu Pro Ser Val Val Arg Arg Glu 1060 1065 1070 GTA CGT TCG GAC GCG GTG ACT TTT GAA ATT ACC CAC GAG ATC GCT TCC 3264 Val Arg Ser Asp Ala Val Thr Phe Glu He Thr His Glu He Ala Ser 1075 1080 1085 CTG CAC ACC GCA CTT GGC TAC TCA TCA GTC ATC GCC CCG GCC CAC GTG 3312 Leu His Thr Ala Leu Gly Tyr Ser Ser Val He Ala Pro Ala His Val 1090 1095 1100 GCC GCC ATA ACT ACA GAC ATG GGA GTA CAT TGT CAG GAC CTC TTT ATG 3360 Ala Ala He Thr Thr Asp Met Gly Val His Cys Gin Asp Leu Phe Met 1105 1110 1115 1120 ATT TTC CCA GGG GAC GCG TAT CAG GAC CGC CAG CTG CAT GAC TAT ATC 3408 He Phe Pro Gly Asp Ala Tyr Gin Asp Arg Gin Leu His Asp Tyr He 1125 1130 1135 AAA ATG AAA GCG GGC GTG CAA ACC GGC TCA CCG GGA AAC AGA ATG GAT 3456 Lys Met Lys Ala Gly Val Gin Thr Gly Ser Pro Gly Asn Arg Met Asp 1140 1145 1150 CAC GTG GGA TAC ACT GCT GGG GTT CCT CGC TGC GAG AAC CTG CCC GGT 3504 His Val Gly Tyr Thr Ala Gly Val Pro Arg Cys Glu Asn Leu Pro Gly 1155 1160 1165 TTG AGT CAT GGT CAG CTG GCA ACC TGC GAG ATA ATT CCC ACG CCG GTC 3552 Leu Ser His Gly Gin Leu Ala Thr Cys Glu He He Pro Thr Pro Val 1170 1175 1180 ACA TCT GAC GTT GCC TAT TTC CAG ACC CCC AGC AAC CCC CGG GGG CGT 3600 Thr Ser Asp Val Ala Tyr Phe Gin Thr Pro Ser Asn Pro Arg Gly Arg 1185 1190 1195 1200 GCG GCG TCG GTC GTG TCG TGT GAT GCT TAC AGT AAC GAA AGC GCA GAG 3648 Ala Ala Ser Val Val Ser Cys Asp Ala Tyr Ser Asn Glu Ser Ala Glu 1205 1210 1215 CGT TTG TTC TAC GAC CAT TCA ATA CCA GAC CCC GCG TAC GAA TGC CGG 3696 Arg Leu Phe Tyr Asp His Ser He Pro Asp Pro Ala Tyr Glu Cys Arg 1220 1225 1230 TCC ACC AAC AAC CCG TGG GCT TCG CAG CGT GGC TCC CTC GGC GAC GTG 3744 Ser Thr Asn Asn Pro Trp Ala Ser Gin Arg Gly Ser Leu Gly Asp Val 1235 1240 1245 CTA TAC AAT ATC ACC TTT CGC CAG ACT GCG CTG CCG GGC ATG TAC AGT 3792 Leu Tyr Asn He Thr Phe Arg Gin Thr Ala Leu Pro Gly Met Tyr Ser 1250 1255 1260 CCT TGT CGG CAG TTC TTC CAC AAG GAA GAC ATT ATG CGG TAC AAT AGG 3840 Pro Cys Arg Gin Phe Phe His Lys Glu Asp He Met Arg Tyr Asn Arg 1265 1270 1275 1280 GGG TTG TAC ACT TTG GTT AAT GAG TAT TCT GCC AGG CTT GCT GGG GCC 3888 Gly Leu Tyr Thr Leu Val Asn Glu Tyr Ser Ala Arg Leu Ala Gly Ala 1285 1290 1295 CCC GCC ACC AGC ACT ACA GAC CTC CAG TAC GTC GTG GTC AAC GGT ACA 3936 Pro Ala Thr Ser Thr Thr Asp Leu Gin Tyr Val Val Val Asn Gly Thr 1300 1305 1310 GAC GTG TTT TTG GAC CAG CCT TGC CAT ATG CTG CAG GAG GCC TAT CCC 3984 Asp Val Phe Leu Asp Gin Pro Cys His Met Leu Gin Glu Ala Tyr Pro 1315 1320 1325 ACG CTC GCC GCC AGC CAC AGA GTT ATG CTT GCC GAG TAC ATG TCA AAC 4032 Thr Leu Ala Ala Ser His Arg Val Met Leu Ala Glu Tyr Met Ser Asn 1330 1335 1340 AAG CAG ACA CAC GCC CCA GTA CAC ATG GGC CAG TAT CTC ATT GAA GAG 4080 Lys Gin Thr His Ala Pro Val His Met Gly Gin Tyr Leu He Glu Glu 1345 1350 1355 1360 GTG GCG CCG ATG AAG AGA CTA TTA AAG CTC GGA AAC AAG GTG GTG TAT 128 Val Ala Pro Met Lys Arg Leu Leu Lys Leu Gly Asn Lys Val Val Tyr 1365 1370 1375 TAG 4131 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1376 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID Nθ:3: Met Glu Ala Thr Leu Glu Gin Arg Pro Phe Pro Tyr Leu Ala Thr Glu 1 5 10 15 Ala Asn Leu Leu Thr Gin He Lys Glu Ser Ala Ala Asp Gly Leu Phe 20 25 30 Lys Ser Phe Gin Leu Leu Leu Gly Lys Asp Ala Arg Glu Gly Ser Val 35 40 45 Arg Phe Glu Ala Leu Leu Gly Val Tyr Thr Asn Val Val Glu Phe Val 50 55 60 Lys Phe Leu Glu Thr Ala Leu Ala Ala Ala Cys Val Asn Thr Glu Phe 65 70 75 80 Lys Asp Leu Arg Arg Met He Asp Gly Lys He Gin Phe Lys He Ser 85 90 95 Met Pro Thr He Ala His Gly Asp Gly Arg Arg Pro Asn Lys Gin Arg 100 105 110 Gin Tyr He Val Met Lys Ala Cys Asn Lys His His He Gly Ala Glu 115 120 125 He Glu Leu Ala Ala Ala Asp He Glu Leu Leu Phe Ala Glu Lys Glu 130 135 140 Thr Pro Leu Asp Phe Thr Glu Tyr Ala Gly Ala He Lys Thr He Thr 145 150 155 160 Ser Ala Leu Gin Phe Gly Met Asp Ala Leu Glu Arg Gly Leu Val Asp 165 170 175 Thr Val Leu Ala Val Lys Leu Arg His Ala Pro Pro Val Phe He Leu 180 185 190 Lys Thr Leu Gly Asp Pro Val Tyr Ser Glu Arg Gly Leu Lys Lys Ala 195 200 205 Val Lys Ser Asp Met Val Ser Met Phe Lys Ala His Leu He Glu His 210 215 220 Ser Phe Phe Leu Asp Lys Ala Glu Leu Met Thr Arg Gly Lys Gin Tyr 225 230 235 240 Val Leu Thr Met Leu Ser Asp Met Leu Ala Ala Val Cys Glu Asp Thr 245 250 255 Val Phe Lys Gly Val Ser Thr Tyr Thr Thr Ala Ser Gly Gin Gin Val 260 265 270 Ala Gly Val Leu Glu Thr Thr Asp Ser Val Met Arg Arg Leu Met Asn 275 280 285 Leu Leu Gly Gin Val Glu Ser Ala Met Ser Gly Pro Ala Ala Tyr Ala 290 295 300 Ser Tyr Val Val Arg Gly Ala Asn Leu Val Thr Ala Val Ser Tyr Gly 305 310 315 320 Arg Ala Met Arg Asn Phe Glu Gin Phe Met Ala Arg He Val Asp His 325 330 335 Pro Asn Ala Leu Pro Ser Val Glu Gly Asp Lys Ala Ala Leu Ala Asp 340 345 350 Gly His Asp Glu He Gin Arg Thr Arg He Ala Ala Ser Leu Val Lys 355 360 365 He Gly Asp Lys Phe Val Ala He Glu Ser Leu Gin Arg Met Tyr Asn 370 375 380 Glu Thr Gin Phe Pro Cys Pro Leu Asn Arg Arg He Gin Tyr Thr Tyr 385 390 395 400 Phe Phe Pro Val Gly Leu His Leu Pro Val Pro Arg Tyr Ser Thr Ser 405 410 415 Val Ser Val Arg Gly Val Glu Ser Pro Ala He Gin Ser Thr Glu Thr 420 425 430 Trp Val Val Asn Lys Asn Asn Val Pro Leu Cys Phe Gly Tyr Gin Asn 435 440 445 Ala Leu Lys Ser He Cys His Pro Arg Met His Asn Pro Thr Gin Ser 450 455 460 Ala Gin Ala Leu Asn Gin Ala Phe Pro Asp Pro Asp Gly Gly His Gly 465 470 475 480 Tyr Gly Leu Arg Tyr Glu Gin Thr Pro Asn Met Asn Leu Phe Arg Thr 485 490 495 Phe His Gin Tyr Tyr Met Gly Lys Asn Val Ala Phe Val Pro Asp Val 500 505 510 Ala Gin Lys Ala Leu Val Thr Thr Glu Asp Leu Leu His Pro Thr Ser 515 520 525 His Arg Leu Leu Arg Leu Glu Val His Pro Phe Phe Asp Phe Phe Val 530 535 540 His Pro Cys Pro Gly Ala Arg Gly Ser Tyr Arg Ala Thr His Arg Thr 545 550 555 560 Met Val Gly Asn He Pro Gin Pro Leu Ala Pro Arg Glu Phe Gin Glu 565 570 575 Ser Arg Gly Ala Gin Phe Asp Ala Val Thr Asn Met Thr His Val He 580 585 590 Asp Gin Leu Thr He Asp Val He Gin Glu Thr Ala Phe Asp Pro Ala 595 600 605 Tyr Pro Leu Phe Cys Tyr Val He Glu Ala Met He His Gly Gin Glu 610 615 620 Glu Lys Phe Val Met Asn Met Pro Leu He Ala Leu Val He Gin Thr 625 630 635 640 Tyr Trp Val Asn Ser Gly Lys Leu Ala Phe Val Asn Ser Tyr His Met 645 650 655 Val Arg Phe He Cys Thr His He Gly Asn Gly Ser He Pro Lys Glu 660 665 670 Ala His Gly His Tyr Arg Lys He Leu Gly Glu Leu He Ala Leu Glu 675 680 685 Gin Ala Leu Leu Lys Leu Ala Gly His Glu Thr Val Gly Arg Thr Pro 690 695 700 He Thr His Leu Val Ser Ala Leu Leu Asp Pro His Leu Leu Pro Pro 705 710 715 720 Phe Ala Tyr His Asp Val Phe Thr Asp Leu Met Gin Lys Ser Ser Arg 725 730 735 Gin Pro He He Lys He Gly Asp Gin Asn Tyr Asp Asn Pro Gin Asn 740 745 750 Arg Ala Thr Phe He Asn Leu Arg Gly Arg Met Glu Asp Leu Val Asn 755 760 765 Asn Leu Val Asn He Tyr Gin Thr Arg Val Asn Glu Asp His Asp Glu • 770 775 780 Arg His Val Leu Asp Val Ala Pro Leu Asp Glu Asn Asp Tyr Asn Pro 785 790 795 800 Val Leu Glu Lys Leu Phe Tyr Tyr Val Leu Met Pro Val Cys Ser Asn 805 810 815 Gly His Met Cys Gly Met Gly Val Asp Tyr Gin Asn Val Ala Leu Thr 820 825 830 Leu Thr Tyr Asn Gly Pro Val Phe Ala Asp Val Val Asn Ala Gin Asp 835 840 845 Asp He Leu Leu His Leu Glu Asn Gly Thr Leu Lys Asp He Leu Gin 850 855 860 Ala Gly Asp He Arg Pro Thr Val Asp Met He Arg Val Leu Cys Thr 865 870 875 880 Ser Phe Leu Thr Cys Pro Phe Val Thr Gin Ala Ala Arg Val He Thr 885 890 895 Lys Arg Asp Pro Ala Gin Ser Phe Ala Thr His Glu Tyr Gly Lys Asp 900 905 910 Val Ala Gin Thr Val Leu Val Asn Gly Phe Gly Ala Phe Ala Val Ala 915 920 925 Asp Arg Ser Arg Glu Ala Ala Glu Thr Met Phe Tyr Pro Val Pro Phe 930 935 940 Asn Lys Leu Tyr Ala Asp Pro Leu Val Ala Ala Thr Leu His Pro Leu 945 950 955 960 Leu Pro Asn Tyr Val Thr Arg Leu Pro Asn Gin Arg Asn Ala Val Val 965 970 975 Phe Asn Val Pro Ser Asn Leu Met Ala Glu Tyr Glu Glu Trp His Lys 980 985 990 Ser Pro Val Ala Ala Tyr Ala Ala Ser Cys Gin Ala Thr Pro Gly Ala 995 1000 1005 He Ser Ala Met Val Ser Met His Gin Lys Leu Ser Ala Pro Ser Phe 1010 1015 1020 He Cys Gin Ala Lys His Arg Met His Pro Gly Phe Ala Met Thr Val 1025 1030 1035 1040 Val Arg Thr Asp Glu Val Leu Ala Glu His He Leu Tyr Cys Ser Arg 1045 1050 1055 Ala Ser Thr Ser Met Phe Val Gly Leu Pro Ser Val Val Arg Arg Glu 1060 1065 1070 Val Arg Ser Asp Ala Val Thr Phe Glu He Thr His Glu He Ala Ser 1075 1080 1085 Leu His Thr Ala Leu Gly Tyr Ser Ser Val He Ala Pro Ala His Val 1090 1095 1100 Ala Ala He Thr Thr Asp Met Gly Val His Cys Gin Asp Leu Phe Met 1105 1110 1115 1120 He Phe Pro Gly Asp Ala Tyr Gin Asp Arg Gin Leu His Asp Tyr He 1125 1130 1135 Lys Met Lys Ala Gly Val Gin Thr Gly Ser Pro Gly Asn Arg Met Asp 1140 1145 1150 His Val Gly Tyr Thr Ala Gly Val Pro Arg Cys Glu Asn Leu Pro Gly 1155 1160 1165 Leu Ser His Gly Gin Leu Ala Thr Cys Glu He He Pro Thr Pro Val 1170 1175 1180 Thr Ser Asp Val Ala Tyr Phe Gin Thr Pro Ser Asn Pro Arg Gly Arg 1185 1190 1195 1200 Ala Ala Ser Val Val Ser Cys Asp Ala Tyr Ser Asn Glu Ser Ala Glu 1205 1210 1215 Arg Leu Phe Tyr Asp His Ser He Pro Asp Pro Ala Tyr Glu Cys Arg 1220 1225 1230 Ser Thr Asn Asn Pro Trp Ala Ser Gin Arg Gly Ser Leu Gly Asp Val 1235 1240 1245 Leu Tyr Asn He Thr Phe Arg Gin Thr Ala Leu Pro Gly Met Tyr Ser 1250 1255 1260 Pro Cys Arg Gin Phe Phe His Lys Glu Asp He Met Arg Tyr Asn Arg 1265 1270 1275 1280 Gly Leu Tyr Thr Leu Val Asn Glu Tyr Ser Ala Arg Leu Ala Gly Ala 1285 1290 1295 Pro Ala Thr Ser Thr Thr Asp Leu Gin Tyr Val Val Val Asn Gly Thr 1300 1305 1310 Asp Val Phe Leu Asp Gin Pro Cys His Met Leu Gin Glu Ala Tyr Pro 1315 1320 1325 Thr Leu Ala Ala Ser His Arg Val Met Leu Ala Glu Tyr Met Ser Asn 1330 1335 1340 Lys Gin Thr His Ala Pro Val His Met Gly Gin Tyr Leu He Glu Glu 1345 1350 1355 1360 Val Ala Pro Met Lys Arg Leu Leu Lys Leu Gly Asn Lys Val Val Tyr 1365 1370 1375 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1143 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: N (iv) ANTI-SENSE: N (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1143 (D) OTHER INFORMATION: (Xi) SEQUENCE DESCRIPTION: SEQ ID N0:4: AGC ATT CGG GGA CAG ACC TTT AAC CTG CTC TAC GTA GAC GAG GCG AAT 48 Ser He Arg Gly Gin Thr Phe Asn Leu Leu Tyr Val Asp Glu Ala Asn 1 5 10 15 TTT ATT AAA AAG GAT GCA CTG CCG GCT ATT CTG GGT TTC ATG CTT CAG 96 Phe He Lys Lys Asp Ala Leu Pro Ala He Leu Gly Phe Met Leu Gin 20 25 30 AAA GAC GCC AAG CTT ATA TTT ATA TCA TCC GTG AAC TCG TCA GAC CGC 144 Lys Asp Ala Lys Leu He Phe He Ser Ser Val Asn Ser Ser Asp Arg 35 40 45 TCC ACG AGT TTC CTG CTT AAC CTC AGG AAC GCC CAG GAA AAG ATG CTG 192 Ser Thr Ser Phe Leu Leu Asn Leu Arg Asn Ala Gin Glu Lys Met Leu 50 55 60 AAT GTG GTC AGT TAC GTG TGT GCG GAC CAC CGA GAA GAT TTC CAC CTG 240 Asn Val Val Ser Tyr Val Cys Ala Asp His Arg Glu Asp Phe His Leu 65 70 75 80 CAA GAC GCA CTA GTG TCC TGT CCT TGT TAC AGA CTG CAC ATT CCG ACG 288 Gin Asp Ala Leu Val Ser Cys Pro Cys Tyr Arg Leu His He Pro Thr 85 90 95 TAC ATC ACC ATC GAC GAA TCC ATC AAA ACC ACC ACC AAC CTC TTT ATG 336 Tyr He Thr He Asp Glu Ser He Lys Thr Thr Thr Asn Leu Phe Met 100 105 110 GAG GGG GCA TTC GAC ACC GAA CTA ATG GGC GAG GGA GCA GCG TCG TCA 384 Glu Gly Ala Phe Asp Thr Glu Leu Met Gly Glu Gly Ala Ala Ser Ser 115 120 125 AAT GCT ACG CTT TAC CGC GTG GTG GGT GAC GCA GCG CTG ACA CAG TTT 432 Asn Ala Thr Leu Tyr Arg Val Val Gly Asp Ala Ala Leu Thr Gin Phe 130 135 140 GAC ATG TGT CGG GTA GAC ACC ACC GCC CAG GAG GTT CAG AAG TGC CTT 480 Asp Met Cys Arg Val Asp Thr Thr Ala Gin Glu Val Gin Lys Cys Leu 145 150 155 160 GGA AAA CAG CTG TTT GTT TAC ATC GAC CCC GCG TAT ACG AAC AAC ACG 528 Gly Lys Gin Leu Phe Val Tyr He Asp Pro Ala Tyr Thr Asn Asn Thr 165 170 175 GAG GCG TCC GGT ACT GGC GTG GGC GCC GTT GTC ACG AGT ACT CAG ACT 576 Glu Ala Ser Gly Thr Gly Val Gly Ala Val Val Thr Ser Thr Gin Thr 180 185 190 CCC ACC AGA AGC CTC ATA TTG GGC ATG GAG CAT TTC TTC CTG CGC GAC 624 Pro Thr Arg Ser Leu He Leu Gly Met Glu His Phe Phe Leu Arg Asp 195 200 205 CTC ACT GGC GCA GCT GCT TAC GAG ATA GCG TCC TGC GCA TGC ACG ATG 672 Leu Thr Gly Ala Ala Ala Tyr Glu He Ala Ser Cys Ala Cys Thr Met 210 215 220 ATT AAG GCG ATC GCT GTG CTC CAC ACC ACA ATT GAG CGC GTG AAC GCG 720 He Lys Ala He Ala Val Leu His Thr Thr He Glu Arg Val Asn Ala 225 230 235 240 GCG GTC GAA GGC AAC AGC AGC CAA GAT TCT GGG GTG GCC ATT GCA ACC 768 Ala Val Glu Gly Asn Ser Ser Gin Asp Ser Gly Val Ala He Ala Thr 245 250 255 GTC CTT AAC GAA ATA TGC CCG CTC CCC ATA CAT TTT CTA CAC TAT ACT 816 Val Leu Asn Glu He Cys Pro Leu Pro He His Phe Leu His Tyr Thr 260 265 270 GAC AAG AGC AGC GCC CTG CAG TGG CCA ATT TAC ATG TTG GGA GGC GAG 864 Asp Lys Ser Ser Ala Leu Gin Trp Pro He Tyr Met Leu Gly Gly Glu 275 280 285 AAA TCC TCC GCG TTT GAG ACA TTC ATC TAC GCT CTG AAC TCC GGC ACC 912 Lys Ser Ser Ala Phe Glu Thr Phe He Tyr Ala Leu Asn Ser Gly Thr 290 295 300 CTG AGC GCC AGC CAG ACG GTG GTG TCC AAC ACC ATC AAA ATA TCA TTT 960 Leu Ser Ala Ser Gin Thr Val Val Ser Asn Thr He Lys He Ser Phe 305 310 315 320 GAC CCG GTG ACC TAC CTG GTA GAA CAG GTC CGC GCG ATC AAG TGC GTC 1008 Asp Pro Val Thr Tyr Leu Val Glu Gin Val Arg Ala He Lys Cys Val 325 330 335 CCG CTT AGG GAT GGA GGG CAG TCA TAC AGC GCC AAG CAA AAG CAC ATG 1056 Pro Leu Arg Asp Gly Gly Gin Ser Tyr Ser Ala Lys Gin Lys His Met 340 345 350 TCG GAC GAC TTA CTT GTG GCA GTT GTC ATG GCC CAT TTT ATG GCT ACC 1104 Ser Asp Asp Leu Leu Val Ala Val Val Met Ala His Phe Met Ala Thr 355 360 365 GAT GAT AGA CAC ATG TAC AAG CCC ATA TCC CCA CAA TAA 1143 Asp Asp Arg His Met Tyr Lys Pro He Ser Pro Gin 370 375 380 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 380 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5 : Ser He Arg Gly Gin Thr Phe Asn Leu Leu Tyr Val Asp Glu Ala Asn 1 5 10 15 Phe He Lys Lys Asp Ala Leu Pro Ala He Leu Gly Phe Met Leu Gin 20 25 30 Lys Asp Ala Lys Leu He Phe He Ser Ser Val Asn Ser Ser Asp Arg 35 40 45 Ser Thr Ser Phe Leu Leu Asn Leu Arg Asn Ala Gin Glu Lys Met Leu 50 55 60 Asn Val Val Ser Tyr Val Cys Ala Asp His Arg Glu Asp Phe His Leu 65 70 75 80 Gin Asp Ala Leu Val Ser Cys Pro Cys Tyr Arg Leu His He Pro Thr 85 90 95 Tyr He Thr He Asp Glu Ser He Lys Thr Thr Thr Asn Leu Phe Met 100 105 110 Glu Gly Ala Phe Asp Thr Glu Leu Met Gly Glu Gly Ala Ala Ser Ser 115 120 125 Asn Ala Thr Leu Tyr Arg Val Val Gly Asp Ala Ala Leu Thr Gin Phe 130 135 140 Asp Met Cys Arg Val Asp Thr Thr Ala Gin Glu Val Gin Lys Cys Leu 145 150 155 160 Gly Lys Gin Leu Phe Val Tyr He Asp Pro Ala Tyr Thr Asn Asn Thr 165 170 175 Glu Ala Ser Gly Thr Gly Val Gly Ala Val Val Thr Ser Thr Gin Thr 180 185 190 Pro Thr Arg Ser Leu He Leu Gly Met Glu His Phe Phe Leu Arg Asp 195 200 205 Leu Thr Gly Ala Ala Ala Tyr Glu He Ala Ser Cys Ala Cys Thr Met 210 215 220 He Lys Ala He Ala Val Leu His Thr Thr He Glu Arg Val Asn Ala 225 230 235 240 Ala Val Glu Gly Asn Ser Ser Gin Asp Ser Gly Val Ala He Ala Thr 245 250 255 Val Leu Asn Glu He Cys Pro Leu Pro He His Phe Leu His Tyr Thr 260 265 270 Asp Lys Ser Ser Ala Leu Gin Trp Pro He Tyr Met Leu Gly Gly Glu 275 280 285 Lys Ser Ser Ala Phe Glu Thr Phe He Tyr Ala Leu Asn Ser Gly Thr 290 295 300 Leu Ser Ala Ser Gin Thr Val Val Ser Asn Thr He Lys He Ser Phe 305 310 315 320 Asp Pro Val Thr Tyr Leu Val Glu Gin Val Arg Ala He Lys Cys Val 325 330 335 Pro Leu Arg Asp Gly Gly Gin Ser Tyr Ser Ala Lys Gin Lys His Met 340 345 350 Ser Asp Asp Leu Leu Val Ala Val Val Met Ala His Phe Met Ala Thr 355 360 365 Asp Asp Arg His Met Tyr Lys Pro He Ser Pro Gin 370 375 380 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 234 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: N (iv) ANTI-SENSE: N (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..234 (D) OTHER INFORMATION: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: ATG GGT GAG CCA GTG GAT CCT GGA CAT GTG GTG AAT GAG AAA GAT TTT 48 Met Gly Glu Pro Val Asp Pro Gly His Val Val Asn Glu Lys Asp Phe 1 5 10 15 GAG GAG TGT GAA CAA TTT TTC AGT CAA CCC CTT AGG GAG CAA GTG GTC 96 Glu Glu Cys Glu Gin Phe Phe Ser Gin Pro Leu Arg Glu Gin Val Val 20 25 30 GCG GGG GTC AGG GCA CTC GAC GGC CTC GGT CTC GCT GAC TCT CTA TGT 144 Ala Gly Val Arg Ala Leu Asp Gly Leu Gly Leu Ala Asp Ser Leu Cys 35 40 45 CAC AAA ACA GAA AGA CTC TGC CTG CTG ATG GAC CTG GTG GGC ACG GAG 192 His Lys Thr Glu Arg Leu Cys Leu Leu Met Asp Leu Val Gly Thr Glu 50 55 60 TGC TTT GCG AGG GTG TGC CGC CTA GAC ACC GGT GCG AAA TGA 234 Cys Phe Ala Arg Val Cys Arg Leu Asp Thr Gly Ala Lys 65 70 75 (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 77 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein ( i) SEQUENCE DESCRIPTION: SEQ ID NO:7 : Met Gly Glu Pro Val Asp Pro Gly His Val Val Asn Glu Lys Asp Phe 1 5 10 15 Glu Glu Cys Glu Gin Phe Phe Ser Gin Pro Leu Arg Glu Gin Val Val 20 25 30 Ala Gly Val Arg Ala Leu Asp Gly Leu Gly Leu Ala Asp Ser Leu Cys 35 40 45 His Lys Thr Glu Arg Leu Cys Leu Leu Met Asp Leu Val Gly Thr Glu 50 55 60 Cys Phe Ala Arg Val Cys Arg Leu Asp Thr Gly Ala Lys 65 70 75 (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 585 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: N (iv) ANTI-SENSE: N (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..585 (D) OTHER INFORMATION: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8 : ATG AAG AGT GTG GCG AGT CCC TTA TGT CAG TTC CAC GGC GTG TTT TGC 48 Met Lys Ser Val Ala Ser Pro Leu Cys Gin Phe His Gly Val Phe Cys 1 5 10 15 CTG TAC CAG TGT CGC CAG TGC CTG GCA TAC CAC GTG TGT GAT GGG GGC 96 Leu Tyr Gin Cys Arg Gin Cys Leu Ala Tyr His Val Cys Asp Gly Gly 20 25 30 GCC GAA TGC GTT CTC CTG CAT ACG CCG GAG AGC GTC ATC TGC GAA CTA 144 Ala Glu Cys Val Leu Leu His Thr Pro Glu Ser Val He Cys Glu Leu 35 40 45 ACG GGT AAC TGC ATG CTC GGC AAC ATT CAA GAG GGC CAG TTT TTA GGG 192 Thr Gly Asn Cys Met Leu Gly Asn He Gin Glu Gly Gin Phe Leu Gly 50 55 60 CCG GTA CCG TAT CGG ACT TTG GAT AAC CAG GTT GAC AGG GAC GCA TAT 240 Pro Val Pro Tyr Arg Thr Leu Asp Asn Gin Val Asp Arg Asp Ala Tyr 65 70 75 80 CAC GGG ATG CTA GCG TGT CTG AAA CGG GAC ATT GTG CGG TAT TTG CAG 288 His Gly Met Leu Ala Cys Leu Lys Arg Asp He Val Arg Tyr Leu Gin 85 90 95 ACA TGG CCG GAC ACC ACC GTA ATC GTG CAG GAA ATA GCC CTG GGG GAC 336 Thr Trp Pro Asp Thr Thr Val He Val Gin Glu He Ala Leu Gly Asp 100 105 110 GGC GTC ACC GAC ACC ATC TCG GCC ATT ATA GAT GAA ACA TTC GGT GAG 384 Gly Val Thr Asp Thr He Ser Ala He He Asp Glu Thr Phe Gly Glu 115 120 125 TGT CTT CCC GTA CTG GGG GAG GCC CAA GGC GGG TAC GCC CTG GTC TGT 432 Cys Leu Pro Val Leu Gly Glu Ala Gin Gly Gly Tyr Ala Leu Val Cys 130 135 140 AGC ATG TAT CTG CAC GTT ATC GTC TCC ATC TAT TCG ACA AAA ACG GTG 480 Ser Met Tyr Leu His Val He Val Ser He Tyr Ser Thr Lys Thr Val 145 150 155 160 TAC AAC AGT ATG CTA TTT AAA TGC ACA AAG AAT AAA AAG TAC GAC TGC 528 Tyr Asn Ser Met Leu Phe Lys Cys Thr Lys Asn Lys Lys Tyr Asp Cys 165 170 175 ATT GCC AAG CGG GTG CGG ACA AAA TGG ATG CGC ATG CTA TCA ACG AAA 576 He Ala Lys Arg Val Arg Thr Lys Trp Met Arg Met Leu Ser Thr Lys 180 185 190 GAT ACG TAG 585 Asp Thr 195 (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 194 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: Met Lys Ser Val Ala Ser Pro Leu Cys Gin Phe His Gly Val Phe Cys 1 5 10 15 Leu Tyr Gin Cys Arg Gin Cys Leu Ala Tyr His Val Cys Asp Gly Gly 20 25 30 Ala Glu Cys Val Leu Leu His Thr Pro Glu Ser Val He Cys Glu Leu 35 40 45 Thr Gly Asn Cys Met Leu Gly Asn He Gin Glu Gly Gin Phe Leu Gly 50 55 60 Pro Val Pro Tyr Arg Thr Leu Asp Asn Gin Val Asp Arg Asp Ala Tyr 65 70 75 80 His Gly Met Leu Ala Cys Leu Lys Arg Asp He Val Arg Tyr Leu Gin 85 90 95 Thr Trp Pro Asp Thr Thr Val He Val Gin Glu He Ala Leu Gly Asp 100 105 110 Gly Val Thr Asp Thr He Ser Ala He He Asp Glu Thr Phe Gly Glu 115 120 125 Cys Leu Pro Val Leu Gly Glu Ala Gin Gly Gly Tyr Ala Leu Val Cys 130 135 140 Ser Met Tyr Leu His Val He Val Ser He Tyr Ser Thr Lys Thr Val 145 150 155 160 Tyr Asn Ser Met Leu Phe Lys Cys Thr Lys Asn Lys Lys Tyr Asp Cys 165 170 175 He Ala Lys Arg Val Arg Thr Lys Trp Met Arg Met Leu Ser Thr Lys 180 185 190 Asp Thr (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 939 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY*, linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: N (iv) ANTI-SENSE: N (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..939 (D) OTHER INFORMATION: (Xi) SEQUENCE DESCRIPTION: SEQ ID Nθ:10: ATG GCT AGC CGG AGG CGC AAA CTT CGG AAT TTC CTA AAC AAG GAA TGC 48 Met Ala Ser Arg Arg Arg Lys Leu Arg Asn Phe Leu Asn Lys Glu Cys 1 5 10 15 ATA TGG ACT GTT AAC CCA ATG TCA GGG GAC CAT ATC AAG GTC TTT AAC 96 He Trp Thr Val Asn Pro Met Ser Gly Asp His He Lys Val Phe Asn 20 25 30 GCC TGC ACC TCT ATC TCG CCG GTG TAT GAC CCT GAG CTG GTA ACC AGC 144 Ala Cys Thr Ser He Ser Pro Val Tyr Asp Pro Glu Leu Val Thr Ser 35 40 45 TAC GCA CTG AGC GTG CCT GCT TAC AAT GTG TCT GTG GCT ATC TTG CTG 192 Tyr Ala Leu Ser Val Pro Ala Tyr Asn Val Ser Val Ala He Leu Leu 50 55 60 CAT AAA GTC ATG GGA CCG TGT GTG GCT GTG GGA ATT AAC GGA GAA ATG 2 C His Lys Val Met Gly Pro Cys Val Ala Val Gly He Asn Gly Glu Met 65 70 75 80 ATC ATG TAC GTC GTA AGC CAG TGT GTT TCT GTG CGG CCC GTC CCG GGG 288 He Met Tyr Val Val Ser Gin Cys Val Ser Val Arg Pro Val Pro Gly 85 90 95 CGC GAT GGT ATG GCG CTC ATC TAC TTT GGA CAG TTT CTG GAG GAA GCA 336 Arg Asp Gly Met Ala Leu He Tyr Phe Gly Gin Phe Leu Glu Glu Ala 100 105 110 TCC GGA CTG AGA TTT CCC TAC ATT GCT CCG CCG CCG TCG CGC GAA CAC 384 Ser Gly Leu Arg Phe Pro Tyr He Ala Pro Pro Pro Ser Arg Glu His 115 120 125 GTA CCT GAC CTG ACC AGA CAA GAA TTA GTT CAT ACC TCC CAG GTG GTG 432 Val Pro Asp Leu Thr Arg Gin Glu Leu Val His Thr Ser Gin Val Val 130 135 140 CGC CGC GGC GAC CTG ACC AAT TGC ACT ATG GGT CTC GAA TTC AGG AAT 480 Arg Arg Gly Asp Leu Thr Asn Cys Thr Met Gly Leu Giu Phe Arg Asn 145 150 155 160 GTG AAC CCT TTT GTT TGG CTC GGG GGC GGA TCG GTG TGG CTG CTG TTC 528 Val Asn Pro Phe Val Trp Leu Gly Gly Gly Ser Val Trp Leu Leu Phe 165 ' 170 175 TTG GGC GTG GAC TAC ATG GCG TTC TGT CCG GGT GTC GAC GGA ATG CCG 576 Leu Gly Val Asp Tyr Met Ala Phe Cys Pro Gly Val Asp Gly Met Pro 180 185 190 TCG TTG GCA AGA GTG GCC GCC CTG CTT ACC AGG TGC GAC CAC CCA GAC 624 Ser Leu Ala Arg Val Ala Ala Leu Leu Thr Arg Cys Asp His Pro Asp 195 200 205 TGT GTC CAC TGC CAT GGA CTC CGT GGA CAC GTT AAT GTA TTT CGT GGG 672 Cys Val His Cys His Gly Leu Arg Gly His Val Asn Val Phe Arg Gly 210 215 220 TAC TGT TCT GCG CAG TCG CCG GGT CTA TCT AAC ATC TGT CCC TGT ATC 72C Tyr Cys Ser Ala Gin Ser Pro Gly Leu Ser Asn He Cys Pro Cys He 225 ' 230 235 ' 240 AAA TCA TGT GGG ACC GGG AAT GGA GTG ACT AGG GTC ACT GGA AAC AGA 768 Lvs Ser Cys Gly Thr Gly Asn Gly Val Thr Arg Val Thr Gly Asn Arg 245 250 " 255 AAT TTT CTG GGT CTT CTG TTC GAT CCC ATT GTC CAG AGC AGG GTA ACA 816 Asn Phe Leu Gly Leu Leu Phe Asp Pro He Val Gin Ser Arg Val Thr 260 265 270 GCT CTG AAG ATA ACT AGC CAC CCA ACC CCC ACG CAC GTC GAG AAT GTG 864 Ala Leu Lys lie Thr Ser His Pro Thr Pro Thr His Val Giu Asn Val 275 280 285 CTA ACA GGA GTG CTC GAC GAC GGC ACC TTG GTG CCG TCC GTC CAA GGC 911 Leu Thr Gly Val Leu Asp Asp Gly Tnr Leu Val Pro Ser Val Gin Gly 290 " 295 30C ACC CTG GGT CCT CTT ACG AAT GTC TGA 939 Thr Leu Gly Pro Leu Thr Asn Val 305 310 (2) INFORMATION FOR SEQ ID NO: 11: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 312 ammo acids (B) TYPE: ammo acid (D) TOPOLOGY, linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: Met Ala Ser Arg Arg Arg Lys Leu Arg Asn Phe Leu Asn Lys Glu Cys 1 5 10 15 He TrD Thr Val Asn Pro Met Ser Gly Asp His He Lys Val Phe Asn 20 25 30 Ala Cys Thr Ser He Ser Pro Val Tyr Asp Pro Glu Leu Val Thr Ser 35 40 45 Tyr Ala Leu Ser Val Pro Ala Tyr Asn Val Ser Val Ala He Leu Leu 50 55 60 His Lys Val Met Gly Pro Cys Val Ala Val Gly He Asn Gly Giu Met 65 70 75 ' 80 He Met Tyr Val Val Ser Gin Cys Val Ser Val Arg Pro Val Pro Gly 85 90 95 Arg Asp Gly Met Ala Leu He Tyr Phe Gly Gin Phe Leu Glu Glu Ala 100 105 110 Ser Gly Leu Arg Phe Pro Tyr He Ala Pro Pro Pro Ser Arg Glu His 115 120 125 Val Pro Asp Leu Thr Arg Gin Glu Leu Val His Thr Ser Gin Val Val 130 135 140 Arg Arg Gly Asp Leu Thr Asn Cys Thr Met Gly Leu Glu Phe Arg Asn 145 150 155 160 Val Asn Pro Phe Val Trp Leu Gly Gly Gly Ser Val Trp Leu Leu Phe 165 170 175 Leu Glv Val Asp Tyr Met Ala Phe Cys Pro Gly Val Asp Gly Met Pro 180 185 190 Ser Leu Ala Arg Val Ala Ala Leu Leu Thr Arg Cys Asp His Pro Asp 195 200 205 Cvs Val His Cys His Gly Leu Arg Gly His Val Asn Val Phe Arg Gly 210 215 220 Tvr Cvs Ser Ala Gin Ser Pro Gly Leu Ser Asn He Cys Pro Cys He 225 ' 230 235 240 Lys Ser Cys Glv Thr Gly Asn Glv Val Thr Arg Val Thr Gly Asn Arg 245 ' 250 255 Asn Phe Leu Glv Leu Leu Phe Asp Pro He Val Gin Ser Arg Val Thr 26 * 0 265 270 Ala Leu Lys He Thr Ser His Pro Thr Pro Thr His Val Glu Asn Val 275 280 285 Leu Thr Gly Val Leu Asp Asp Gly Thr Leu Val Pro Ser Val Gin Gly 290 295 300 Thr Leu Glv Pro Leu Thr Asn Val 305 310 (2) INFORMATION FOR SEQ ID NO: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 86 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii; MOLECULE TYPE: DNA (genomic) (iii. HYPOTHETICAL: N (iv) ANTI-SENSE: N (i > FEATURE : (A) NAME/KEY: CDS (B) LOCATION: 1..86 (P) OTHER INFORMATION: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: ATG GAC TCA ACC AAC TCT AAA AGA GAG TTT ATT AAG TCG GCT CTG GAG 48 Met Asp Ser Thr Asn Ser Lys Arg Glu Phe He Lys Ser Ala Leu Glu 1 5 10 15 GCC AAC ATC AAC AGG AGG GCA GCT GTA TCG CTA TTT GA 86 Ala Asn He Asn Arg Arg Ala Ala Val Ser Leu Phe 20 25 (2) INFORMATION FOR SEQ ID NO:13: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13: Met ASD Ser Thr Asn Ser Lys Arg Glu Phe He Lvs Ser Ala Leu Glu 1 5 10 ' 15 Ala Asn He Asn Arg Arg Ala Ala Val Ser Leu Phe 20 25 INFORMATION FOR SEQ ID NO:14: ii SEQUENCE CHARACTERISTICS: (A) LENGTH: 1743 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: N ( iv) ANT I - SENSE : N ( ix) FEATURE : (A) NAME/KEY: CDS (B) LOCATION: 1..1743 (D) OTHER INFORMATION: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: ATG GCA GAA GGC GGT TTT GGA GCG GAC TCG GTG GGG CGC GGC GGA GAA 48 Met Ala Glu Gly Gly Phe Gly Ala Asp Ser Val Gly Arg Gly Gly Glu 1 5 10 15 AAG GCC TCT GTG ACT AGG GGA GGC AGG TGG GAC TTG GGG AGC TCG GAC 96 Lys Ala Ser Val Thr Arg Gly Gly Arg Trp Asp Leu Gly Ser Ser Asp 20 25 30 GAC GAA TCA AGC ACC TCC ACA ACC AGC ACG GAT ATG GAC GAC CTC CCT 144 Asp Glu Ser Ser Thr Ser Thr Thr Ser Thr Asp Met Asp Asp Leu Pro 35 40 45 GAG GAG AGG AAA CCA CTA ACG GGA AAG TCT GTA AAA ACC TCG TAC ATA 192 Glu Giu Arg Lys Pro Leu Thr Gly Lys Ser Val Lys Thr Ser Tyr He 50 55 60 TAC GAC GTG CCC ACC GTC CCG ACC AGC AAG CCG TGG CAT TTA ATG CAC 240 Tyr Asp Val Pro Thr Val Pro Thr Ser Lys Pro Trp His Leu Met His 65 70 75 80 GAC AAC TCC CTC TAC GCA ACG CCT AGG TTT CCG CCC AGA CCT CTC ATA 288 Asp Asn Ser Leu Tyr Ala Thr Pro Arg Phe Pro Pro Arg Pro Leu He 85 90 95 CGG CAC CCT TCC GAA AAA GGC AGC ATT TTT GCC AGT CGG TTG TCA GCG 336 Arg His Pro Ser Glu Lys Gly Ser He Phe Ala Ser Arg Leu Ser Ala 100 105 110 ACT GAC GAC GAC TCG GGA GAC TAC GCG CCA ATG GAT CGC TTC GCC TTC 384 Thr Asp Asp Asp Ser Gly Asp Tyr Ala Pro Met Asp Arg Phe Ala Phe 115 120 125 CAG AGC CCC AGG GTG TGT GGT CGC CCT CCC CTT CCG CCT CCA AAT CAC 432 Gin Ser Pro Arg Val Cys Gly Arg Pro Pro Leu Pro Pro Pro Asn His 130 135 140 CCA CCT CCG GCA ACT AGG CCG GCA GAC GCG TCA ATG GGG GAC GTG GGC 480 Pro Pro Pro Ala Thr Arg Pro Ala Asp Ala Ser Met Gly Asp Val Gly 145 150 155 ' 160 TGG GCG GAT CTG CAG GGA CTC AAG AGG ACC CCA AAG GGA TTT TTA AAA 528 Tro Ala Asp Leu Gin Gly Leu Lys Arg Thr Pro Lys Gly Phe Leu Lys 165 170 175 ACA TCT ACC AAG GGG GGC AGT CTC AAA GCC CGT GGA CGC GAT GTA GGT 576 Thr Ser Thr Lvs Gly Gly Ser Leu Lys Ala Arg Gly Arg Asp Val Gly 180 * 185 190 GAC CGT CTC AGG GAC GGC GGC TTT GCC TTT AGT CCT AGG GGC GTG AAA 624 Asp Arα Leu Arg Aso Gly Gly Phe Ala Phe Ser Pro Arg Gly Val Lys 195 " ' 200 205 TCT GCC ATA GGG CAA AAC ATT AAA TCA TGG TTG GGG ATC GGA GAA TCA 672 Ser Ala He Gly Gin Asn He Lys Ser Trp Leu Gly He Gly Glu Ser 210 215 220 TCG GCG ACT GCT GTC CCC GTC ACC ACG CAG CTT ATG GTA CCG GTG CAC 720 Ser Ala Thr Ala Val Pro Val Thr Thr Gin Leu Met Val Pro Val His 225 230 235 240 CTC ATT AGA ACG CCT GTG ACC GTG GAC TAC AGG AAT GTT TAT TTG CTT 768 Leu He Arg Thr Pro Val Thr Val Asp Tyr Arg Asn Val Tyr Leu Leu 245 250 255 TAC TTA GAG GGG GTA ATG GGT GTG GGC AAA TCA ACG CTG GTC AAC GCC 816 Tyr Leu Glu Gly Val Met Gly Val Gly Lys Ser Thr Leu Val Asn Ala 260 265 270 GTG TGC GGG ATC TTG CCC CAG GAG AGA GTG ACA AGT TTT CCC GAG CCC 864 Val Cys Gly He Leu Pro Gin Glu Arg Val Thr Ser Phe Pro Glu Pro 275 280 285 ATG GTG TAC TGG ACG AGG GCA TTT ACA GAT TGT TAC AAG GAA ATT TCC 912 Met Val Tyr Trp Thr Arg Ala Phe Thr Asp Cys Tvr Lys Glu He Ser 290 * 295 * 300 CAC CTG ATG AAG TCT GGT AAG GCG GGA GAC CCG CTG ACG TCT GCC AAA 960 His Leu Met Lys Ser Gly Lys Ala Gly Asp Pro Leu Thr Ser Ala Lys 305 310 ' 315 320 ATA TAC TCA TGC CAA AAC AAG TTT TCG CTC CCC TTC CGG ACG AAC GCC 1008 He Tyr Ser Cvs Gin Asn Lys Phe Ser Leu Pro Phe Arg Thr Asn Ala 325 330 335 ACC GCT ATC CTG CGA ATG ATG CAG CCC TGG AAC GTT GGG GGT GGG TCT 1056 Thr Ala He Leu Arg Met Met Gin Pro Trp Asn Val Gly Gly Gly Ser 340 345 350 GGG AGG GGC ACT CAC TGG TGC GTC TTT GAT AGG CAT CTC CTC TCC CCA 1104 Gly Arg Gly Thr His Trp Cys Val Phe Asp Arg His Leu Leu Ser Pro 355 360 365 GCA GTG GTG TTC CCT CTC ATG CAC CTG AAG CAC GGC CGC CTA TCT TTT 1152 Ala Val Val Phe Pro Leu Met His Leu Lys His Gly Arg Leu Ser Phe 370 375 380 GAT CAC TTC TTT CAA TTA CTT TCC ATC TTT AGA GCC ACA GAA GGC GAC 1200 Asp His Phe Phe Gin Leu Leu Ser He Phe Arg Ala Thr Glu Gly Asp 385 390 395 400 GTG GTC GCC ATT CTC ACC CTC TCC AGC GCC GAG TCG TTG CGG CGG GTC 1248 Val Val Ala He Leu Thr Leu Ser Ser Ala Glu Ser Leu Arg Arg Val 405 410 415 AGG GCG AGG GGA AGA AAG AAC GAC GGG ACG GTG GAG CAA AAC TAC ATC 1296 Arg Ala Arg Gly Arg Lys Asn Asp Gly Thr Val Glu Gin Asn Tyr He 420 425 430 AGA GAA TTG GCG TGG GCT TAT CAC GCC GTG TAC TGT TCA TGG ATC ATG 1344 Arg Glu Leu Ala Trp Ala Tyr His Ala Val Tyr Cys Ser Trp He Met 435 440 445 TTG CAG TAC ATC ACT GTG GAG CAG ATG GTA CAA CTA TGC GTA CAA ACC 1392 Leu Gin Tyr He Thr Val Glu Gin Met Val Gin Leu Cys Val Gin Thr 450 455 46C ACA AAT ATT CCG GAA ATC TGC TTC CGC AGC GTG CGC CTG GCA CAC AAG 1440 Thr Asn He Pro Glu He Cys Phe Arg Ser Val Arg Leu Ala His Lys 465 470 ' 475 480 GAG GAA ACT TTG AAA AAC CTT CAC GAG CAG AGC ATG CTA CCT ATG ATC 1488 Glu Giu Thr Leu Lys Asn Leu His Glu Gin Ser Met Leu Pro Met He 485 490 495 ACC GGT GTA CTG GAT CCC GTG AGA CAT CAT CCC GTC GTG ATC GAG CTT 1536 Thr Gly Val Leu Asp Pro Val Arg His His Pro Val Val He Glu Leu 500 505 510 TGC TTT TGT TTC TTC ACA GAG CTG AGA AAA TTA CAA TTT ATC GTA GCC 1584 Cys Phe Cys Phe Phe Thr Giu Leu Arg Lys Leu Gin Phe He Val Ala 515 520 525 GAC GCG GAT AAG TTC CAC GAC GAC GTA TGC GGC CTG TGG ACC GAA ATC 1632 Asp Ala Asp Lys Phe His Asp Asp Val Cys Gly Leu Trp Thr Glu He 530 535 540 TAC AGG CAG ATC CTG TCC AAT CCG GCT ATT AAA CCC AGG GCC ATC AAC 168C Tyr Arg Gin He Leu Ser Asn Pro Ala He Lys Pro Arg Ala He Asn 545 550 555 560 TGG CCA GCA TTA GAG AGC CAG TCT AAA GCA GTT AAT CAC CTA GAG GAG 1728 Trp Pro Ala Leu Glu Ser Gin Ser Lys Ala Val Asn His Leu Glu Glu 565 570 575 ACA TGC AGG GTC TAG 1743 Thr Cys Arg Val 580 (2) INFORMATION FOR SEQ ID NO: 15: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 580 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15: Met Ala Glu Gly Gly Phe Gly Ala Asp Ser Val Gly Arg Gly Gly Glu 1 5 10 15 Lys Ala Ser Val Thr Arg Gly Gly Arg Trp Asp Leu Gly Ser Ser Asp 20 25 30 Asp Glu Ser Ser Thr Ser Thr Thr Ser Thr Asp Met Asp Asp Leu Pro 35 40 45 Glu Glu Arg Lys Pro Leu Thr Gly Lys Ser Val Lys Thr Ser Tyr He 50 ' 55 60 Tvr Asp Val Pro Thr Val Pro Thr Ser Lys Pro Trp His Leu Met His 65 70 75 80 Asp Asn Ser Leu Tyr Ala Thr Pro Arg Phe Pro Pro Arg Pro Leu He 85 90 95 Arg His Pro Ser Glu Lys Gly Ser He Phe Ala Ser Arg Leu Ser Ala 100 105 110 Thr AΞD Aso Ast> Ser Gly Asp Tyr Ala Pro Met Asp Arg Phe Ala Phe 115 " * 120 125 Gin Ser Pro Arg Val Cys Gly Arg Pro Pro Leu Pro Pro Pro Asn His 130 135 140 Pro Pro Pro Ala Thr Arg Pro Ala Asp Ala Ser Met Gly Asp Val Gly 145 150 155 160 Trp Ala Asp Leu Gin Gly Leu Lys Arg Thr Pro Lys Gly Phe Leu Lys 165 170 175 Thr Ser Thr Lys Gly Gly Ser Leu Lys Ala Arg Gly Arg Asp Val Gly 180 185 190 Asp Arg Leu Arg Asp Gly Gly Phe Ala Phe Ser Pro Arg Gly Val Lys 195 200 205 Ser He Gly Glu Ser Ser Ala Thr Ala Val Pro Val Thr Thr Gin Leu Met Val Pro Val His 225 230 235 240 Leu He Arg Thr Pro Val Thr Val Asp Tyr Arg Asn Val Tyr Leu Leu 245 250 255 Tyr Leu Glu Gly Val Met Gly Val Gly Lys Ser Thr Leu Val Asn Ala 260 265 270 Val Cys Gly He Leu Pro Gin Glu Arg Val Thr Ser Phe Pro Glu Pro 275 280 285 Met Val Tyr Trp Thr Arg Ala Phe Thr Asp Cys Tvr Lys Glu He Ser 290 295 300 His Leu Met Lys Ser Gly Lys Ala Gly Asp Pro Leu Thr Ser Ala Lys 305 310 315 320 He Tyr Ser Cys Gin Asn Lys Phe Ser Leu Pro Phe Arg Thr Asn Ala 325 330 335 Thr Ala He Leu Arg Met Met Gin Pro Trp Asn Val Gly Gly Gly Ser 340 345 350 Gly Arg Gly Thr His Trp Cys Val Phe Asp Arg His Leu Leu Ser Pro 355 360 365 Ala Val Val Phe Pro Leu Met His Leu Lys His Gly Arg Leu Ser Phe 370 375 380 Asp His Phe Phe Gin Leu Leu Ser He Phe Arg Ala Thr Glu Gly Asp 385 390 395 ' 400 Val Val Ala He Leu Thr Leu Ser Ser Ala Glu Ser Leu Arg Arg Val 405 410 415 Arg Ala Arg Gly Arg Lys Asn Asp Gly Thr Val Glu Gin Asn Tyr He 420 425 430 Arg Glu Leu Ala Trp Ala Tyr His Ala Val Tyr Cys Ser Trp He Met 435 440 445 Leu Gin Tyr He Thr Val Glu Gin Met Val Gin Leu Cys Val Gin Thr 450 455 460 Thr Asr. He Pro Glu He Cys Phe Arg Ser Val Arg Leu Ala His Lys 465 470 475 480 Glu Glu Thr Leu Lys Asn Leu His Glu Gin Ser Met Leu Pro Met He 485 490 495 Thr Gly Val Leu Asp Pro Val Arg His His Pro Val Val He Glu Leu 500 505 510 Cys Phe Cys Phe Phe Thr Glu Leu Arg Lys Leu Gin Phe He Val Ala 515 520 525 Asp Ala Asp Lys Phe His Asp Asp Val Cys Gly Leu Trp Thr Glu He 530 535 540 Tyr Arg Gin He Leu Ser Asn Pro Ala He Lys Pro Arg Ala He Asn 545 550 555 560 Trp Pro Ala Leu Glu Ser Gin Ser Lys Ala Val Asn His Leu Glu Glu 565 570 575 Thr Cys Arg Val 580 (2) INFORMATION FOR SEQ ID NO:16: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2193 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: Single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (lli) HYPOTHETICAL: N (iv) ANTI-SENSE: N ( x) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..2193 (D) OTHER INFORMATION: (xi) SEQUENCE DESCRIPTION: SEQ ID Nθ:16: ATG CAG GGT CTA GCC TTC TTG GCG GCC CTT GCA TGC TGG CGA TGC ATA 48 Met Gin Gly Leu Ala Phe Leu Ala Ala Leu Ala Cys Trp Arg Cys He 1 5 10 15 TCG TTG ACA TGT GGA GCC ACT GGC GCG TTG CCG ACA ACG GCG ACG ACA 96 Ser Leu Thr Cys Gly Ala Thr Gly Ala Leu Pro Thr Thr Ala Thr Thr 20 25 30 ATA ACC CGC TCC GCC ACG CAG CTC ATC AAT GGG AGA ACC AAC CTC TCC 144 He Thr Arg Ser Ala Thr Gin Leu He Asn Gly Arg Thr Asn Leu Ser 35 40 45 ATA GAA CTG GAA TTC AAC GGC ACT AGT TTT TTT CTA AAT TGG CAA AAT 192 lie Glu Leu Glu Phe Asn Gly Thr Ser Phe Phe Leu Asn Trp Gin Asn 50 55 60 CTG TTG AAT GTG ATC ACG GAG CCG GCC CTG ACA GAG TTG TGG ACC TCC 2 C Leu Leu Asn Val He Thr Giu Pro Ala Leu Thr Glu Leu Trp Thr Ser 65 70 75 80 GCC GAA GTC GCC GAG GAC CTC AGG GTA ACT CTG AAA AAG AGG CAA AGT 288 Ala Giu Val Ala Glu Asp Leu Arg Val Thr Leu Lys Lys Arg Gin Ser B5 90 ' 95 CTT TTT TTC CCC AAC AAG ACA GTT GTG ATC TCT GGA GAC GGC CAT CGC 336 Leu Phe Phe Pro Asn Lys Thr Val Val He Ser Gly Asp Gly His Arg 100 ' 105 ' * 11 * 0 TAT ACG TGC GAG GTG CCG ACG TCG TCG CAA ACT TAT AAC ATC ACC AAG 384 Tyr Thr Cys Glu Val Pro Thr Ser Ser Gin Thr Tyr Asn He Thr Lys 115 120 125 GGC TTT AAC TAT AGC GCT CTG CCC GGG CAC CTT GGC GGA TTT GGG ATC 432 Gly Phe Asn Tyr Ser Ala Leu Pro Gly His Leu Gly Gly Phe Gly He 130 135 140 AAC GCG CGT CTG GTA CTG GGT GAT ATC TTC GCA TCA AAA TGG TCG CTA 480 Asn Ala Arg Leu Val Leu Gly Asp He Phe Ala Ser Lys Trp Ser Leu 145 150 155 160 TTC GCG AGG GAC ACC CCA GAG TAT CGG GTG TTT TAC CCA ATG AAT GTC 528 Phe Ala Arg Asp Thr Pro Glu Tyr Arg Val Phe Tyr Pro Met Asn Val 165 170 175 ATG GCC GTC AAG TTT TCC ATA TCC ATT GGC AAC AAC GAG TCC GGC GTA 576 Met Ala Val Lys Phe Ser He Ser He Gly Asn Asn Glu Ser Gly Val 180 185 190 GCG CTC TAT GGA GTG GTG TCG GAA GAT TTC GTG GTC GTC ACG CTC CAC 624 Ala Leu Tvr Gly Val Val Ser Glu Asp Phe Val Val Val Thr Leu His 195 200 205 AAC AGG TCC AAA GAG GCT AAC GAG ACG GCG TCC CAT CTT CTG TTC GGT 672 Asn Arg Ser Lys Glu Ala Asn Glu Thr Ala Ser His Leu Leu Phe Gly 210 215 220 CTC CCG GAT TCA CTG CCA TCT CTG AAG GGC CAT GCC ACC TAT GAT GAA 720 Leu Pro Asp Ser Leu Pro Ser Leu Lys Gly His Ala Thr Tyr Asp Glu 225 230 235 * 240 CTC ACG TTC GCC CGA AAC GCA AAA TAT GCG CTA GTG GCG ATC CTG CCT 768 Leu Thr Phe Ala Arg Asn Ala Lys Tyr Ala Leu Val Ala He Leu Pro 245 250 255 AAA GAT TCT TAC CAG ACA CTC CTT ACA GAG AAT TAC ACT CGC ATA TTT 816 Lys Asp Ser Tyr Gin Thr Leu Leu Thr Glu Asn Tyr Thr Arg He Phe 260 265 270 CTG AAC ATG ACG GAG TCG ACG CCC CTC GAG TTC ACG CGG ACG ATC CAG 864 Leu Asn Met Thr Glu Ser Thr Pro Leu Glu Phe Thr Arg Thr He Gin 275 280 285 ACC AGG ATC GTA TCA ATC GAG GCC AGG CGC GCC TGC GCA GCT CAA GAG 912 Thr Arg He Val Ser He Glu Ala Arg Arg Ala Cys Ala Ala Gin Glu 290 295 300 GCG GCG CCG GAC ATA TTC TTG GTG TTG TTT CAG ATG TTG GTG GCA CAC 960 Ala Ala Pro Asp He Phe Leu Val Leu Phe Gin Met Leu Val Ala His 305 310 315 320 TTT CTT GTT GCG CGG GGC ATT GCC GAG CAC CGA TTT GTG GAG GTG GAC 1008 Phe Leu Val Ala Arg Gly He Ala Glu His Arg Phe Val Glu Val Asp 325 330 335 TGC GTC- TGT CGG CAG TAT GCG GAA CTG TAT TTT CTC CGC CGC ATC TCG 1056 Cys Val Cys Arg Gin Tyr Ala Glu Leu Tyr Phe Leu Arg Arg He Ser 340 345 350 CGT CTC- TGC ATG CCC ACG TTC ACC ACT GTC GGG TAT AAC CAC ACC ACC 1104 Ar Leu Cvs Met Pro Thr Phe Thr Thr Val Gly Tyr Asn His Thr Thr 355 360 365 CTT GGC GCT GTG GCC GCC ACA CAA ATA GCT CGC GTG TCC GCC ACG AAG 1152 Leu Glv Ala Val Ala Ala Thr Gin He Ala Arg Val Ser Ala Thr Lys 370 375 380 TTG GCC AGT TTG CCC CGC TCT TCC CAG GAA ACA GTG CTG GCC ATG GTC 1200 Leu Ala Ser Leu Pro Arg Ser Ser Gin Glu Thr Val Leu Ala Met Val 385 390 395 400 CAG CTT GGC GCC CGT GAT GGC GCC GTC CCT TCC TCC ATT CTG GAG GGC 1248 Gin Leu Gly Ala Arg Asp Gly Ala Val Pro Ser Ser He Leu Glu Gly 405 410 415 ATT GCT ATG GTC GTC GAA CAT ATG TAT ACC GCC TAC ACT TAT GTG TAC 1296 He Ala Met Val Val Glu His Met Tyr Thr Ala Tyr Thr Tyr Val Tvr 420 425 430 ACA CTC GGC GAT ACT GAA AGA AAA TTA ATG TTG GAC ATA CAC ACG GTC 1344 Thr Leu Gly Asp Thr Glu Arg Lys Leu Met Leu Asp He His Thr Val 435 440 445 CTC ACC GAC AGC TGC CCG CCC AAA GAC TCC GGA GTA TCA GAA AAG CTA 13S2 Leu Thr Asp Ser Cys Pro Pro Lys Asp Ser Gly Val Ser Glu Lys Leu 450 455 460 CTG AGA ACA TAT TTG ATG TTC ACA TCA ATG TGT ACC AAC ATA GAG CTG 14 C Leu Arg Thr Tyr Leu Met Phe Thr Ser Met Cys Thr Asn He Glu Leu 465 470 475 480 GGC GAA ATG ATC GCC CGC TTT TCC AAA CCG GAC AGC CTT AAC ATC TAT 1488 Gly Glu Met He Ala Arg Phe Ser Lys Pro Asp Ser Leu Asn He Tyr 485 490 495 AGG GCA TTC TCC CCC TGC TTT CTA GGA CTA AGG TAC GAT TTG CAT CCA 1536 Arg Ala Phe Ser Pro Cys Phe Leu Gly Leu Arg Tyr Asp Leu His Pro 500 505 510 GCC AAG TTG CGC GCC GAG GCG CCG CAG TCG TCC GCT CTG ACG CGG ACT 1584 Ala Lys Leu Arg Ala Glu Ala Pro Gin Ser Ser Ala Leu Thr Arg Thr 515 520 525 GCC GTT GCC AGA GGA ACA TCG GGA TTC GCA GAA TTG CTC CAC GCG CTG 1632 Ala Val Ala Arg Gly Thr Ser Gly Phe Ala Glu Leu Leu His Ala Leu 530 535 540 CAC CTC GAT AGC TTA AAT TTA ATT CCG GCG ATT AAC TGT TCA AAG ATT 1680 His Leu Asp Ser Leu Asn Leu He Pro Ala He Asn Cys Ser Lys He 545 550 555 560 ACA GCC GAC AAG ATA ATA GCT ACG GTA CCC TTG CCT CAC GTC ACG TAT 1728 Tnr Ala Asp Lys He He Ala Thr Val Pro Leu Pro His Val Thr Tyr 565 570 575 ATC ATC AGT TCC GAA GCA CTC TCG AAC GCT GTT GTC TAC GAG GTG TCG 1776 lie lie Ser Ser Giu Ala Leu Ser Asn Ala Val Val Tyr Glu Val Ser 580 585 590 GAG ATC TTC CTC AAG AGT GCC ATG TTT ATA TCT GCT ATC AAA CCC GAT 1824 Glu He Phe Leu Lys Ser Ala Met Phe He Ser Ala He Lys Pro Asp 595 600 605 TGC TCC GGC TTT AAC TTT TCT CAG ATT GAT AGG CAC ATT CCC ATA GTC 1872 Cys Ser Gly Phe Asn Phe Ser Gin He Asp Arg His He Pro He Val 610 ' 615 620 TAC AAC ATC AGC ACA CCA AGA AGA GGT TGC CCC CTT TGT GAC TCT GTA 1920 Tvr Asn He Ser Thr Pro Arg Arg Gly Cys Pro Leu Cys Asp Ser Val 625 630 * 635 640 ATC ATG AGC TAC GAT GAG AGC GAT GGC CTG CAG TCT CTC ATG TAT GTC 1968 He Met Ser Tyr Asp Glu Ser Asr> Gly Leu Gin Ser Leu Met Tyr Val 645 " 650 655 ACT AAT GAA AGG GTG CAG ACC AAC CTC TTT TTA GAT AAG TCA CCT TTC 2016 Thr Asn Glu Arg Val Gin Thr Asn Leu Phe Leu Asp Lys Ser Pro Phe 660 665 670 TTT GAT AAT AAC AAC CTA CAC ATT CAT TAT TTG TGG CTG AGG GAC AAC 2064 Phe Asp Asn Asn Asn Leu His He His Tyr Leu Trp Leu Arg Asp Asn 675 680 685 GGG ACC GTA GTG GAG ATA AGG GGC ATG TAT AGA AGA CGC GCA GCC AGT 2112 Gly Thr Val Val Glu He Arg Gly Met Tyr Arg Arg Arg Ala Ala Ser 690 695 700 GCT TTG TTT CTA ATT CTC TCT TTT ATT GGG TTC TCG GGG GTT ATC TAC 2160 Ala Leu Phe Leu He Leu Ser Phe He Gly Phe Ser Gly Val He Tyr 705 710 715 720 TTT CTT TAC AGA CTG TTT TCC ATC CTT TAT TAG 2193 Pne Leu Tyr Arg Leu Phe Ser He Leu Tyr 725 730 (2) INFORMATION FOR SEQ ID NO:17: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 730 ammo acids (B) TYPE: ammo acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17: Met Gin Gly Leu Ala Phe Leu Ala Ala Leu Ala Cys Trp Arg Cys He 1 5 10 15 Ser Leu Thr Cys Gly Ala Thr Gly Ala Leu Pro Thr Thr Ala Thr Thr 20 25 30 He Thr Arg Ser Ala Thr Gin Leu He Asn Gly Arg Thr Asn Leu Ser 35 40 45 He Glu Leu Glu Phe Asn Gly Thr Ser Phe Phe Leu Asn Trp Gin Asn 50 55 60 Leu Leu Asn Val He Thr Glu Pro Ala Leu Thr Glu Leu Trp Thr Ser 65 70 75 80 Ala Giu Val Ala Glu Asp Leu Arg Val Thr Leu Lys Lys Arg Gin Ser 85 90 * 95 Leu Phe Phe Pro Asn Lys Thr Val Val He Ser Gly Asp Gly His Arg 100 105 HO Tyr Thr He Thr Lys Gly Phe Asn Tyr Ser Ala Leu Pro Gly His Leu Gly Gly Phe Gly He 130 135 140 Asn Ala Arg Leu Val Leu Gly Asp He Phe Ala Ser Lys Trp Ser Leu 145 150 155 160 Phe Ala Arg Asp Thr Pro Glu Tyr Arg Val Phe Tyr Pro Met Asn Val 165 170 ' 175 Met Ala Val Lys Phe Ser He Ser He Gly Asn Asn Glu Ser Gly Val 180 185 190 Ala Leu Tyr Gly Val Val Ser Glu Asp Phe Val Val Val Thr Leu His 195 200 205 Asn Arg Ser Lys Glu Ala Asn Glu Thr Ala Ser His Leu Leu Phe Gly 210 215 220 Leu Pro Asp Ser Leu Pro Ser Leu Lys Gly His Ala Thr Tvr Asp Glu 225 230 235 ' 240 Leu Thr Phe Ala Arg Asn Ala Lys Tyr Ala Leu Val Ala He Leu Pro 245 250 255 Lys Asp Ser Tyr Gin Thr Leu Leu Thr Glu Asn Tyr Thr Arg He Phe 260 265 270 Leu Asn Met Thr Glu Ser Thr Pro Leu Glu Phe Thr Arg Thr He Gin 275 280 285 Thr Arc He Val Ser He Glu Ala Arg Arg Ala Cys Ala Ala Gin Glu 290 295 300 Ala Ala Pro Asp He Phe Leu Val Leu Phe Gin Met Leu Val Ala His 305 310 315 320 Phe Leu Val Ala Arg Gly He Ala Glu His Arg Phe Val Glu Val Asp 325 330 335 Cys Val Cys Arg Gin Tyr Ala Glu Leu Tyr Phe Leu Arg Arg He Ser 340 345 ' 350 Arg Leu Cys Met Pro Thr Phe Thr Thr Val Gly Tyr Asn His Thr Thr 355 360 365 Leu Gly Ala Val Ala Ala Thr Gin He Ala Arg Val Ser Ala Thr Lys 370 375 380 Leu Ala Ser Leu Pro Arg Ser Ser Gin Glu Thr Val Leu Ala Met Val 385 390 395 400 Gin Leu Gly Ala Arg Asp Gly Ala Val Pro Ser Ser He Leu Glu Gly 405 410 415 He Ala Met Val Val Glu His Met Tyr Thr Ala Tyr Thr Tyr Val Tyr 420 425 430 Thr Leu Gly Asp Thr Glu Arg Lys Leu Met Leu Asp He His Thr Val 435 " 440 445 Leu Thr Asp Ser Cys Pro Pro Lys Asp Ser Gly Val Ser Glu Lys Leu 450 455 460 Leu Ar Thr Tyr Leu Met Phe Thr Ser Met Cvs Thr Asn He Glu Leu 465 " 470 475 480 Gly Glu Met He Ala Arg Phe Ser Lys Pro Asp Ser Leu Asn He Tyr 485 490 495 Arg Ala Phe Ser Pro Cys Phe Leu Gly Leu Arg Tyr Asp Leu His Pro 500 505 510 Ala Lys Leu Arg Ala Glu Ala Pro Gin Ser Ser Ala Leu Thr Arg Thr 515 520 525 Ala Val Ala Arg Gly Thr Ser Gly Phe Ala Glu Leu Leu His Ala Leu 530 535 540 His Leu Asp Ser Leu Asn Leu He Pro Ala He Asn Cys Ser Lys He 545 550 555 560 Thr Ala Asp Lys He He Ala Thr Val Pro Leu Pro H s Val Thr Tyr 565 570 575 He He Ser Ser Glu Ala Leu Ser Asn Ala Val Val Tyr Glu Val Ser 580 585 590 Glu He Phe Leu Lys Ser Ala Met Phe He Ser Ala He Lys Pro Asp 595 600 605 Cys Ser Gly Phe Asn Pne Ser Gin He Asp Arg His He Pro He Val 610 615 620 Tyr Asn He Ser Thr Pro Arg Arg Gly Cys Pro Leu Cys Asp Ser Val 625 630 635 * 640 He Met Ser Tyr Asp Glu Ser Asp Gly Leu Gin Ser Leu Met Tyr Val 645 650 655 Thr Asn Glu Arg Val Gin Thr Asn Leu Phe Leu Asp Lys Ser Pro Phe 660 665 " 670 Phe Asp Asn Asn Asn Leu His He His Tyr Leu Trp Leu Arg Asp Asn 675 680 * 665 Gly Thr Val Val Glu He Arg Gly Met Tyr Arg Arg Arg Ala Ala Ser 690 695 700 Ala Leu Phe Leu He Leu Ser Phe He Gly Phe Ser Gly Val He Tyr 705 710 715 ' 720 Phe Leu Tyr Arg Leu Phe Ser He Leu Tyr 725 730 (2) INFORMATION FOR SEQ ID NO:18: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1215 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (Di TOPOLOGY* linear (ill MOLECULE TYPE: DNA (genomic) llll) HYPOTHETICAL: N livl ANTI-SENSE: N (ix) FEATURE. (A) NAME/KEY: CDS (B) LOCATION: 1..1215 (D. OTHER INFORMATION: (x i SEQUENCE DESCRIPTION: SEQ ID NO: 18 ATG TTA CGA GTT CCG GAC GTG AAG GCT AGT CTA GTA GAG GGC GCG GCG 48 Met Leu Arg Val Pro Asp Val Lys Ala Ser Leu Val Glu Gly Ala Ala 1 5 10 15 CGC CTG TCG ACA GGC GAG CGC GTG TTT CAC GTC TTG ACC TCT CCG GCG 96 Arg Leu Ser Tnr Gly Glu Arg Val Phe His Val Leu Thr Ser Pro Ala 20 ' 25 30 GTG GCG GCC ATG GTG GGA GTC TCT AAT CCT GAA GTC CCG ATG CCA CTG 144 Val Ala Ala Met Val Gly Val Ser Asn Pro Glu Val Pro Met Pro Leu 35 40 45 TTG TTC GAA AAG TTT GGG ACT CCG GAC TCG TCT ACC CTG CCA CTC TAC 192 Leu Phe Glu Lys Phe Gly Thr Pro Asp Ser Ser Thr Leu Pro Leu Tyr 50 55 60 GCG GCT AGG CAC CCG GAA CTA TCG TTG CTA CGG ATC ATG CTC TCA CCG 240 Ala Ala Arg His Pro Glu Leu Ser Leu Leu Arg He Met Leu Ser Pro 65 70 75 80 CAC CCC TAC GCG TTA AGA AGC CAC TTG TGC GTA GGC GAA GAG ACC GCA 288 His Pro Tyr Ala Leu Arg Ser His Leu Cys Val Gly Glu Glu Thr Ala 85 90 95 TCT CTT GGC GTT TAC CTG CAC TCC AAG CCA GTC GTA CGC GGC CAC GAA 336 Ser Leu Gly His Glu TTC GAG GAC ACG CAG ATA CTA CCG GAG TGC CGG CTG GCC ATA ACG AGC 384 Phe Glu Asp Thr Gin He Leu Pro Glu Cys Arg Leu Ala He Thr Ser 115 120 125 GAC CAG TCT TAT ACC AAC TTT AAG ATT ATA GAT CTG CCA GCG GGA TGC 432 ASD Gin Ser Tyr Thr Asn Phe Lys He He Asp Leu Pro Ala Gly Cys 130 135 140 CGT CGC GTC CCC ATA CAC GCC ' GCG AAC AAG CGT GTC GTC ATC GAC GAG 480 Arg Arg Val Pro He His Ala Ala Asn Lys Arg Val Val He Asp Glu 145 150 155 160 GCC GCC AAC CGC ATA AAG GTG TTT GAC CCA GAG TCG CCT TTA CCG CGT 52B Ala Ala Asn Arg He Lys Val Phe Asp Pro Glu Ser Pro Leu Pro Arg 165 170 175 CAC CCC ATA ACA CCC CGT GCC GGT CAG ACC AGA TCT ATA CTG AAA CAC 576 His Pro He Thr Pro Arg Ala Gly Gin Thr Arg Ser He Leu Lys His 180 185 190 AAC ATC GCA CAG GTT TGC GAA CGG GAT ATC GTG TCA CTT AAC ACA GAC 624 Asn He Ala Gin Val Cys Glu Arg Asp He Val Ser Leu Asn Thr Asp 195 200 205 AAC GAG GCC GCG TCT ATG TTC TAC ATG ATT GGA CTC AGG CGG CCG AGA 672 Asn Glu Ala Ala Ser Met Phe Tyr Met He Gly Leu Arg Arg Pro Arg 210 215 220 CTC GGA GAA AGC CCG GTC TGT GAC TTC AAC ACC GTT ACC ATC ATG GAG 720 Leu Glv Glu Ser Pro Val Cys Asp Phe Asn Thr Val Thr He Met Glu 225 ' 230 235 240 CGT GCT AAC AAC TCG ATA ACT TTT CTA CCC AAG CTA AAA CTG AAC CGG 768 Arg Ala Asn Asn Ser He Thr Phe Leu Pro Lys Leu Lys Leu Asn Arg 245 250 255 CTA CAA CAC CTG TTC CTG AAG CAC GTG TTG CTG CGC AGC ATG GGG CTG 816 Leu Gin His Leu Phe Leu Lys His Val Leu Leu Arg Ser Met Gly Leu 260 265 270 GAA AAC ATC GTG TCG TGT TTC TCA TCG CTG TAC GGC GCA GAA CTT GCC 864 Glu Asn He Val Ser Cys Phe Ser Ser Leu Tyr Gly Ala Giu Leu Ala 275 280 285 CCT GCG AAA ACA CAC GAG CGG GAG TTC TTC GGC GCT CTG CTA GAA AGA 912 Pro Ala Lys Thr His Glu Arg Giu Phe Phe Gly Ala Leu Leu Giu Arg 290 295 300 CTC AAA CGT CGG GTG GAG GAC GCG GTC TTC TGC CTG AAT ACC ATA GAG 960 Leu Lys Arg Arg Val Glu Asp Ala Val Phe Cys Leu Asn Thr He Glu 305 310 315 320 GAT TTC CCG TTT AGG GAA CCC ATT CGC CAA CCC CCA GAT TGT TCC AAG 1008 ASP Phe Pro Phe Arg Glu Pro He Arg Gin Pro Pro Asp Cys Ser Lys 325 330 335 GTG CTT ATA GAA GCC ATG GAA AAG TAC TTT ATG ATG TGT AGC CCC AAA 1056 Val Leu He Glu Ala Met Glu Lys Tyr Phe Met Met Cys Ser Pro Lys 340 345 350 GAC CGT CAA AGC GCC GCA TGG CTA GGT GCA GGG GTG GTC GAA CTG ATA 1104 Asp Arg Gin Ser Ala Ala Trp Leu Gly Ala Gly Val Val Glu Leu He 355 360 ' 365 TGT GAC GGC AAT CCA CTT TCT GAG GTG CTC GGA TTT CTT GCC AAG TAT 1152 Cys Asp Gly Asn Pro Leu Ser Glu Val Leu Gly Phe Leu Ala Lys Tvr 370 375 380 ATG CCC ATA CAA AAA GAA TGC ACA GGA AAC CTT TTA AAA ATC TAC GCT 1200 Met Pro lie Gin Lys Glu Cys Thr Gly Asn Leu Leu Lys He Tyr Ala 385 390 * 395 ' 400 TTA TTG ACC GTC TAA 1215 Lea Leu Thr Val (2) INFORMATION FOR SEQ ID NO: 19: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 404 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (Xl) SEQUENCE DESCRIPTION: SEQ ID NO:19: Met Leu Arg Val Pro Asp Val Lys Ala Ser Leu Val Glu Gly Ala Ala 1 5 10 15 Arg Leu Ser Thr Gly Glu Arg Val Phe His Val Leu Thr Ser Pro Ala 20 25 30 Val Ala Ala Met Val Gly Val Ser Asn Pro Glu Val Pro Met Pro Leu 35 40 45 Leu Phe Glu Lys Phe Gly Thr Pro Asp Ser Ser Thr Leu Pro Leu Tyr 50 55 60 Ala Ala Arg His Pro Glu Leu Ser Leu Leu Arg He Met Leu Ser Pro 65 70 75 80 His Pre Tvr Ala Leu Arg Ser His Leu Cys Val Gly Glu Glu Thr Ala 85 90 ' 95 Ser Leu Gly Val Tyr Leu His Ser Lys Pro Val Val Arg Gly His Glu 100 105 " 110 Phe Glu Asp Thr Gin He Leu Pro Glu Cys Arg Leu Ala He Tnr Ser 115 120 125 ASD Gin Ser Tyr Thr Asn Phe Lys He He Asp Leu Pro Ala Gly Cys 130 135 140 Arg Arg Val Pro He His Ala Ala Asn Lys Arg Val Val He Asp Glu 145 150 155 160 Ala Ala Asn Arg He Lys Val Phe Asp Pro Glu Ser Pro Leu Pro Arg 165 170 175 His Pro He Thr Pro Arg Ala Gly Gin Thr Arg Ser He Leu Lys His 180 185 190 Asn He Ala Gin Val Cys Glu Arg Asp He Val Ser Leu Asn Thr Asp 195 200 205 Asn Glu Ala Ala Ser Met Phe Tyr Met He Gly Leu Arg Arg Pro Arg 210 215 220 Leu Gly Glu Ser Pro Val Cys Asp Phe Asn Thr Val Thr He Met Glu 225 ' 230 235 240 Arg Ala Asn Asn Ser He Thr Phe Leu Pro Lys Leu Lys Leu Asn Arg 245 250 * 255 Leu Gin His Leu Phe Leu Lys His Val Leu Leu Arg Ser Met Gly Leu 260 265 270 Glu Asn He Val Ser Cys Phe Ser Ser Leu Tyr Gly Ala Glu Leu Ala 275 280 ' 2B5 Pro Ala Lys Tnr His Glu Arg Glu Phe Phe Gly Ala Leu Leu Glu Arg 290 295 ' 300 Leu Lys Arg Arg Val Glu Asp Ala Val Phe Cys Leu Asn Thr He Glu 305 ' 310 315 320 Asp Phe Pro Phe Arg Glu Pro He Arg Gin Pro Pro Asp Cys Ser Lys 325 330 335 Val Leu He Glu Ala Met Glu Lys Tyr Phe Met Met Cys Ser Pro Lys 340 345 350 Asp Arg Gin Ser Ala Ala Trp Leu Gly Ala Gly Val Val Glu Leu He 355 360 365 Cys Asp Gly Asn Pro Leu Ser Glu Val Leu Gly Phe Leu Ala Lys Tyr 370 375 380 Met Pro He Gin Lys Glu Cys Thr Gly Asn Leu Leu Lys He Tyr Ala 385 390 395 * 400 Leu Leu Thr Val (2' INFORMATION FOR SEQ ID NO:20: (ιϊ SEQUENCE CHARACTERISTICS: (A) LENGTH. 2259 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (i ) MOLECULE TYPE: DNA (genomic) Iil ; HYPOTHETICAL: N (iv) ANTI-SENSE: N (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..2259 (D) OTHER INFORMATION: (XI) SEQUENCE DESCRIPTION: SEQ ID NO:20: ATG GCA GCG CTC GAG GGC CCC CTA CTA CTG CCA CCG AGC GCC TCC CTG 48 Met Ala Ala Leu Glu Gly Pro Leu Leu Leu Pro Pro Ser Ala Ser Leu 1 5 10 15 ACG ACG AGT CCG CAG ACC ACG TGT TAT CAA GCG ACT TGG GAA TCA CAG 96 Thr Thr Ser Pro Gin Thr Thr Cys Tyr Gin Ala Thr Trp Glu Ser Gin 20 25 30 CTG GAA ATA TTC TGC TGT CTG GCC ACC AAC TCG CAC CTG CAG GCA GAG 144 Leu Giu He Phe Cys Cys Leu Ala Thr Asn Ser His Leu Gin Ala Glu 35 40 45 CTG ACC TTA GAA GGT CTT GAT AAG ATG ATG CAG CCC GAG CCC ACC TTT 192 Leu Thr Leu Giu Gly Leu Asp Lys Met Met Gin Pro Glu Pro Thr Phe 5C 55 60 TTC GCC TGC AGA GCG ATA CGC AGA CTA CTC CTG GGG GAA CGC CTC CAC 240 Phe Ala Cys Arg Ala He Arg Arg Leu Leu Leu Gly Giu Arg Leu His 65 ' 70 75 80 CCT TTT ATA CAT CAA GAA GGG ACT CTT TTG GGA AAA GTG GGT CGA CGG 288 Pro Pne He His Gin Giu Gly Thr Leu Leu Gly Lys Val Gly Arg Arg 85 90 95 TAC AGC GGC GAA GGT TTA ATA ATT GAC GGT GGT GGA GTG TTT ACG CGC 336 Tyr Ser Gly Glu Gly Leu He He Asp Gly Gly Gly Val Phe Thr Arg 100 105 110 GGA CAG ATA GAC ACC GAC AAC TAC CTA CCT GCG GTG GGA TCA TGG GAA 384 Gly Gin He Asp Thr Asp Asn Tyr Leu Pro Ala Val Gly Ser Trp Glu 115 120 125 CTT ACC GAT GAT TGT GAT AAA CCC TGC GAA TTC AGG GAG CTA CGC TCG 432 Leu Thr Asp Asp Cys Asp Lys Pro Cys Glu Phe Arg Glu Leu Arg Ser 130 135 140 CTG TAT CTT CCC GCG CTA CTA ACG TGC ACC ATA TGT TAC AAA GCC ATG 480 Leu Tyr Leu Pro Ala Leu Leu Thr Cys Thr He Cys Tyr Lys Ala Met 145 * 150 155 160 TTC AGG ATA GTG TGC AGG TAC CTG GAG TTC TGG GAG TTC GAA CAG TGT 528 Phe Arg lie Val Cys Arg Tyr Leu Glu Phe Trp Glu Phe Glu Gin Cys 165 170 175 TTT CAT GCG TTT CTG GCG GTG TTG CCC CAT AGT CTA CAA CCC ACA ATC 576 Phe His Ala Phe Leu Ala Val Leu Pro His Ser Leu Gin Pro Thr He 180 185 190 TAT CAA AAT TAT TTT GCA CTC CTG GAG AGC CTG AAG CAT CTC TCG TTT 624 Tyr Gin Asn Tyr Phe Ala Leu Leu Giu Ser Leu Lys His Leu Ser Phe 195 * 200 205 TCA ATA ATG CCA CCC GCA TCC CCA GAC GCA CAG CTA CAT TTT TTA AAG 672 Ser He Met Pro Pro Ala Ser Pro Asp Ala Gin Leu His Phe Leu Lys 210 215 220 TTT AAC ATC AGC AGC TTC ATG GCC ACG TGG GGG TGG CAC GGA GAG CTG 720 Phe Asn He Ser Ser Phe Met Ala Thr Trp Gly Trp His Gly Glu Leu 225 230 235 " 240 GTC TCG CTG CGC CGT GCC ATC GCT CAC AAC GTA GAG CGA CTG CCC ACC 768 Val Ser Leu Arg Arg Ala He Ala His Asn Val Glu Arg Leu Pro Thr 245 250 255 GTG CTG AAG AAC CTG TCG AAA CAG AGT AAG CAC CAG GAC GTC AAG GTT 816 Val Leu Lvs Asn Leu Ser Lys Gin Ser Lys His Gin Asp Val Lvs Val 260 265 270 AAC GGA CGG GAT CTG GTG GGC TTT CAG CTG GCT CTA AAC CAG CTC GTG 864 Asn Gly Arg Asp Leu Val Gly Phe Gin Leu Ala Leu Asn Gin Leu Val 275 280 285 TCC CGT CTG CAC GTA AAA ATC CAA CGC AAG GAC CCC GGA CCA AAG CCA 912 Ser Arg Leu His Val Lys He Gin Arg Lys Asp Pro Gly Pro Lys Pro 290 295 300 TAC AGG GTG GTC GTC AGT ACC CCA GAT TGT ACC TAC TAT CTA GTG TAT 96C Tvr Arg Val Val Val Ser Thr Pro Asp Cys Thr Tyr Tyr Leu Val Tyr 305 " 310 315 320 CCG GGC ACA CCG GCC ATC TAC AGA CTC GTC ATG TGT ATG GCA GTG GCA 1008 Pro Gly Thr Pro Ala He Tyr Arg Leu Val Met Cys Met Ala Val Ala 325 330 335 GAC TGC ATC GGC CAC TCG TGC AGC GGA CTG CAC CCC TGC GCA AAC TTT 1056 Asp Cvs He Gly His Ser Cys Ser Gly Leu His Pro Cys Ala Asn Phe 340 345 350 TTA GGC ACC CAC GAG ACA CCG CGT CTC CTG GCG GCG ACG CTT TCA AGA 1104 Leu Gly Tnr His Glu Thr Pro Arg Leu Leu Ala Ala Thr Leu Ser Arg 355 360 365 ATC CGG TAC GCG CCG AAA GAC CGG CGA GCA GCC ATG AAA GGA AAT TTG 1152 He Arg Tyr Ala Pro Lys Asp Arg Arg Ala Ala Met Lys Gly Asn Leu 370 375 380 CAG GCG TGC TTC CAA CGA TAC GCG GCC ACG GAC GCG CGG ACT CTG GGC 1200 Gin Ala Cys Phe Gin Arg Tyr Ala Ala Thr Asp Ala Arg Thr Leu Gly 385 390 395 400 AGC TCT ACA GTG TCA GAC ATG CTG GAA CCC ACA AAA CAC GTC AGT TTG 124B Ser Ser Thr Val Ser Asp Met Leu Glu Pro Thr Lys His Val Ser Leu 405 410 415 GAA AAC TTC AAG ATC ACC ATA TTC AAC ACC AAC ATG GTG ATT AAC ACT 1296 Giu Asn Phe Lys He Thr He Phe Asn Thr Asn Met Val He Asn Thr 420 425 430 AAG ATA AGC TGC CAC GTT CCT AAC ACC CTG CAA AAG ACT ATT TTA AAC 1344 Lys He Ser Cys His Val Pro Asn Thr Leu Gin Lys Thr He Leu Asn 435 * 440 445 ATC CCC AGA TTG ACC AAC AAT TTT GTT ATA CGA AAG TAC TCC GTA AAG 1392 He Pro Arg Leu Thr Asn Asn Phe Val He Arg Lys Tyr Ser Val Lys 450 455 460 GAA CCT TCT TTT ACC ATA AGC GTG TTT TTT TCC GAC AAC ATG TGT CAA 1440 Glu Pro Ser Phe Thr He Ser Val Pne Phe Ser Asp Asn Met Cys Gin 465 470 475 480 GGC ACC GCA ATA AAC ATC AAC ATC AGT GGG GAC ATG CTG CAC TTT CTC 1486 Glv T r Ala lie Asn He Asn He Ser Gly Asp Met Leu His Phe Leu 485 490 " 495 TTC GCA ATG GGT ACG CTG AAA TGC TTT CTG CCA ATC AGG CAC ATA TTT 1536 Pne Ala Met Gly Thr Leu Lys Cys Phe Leu Pro He Arg His He Phe 500 505 510 CCT GTA TCG ATA GCA AAT TGG AAC TCC ACG TTG GAC CTG CAC GGA CTG 1584 Pro Val Ser He Ala Asn Trp Asn Ser Thr Leu Asp Leu His Gly Leu 515 520 525 GAA AAC CAG TAC ATG GTG AGA ATG GGG CGA AAA AAC GTA TTT TGG ACC 1632 Glu Asn Gin Tyr Met Val Arg Met Gly Arg Lys Asn Val Phe Trp Thr 530 535 ' 540 ACA AAC TTT CCA TCT GTG GTC TCC AGC AAG GAT GGG CTA AAC GTG TCC 1680 Thr Asn Phe Pro Ser Val Val Ser Ser Lys Asp Gly Leu Asn Val Ser 545 550 555 560 TGG TTT AAG GCC GCG ACA GCC ACG ATT TCT AAA GTG TAC GGG CAG CCT 1728 Trp Phe Lvs Ala Ala Thr Ala Thr He Ser Lys Val Tyr Gly Gin Pro 565 570 ' 575 CTT GTG GAA CAG ATT CGC CAC GAG CTG GCG CCC ATT CTC ACG GAC CAG 1776 Leu Val Giu Gin He Arg His Glu Leu Ala Pro He Leu Thr Asp Gin 580 585 590 CAC GCG CGC ATC GAC GGA AAC AAA AAT AGA ATA TTC TCC CTA CTT GAG 1824 His Ala Arg He Asp Gly Asn Lys Asn Arg He Phe Ser Leu Leu Glu 595 600 605 CAC AGA AAC CGT TCC CAA ATA CAG ACG CTA CAC AAA AGG TTC CTG GAG 1872 His Arg Asn Arg Ser Gin He Gin Thr Leu His Lys Arg Phe Leu Glu 610 615 620 TGT CTG GTG GAA TGC TGT TCG TTT CTC AGG CTT GAC GTG GCT TGC ATT 1920 Cys Leu Val Glu Cys Cys Ser Phe Leu Arg Leu Asp Val Ala Cys He 625 630 635 ' 640 AGG CGA GCC GCC GCC CGG GGC CTG TTT GAC TTC TCA AAG AAG ATA ATC 1968 Arg Arg Ala Ala Ala Arg Gly Leu Phe Asp Phe Ser Lys Lys He He 645 650 655 AGT CAC ACT AAA AGC AAA CAC GAG TGC GCA GTA CTG GGA TAT AAA AAG 2016 Ser His Thr Lys Ser Lys His Glu Cys Ala Val Leu Gly Tyr Lys Lys 660 665 670 TGT AAC CTA ATC CCG AAA ATC TAT GCC CGA AAC AAG AAG ACC AGG CTA 2064 Cys Asn Leu He Pro Lys He Tyr Ala Arg Asn Lys Lys Thr Arg Leu 675 680 685 GAC GAG TTG GGC CGC AAT GCA AAC TTC ATT TCG TTC GTC GCC ACC ACG 2112 Asp Giu Leu Gly Arg Asn Ala Asn Phe He Ser Phe Val Ala Thr Thr 69? 695 700 GGT CAT CGG TTC GCC GCT CTA AAG CCA CAA ATT GTC CGT CAC GCC ATT 2160 Glv His Arg Phe Ala Ala Leu Lys Pro Gin He Val Arg His Ala He 705 710 715 720 CGC AAA CTA GGC CTG CAC TGG CGC CAC CGA ACG GCC GCG TCC AAC GAG 2208 Arg Lys Leu Gly Leu His Trp Arg His Arg Thr Ala Ala Ser Asn Glu 725 730 735 CAG ACA CCG CCA GCC GAT CCC CGC GTA CGT TGC GTC CGT CCG CTG GTC 2256 Gin Thr Pro Pro Ala Asp Pro Arg Val Arg Cys Val Arg Pro Leu Val 740 745 750 TAA 225S (2) INFORMATION FOR SEQ ID NO:21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 752 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: Met Ala Ala Leu Glu Gly Pro Leu Leu Leu Pro Pro Ser Ala Ser Leu 1 5 10 15 Thr Thr Ser Pro Gin Thr Thr Cys Tyr Gin Ala Thr Trp Glu Ser Gin 20 25 30 Leu Glu He Phe Cys Cys Leu Ala Thr Asn Ser His Leu Gin Ala Glu 35 ' 40 45 Leu Thr Leu Glu Gly Leu Asp Lys Met Met Gin Pro Glu Pro Thr Phe 50 55 ' 60 Phe Ala Cvs Arg Ala He Arg Arg Leu Leu Leu Gly Glu Arg Leu His 65 ' 70 75 80 Pro Phe He His Gin Glu Gly Thr Leu Leu Gly Lys Val Gly Arg Arg 85 90 95 Tyr Ser Gly Glu Gly Leu He He Asp Gly Gly Gly Val Phe Thr Arg 100 105 110 Gly Gin He Asp Thr Asp Asn Tyr Leu Pro Ala Val Gly Ser Trp Glu 115 120 125 Leu Thr Asp Asp Cys Asp Lys Pro Cys Glu Phe Arg Glu Leu Arg Ser 130 135 140 Leu Tyr Leu Pro Ala Leu Leu Thr Cys Thr He Cys Tyr Lys Ala Met 145 150 155 160 Phe Arg He Val Cys Arg Tyr Leu Glu Phe Trp Glu Phe Glu Gin Cys 165 170 175 Phe His Ala Phe Leu Ala Val Leu Pro His Ser Leu Gin Pro Thr He 180 185 190 Tvr Gin Asn Tyr Phe Ala Leu Leu Glu Ser Leu Lys His Leu Ser Phe 195 ' 200 205 Ser He Met Pro Pro Ala Ser Pro Asp Ala Gin Leu His Phe Leu Lys 210 215 220 Phe Asn He Ser Ser Phe Met Ala Thr Trp Gly Trp His Gly Glu Leu 225 230 235 240 Val Ser Leu Arg Arg Ala He Ala His Asn Val Glu Arg Leu Pro Thr 245 250 255 Val Leu Lvs Asn Leu Ser Lys Gin Ser Lys His Gin Aso Val Lys Val 260 265 * 270 Asn Gly Arg Asp Leu Val Gly Phe Gin Leu Ala Leu Asn Gin Leu Val 275 280 2B5 Ser Arg Leu His Val Lys He Gin Arg Lys Asp Pro Gly Pro Lys Pro 290 295 300 Tyr Arσ Val Val Val Ser Thr Pro Asp Cys Thr Tyr Tyr Leu Val Tyr 305 " 310 " 315 320 Pro Gly Thr Pro Ala He Tyr Arg Leu Val Met Cvs Met Ala Val Ala 325 330 335 Asp Cys He Gly His Ser Cys Ser Gly Leu His Pro Cys Ala Asn Phe 340 345 350 Leu Gly Thr His Glu Thr Pro Arg Leu Leu Ala Ala Thr Leu Ser Arg 355 360 365 He Arg Tyr Ala Pro Lys Asp Arg Arg Ala Ala Met Lys Gly Asn Leu 370 375 380 Gin Ala Cys Phe Gin Arg Tyr Ala Ala Thr Asp Ala Arg Thr Leu Gly 385 ' 390 395 400 Ser Ser Thr Val Ser Asp Met Leu Glu Pro Thr Lys His Val Ser Leu 405 410 415 Glu Asn Phe Lys He Thr He Phe Asn Thr Asn Met Val He Asn Thr 420 425 430 Lys He Ser Cys His Val Pro Asn Thr Leu Gin Lys Thr He Leu Asn 435 440 445 He Pro Arg Leu Thr Asn Asn Phe Val He Arg Lys Tyr Ser Val Lys 450 455 460 Glu Pro Ser Phe Thr He Ser Val Phe Phe Ser Asp Asn Met Cys Gin 465 470 475 480 Gly Thr Ala He Asn He Asn He Ser Gly Asp Met Leu His Phe Leu 485 490 495 Phe Ala Met Gly Thr Leu Lys Cys Phe Leu Pro He Arg His He Phe 500 505 510 Pro Val Ser He Ala Asn Trp Asn Ser Thr Leu Asp Leu His Gly Leu 515 520 525 Glu Asn Gin Tyr Met Val Arg Met Gly Arg Lys Asn Val Phe Trp Thr 530 535 540 Thr Asn Phe Pro Ser Val Val Ser Ser Lys Asp Gly Leu Asn Val Ser 545 550 555 560 Trp Phe Lys Ala Ala Thr Ala Thr He Ser Lys Val Tyr Gly Gin Pro 565 570 575 Leu Val Glu Gin He Arg His Glu Leu Ala Pro He Leu Thr Asp Gin 580 585 590 His Ala Arg He Asp Gly Asn Lys Asn Arg He Phe Ser Leu Leu Glu 595 600 605 His Arg Asn Arg Ser Gin He Gin Thr Leu His Lys Arg Phe Leu Glu 610 615 620 Cvs Leu Val Glu Cys Cys Ser Phe Leu Arg Leu Asp Val Ala Cys He 625 630 635 * ' 640 Arg Arg Ala Ala Ala Arg Gly Leu Phe Asp Phe Ser Lys Lys He He 645 650 655 Ser His Thr Lvs Ser Lys His Glu Cys Ala Val Leu Gly Tyr Lys Lys 660 665 670 Cvs Asn Leu He Pro Lys He Tyr Ala Arg Asn Lys Lys Thr Arg Leu 675 680 685 Asp Glu Leu Gly Arg Asn Ala Asn Phe He Ser Phe Val Ala Thr Thr 690 695 700 Gly His Arg Phe Ala Ala Leu Lys Pro Gin He Val Arg His Ala He 705 710 715 720 Arg Lys Leu Gly Leu His Trp Arg His Arg Thr Ala Ala Ser Asn Glu 725 730 735 Gin Thr Pro Pro Ala Asp Pro Arg Val Arg Cys Val Arg Pro Leu Val 740 745 750 (2) INFORMATION FOR SEQ ID NO:22: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 364 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii; MOLECULE TYPE: DNA (genomic) (ill) HYPOTHETICAL: N (iv) ANTI-SENSE: N (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..364 (D) OTHER INFORMATION: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22: ATG GTA CGT CCA ACC GAG GCC GAG GTT AAG AAA TCC CTG AGC AGG CTT 48 Met Val Arg Pro Thr Glu Ala Glu Val Lys Lys Ser Leu Ser Arg Leu 1 5 10 15 CCA GCA GCA CGC AAA AGA GCA GGT AAC CGG GCC CAC CTG GCC ACC TAC 96 Pro Ala Ala Arg Lys Arg Ala Gly Asn Arg Ala His Leu Ala Thr Tyr 20 25 30 CGC CGG CTC CTC AAG TAC TCC ACC CTG CCC GAT CTA TGG CGG TTT CTA 144 Arg Arg Leu Leu Lys Tyr Ser Thr Leu Pro Asp Leu Trp Arg Phe Leu 35 40 45 AGT AGC CGG CCC CAG AAC CCT CCC CTT GGA CAC CAC AGA TTA TTC TTT 192 Ser Ser Arg Pro Gin Asn Pro Pro Leu Gly His His Arg Leu Phe Phe 50 55 60 GAG GTG ACT CTA GGG CAC AGA ATT GCC GAC TGC GTA ATT CTG GTA TCG 240 Glu Val Thr Leu Gly His Arg He Ala Asp Cys Val He Leu Val Ser 65 70 75 80 GGT GG3 CAT CAG CCC GTA TGT TAC GTT GTA GAG CTC AAG ACT TGT CTG 288 Glv Glv His Gin Pro Val Cys Tyr Val Val Glu Leu Lys Thr Cys Leu 85 90 95 AGT CAC CAG CTG ATC CCA ACC AAC ACC GTG AGA ACG TCA CAG CGA GCT 336 Ser His Gin Leu He Pro Thr Asn Thr Val Arg Thr Ser Gin Arg Ala 100 105 110 CAA GGC CTG TGC CAA CTC TCC GAC TCG A 364 Gin Glv Leu Cys Gin Leu Ser Asp Ser 115 120 (2) INFORMATION FOR SEQ ID NO:23: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 121 ammo acids (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23* Met Val Arg Pro Thr Glu Ala Glu Val Lys Lys Ser Leu Ser Arg Leu 1 5 10 15 Pro Ala Ala Arg Lys Arg Ala Gly Asn Arg Ala His Leu Ala Thr Tyr 20 25 3 0 Arg Arg Leu Leu Lys Tyr Ser Thr Leu Pro Asp Leu Trυ Arg Phe Leu 35 40 45 Ser Ser Arg Pro Gin Asn Pro Pro Leu Gly His His Arg Leu Phe Phe 50 55 ' 60 Glu Val Thr Leu Gly His Arg He Ala Asp Cys Val He Leu Val Ser 65 70 75 80 Gly Gly His Gin Pro Val Cys Tyr Val Val Glu Leu Lvs Thr Cys Leu 85 90 ' 95 Ser His Gin Leu He Pro Thr Asn Thr Val Arg Thr Ser Gin Arg Ala 100 105 no Gin Gly Leu Cys Gin Leu Ser Asp Ser 115 120 (2) INFORMATION FOR SEQ ID NO:24: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 91B base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (in) HYPOTHETICAL: N (iv* ANTI-SENSE: N (1X1 FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..918 (D) OTHER INFORMATION: (XI* SEQUENCE DESCRIPTION: SEQ ID NO:24: ATG GCA CTC GAC AAG AGT ATA GTG GTT AAC TTC ACC TCC AGA CTC TTC 48 Met Ala Leu Asp Lys Ser He Val Val Asn Phe Thr Ser Arg Leu Phe 1 5 10 15 GCT GAT GAA CTG GCC GCC CTT CAG TCA AAA ATA GGG AGC GTA CTG CCG 96 Ala Asp Glu Leu Ala Ala Leu Gin Ser Lys He Gly Ser Val Leu Pro 20 25 30 CTC GGA GAT TGC CAC CGT TTA CAA AAT ATA CAG GCA TTG GGC CTG GGG 144 Leu Gly Asp Cys His Arg Leu Gin Asn He Gin Ala Leu Gly Leu Gly 35 40 45 TGC GTA TGC TCA CGT GAG ACA TCT CCG GAC TAC ATC CAA ATT ATG CAG 192 Cys Val Cys Ser Arg Glu Thr Ser Pro Asp Tyr He Gin He Met Gin 50 55 60 TAT CTA TCC AAG TGC ACA CTC GCT GTC CTG GAG GAG GTT CGC CCG GAC 240 Tyr Leu Ser Lys Cys Thr Leu Ala Val Leu Glu Glu Val Arg Pro Asp 65 70 75 80 AGC CTG CGC CTA ACG CGG ATG GAT CCC TCT GAC AAC CTT CAG ATA AAA 288 Ser Leu Arg Leu Thr Arg Met Asp Pro Ser Asp Asn Leu Gin He Lys 85 90 95 AAC GTA TAT GCC CCC TTT TTT CAG TGG GAC AGC AAC ACC CAG CTA GCA 336 Asn Val Tyr Ala Pro Phe Phe Gin Trp Asp Ser Asn Thr Gin Leu Ala 100 105 110 GTG CTA CCC CCA TTT TTT AGC CGA AAG GAT TCC ACC ATT GTG CTC GAA 384 Val Leu Pro Pro Phe Phe Ser Arg Lys Asp Ser Thr He Val Leu Glu 115 120 " 125 TCC AAC GGA TTT GAC CCC GTG TTC CCC ATG GTC GTG CCG CAG CAA CTG 432 Ser Asn Gly Phe Asp Pro Val Phe Pro Met Val Val Pro Gin Gin Leu 130 135 140 GGG CAC GCT ATT CTG CAG CAG CTG TTG GTG TAC CAC ATC TAC TCC AAA 480 Gly His Ala He Leu Gin Gin Leu Leu Val Tyr His He Tyr Ser Lys 145 150 155 160 ATA TCG GCC GGG GCC CCG GAT GAT GTA AAT ATG GCG GAA CTT GAT CTA 528 He Ser Ala Gly Ala Pro Asp Asp Val Asn Met Ala Glu Leu Asp Leu 165 170 175 TAT ACC ACC AAT GTG TCA TTT ATG GGG CGC ACA TAT CGT CTG GAC GTA 576 Tyr Thr Thr Asn Val Ser Phe Met Gly Arg Thr Tyr Arg Leu Asp Val 180 185 190 GAC AAC ACG GAT CCA CGT ACT GCC CTG CGA GTG CTT GAC GAT CTG TCC 624 Asp Asn Thr Asp Pro Arg Thr Ala Leu Arg Val Leu Asp Asp Leu Ser 195 200 205 ATG TAC CTT TGT ATC CTA TCA GCC TTG GTT CCC AGG GGG TGT CTC CGT 672 Met Tvr Leu Cys He Leu Ser Ala Leu Val Pro Arg Gly Cys Leu Arg 210 ' 215 220 CTG CTC ACG GCG CTC GTG CGG CAC GAC AGG CAT CCT CTG ACA GAG GTG 720 Leu Leu Thr Ala Leu Val Arg His Asp Arg His Pro Leu Thr Glu Val 225 230 235 240 TTT GAG GGG GTG GTG CCA GAT GAG GTG ACC AGG ATA GAT CTC GAC CAG 768 Phe Glu Gly Val Val Pro Asp Glu Val Thr Arg He Asp Leu Asp Gin 245 250 255 TTG AGC GTC CCA GAT GAC ATC ACC AGG ATG CGC GTC ATG TTC TCC TAT 816 Leu Ser Val Pro Asp Asp He Thr Arg Met Arg Val Met Phe Ser Tyr 260 265 270 CTT CAG AGT CTC AGT TCT ATA TTT AAT CTT GGC CCC AGA CTG CAC GTG B64 Leu Gin Ser Leu Ser Ser He Phe Asn Leu Gly Pro Arg Leu His Val 275 280 285 TAT GCC TAC TCG GCA GAG ACT TTG GCG GCC TCC TGT TGG TAT TCC CCA 912 Tyr Ala Tyr Ser Ala Glu Thr Leu Ala Ala Ser Cys Trp Tyr Ser Pro 290 295 300 CGC TAA 91E Arg 305 (2) INFORMATION FOR SEQ ID NO:25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 305 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (i ) MOLECULE TYPE: protein ( i) SEQUENCE DESCRIPTION: SEQ ID NO: 25: Met Ala Leu Asp Lys Ser He Val Val Asn Phe Thr Ser Arg Leu Phe 1 * 5 10 15 Ala Asp Glu Leu Ala Ala Leu Gin Ser Lvs He Gly Ser Val Leu Pro 20 25 ' 30 Leu Gly Asp Cys His Arg Leu Gin Asn He Gin Ala Leu Gly Leu Gly 35 " 40 45 Cys Val Cys Ser Arg Glu Thr Ser Pro Asp Tyr He Gin He Met Gin 50 55 60 Tyr Leu Ser Lys Cys Thr Leu Ala Val Leu Glu Glu Val Arg Pro Asp 65 70 75 80 Ser Leu Arg Leu Thr Arg Met Asp Pro Ser Asp Asn Leu Gin He Lys 85 90 95 Asn Val Tyr Ala Pro Phe Phe Gin Trp Asp Ser Asn Thr Gin Leu Ala 100 105 110 Val Leu Pro Pro Phe Phe Ser Arg Lys Asp Ser Thr He Val Leu Glu 115 120 125 Ser Asn Gly Phe Asp Pro Val Phe Pro Met Val Val Pro Gin Gin Leu 130 135 140 Gly His Ala He Leu Gin Gin Leu Leu Val Tyr His He Tyr Ser Lys 145 150 155 160 He Ser Ala Gly Ala Pro Asp Asp Val Asn Met Ala Glu Leu Asp Leu 165 170 175 Tyr Thr Thr Asn Val Ser Phe Met Gly Arg Thr Tyr Arg Leu Asp Val 180 185 190 Asp Asn Thr Asp Pro Arg Thr Ala Leu Arg Val Leu Aso Asp Leu Ser 195 200 205 Met Tyr Leu Cys He Leu Ser Ala Leu Val Pro Arg Gly Cys Leu Arg 210 215 220 Leu Leu Thr Ala Leu Val Arg His Asp Arg His Pro Leu Thr Glu Val 225 230 " 235 240 Phe Glu Gly Val Val Pro Asp Glu Val Thr Arg He Asp Leu Asp Gin 245 250 255 Leu Ser Val Pro Asp Asp He Thr Arg Met Arg Val Met Phe Ser Tyr 260 265 270 Leu Gin Ser Leu Ser Ser He Phe Asn Leu Gly Pro Arg Leu His Val 275 280 285 Tyr Ala Tyr Ser Ala Glu Thr Leu Ala Ala Ser Cys Trp Tyr Ser Pro 290 295 300 Arg 305 (2) INFORMATION FOR SEQ ID NO.26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 873 base pairs (B) TYPE: nucleic ac d (C) STRANDEDNESS: single (D) TOPOLOGY: linear (n) MOLECULE TYPE: DNA (genomic) (ill) HYPOTHETICAL: N (iv) ANTI-SENSE: N (ix ■ FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..873 (D) OTHER INFORMATION: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26: ATG GCG TCA TCT GAT ATT CTG TCG GTT GCA AGG ACG GAT GAC GGC TCC 48 Met Ala Ser Ser Asp He Leu Ser Val Ala Arg Thr Asp Asp Gly Ser 1 5 10 15 GTC TGT GAA GTC TCC CTG CGT GGA GGT AGG AAA AAA ACT ACC GTC TAC 96 Val Cys Glu Val Ser Leu Arg Gly Gly Arg Lys Lvs Thr Thr Val Tyr 20 25 ' 30 CTG CCG GAC ACT GAA CCC TGG GTG GTA GAG ACC GAC GCC ATC AAA GAC 144 Leu Pro Asp Thr Glu Pro Trp Val Val Glu Thr Asp Ala He Lys Asp 35 40 * 45 GCC TTC CTC AGC GAC GGG ATC GTG GAT ATG GCT CGA AAG CTT CAT CGT 192 Ala Phe Leu Ser Asp Gly He Val Asp Met Ala Arg Lys Leu His Arg 50 55 60 GGT GCC CTG CCC TCA AAT TCT CAC AAC GGC TTG AGG ATG GTG CTT TTT 240 Glv Ala Leu Pro Ser Asn Ser His Asn Gly Leu Arg Met Val Leu Phe 65 70 75 80 TGT TAT TGT TAC TTG CAA AAT TGT GTG TAC CTA GCC CTG TTT CTG TGC 288 Cvs Tvr Cys Tvr Leu Gin Asn Cys Val Tyr Leu Ala Leu Phe Leu Cys 85 90 95 CCC CTT AAT CCT TAC TTG GTA ACT CCC TCA AGC ATT GAG TTT GCC GAG 336 Pro Leu Asn Pro Tyr Leu Val Thr Pro Ser Ser He Giu Pne Ala Glu 100 105 110 CCC GTT GTG GCA CCT GAG GTG CTC TTC CCA CAC CCG GCT GAG ATG TCT 384 Pro Val Val Ala Pro Glu Val Leu Phe Pro His Pro Ala Glu Met Ser 115 120 125 CGC GGT TGC GAT GAC GCG ATT TTC TGT AAA CTG CCC TAT ACC GTG CCT 432 Arg Gly Cys Asp Asp Ala He Phe Cys Lys Leu Pro Tyr Thr Val Pro 130 135 140 ATA ATC AAC ACC ACG TTT GGA CGC ATT TAC CCG AAC TCT ACA CGC GAG 480 He He Asn Thr Thr Phe Gly Arg He Tyr Pro Asn Ser Thr Arg Glu 145 150 155 160 CCG GAC GGC AGG CCT ACG GAT TAC TCC ATG GCC CTT AGA AGG GCT TTT 528 Pro Asp Gly Arg Pro Thr Asp Tyr Ser Met Ala Leu Arg Arg Ala Phe 165 170 175 GCA GTT ATG GTT AAC ACG TCA TGT GCA GGA GTG ACA TTG TGC CGC GGA 576 Ala Val Met Val Asn Thr Ser Cys Ala Gly Val Thr Leu Cys Arg Gly 180 185 190 GAA ACT CAG ACC GCA TCC CGT AAC CAC ACT GAG TGG GAA AAT CTG CTG 624 Glu Thr Gin Thr Ala Ser Arg Asn His Thr Glu Trp Glu Asn Leu Leu 195 200 205 GCT ATG TTT TCT GTG ATT ATC TAT GCC TTA GAT CAC AAC TGT CAC CCG 672 Ala Met Phe Ser Val He He Tyr Ala Leu Asp His Asn Cys His Pro 210 215 220 GAA GCA CTG TCT ATC GCG AGC GGC ATC TTT GAC GAG CGT GAC TAT GGA 720 Glu Ala Leu Ser He Ala Ser Gly He Phe Asp Glu Arg Asp Tyr Gly 225 230 235 "* 240 TTA TTC ATC TCT CAG CCC CGG AGC GTG CCC TCG CCT ACC CCT TGC GAC 768 Leu Phe He Ser Gin Pro Arg Ser Val Pro Ser Pro Thr Pro Cys Asp 245 250 255 GTG TCG TGG GAA GAT ATC TAC AAC GGG ACT TAC CTA GCT CGG CCT GGA 816 Val Ser Trp Glu Asp He Tyr Asn Gly Thr Tyr Leu Ala Arg Pro Gly 260 265 270 AAC TGT GAC CCC TGG CCC AAT CTA TCC ACC CCT CCC TTG ATT CTA AAT 864 Asn Cys Asp Pro Trp Pro Asn Leu Ser Thr Pro Pro Leu He Leu Asn 275 280 285 TTT AAA TAA 873 Phe Lys 290 (2; INFORMATION FOR SEQ ID NO:27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 290 amino acids (B) TYPE: ammo acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:27: Met Ala Ser Ser Asp He Leu Ser Val Ala Arg Thr Asp Asp Glv Ser 1 5 10 " 15 Val Cvs Glu Val Ser Leu Arg Gly Gly Arg Lys Lys Thr Thr Val Tyr 20 25 ' 30 Leu Pro Asp Thr Giu Pro Trp Val Val Glu Thr Asp Ala He Lys Asp 35 40 45 Ala Phe Leu Ser Asp Gly He Val Asp Met Ala Arg Lys Leu His Arg 50 55 60 Glv Ala Leu Pro Ser Asn Ser His Asn Gly Leu Arg Met Val Leu Phe 65 70 75 80 Cys Tyr Cys Tyr Leu Gin Asn Cys Val Tyr Leu Ala Leu Phe Leu Cys 85 90 95 Pro Leu Asn Pro Tyr Leu Val Thr Pro Ser Ser He Glu Phe Ala Glu 100 105 110 Pro Val Val Ala Pro Glu Val Leu Phe Pro His Pro Ala Glu Met Ser 115 120 125 Arg Gly Cys Asp Asp Ala He Phe Cys Lys Leu Pro Tyr Thr Val Pro 130 135 140 He He Asn Thr Thr Phe Gly Arg He Tyr Pro Asn Ser Thr Arg Glu 145 150 155 160 Pro Asp Gly Arg Pro Thr Asp Tyr Ser Met Ala Leu Arg Arg Ala Phe 165 170 175 Ala Val Met Val Asn Thr Ser Cys Ala Gly Val Thr Leu Cys Arg Gly 180 185 190 Glu Thr Gin Thr Ala Ser Arg Asn His Thr Glu Trp Glu Asn Leu Leu 195 200 205 Ala Met Phe Ser Val He He Tyr Ala Leu Asp His Asn Cys His Pro 210 215 220 Glu Ala Leu Ser He Ala Ser Gly He Phe Asp Glu Arg Asp Tyr Gly 225 230 235 240 Leu Phe He Ser Gin Pro Arg Ser Val Pro Ser Pro Thr Pro Cys Asp 245 250 255 Val Ser Trp Glu Asp He Tyr Asn Gly Thr Tyr Leu Ala Arg Pro Gly 260 265 270 Asn Cvs Asp Pro Trp Pro Asn Leu Ser Thr Pro Pro Leu He Leu Asn 275 280 285 Phe Lys 290 (2) INFORMATION FOR SEQ ID NO:28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 363 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: Single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) ( ll) HYPOTHETICAL: N (iv) ANTI-SENSE: N (ixi FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..363 (D) OTHER INFORMATION: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28: ATG AGC ATG ACT TTC CCC GTC TCC AGT CAC CGG AGG AAT GGT GGA CGG 48 Met Ser Met Thr Phe Pro Val Ser Ser His Arg Arg Asn Gly Gly Arg 1 5 10 15 CTC CGT CCT GGT GCG AAT GGC CAC CAA GCC TCC CGT GAT TGG TCT TAT 96 Leu Arg Pro Gly Ala Asn Gly His Gin Ala Ser Arg Asp Trp Ser Tyr 20 25 30 AAC AGT GCT CTT CCT CCT AGT CAT AGG CGC CTG CGT CTA CTG CTG CAT 144 Asn Ser Aia Leu Pro Pro Ser His Arg Arg Leu Arg Leu Leu Leu His 35 40 45 TCG CGT GTT CCT GGC GGC TCG ACT GTG GCG CGC CAC CCC ACT AGG CAG 192 Ser Arg Val Pro Gly Gly Ser Thr Val Ala Arg His Pro Thr Arg Gin 50 55 60 GGC CAC CGT GGC GTA TCA GGT CCT TCG CAC CCT GGG ACC GCA GGC CGG 240 Gly His Arg Gly Val Ser Gly Pro Ser His Pro Gly Thr Ala Gly Arg 65 70 75 80 GTC ACA TGC ACC GCC GAC GGT GGG CAT AGC TAC CCA GGA GCC CTA CCG 288 Val Thr Cys Thr Ala Asp Gly Gly His Ser Tyr Pro Gly Ala Leu Pro 85 90 95 TAC AAT ATA CAT GCC AGA TTA GAA CGG GGT GTG TGC TAT AAT GGA TGG 336 Tyr Asn He His Ala Arg Leu Glu Arg Gly Val Cys Tyr Asn Gly Trp 100 105 110 CTA TGG GGG GGG GCT GTA GAT AAT TGA 363 Leu Trp Gly Gly Ala Val Asp Asn 115 120 (2) INFORMATION FOR SEQ ID NO:29: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 120 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29: Met Ser Met Thr Phe Pro Val Ser Ser His Arg Arg Asn Gly Gly Arg 1 5 10 15 Leu Arg Pro Gly Ala Asn Gly His Gin Ala Ser Arg Asp Trp Ser Tyr 20 25 30 Asn Ser Aia Leu Pro Pro Ser His Arg Arg Leu Arg Leu Leu Leu His 35 40 45 Ser Arσ Val Pro Gly Gly Ser Thr Val Ala Arg His Pro Thr Arg Gin 50 55 60 Glv His Arg Gly Val Ser Gly Pro Ser His Pro Gly Thr Ala Glv Arg 6 * 5 70 75 80 Val Thr Cvs Thr Ala Asp Gly Gly His Ser Tyr Pro Gly Ala Leu Pre 85 90 95 Tyr Asn He His Ala Arg Leu Glu Arg Gly Val Cys Tyr Asn Gly Trp 100 105 ' 110 Leu Trn Gly Gly Ala Val Asp Asn 115 120 (2) INFORMATION FOR SEQ ID NO:30: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 921 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ill) HYPOTHETICAL: N (iv) ANTI-SENSE: N (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..921 (D) OTHER INFORMATION: (xi) SEQUENCE DESCRIPTION: SEQ ID NO-.30 ATG CTG CTC AGC CGT CAC AGG GAG CGC CTT GCC GCC AAC CTG GAG GAG 48 Met Leu Leu Ser Arg His Arg Glu Arg Leu Ala Aia Asn Leu Glu Glu 1 5 10 15 ACC GCC AAA GAC GCC GGA GAG AGG TGG GAA CTG AGT GCC CCG ACA TTC 96 Tnr Ala Lys Asp Ala Gly Glu Arg Trp Glu Leu Ser Ala Pro Thr Phe 20 25 30 ACG CGA CAC TGT CCC AAA ACG GCA CGG ATG GCG CAC CCT TTT ATT GGC 144 Thr Arg His Cys Pro Lys Thr Ala Arg Met Ala His Pro Phe He Gly 35 40 45 GTG GTG CAC AGA ATA AAC TCA TAC AGT TCG GTC CTG GAA ACA TAC TGC 192 Val Val His Arg He Asn Ser Tyr Ser Ser Val Leu Giu Thr Tyr Cys 50 55 60 ACA CGG CAC CAT CCC GCC ACG CCC ACG TCA GCA AAT CCC GAC GTG GGA 240 Tnr Arg His His Pro Ala Thr Pro Thr Ser Ala Asn Pro Asp Val Gly 65 70 75 80 ACC CCC AGA CCG TCC GAG GAC AAC GTC CCC GCA AAG CCG CGC CTA TTG 288 Thr Pro Arg Pro Ser Glu Asp Asn Val Pro Ala Lys Pro Arg Leu Leu 85 90 * 95 GAG TCC CTA TCA ACA TAC TTG CAG ATG CGG TGT GTG CGC GAG GAC GCG 336 Giu Ser Leu Ser Thr Tyr Leu Gin Met Arg Cys Val Arg Glu Asp Ala 100 105 110 CAC GTC TCC ACG GCC GAT CAA CTG GTC GAG TAC CAG GCG GGC AGA AAA 3B4 His Val Ser Thr Aia Asp Gin Leu Val Glu Tyr Gin Aia Gly Arg Lys 115 120 125 ACA CAC GAC TCC CTG CAC GCC TGC TCT GTC TAC CGC GAA CTT CAG GCT 432 Tnr His Asp Ser Leu His Ala Cys Ser Val Tyr Arg Glu Leu Gin Ala 130 135 140 TTT CTG GTT AAC CTT TCG TCC TTT CTG AAC GGC TGT TAC GTT CCC GGG 480 Phe Leu Val Asn Leu Ser Ser Phe Leu Asn Gly Cys Tyr Val Pro Gly 145 150 155 ' 160 GTG CAC TGG CTG GAG CCC TTC CAA CAG CAG CTA GTA ATG CAC ACT TTT 528 Val His Trp Leu Glu Pro Phe Gin Gin Gin Leu Val Met His Thr Phe 165 170 175 TTC TTT TTG GTT TCA ATC AAG GCC CCA CAA AAG ACG CAC CAG TTG TTT 576 Pne Pne Leu Val Ser He Lys Ala Pro Gin Lys Thr His Gin Leu Phe 180 165 190 GGA TTG TTT AAG CAG TAC TTC GGT TTA TTT GAA ACT CCA AAC AGT GTT 624 Glv Leu Phe Lys Gin Tyr Phe Gly Leu Phe Glu Thr Pro Asn Ser Val 195 200 205 TTA CAG ACG TTT AAG CAA AAG GCA AGC GTA TTC CTA ATA CCA AGG AGA 672 Leu Gin Thr Phe Lys Gin Lys Ala Ser Val Phe Leu He Pro Arg Arg 210 215 220 CAC GGA AAG ACA TGG ATA GTG GTG GCG ATC ATC AGC ATG CTA CTG GCA 720 His Gly Lys Thr Trp He Val Val Ala He He Ser Met Leu Leu Ala 225 230 235 240 TCC GTA GAG AAC ATT AAC ATT GGG TAC GTA GCC CAC CAA AAG CAC GTA 768 Ser Val Giu Asn He Asn He Gly Tyr Val Ala His Gin Lys His Val 245 250 255 GCC AAC TCC GTG TTC GCG GAA ATC ATA AAG ACG CTT TGT CGG TGG TTC 816 Ala Asn Ser Val Phe Ala Glu He He Lys Thr Leu Cvs Arg Trp Phe 260 265 ' 270 CCC CCC AAA AAT TTA AAC ATC AAG AAG GAG AAC GGA ACC ATA ATC TAC 864 Pro Pro Lys Asn Leu Asn He Lys Lys Glu Asn Gly Thr lie He Tyr 275 280 ' 285 ACG CGA CCC GGA GGA CGG TCC AGC TCG CTG ATG TGC GCA ACA TGC TTC 912 Thr Arg Pro Gly Gly Arg Ser Ser Ser Leu Met Cvs Ala Thr Cys Phe 290 295 3 * 00 AAT AAG AAC 921 Asn Lys Asn 305 (2) INFORMATION FOR SEQ ID NO:31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 307 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (Xl; SEQUENCE DESCRIPTION: SEQ ID NO:31: Met Leu Leu Ser Arg His Arg Glu Arg Leu Ala Ala Asn Leu Glu Glu 1 5 10 15 Thr Ala Lys Asp Ala Gly Glu Arg Trp Glu Leu Ser Ala Pro Thr Phe 20 25 30 Thr Arg His Cys Pro Lys Thr Ala Arg Met Ala His Pro Phe He Gly 35 40 45 Val Val His Arg He Asn Ser Tyr Ser Ser Val Leu Glu Thr Tyr Cys 50 55 60 Thr Arg His His Pro Ala Thr Pro Thr Ser Ala Asn Pro Asp Val Gly 65 70 75 80 Thr Pro Arg Pro Ser Glu Asp Asn Val Pro Ala Lys Pro Arg Leu Leu 85 90 95 Glu Ser Leu Ser Thr Tyr Leu Gin Met Arg Cys Val Arg Glu Asp Ala 100 105 110 His Val Ser Thr Ala Asp Gin Leu Val Glu Tyr Gin Ala Gly Arg Lys 115 120 125 Thr His Asp Ser Leu His Ala Cys Ser Val Tyr Arg Glu Leu Gin Ala 130 135 140 Phe Leu Val Asn Leu Ser Ser Phe Leu Asn Gly Cys Tyr Val Pro Gly 145 150 155 160 Val His Trp Leu Glu Pro Phe Gin Gin Gin Leu Val Met His Thr Phe 165 170 175 Pne Phe Leu Val Ser He Lys Ala Pro Gin Lys Thr His Gin Leu Phe 180 185 190 Gly Leu Phe Lys Gin Tyr Phe Gly Leu Phe Glu Thr Pro Asn Ser Val 195 ' 200 205 Leu Gin Thr Phe Lys Gin Lys Ala Ser Val Phe Leu He Pro Arg Arg 210 215 220 His Gly Lys Thr Trp He Val Val Ala He He Ser Met Leu Leu Ala 225 230 235 240 Ser Val Glu Asn He Asn He Gly Tyr Val Ala His Gin Lvs His Val 245 250 ' 255 Ala Asn Ser Val Phe Ala Glu He He Lys Thr Leu Cys Arg Trp Phe 260 265 ' 270 Pro Pro Lys Asn Leu Asn He Lys Lys Glu Asn Gly Thr He He Tyr 2 * 75 280 285 Thr Arg Pro Gly Gly Arg Ser Ser Ser Leu Met Cys Ala Thr Cys Phe 290 295 300 Asn Lys Asn 305 (2) INFORMATION FOR SEQ ID NO: 32: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1365 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ill) HYPOTHETICAL: N (iv) AN I-SENSE: N (I ' FEATURE : (A) NAME/KEY: CDS (B) LOCATION: 1..1365 (D) OTHER INFORMATION: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32: ATG GAT GCG CAT GCT ATC AAC GAA AGA TAC GTA GGT CCT CGC TGC CAC 48 Met Asp Aia His Ala He Asn Giu Arg Tyr Val Gly Pro Arg Cys His 1 5 10 15 CGT TTG GCC CAC GTG GTG CTG CCT AGG ACC TTT CTG CTG CAT CAC GCC 96 Arg Leu Ala His Val Val Leu Pro Arg Thr Phe Leu Leu His His Ala 20 25 30 ATA CCC CTG GAG CCC GAG ATC ATC TTT TCC ACC TAC ACC CGG TTC AGC 144 He Pro Leu Glu Pro Glu He He Phe Ser Thr Tyr Thr Arg Phe Ser 35 40 45 CGG TCG CCA GGG TCA TCC CGC CGG TTG GTG GTG TGT GGG AAA CGT GTC 192 Arg Ser Pro Gly Ser Ser Arg Arg Leu Val Val Cvs Gly Lys Arg Val 50 55 60 CTG CCA GGG GAG GAA AAC CAA CTT GCG TCT TCA CCT TCT GGT TTG GCG 24C Leu Pro Gly Glu Glu Asn Gin Leu Ala Ser Ser Pro Ser Gly Leu Ala 65 70 75 80 CTT AGC CTG CCT CTG TTT TCC CAC GAT GGG AAC TTT CAT CCA TTT GAC 288 Leu Ser Leu Pro Leu Phe Ser His Asp Gly Asn Phe His Pro Phe Asp 85 9 * 0 95 ATC TCG GTA CTG CGC ATT TCC TGC CCT GGT TCT AAT CTT AGT CTT ACT 336 lie Ser Val Leu Arg He Ser Cys Pro Gly Ser Asn Leu Ser Leu Thr 100 105 110 GTC AGA TTT CTC TAT CTA TCT CTG GTG GTG GCT ATG GGG GCG GGA CGG 384 Val Arg Phe Leu Tyr Leu Ser Leu Val Val Ala Met Gly Ala Gly Arg 115 120 125 AAT AAT GCG CGG AGT CCG ACC GTT GAC GGG GTA TCG CCG CCA GAG GGC 432 Asn Asn Ala Arg Ser Pro Thr Val Asp Gly Val Ser Pro Pro Glu Gly 130 135 140 GCC GTA GCC CAC CCT TTG GAG GAA CTG CAG AGG CTG GCG CGT GCT ACG 480 Ala Val Ala His Pro Leu Glu Glu Leu Gin Arg Leu Ala Arg Ala Thr 145 150 155 160 CCG GAC CCG GCA CTC ACC CGT GGA CCG TTG CAG GTC CTG ACC GGC CTT 528 Pro Asp Pro Ala Leu Thr Arg Gly Pro Leu Gin Val Leu Thr Gly Leu 165 170 175 CTC CGC GCA GGG TCA GAC GGA GAC CGC GCC ACT CAC CAC ATG GCG CTC 576 Leu Arg Ala Gly Ser Asp Gly Asp Arg Ala Thr His His Met Ala Leu 180 185 190 GAG GCT CCG GGA ACC GTG CGT GGA GAA AGC CTA GAC CCG CCT GTT TCA 624 Glu Ala Pro Gly Thr Val Arg Gly Glu Ser Leu Asp Pro Pro Val Ser 195 200 205 CAG AAG GGG CCA GCG CGC ACA CGC CAC AGG CCA CCC CCC GTG CGA CTG 672 Gin Lvs Gly Pro Ala Arg Thr Arg His Arg Pro Pro Pro Val Arg Leu 2 * 10 215 220 AGC TTC AAC CCC GTC AAT GCC GAT GTA CCC GCT ACC TGG CGA GAC GCC 72C Ser Phe Asn Pro Val Asn Ala Asp Val Pro Ala Thr Trp Arg Asp Ala 225 230 235 240 ACT AAC GTG TAC TCG GGT GCT CCC TAC TAT GTG TGT GTT TAC GAA CGC 768 Thr Asn Val Tyr Ser Gly Aia Pro Tyr Tyr Val Cys Val Tyr Giu Arg 245 250 255 GGT GGC CGT CAG GAA GAC GAC TGG CTG CCG ATA CCA CTG AGC TTC CCA 516 Gly Glv Arg Gin Glu Asp Asp Trp Leu Pro He Pro Leu Ser Pne Pro 260 265 270 GAA GAG CCC GTG CCC CCG CCA CCG GGC TTA GTG TTC ATG GAC GAC TTG 864 Glu Giu Pro Val Pro Pro Pro Pro Gly Leu Val Phe Met Asp Asp Leu 275 280 ' 285 TTC ATT AAC ACG AAG CAG TGC GAC TTT GTG GAC ACG CTA GAG GCC GCC 912 Phe He Asn Thr Lys Gin Cys Asp Phe Val Asp Thr Leu Glu Ala Ala 290 295 300 TGT CGC ACG CAA GGC TAC ACG TTG AGA CAG CGC GTG CCT GTC GCC ATT 960 Cys Arg Thr Gin Gly Tyr Thr Leu Arg Gin Arg Val Pro Val Ala He 305 310 315 320 CCT CGC GAC GCG GAA ATC GCA GAC GCA GTT AAA TCG CAC TTT TTA GAG 1008 Pro Arg Asp Ala Glu He Ala Asp Ala Val Lys Ser His Phe Leu Glu 325 330 335 GCG TGC CTA GTG TTA CGG GGG CTG GCT TCG GAG GCT AGT GCC TGG ATA 1056 Ala Cys Leu Val Leu Arg Gly Leu Ala Ser Glu Ala Ser Ala Trp He 340 345 350 AGA GCT GCC ACG TCC CCG CCC CTT GGC CGC CAC GCC TGC TGG ATG GAC 1104 Arg Aia Ala Thr Ser Pro Pro Leu Gly Arg His Ala Cys Trp Met Asp 355 360 365 GTG TTA GGA TTA TGG GAA AGC CGC CCC CAC ACT CTA GGT TTG GAG TTA 1152 Val Leu Gly Leu Trp Glu Ser Arg Pro His Thr Leu Gly Leu Glu Leu 370 375 380 CGC GGC GTA AAC TGT GGC GGC ACG GAC GGT GAC TGG TTA GAG ATT TTA 1200 Arg Gly Val Asn Cys Gly Gly Thr Asp Gly Asp Trp Leu Giu lie Leu 385 ' 390 395 400 AAA CAG CCC GAT GTG CAA AAG ACA GTC AGC GGG AGT CTT GTG GCA TGC 1248 Lys Gin Pro Asp Val Gin Lys Thr Val Ser Gly Ser Leu Val Ala Cys 405 410 415 GTG ATC GTC ACA CCC GCA TTG GAA GCC TGG CTT GTG TTA CCT GGG GGT 1296 Val He Val Thr Pro Ala Leu Glu Ala Trp Leu Val Leu Pro Gly Gly 420 425 430 TTT GCT ATT AAA GCC CGC TAT AGG GCG TCG AAG GAG GAT CTG GTG TTC 1344 Phe Ala He Lys Ala Arg Tyr Arg Ala Ser Lys Glu Asp Leu Val Phe 435 440 445 ATT CGA GGC CGC TAT GGC TAG 1365 He Arg Gly Arg Tyr Gly 450 Cι INFORMATION FOR SEQ ID NO:33: 11) SEQUENCE CHARACTERISTICS: (A) LENGTH: 454 am no acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33: Met ASD Ala His Ala He Asn Glu Arg Tyr Val Gly Pro Arg Cys His 1 5 10 is Arg Leu Ala His Val Val Leu Pro Arg Thr Phe Leu Leu His His Ala 20 25 30 He Pro Leu Glu Pro Glu He He Phe Ser Thr Tyr Thr Arg Phe Ser 35 40 45 Arg Ser Pro Glv Ser Ser Arg Arg Leu Val Val Cys Gly Lys Arg Val 50 ' 55 60 Leu Pro Gly Glu Glu Asn Gin Leu Ala Ser Ser Pro Ser Gly Leu Ala 65 70 75 80 Leu Ser Leu Pro Leu Phe Ser His Asp Gly Asn Phe His Pro Phe Asp 85 90 95 He Ser Val Leu Arg He Ser Cys Pro Gly Ser Asn Leu Ser Leu Thr 100 105 HO Val Arg Phe Leu Tyr Leu Ser Leu Val Val Ala Met Gly Ala Gly Arg 115 120 125 Asn Asn Ala Arg Ser Pro Thr Val Asp Gly Val Ser Pro Pro Glu Gly 130 135 140 Ala Val Ala His Pro Leu Glu Glu Leu Gin Arg Leu Ala Arg Ala Thr 145 150 155 160 Pro Asp Pro Ala Leu Thr Arg Gly Pro Leu Gin Val Leu Thr Gly Leu 165 170 175 Leu Arg Ala Gly Ser Asp Gly Asp Arg Ala Thr His His Met Ala Leu 180 185 190 Glu Ala Pro Gly Thr Val Arg Gly Glu Ser Leu Asp Pro Pro Val Ser 195 200 205 Gin Lys Gly Pro Ala Arg Thr Arg His Arg Pro Pro Pro Val Arg Leu 210 215 220 Ser Phe Asn Pro Val Asn Ala Asp Val Pro Ala Thr Trp Arg Asp Ala 225 230 235 240 Thr Asn Val Tyr Ser Gly Ala Pro Tyr Tyr Val Cys Val Tyr Glu Arg 245 250 255 Gly Gly Arg Gin Glu Asp Asp Trp Leu Pro He Pro Leu Ser Phe Pro 260 265 270 Glu Glu Pro Val Pro Pro Pro Pro Gly Leu Val Phe Met Asp Asp Leu 275 280 285 Phe He Asn Thr Lys Gin Cys Asp Phe Val Asp Thr Leu Glu Ala Ala 290 295 300 Cys Arg Thr Gin Gly Tyr Thr Leu Arg Gin Arg Val Pro Val Ala He 305 310 315 320 Pro Arg Asp Ala Glu He Ala Asp Ala Val Lys Ser His Phe Leu Glu 325 330 335 Ala Cys Leu Val Leu Arg Gly Leu Ala Ser Glu Ala Ser Ala Trp He 340 345 350 Arg Ala Ala Thr Ser Pro Pro Leu Gly Arg His Ala Cys Trp Met Asp 355 360 365 Val Leu Glv Leu Trp Glu Ser Arg Pro His Thr Leu Gly Leu Giu Leu 370 ' 375 380 Arg Glv Val Asn Cys Gly Gly Thr Asp Gly Asp Trp Leu Glu He Leu 385 ' 390 395 400 Lys Gin Pro Asp Val Gin Lys Thr Val Ser Gly Ser Leu Val Ala Cys 405 410 415 Val He Val Thr Pro Ala Leu Glu Ala Trp Leu Val Leu Pro Gly Gly 420 425 430 Phe Ala He Lys Ala Arg Tyr Arg Ala Ser Lys Glu Asp Leu Val Phe 435 440 445 He Arg Gly Arg Tyr Gly 450 (2) INFORMATION FOR SEQ ID NO:34: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 984 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ill) HYPOTHETICAL: N (iv) ANTI-SENSE: N (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..984 (D) OTHER INFORMATION: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34 : ATG TTT GCT TTG AGC TCG CTC GTG TCC GAG GGT GAC CCG GAG GTG ACC 48 Met Phe Ala Leu Ser Ser Leu Val Ser Glu Gly Asp Pro Glu Val Thr 1 5 10 15 AGT AGG TAC GTC AAG GGC GTA CAA CTT GCC CTG GAC CTT AGC GAG AAC 96 Ser Arg Tyr Val Lys Gly Val Gin Leu Ala Leu Asp Leu Ser Glu Asn 20 25 30 ACA CCT GGA CAA TTT AAG TTG ATA GAA ACT CCC CTG AAC AGC TTC CTC 144 Thr Pro Gly Gin Phe Lys Leu He Glu Thr Pro Leu Asn Ser Phe Leu 35 40 45 TTG GTT TCC AAC GTG ATG CCC GAG GTC CAG CCA ATC TGC AGT GGC CGG 192 Leu Val Ser Asn Val Met Pro Glu Val Gin Pro He Cys Ser Gly Arg 50 55 60 CCG GCC TTG CGG CCA GAC TTT AGT AAT CTC CAC TTG CCT AGA CTG GAG 240 Pro Ala Leu Arg Pro Asp Phe Ser Asn Leu His Leu Pro Arg Leu Glu 65 70 75 80 AAG CTC CAG AGA GTC CTC GGG CAG GGT TTC GGG GCG GCG GGT GAG GAA 288 Lys Leu Gin Arg Val Leu Gly Gin Gly Phe Gly Ala Ala Gly Glu Glu 85 90 95 ATC GCA CTG GAC CCG TCT CAC GTA GAA ACA CAC GAA AAG GGC CAG GTG 336 He Ala Leu Asp Pro Ser His Val Glu Thr His Glu Lys Gly Gin Val 100 105 110 TTC TAC AAC CAC TAT GCT ACC GAG GAG TGG ACG TGG GCT TTG ACT CTG 384 Phe Tyr Asn His Tyr Ala Thr Glu Glu Trp Thr Trp Ala Leu Thr Leu 115 120 125 AAT AAG GAT GCG CTC CTT CGG GAG GCT GTA GAT GGC CTG TGT GAC CCC 432 Asn Lvs Asp Ala Leu Leu Arg Giu Ala Val Asp Gly Leu Cys Asp Pro 1 * 30 135 140 GGA ACT TGG AAG GGT CTT CTT CCT GAC GAC CCC CTT CCG TTG CTA TGG 480 Gly Thr Trp Lys Gly Leu Leu Pro Asp Asp Pro Leu Pro Leu Leu Trp 145 150 155 160 CTG CTG TTC AAC GGA CCC GCC TCT TTT TGT CGG GCC GAC TGT TGC CTG 528 Leu Leu Phe Asn Gly Pro Ala Ser Phe Cys Arg Ala Asp Cys Cys Leu 165 170 175 TAC AAG CAG CAC TGC GGT TAC CCG GGC CCG GTG CTA CTT CCA GGT CAC 576 Tyr Lys Gin His Cys Gly Tyr Pro Gly Pro Val Leu Leu Pro Gly His 180 185 190 ATG TAC GCT CCC AAA CGG GAT CTT TTG TCG TTC GTT AAT CAT GCC CTG 624 Met Tyr Ala Pro Lys Arg Asp Leu Leu Ser Phe Val Asn His Ala Leu 195 200 205 AAG TAC ACC AAG TTT CTA TAC GGA GAT TTT TCC GGG ACA TGG GCG GCG 672 Lys Tyr Thr Lys Phe Leu Tyr Gly Asp Phe Ser Gly Thr Trp Ala Ala 210 215 220 GCT TGC CGC CCG CCA TTC GCT ACT TCT CGG ATA CAA AGG GTA GTG AGT 720 Ala Cys Arg Pro Pro Phe Ala Thr Ser Arg He Gin Arg Val Val Ser 225 230 235 240 CAG ATG AAA ATC ATA GAT GCT TCC GAC ACT TAC ATT TCC CAC ACC TGC 768 Gin Met Lys He He Asp Ala Ser Asp Thr Tyr He Ser His Thr Cys 245 250 255 CTC TTG TGT CAC ATA TAT CAG CAA AAT AGC ATA ATT GCG GGT CAG GGG 816 Leu Leu Cys His He Tyr Gin Gin Asn Ser He He Ala Gly Gin Gly 260 265 270 ACC CAC GTG GGT GGA ATC CTA CTG TTG AGT GGA AAA GGG ACC CAG TAT 864 Thr His Val Gly Gly He Leu Leu Leu Ser Gly Lys Gly Thr Gin Tyr 275 280 285 ATA ACA GGC AAT GTT CAG ACC CAA AGG TGT CCA ACT ACG GGC GAC TAT 912 He Thr Gly Asn Val Gin Thr Gin Arg Cys Pro Thr Thr Gly Asp Tyr 290 295 300 CTA ATC ATC CCA TCG TAT GAC ATA CCG GCG ATC ATC ACC ATG ATC AAG 960 Leu lie He Pro Ser Tyr Asp He Pro Ala He He Thr Met He Lys 305 310 315 320 GAG AAT GGA CTC AAC CAA CTC TAA 984 Glu Asn Gly Leu Asn Gin Leu 325 (2) INFORMATION FOR SEQ ID NO:35: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 327 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35: Met Phe Ala Leu Ser Ser Leu Val Ser Glu Gly Asp Pro Glu Val Thr 1 5 10 " 15 Ser Arg Tyr Val Lys Gly Val Gin Leu Ala Leu Asp Leu Ser Giu Asn 20 25 30 Thr Pro Glv Gin Phe Lys Leu He Glu Thr Pro Leu Asn Ser Phe Leu 35 40 45 Leu Val Ser Asn Val Met Pro Glu Val Gin Pro He Cys Ser Gly Arg 50 55 60 (2) INFORMATION FOR SEQ ID NO:36: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 330 base pairs (E) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: N (iv) ANTI-SENSE: N (xi) SEQUENCE DESCRIPTION: SEQ ID NO:36: GGATCCCTCT GACAACCTTC AGATAAAAAA CGTATATGCC CCCTTTTTTC AGTGGGACAG 60 CAACACCCAG CTAGCAGTGC TACCCCCATT TTTTAGCCGA AAGGATTCCA CCATTGTGCT 120 CGAATCCAAC GGATTTGACC CCGTGTTCCC CATGGTCGTG CCGCAGCAAC TGGGGCACGC 180 TATTCTGCAG CAGCTGTTGG TGTACCACAT CTACTCCAAA ATATCGGCCG GGGCCCCGGA 240 TGATGTAAAT ATGGCGGAAC TTGATCTATA TACCACCAAT GTGTCATTTA TGGGGCGCAC 300 ATATCGTCTG GACGTAGACA ACACGGATCC 330 (2) INFORMATION FOR SEQ ID NO:37: (ι> SEQUENCE CHARACTERISTICS: (A) LENGTH: 627 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (mi HYPOTHETICAL: N (iv) ANTI-SENSE: N (Xl) SEQUENCE DESCRIPTION: SEQ ID NO:37: GGATCCGCTG GCAGGTGGGC GCGCACCTCG TCGGGTAGCT TGGAGACAAA CAGCTCCAGG 60 CCAGTCCGCG CCGTAGCGCC TGCAGGTGCC TCACCACCGG GGCCGGGTCA TGCGATCTGT 120 TTAGTCCGGA GAAGATAGGG CCCTTGGGAA GCCGCTGAAC CAGCTCCAGG GTCTCCAAGA 180 TGCGCACCGG TTGTCGGAGC TGTCGCGATA GAGGTTAGGG TAGGTGTCCG GTCCGTCCGT 240 GGGCTCAAAC CTGCCCAGAC ACACCACTGT CTGCTGGGGG ATCATCCTTC TCAGGGAGAT 300 GCATTCTTTG GAAGTAGTGG TAGAGATGGA GCAGACTGCC AGGGCGTTGC AGGAGTGGTG 360 GCGATGGTGC GCACCGTTTT TAAGAAACCC CCCAGGGTGG GGACTCCCGC TCCCTGCAGC 420 ATCTCGGCCT GCTGTACGTC CTTGGCGAAT ATGCGACGAA ATCGGCTGTG CGCACGGGGT 480 CCCAGGGCCG GTCCGGTGGC ATACAGGCCG GTGAGGGCCC CCTGGGTCTG TCCGCCTGGA 540 AACAGGGTGC TGTGAAACAA CAGGTTGCAA GGCCGCGAAT ACCCCTCTGC ACGCTGCTGT 600 GGACGTGGGT GTATGCTCCG TGGATCC 627 (2) INFORMATION FOR SEQ ID NO:38: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 233 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ill) HYPOTHETICAL: N (iv) ANTI-SENSE: N (XI) SEQUENCE DESCRIPTION: SEQ ID NO:38: AGCCGAAAGG ATTCCACCAT TGTGCTCGAA TCCAACGGAT TTGACCCCGT GTTCCCCATG 60 GTCGTGCCGC AGCAACTGGG GCACGCTATT CTGCAGCAGC TGTTGGTGTA CCACATCTAC 120 TCCAAAATAT CGGCCGGGGC CCCGGATGAT GTAAATATGG CGGAACTTGA TCTATATACC 180 ACCAATGTGT CATTTATGGG GCGCACATAT CGTCTGGACG TAGACAACAC GGA 233 (2) INFORMATION FOR SEQ ID NO:39: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 328 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: Single (D) TOPOLOGY: linear (n) MOLECULE TYPE: DNA (genomic) (ill) HYPOTHETICAL: N (iv) ANTI-SENSE: N (XI) SEQUENCE DESCRIPTION: SEQ ID NO:39: GAAATTACCC ACGAGATCGC TTCCCTGCAC ACCGCACTTG GCTACTCATC AGTCATCGCC 60 CCGGCCCACG TGGCCGCCAT AACTACAGAC ATGGGAGTAC ATTGTCAGGA CCTCTTTATG 120 ATTTTCCCAG GGGACGCGTA TCAGGACCGC CAGCTGCATG ACTATATCAA AATGAAAGCG 180 GGCGTGCAAA CCGGCTCACC GGGAAACAGA ATGGATCACG TGGGATACAC TGCTGGGGTT 240 CCTCGCTGCG AGAACCTGCC CGGTTTGAGT CATGGTCAGC TGGCAACCTG CGAGATAATT 300 CCCACGCCGG TCACATCTGA CGTTGCCT 328 (2) INFORMATION FOR SEQ ID NO:40: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 132 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ill) HYPOTHETICAL: N (iv) ANTI-SENSE: N (Xl) SEQUENCE DESCRIPTION: SEQ ID NO: 0: AACACGTCAT GTGCAGGAGT GACATTGTGC CGCGGAGAAA CTCAGACCGC ATCCCGTAAC 60 CACACTGAGT GGGAAAATCT GCTGGCTATG TTTTCTGTGA TTATCTATGC CTTAGATCAC 120 AACTGTCACC CG 132 (2) INFORMATION FOR SEQ ID NO-.41: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 40 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (11) MOLECULE TYPE: DNA (genomic) (ill) HYPOTHETICAL: N (iv) ANTI-SENSE: N (XI) SEQUENCE DESCRIPTION: SEQ ID NO: 1: AGCCGAAAGG ATTCCACCAT TCCGTGTTGT CTACGTCCAG 40 (2) INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 38 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: Single (D) TOPOLOGY: linear (n) MOLECULE TYPE: DNA (genomic) (ill) HYPOTHETICAL: N (iv) ANTI-SENSE: N (xi) SEQUENCE DESCRIPTION: SEQ ID NO:42: GAAATTACCC ACGAGATCGC AGGCAACGTC AGATGTGA 38 (2) INFORMATION FOR SEQ ID NO:43: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 46 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii'' MOLECULE TYPE: DNA (genomic) (ill) HYPOTHETICAL: N 'ivi ANTI-SENSE: N (xi) SEQUENCE DESCRIPTION: SEQ ID NO:43: AACACGTCAT GTGCAGGAGT GACCGGGTGA CAGTTGTGAT CTAAGG 46 (2) INFORMATION FOR SEQ ID NO:44: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ill) HYPOTHETICAL: N (iv) ANTI-SENSE: N (Xl) SEQUENCE DESCRIPTION: SEQ ID NO:44: ACAGGGCTGG TTGCCCAGGG T 21 (2) INFORMATION FOR SEQ ID NO:45: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: N (iv) ANTI-SENSE: N (xi) SEQUENCE DESCRIPTION: SEQ ID NO:45: AGTTGCAAAC CAGACCTCAG 20

Claims: What is claimed is: 1. An isolated DNA molecule which is at least 30 nucleotides in length and uniquely defines a herpesvirus associated with Kaposi's sarcoma. 5 2. The isolated DNA molecule of claim 1, wherein the isolated DNA molecule is cDNA. 3. The isolated DNA molecule of claim 1, wherein the 0 isolated DNA molecule is genomic DNA. 4. An isolated RNA molecule which is derived from the isolated nucleic acid molecule of claim 1. 5 5. The isolated DNA molecule of claim 1 which is labelled with a detectable marker. 6. The isolated DNA molecule of claim 5, wherein the marker is a radioactive label, or a calorimetric, 0 a luminescent, or a fluorescent marker. 7. A replicable vector comprising the isolated DNA molecule of claim 1. 5 8. A plasmid, cosmid, λ phage or YAC containing at least a portion of the isolated DNA molecule of claim 1. S. A host cell containing the vector of claim 7. C 1C. The cell of claim 9 which is a eukaryotic cell. 11. The cell of claim 9 which is a bacterial cell. 5 12. An isolated herpesvirus associated with Kaposi's sarcoma. 13. A nucleic acid molecule of at least 14 nucleotides capable of specifically hybridizing with the isolated DNA molecule of claim 1. 14. A DNA molecule of claim 13. 15. A nucleic acid molecule of at least 14 nucleotides capable of specifically hybridizing with a nucleic acid molecule which is complementary to the isolated DNA molecule of claim 1. 16. A nucleic acid molecule of claim 15 wherein the nucleic acid molecule is capable of hybridizing with moderate stringency to at least a portion of a nucleotide sequence as shown in Figure 3A (SEQ ID NO: 1) . 17. An isolated peptide encoded by at least a portion of a nucleic acid molecule with a sequence as set forth in (SEQ ID NOs: 1-37) . 18. A host cell which expresses the peptide of claim 17. 19. The isolated peptide of claim 17, wherein the peptide is linked to a second peptide to form a fusion protein. 20. The fusion protein of claim 17, wherein the second peptide is beta-galactosidase . 21. An antibody which specifically binds to the peptide encoded by the isolated DNA molecule of claim 17. 22. The antibody of claim 21, wherein the antibody is monoclonal antibody. 23. The antibody of claim 21, wherein the antibody is a polyclonal antibody. 24. The antibody of claim 21, wherein the antibody is labelled with a detectable marker. 2Ξ . The labelled antibody of claim 24, wherein the marker is a radioactive label, or a calorimetric, a luminescent, or a fluorescent marker. 26. An antisense molecule capable of hybridizing to the isolated DNA molecule of claim 1. 27. The antisense molecule of claim 26, wherein the molecule is a DNA. 26. The antisense molecule of claim 26, wherein the molecule is a RNA. 29. A triplex oligonucleotide capable of hybridizing with a double stranded isolated DNA molecule of claim 1. 3C. A transgenic nonhuman mammal which comprises at least a portion of the isolated DNA molecule of claim 1 introduced into the mammal at an embryonic stage. 31. A vaccine which comprises an effective immunizing amount of the isolated herpesvirus of claim 12 and a suitable Dharmaceuuical carrier. 32. A method of diagnosing Kaposi's sarcoma which comprises: (a) obtaining a nucleic acid molecule from a tumor lesion of the subject; (b) contacting the nucleic acid molecule with the labelled nucleic acid molecule of claim 13 under hybridizing conditions; and (c) determining the 5 presence of the nucleic acid molecule hybridized, the presence of which is indicative of Kaposi's sarcoma in the subject, thereby diagnosing Kaposi's sarcoma. 0 33. The method of claim 32 wherein the DNA molecule from the tumor lesion is amplified before step (b) . 34. A method of diagnosing Kaposi's sarcoma which 5 comprises: (a) obtaining a nucleic acid molecule from a suitable bodily fluid of a subject; (b) contacting the nucleic acid molecule with the labelled nucleic acid molecule of claim 13 under hybridizing conditions; and (c) determining the 0 presence of the nucleic acid molecule hybridized, the presence of which is indicative of Kaposi's sarcoma in the subject, thereby diagnosing Kaposi's sarcoma. 5 35. A method of diagnosing a DNA virus associated with Kaposi's sarcoma which comprises (a) obtaining a suitable bodily fluid sample from a subject, (b) contacting the suitable bodily fluid of the subject to a support having already bound C thereto a Kaposi's sarcoma antibody, so as to bind Kaposi's sarcoma antibody to a specific Kaposi's sarcoma antigen, (c) removing unbound bodily fluid from the support, and (d) determining the level of Kaposi's sarcoma 5 antibody bound by the Kaposi's sarcoma antigen, thereby diagnosing Kaposi's sarcoma. 36. A method of diagnosing a DNA virus associated with Kaposi's sarcoma which comprises (a) obtaining a suitable bodily fluid sample from a subject, (b) contacting the suitable bodily fluid of the subject to a support having already bound thereto a Kaposi's sarcoma antigen, so as to bind Kaposi's sarcoma antigen to a specific Kaposi's sarcoma antibody, (c) removing unbound bodily fluid from the support, and (d) determining the level of the Kaposi's sarcoma antigen bound by the Kaposi's sarcoma antibody, thereby diagnosing Kaposi's sarcoma. 37. A method of treating a subject with Kaposi's sarcoma, comprising administering to the subject an effective amount of an antisense molecule of claim 26 under conditions such that the antisense molecule selectively enters a tumor cell of the subject, so as to treat the subject. 38. A method for treating a subject with Kaposi's sarcoma (KS) comprising administering to the subject having a human herpesvirus-associated KS a pharmaceutically effective amount of an antiviral agent in a pharmaceutically acceptable carrier, wherein the agent is effective to treat the subject with KS-associated human herpes virus of claim 12. 39. A method of prophylaxis or treatment for Kaposi's sarcoma (KS) by administering to a subject at risk for KS, an antibody that binds to the human herpesvirus of claim 12 in a pharmaceutically acceptable carrier. 40. A method of vaccinating a subject against Kaposi's sarcoma, comprising administering to the subject an effective amount of the peptide of claim 17, and a suitable acceptable carrier, thereby vaccinating the subject. 41. A method of immunizing a subject against a disease caused by the herpesvirus associated with Kaposi's sarcoma which comprises administering to the subject an effective immunizing dose cf the vaccine of claim 12. 42. A method for preventing the development or transmission of herpesvirus associated Kaposi's sarcoma in a subject by treating a subject with Kaposi's sarcoma (KS) comprising administering to the subject having a human herpesvirus-associated KS a pharmaceutically effective amount of an antiviral agent in a pharmaceutically acceptable carrier, wherein the agent is effective to preventing the development or transmission of the KS-associated human herpes virus of claim 12.

Inventors: CHANG YUAN, MOORE PATRICK S, CHANG, YUAN, MOORE, PATRICK, S.
Applicants: CHANG YUAN, MOORE PATRICK S, UNIV COLUMBIA, CHANG, YUAN, MOORE, PATRICK, S., THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF
Application year: 1995
Main classification: C12N1
IPC codes: A01K67, A61K38, A61K39, A61K48, C07K14, C07K16, C07K19, C12N1, C12N5, C12N7, C12N15, C12P21, C12Q1, C12R1